


**CUMULATIVE  
SUPPLEMENT 6  
JUNE 2016**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**36th EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy**

**2016**

Prepared By  
Food and Drug Administration  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Office of Generic Drugs  
Office of Generic Drug Policy

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**36<sup>th</sup> EDITION**

**Cumulative Supplement 6**

**June 2016**

**CONTENTS**

	<i>PAGE</i>
1.0 INTRODUCTION.....	v
1.1 How to use the Cumulative Supplement.....	v
1.2 Cumulative Supplement Content .....	vi
1.3 Applicant Name Changes .....	vii
1.4 Levothyroxine Sodium.....	vii
1.5 Availability of the Edition .....	viii
1.6 Report of Counts for the Prescription Drug Product List.....	ix
1.7 Cumulative Supplement Legend.....	x
DRUG PRODUCT LISTS	
Prescription Drug Product List .....	1-1
OTC Drug Product List .....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List .....	3-1
Orphan Product Designations and Approvals List .....	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution .....	5-1
PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists .....	A-1
B. Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS**  
**with**  
**THERAPEUTIC EQUIVALENCE EVALUATIONS**

**36<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 06**  
**June 2016**

**1.0 INTRODUCTION**

**1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT**

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 36th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; approved over-the-counter (OTC) drug products for those drugs that may not be marketed without NDAs or ANDAs because they are not covered under existing OTC monographs; drug products with approval under Section 505 of the Federal Food, Drug, and Cosmetic Act (FD&C Act) administered by the Center for Biologics Evaluation and Research; and approved products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons, or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, Discontinued Drug Product, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing and we have not determined that they were withdrawn for safety or effectiveness reasons or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the

next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >A>. The Patent and Exclusivity List new additions are indicated by the symbol >A> to the left of Patent Number or Exclusivity Code. The >A> symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol >D> (DELETE) to the left of the line. The information line with the >D> symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).

- New Drug Application (NDA) approvals appear in the CS month they were approved.
- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at [orangebook@fda.hhs.gov](mailto:orangebook@fda.hhs.gov).

mail to:                                FDA/CDER Orange Book Staff  
    Office of Generic Drugs  
    7620 Standish Place  
    Rockville, MD 20855-2773

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
BD RX INC (BD RX)	FRESENIUS KABI USA LLC (FRESENIUS KABI USA)
CITRON PHARMA LLC (CITRON PHARMA LLC)	CASPER PHARMA LLC (CASPER PHARMA LLC)
PROSAM LABS LLC (PROSAM LABS)	OXFORD PHARMACEUTICALS LLC (OXFORD PHARMS)

### 1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies

to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 076187), Levoxyl (King Pharms NDA 021301), Synthroid (Abbvie NDA 021402), and Levo-T (Alara NDA 021342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets.

Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 076187), and Unithroid (Jerome Stevens NDA 021210) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbvie NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 076187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products in the active section of the Orange Book. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Strength	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	076187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	021301	001
SYNTHROID	ABBVIE	0.025MG	AB1	021402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	021342	001
SYNTHROID	ABBVIE	0.025MG	AB2	021402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	076187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	021342	001
UNITHROID	STEVENS J	0.025MG	AB2	021210	001
LEVOXYL	KING PHARMS	0.025MG	AB3	021301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	021342	001
UNITHROID	STEVENS J	0.025MG	AB3	021210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	076187	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	076187	001

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been

available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (December of the previous Annual Edition) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

Drug Product



For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.

### REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2015</u>	<u>MAR 2016</u>	<u>JUN 2016</u>	<u>SEP 2016</u>	<u>DEC 2016</u>
DRUG PRODUCTS LISTED SINGLE SOURCE	17151 2664 (15.5%)	17251 2693 (15.6%)	17528 2664 (15.2%)		
MULTISOURCE	14487 (84.5%)	14558 (84.4%)	14864 (84.8%)		
THERAPEUTICALLY EQUIVALENT	14366 (83.8%)	14434 (83.7%)	14731 (84%)		
NOT THERAPEUTICALLY EQUIVALENT	121 (0.7%)	124 (0.7%)	133 (0.8%)		
EXCEPTIONS <sup>1</sup>	73 (0.4%)	73 (0.4%)	73 (0.4%)		
NEW MOLECULAR ENTITIES APPROVED	28	9	20		
NUMBER OF APPLICANTS	1011	1007	1023		

<sup>1</sup>Amino acid-containing products of varying composition (see Introduction, page xx of the List).

### 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route of Administration and then by trade name (or established name of the active ingredient, if no trade name exists).

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form, new route(s) of administration, new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.
CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL  
ACAMPROSATE CALCIUM

AB + GLENMARK GENERICS 333MG A202229 001 Jul 16, 2013 May CRLD

ACETAMINOPHEN

SOLUTION;IV (INFUSION)  
ACETAMINOPHEN

AP PADDOCK LLC 1GM/100ML (10MG/ML) A202605 001 Jun 13, 2016 May NEWA  
AP SANDOZ INC 1GM/100ML (10MG/ML) A204052 001 Mar 22, 2016 Mar NEWA  
OFIRMEV  
AP + MALLINCKRODT IP 1GM/100ML (10MG/ML) N022450 001 Nov 02, 2010 Mar CFTG

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL  
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

>A> + METRIC 325MG;50MG;40MG A089007 001 Mar 17, 1986 Jun CAHN  
>D> + MIKART 325MG;50MG;40MG A089007 001 Mar 17, 1986 Jun CAHN

TABLET;ORAL  
BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

@ INGENUS PHARMS NJ 325MG;50MG;40MG A040864 001 Dec 01, 2008 Jan CAHN  
@ SUN PHARM INDS 325MG;50MG;40MG A040601 001 Jul 29, 2005 Jan CAHN  
FIORICET  
AA ACTAVIS LABS UT INC 325MG;50MG;40MG A088616 001 Nov 09, 1984 May CMFD

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL  
FIORICET W/ CODEINE

AB + ALLERGAN SALES LLC 325MG;50MG;40MG;30MG N020232 001 Jul 30, 1992 Apr CAHN

ACETAMINOPHEN; CODEINE PHOSPHATE

TABLET;ORAL  
ACETAMINOPHEN AND CODEINE PHOSPHATE  
@ SUN PHARM INDS 300MG;60MG

A089673 001 Feb 10, 1988 Mar CAHN

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL  
ZYFREL

AA CYPRESS PHARM INC 325MG/15ML;7.5MG/15ML A090468 001 Apr 14, 2016 Apr NEWA

TABLET;ORAL  
HYDROCODONE BITARTRATE AND ACETAMINOPHEN

AA ACTAVIS LABS FL INC 300MG;5MG A206470 001 Jun 02, 2016 May NEWA  
AA 300MG;7.5MG A206470 002 Jun 02, 2016 May NEWA  
AA 300MG;10MG A206470 003 Jun 02, 2016 May NEWA  
>D> @ 500MG;10MG A040148 002 Feb 14, 1997 Jun CAHN  
>A> @ ALLERGAN SALES LLC 500MG;10MG A040148 002 Feb 14, 1997 Jun CAHN  
AA AMNEAL PHARMS NY 325MG;2.5MG A040746 002 May 10, 2016 Apr NEWA  
>A> AA LARKEN LABS INC 325MG;5MG A202935 002 Jun 15, 2016 Jun NEWA  
>A> AA 325MG;7.5MG A202935 003 Jun 15, 2016 Jun NEWA  
>A> AA 325MG;10MG A202935 004 Jun 15, 2016 Jun NEWA  
>A> AA PAR PHARM 300MG;5MG A205001 001 Jul 05, 2016 Jun NEWA  
>A> AA 300MG;7.5MG A205001 002 Jul 05, 2016 Jun NEWA  
>A> AA 300MG;10MG A205001 003 Jul 05, 2016 Jun NEWA  
AA RHODES PHARMS 325MG;5MG A202991 001 Apr 12, 2016 Mar NEWA  
AA 325MG;7.5MG A202991 002 Apr 12, 2016 Mar NEWA  
AA 325MG;10MG A202991 003 Apr 12, 2016 Mar NEWA  
>A> AA TRIS PHARMA INC 300MG;5MG A202214 004 Mar 15, 2016 Jun NEWA  
>A> AA 300MG;7.5MG A202214 005 Mar 15, 2016 Jun NEWA  
>A> AA 300MG;10MG A202214 006 Mar 15, 2016 Jun NEWA

NORCO

>D> AA ACTAVIS LABS FL INC 325MG;2.5MG A040148 004 Jul 07, 2014 Jun CAHN  
>D> AA 325MG;5MG A040148 005 Jul 07, 2014 Jun CAHN  
>D> AA + 325MG;7.5MG A040148 003 Sep 12, 2000 Jun CAHN  
>D> AA + 325MG;10MG A040148 001 Feb 14, 1997 Jun CAHN  
>A> AA ALLERGAN SALES LLC 325MG;2.5MG A040148 004 Jul 07, 2014 Jun CAHN  
>A> AA + 325MG;5MG A040099 001 Jun 25, 1997 Jun CAHN  
>A> AA 325MG;5MG A040148 005 Jul 07, 2014 Jun CAHN  
>A> AA + 325MG;7.5MG A040148 003 Sep 12, 2000 Jun CAHN  
>A> AA + 325MG;10MG A040148 001 Feb 14, 1997 Jun CAHN  
>D> AA + WATSON LABS 325MG;5MG A040099 001 Jun 25, 1997 Jun CAHN

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

SOLUTION; ORAL		OXYCODONE AND ACETAMINOPHEN					
AA	MALLINCKRODT INC	325MG/5ML; 5MG/5ML		A 040680	001	Sep 29, 2006	May CMFD
TABLET; ORAL		OXYCODONE AND ACETAMINOPHEN					
AA	ALVOGEN MALTA	325MG; 5MG		A 202677	003	Mar 08, 2016	Feb NEWA
AA		325MG; 7.5MG		A 202677	001	Jul 26, 2012	Jan CAHN
AA		325MG; 10MG		A 202677	002	Jul 26, 2012	Jan CAHN
AA	AMNEAL PHARMS NY	325MG; 7.5MG		A 040778	002	Jun 27, 2014	Apr NEWA
AA	MAYNE PHARMA INC	325MG; 2.5MG		A 090177	001	Oct 20, 2008	Feb CAHN
AA		325MG; 5MG		A 090177	002	Oct 20, 2008	Feb CAHN
AA		325MG; 7.5MG		A 090177	003	Oct 20, 2008	Feb CAHN
AA		325MG; 10MG		A 090177	004	Oct 20, 2008	Feb CAHN
	@	500MG; 7.5MG		A 090177	005	Oct 20, 2008	Feb CAHN
	@	650MG; 10MG		A 090177	006	Oct 20, 2008	Feb CAHN

ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE

TABLET; ORAL		TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN					
AB	ATLAS PHARMS LLC	325MG; 37.5MG		A 202076	001	Mar 30, 2012	May CAHN

ACETAZOLAMIDE

CAPSULE, EXTENDED RELEASE; ORAL		ACETAZOLAMIDE					
AB	NOSTRUM LABS INC	500MG		A 204691	001	Mar 29, 2016	Mar NEWA

ACETYLCYSTEINE

INJECTABLE; INTRAVENOUS		ACETYLCYSTEINE					
AP	AUROBINDO PHARMA LTD	6GM/30ML (200MG/ML)		A 207358	001	Feb 29, 2016	Feb NEWA
TABLET, EFFERVESCENT; ORAL		CETYLEV					
	ARBOR PHARMS LLC	500MG		N 207916	001	Jan 29, 2016	Jan NEWA
	+	2.5GM		N 207916	002	Jan 29, 2016	Jan NEWA

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDE

CAPSULE; ORAL		SEMPREX-D					
	+	AUXILIUM PHARMS INC	8MG; 60MG	N 019806	001	Mar 25, 1994	Mar CAHN

ACYCLOVIR

CAPSULE; ORAL		ACYCLOVIR					
	@	RANBAXY	200MG	A 074975	001	Sep 30, 1998	Feb DISC
AB		ZYDUS PHARMS USA INC	200MG	A 204313	001	Mar 25, 2016	Mar NEWA
OINTMENT; TOPICAL		ACYCLOVIR					
AB		FOUGERA PHARMS INC	5%	A 206633	001	May 11, 2016	Apr NEWA
TABLET; BUCCAL		SITAVIG					
	+	CIPHER PHARMS US	50MG	N 203791	001	Apr 12, 2013	Jan CAHN
TABLET; ORAL		ACYCLOVIR					
	@	SUN PHARM INDS LTD	400MG	A 074980	001	Sep 30, 1998	Feb DISC
	@		800MG	A 074980	002	Sep 30, 1998	Feb DISC

ACYCLOVIR SODIUM

INJECTABLE; INJECTION		ACYCLOVIR IN SODIUM CHLORIDE 0.9% PRESERVATIVE FREE					
	@	HIKMA MAPLE	EQ 500MG BASE/VIAL	A 074885	001	Dec 19, 1997	Feb DISC
	@		EQ 1GM BASE/VIAL	A 074885	002	Dec 19, 1997	Feb DISC
ACYCLOVIR SODIUM							
>A>	@	AMPHASTAR PHARMS INC	EQ 500MG BASE/VIAL	A 074596	002	Apr 22, 1997	Jun CAHN
>A>	@		EQ 1GM BASE/VIAL	A 074596	001	Apr 22, 1997	Jun CAHN
	@	BEDFORD	EQ 500MG BASE/VIAL	A 074596	002	Apr 22, 1997	Feb DISC
	@		EQ 1GM BASE/VIAL	A 074596	001	Apr 22, 1997	Feb DISC
AP	+		EQ 1GM BASE/VIAL	A 074596	001	Apr 22, 1997	Feb CTEC
>D>	@	EUROHLTH INTL SARL	EQ 500MG BASE/VIAL	A 074596	002	Apr 22, 1997	Jun CAHN
	@		EQ 500MG BASE/VIAL	A 074596	002	Apr 22, 1997	Apr CAHN
>D>	@		EQ 1GM BASE/VIAL	A 074596	001	Apr 22, 1997	Jun CAHN

INJECTABLE; INJECTION  
ACYCLOVIR SODIUM

	@		EQ 1GM BASE/VIAL	A074596	001	Apr 22, 1997	Apr CAHN
AP		HIKMA PHARMS LLC	EQ 500MG BASE/VIAL	A205771	001	Feb 29, 2016	Feb NEWA
	+		EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Feb CRLD
AP			EQ 1GM BASE/VIAL	A205771	002	Feb 29, 2016	Feb NEWA

ADAPALENE

GEL; TOPICAL  
ADAPALENE

>A>	AB	TARO	0.3%	A208322	001	Jun 23, 2016	Jun NEWA
-----	----	------	------	---------	-----	--------------	----------

ADENOSINE

INJECTABLE; INJECTION  
ADENOSINE

AP		EUROHLTH INTL SARL	3MG/ML	A076404	001	Jun 16, 2004	Apr CAHN
		SOLUTION; IV (INFUSION)					
		ADENOSCAN					
	@	ASTELLAS	60MG/20ML (3MG/ML)	N020059	001	May 18, 1995	Apr DISC
	@		90MG/30ML (3MG/ML)	N020059	002	May 18, 1995	Apr DISC
		ADENOSINE					
AP	+	TEVA PHARMS USA	60MG/20ML (3MG/ML)	A077425	001	Aug 29, 2013	Apr CRLD
AP	+		90MG/30ML (3MG/ML)	A077425	002	Aug 29, 2013	Apr CRLD

ALBUTEROL SULFATE

SOLUTION; INHALATION  
ALBUTEROL SULFATE

	@	HI TECH PHARMA	EQ 0.083% BASE	A075063	001	Feb 09, 1999	Mar DISC
	@	LANDELA PHARM	EQ 0.083% BASE	A077569	001	Apr 04, 2006	Mar DISC
	@	MYLAN SPECLT	EQ 0.083% BASE	A072652	001	Feb 21, 1992	Mar DISC
AN	+	NEPHRON	EQ 0.083% BASE	A074880	001	Sep 17, 1997	Mar CRLD
	@	TEVA PHARMS	EQ 0.083% BASE	A075343	001	Nov 09, 1999	Mar DISC
	@	WATSON LABS INC	EQ 0.083% BASE	A076370	001	Nov 24, 2003	Mar DISC

## TABLET; ORAL

		ALBUTEROL SULFATE					
AB		SUN PHARM INDS	EQ 2MG BASE	A072637	002	Dec 05, 1989	Mar CAHN
AB			EQ 4MG BASE	A072637	001	Dec 05, 1989	Mar CAHN

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

## SOLUTION; INHALATION

>D>		DUONEB						
>D>	AN	+	MYLAN SPECLT	EQ 0.083% BASE; 0.017%	N020950	001	Mar 21, 2001	Jun DISC
>A>		@		EQ 0.083% BASE; 0.017%	N020950	001	Mar 21, 2001	Jun DISC

ALENDRONATE SODIUM

## TABLET; ORAL

		ALENDRONATE SODIUM					
>D>	AB	CADISTA PHARMS	EQ 5MG BASE	A090557	001	Feb 18, 2010	Jun CAHN
>D>	AB		EQ 10MG BASE	A090557	002	Feb 18, 2010	Jun CAHN
>D>	AB		EQ 35MG BASE	A090557	003	Feb 18, 2010	Jun CAHN
>D>	AB		EQ 70MG BASE	A090557	004	Feb 18, 2010	Jun CAHN
>A>	AB	JUBILANT CADISTA	EQ 5MG BASE	A090557	001	Feb 18, 2010	Jun CAHN
>A>	AB		EQ 10MG BASE	A090557	002	Feb 18, 2010	Jun CAHN
>A>	AB		EQ 35MG BASE	A090557	003	Feb 18, 2010	Jun CAHN
>A>	AB		EQ 70MG BASE	A090557	004	Feb 18, 2010	Jun CAHN

ALFUZOSIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL  
ALFUZOSIN HYDROCHLORIDE

AB		UNICHEM LABS LTD	10MG	A203192	001	Jan 28, 2016	Jan NEWA
----	--	------------------	------	---------	-----	--------------	----------

ALLOPURINOL

TABLET; ORAL  
ALLOPURINOL

AB		SUN PHARM INDS	300MG	A071450	001	Jan 09, 1987	Mar CAHN
		ZYLOPRIM					
AB		SEBELA IRELAND LTD	100MG	N016084	001		Jan CAHN
AB	+		300MG	N016084	002		Jan CAHN

ALMOTRIPTAN MALATE

TABLET; ORAL

ALMOTRIPTAN MALATE

AB	AJANTA PHARMA LTD	EQ 6.25MG BASE	A205523	001	Mar 03, 2016	Feb NEWA
AB		EQ 12.5MG BASE	A205523	002	Mar 03, 2016	Feb NEWA

ALOSETRON HYDROCHLORIDE

TABLET; ORAL

LOTRONEX

AB	SEBELA IRELAND LTD	EQ 0.5MG BASE	N021107	002	Dec 23, 2003	Feb CAHN
AB	+	EQ 1MG BASE	N021107	001	Feb 09, 2000	Feb CAHN

ALPRAZOLAM

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

	@ ACTAVIS LABS FL INC	0.5MG	A077198	001	May 13, 2010	Jan DISC
	@	1MG	A077198	002	May 13, 2010	Jan DISC
	@	2MG	A077198	003	May 13, 2010	Jan DISC
	@	3MG	A077198	004	May 13, 2010	Jan DISC
	@ COREPHARMA	0.5MG	A077996	001	Jan 31, 2007	Mar DISC
	@	1MG	A077996	002	Jan 31, 2007	Mar DISC
	@	2MG	A077996	003	Jan 31, 2007	Mar DISC
	@	3MG	A077996	004	Jan 31, 2007	Mar DISC
	@ IMPAX LABS	0.5MG	A077968	004	May 24, 2007	Jan DISC
	@	1MG	A077968	003	May 24, 2007	Jan DISC
	@	2MG	A077968	002	May 24, 2007	Jan DISC
	@	3MG	A077968	001	May 24, 2007	Jan DISC

ALPROSTADIL

INJECTABLE; INJECTION

EDEX

	@ AUXILIUM PHARMS INC	0.005MG/VIAL	N020649	001	Jun 12, 1997	Mar CAHN
AP		0.01MG/VIAL	N020649	002	Jun 12, 1997	Mar CAHN
	+	0.01MG/VIAL	N020649	005	Jul 30, 1998	Mar CAHN
AP		0.02MG/VIAL	N020649	003	Jun 12, 1997	Mar CAHN
	+	0.02MG/VIAL	N020649	006	Jul 30, 1998	Mar CAHN
AP		0.04MG/VIAL	N020649	004	Jun 12, 1997	Mar CAHN
	+	0.04MG/VIAL	N020649	007	Jul 30, 1998	Mar CAHN

SUPPOSITORY; URETHRAL

MUSE

	+ MEDA PHARMS	0.125MG	N020700	001	Nov 19, 1996	Jan CRLD
	+	0.25MG	N020700	002	Nov 19, 1996	Jan CRLD
	+	0.5MG	N020700	003	Nov 19, 1996	Jan CRLD

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL

AMANTADINE HYDROCHLORIDE

AB	BIONPHARMA INC	100MG	A078720	001	May 29, 2008	Jan CAHN
AB	ZYDUS PHARMS USA INC	100MG	A208278	001	May 31, 2016	May NEWA

AMIKACIN SULFATE

INJECTABLE; INJECTION

AMIKACIN SULFATE

AP	+	EMCURE PHARMS LTD	EQ 250MG BASE/ML	A204040	001	Dec 12, 2013	May CRLD
AP		EUROHLTH INTL SARL	EQ 250MG BASE/ML	A063315	001	Apr 11, 1994	May CRLD
AP		SAGENT PHARMS	EQ 250MG BASE/ML	A203323	001	May 12, 2016	Apr NEWA

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

INJECTABLE; INJECTION

CLINIMIX E 2.75/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 10GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	002	Mar 26, 1997	Mar CMS1
---	-----------------	--	---------	-----	--------------	----------

CLINIMIX E 2.75/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 25GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	005	Mar 26, 1997	Mar CMS1
---	-----------------	--	---------	-----	--------------	----------

CLINIMIX E 2.75/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER

+	BAXTER HLTHCARE	2.75%; 33MG/100ML; 5GM/100ML; 51MG/100ML; 261MG/100ML; 217MG/100ML; 112MG/100ML	N020678	001	Mar 26, 1997	Mar CMS1
---	-----------------	---	---------	-----	--------------	----------

## INJECTABLE; INJECTION

	CLINIMIX E 4.25/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	4.25%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	009	Mar 26, 1997	Mar	CMS1
	CLINIMIX E 4.25/20 SULFITE FREE W/ ELECT IN DEXTROSE 20% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	4.25%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	011	Mar 26, 1997	Mar	CMS1
	CLINIMIX E 4.25/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	4.25%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	012	Mar 26, 1997	Mar	CMS1
	CLINIMIX E 4.25/5 SULFITE FREE W/ ELECT IN DEXTROSE 5% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	4.25%;33MG/100ML;5GM/100ML;51MG/100ML;261MG/100ML;297MG/100ML;77MG/100ML	N020678	008	Mar 26, 1997	Mar	CMS1
	CLINIMIX E 5/10 SULFITE FREE W/ ELECT IN DEXTROSE 10% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	5%;33MG/100ML;10GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	016	Mar 26, 1997	Mar	CMS1
	CLINIMIX E 5/15 SULFITE FREE W/ ELECT IN DEXTROSE 15% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	5%;33MG/100ML;15GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	017	Mar 26, 1997	Mar	CMS1
	CLINIMIX E 5/20 SULFITE FREE W/ ELECT IN 20% DEXTROSE W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	5%;33MG/100ML;20GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	018	Mar 26, 1997	Mar	CMS1
	CLINIMIX E 5/25 SULFITE FREE W/ ELECT IN DEXTROSE 25% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	5%;33MG/100ML;25GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	019	Mar 26, 1997	Mar	CMS1
	CLINIMIX E 5/35 SULFITE FREE W/ ELECT IN DEXTROSE 35% W/ CALCIUM IN PLASTIC CONTAINER						
+	BAXTER HLTHCARE	5%;33MG/100ML;35GM/100ML;51MG/100ML;261MG/100ML;340MG/100ML;59MG/100ML	N020678	021	Mar 26, 1997	Mar	CMS1

AMINOLEVULINIC ACID HYDROCHLORIDE

GEL; TOPICAL

AMELUZ

+	BIOFRONTERA	10%	N208081	001	May 10, 2016	May	NEWA
---	-------------	-----	---------	-----	--------------	-----	------

AMINOPHYLLINE

TABLET; ORAL

AMINOPHYLLINE

	@ IDT AUSTRALIA LTD	100MG	A085261	003		May	CAHN
	@	100MG	A085262	002		May	CAHN
	@	200MG	A085261	002		May	CAHN

AMIODARONE HYDROCHLORIDE

TABLET; ORAL

AMIODARONE HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	200MG	A204742	001	Jun 03, 2016	May	NEWA
----	----------------------	-------	---------	-----	--------------	-----	------

AMITRIPTYLINE HYDROCHLORIDE

TABLET; ORAL

AMITRIPTYLINE HYDROCHLORIDE

	@ SUN PHARM INDS INC	10MG	A040816	002	Jun 27, 2008	Mar	DISC
	@	10MG	A089399	002	Jul 14, 1987	Mar	DISC
AB	@	10MG	A089399	002	Jul 14, 1987	Mar	CAHN
	@	25MG	A040816	001	Jun 27, 2008	Mar	DISC
	@	25MG	A089399	001	Jul 14, 1987	Mar	DISC
AB	@	25MG	A089399	001	Jul 14, 1987	Mar	CAHN
	@	50MG	A040816	003	Jun 27, 2008	Mar	DISC
	@	50MG	A089399	003	Jul 14, 1987	Mar	DISC
AB	@	50MG	A089399	003	Jul 14, 1987	Mar	CAHN
	@	75MG	A040816	004	Jun 27, 2008	Mar	DISC
	@	75MG	A089399	004	Jul 14, 1987	Mar	DISC
AB	@	75MG	A089399	004	Jul 14, 1987	Mar	CAHN
	@	100MG	A040816	005	Jun 27, 2008	Mar	DISC
	@	100MG	A089399	005	Jul 14, 1987	Mar	DISC
AB	@	100MG	A089399	005	Jul 14, 1987	Mar	CAHN
	@	150MG	A040816	006	Jun 27, 2008	Mar	DISC
	@	150MG	A089399	006	Jul 14, 1987	Mar	DISC

## TABLET;ORAL

## AMITRIPTYLINE HYDROCHLORIDE

AB		150MG		A089399	006	Jul 14, 1987	Mar CAHN
----	--	-------	--	---------	-----	--------------	----------

AMITRIPTYLINE HYDROCHLORIDE; CHLORDIAZEPOXIDE

## TABLET;ORAL

## CHLORDIAZEPOXIDE AND AMITRIPTYLINE HYDROCHLORIDE

	@ SUN PHARM INDS	EQ 12.5MG BASE;5MG		A070765	001	Dec 10, 1986	Mar CAHN
	@	EQ 25MG BASE;10MG		A070766	001	Dec 10, 1986	Mar CAHN

AMITRIPTYLINE HYDROCHLORIDE; PERPHENAZINE

## TABLET;ORAL

## PERPHENAZINE AND AMITRIPTYLINE HYDROCHLORIDE

	@ SUN PHARM INDS	10MG;2MG		A071077	001	Nov 12, 1986	Mar CAHN
	@	10MG;4MG		A071078	001	Nov 12, 1986	Mar CAHN
	@	25MG;2MG		A070297	001	Nov 12, 1986	Mar CAHN
	@	25MG;4MG		A071079	001	Nov 12, 1986	Mar CAHN

AMLODIPINE BESYLATE

## TABLET;ORAL

## AMLODIPINE BESYLATE

AB	CHINA RESOURCES	EQ 2.5MG BASE		A090752	003	May 16, 2016	May NEWA
AB	INVAGEN PHARMS	EQ 2.5MG BASE		A206367	001	Dec 10, 2015	Feb CAHN
AB		EQ 5MG BASE		A206367	002	Dec 10, 2015	Feb CAHN
AB		EQ 10MG BASE		A206367	003	Dec 10, 2015	Feb CAHN
>A>	AB	POLYGEN PHARMS	EQ 2.5MG BASE	A207821	001	Jul 11, 2016	Jun NEWA
>A>	AB		EQ 5MG BASE	A207821	002	Jul 11, 2016	Jun NEWA
>A>	AB		EQ 10MG BASE	A207821	003	Jul 11, 2016	Jun NEWA
	@ SUN PHARM INDS	EQ 2.5MG BASE		A078081	001	Jan 31, 2008	Mar CAHN
	@	EQ 5MG BASE		A078081	002	Jan 31, 2008	Mar CAHN
	@	EQ 10MG BASE		A078081	003	Jan 31, 2008	Mar CAHN

AMLODIPINE BESYLATE; VALSARTAN

## TABLET;ORAL

## AMLODIPINE BESYLATE AND VALSARTAN

AB	AUROBINDO PHARMA LTD	EQ 5MG BASE;160MG		A206512	001	Apr 22, 2016	Apr NEWA
AB		EQ 5MG BASE;320MG		A206512	002	Apr 22, 2016	Apr NEWA
AB		EQ 10MG BASE;160MG		A206512	003	Apr 22, 2016	Apr NEWA
AB		EQ 10MG BASE;320MG		A206512	004	Apr 22, 2016	Apr NEWA

AMMONIA N-13

## INJECTABLE;INTRAVENOUS

## AMMONIA N 13

AP	MA GENERAL HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)		A207025	001	Feb 03, 2016	Jan NEWA
AP	MIDWEST MEDCL	30mCi-300mCi/8ML (3.75-37.5mCi/ML)		A204457	001	Nov 18, 2015	Jan NEWA

AMMONIUM LACTATE

## CREAM;TOPICAL

## AMMONIUM LACTATE

AB	+ PERRIGO NEW YORK	EQ 12% BASE		A075774	001	May 01, 2002	Apr CRLD
	LAC-HYDRIN						
	@ RANBAXY	EQ 12% BASE		N020508	001	Aug 29, 1996	Apr DISC

## LOTION;TOPICAL

## AMMONIUM LACTATE

AB	+ PERRIGO NEW YORK	EQ 12% BASE		A075570	001	Jun 23, 2004	Apr CRLD
	LAC-HYDRIN						
	@ RANBAXY	EQ 12% BASE		N019155	001	Apr 24, 1985	Apr DISC

AMOXICILLIN

## CAPSULE;ORAL

## AMOXICILLIN

	@ SUN PHARM INDS LTD	250MG		A065016	001	Apr 08, 1999	Feb DISC
	@	500MG		A065016	002	Apr 08, 1999	Feb DISC

## TABLET;ORAL

## AMOXICILLIN

	@ SUN PHARM INDS LTD	500MG		A065059	001	Nov 24, 2000	Feb DISC
	@	875MG		A065059	002	Nov 24, 2000	Feb DISC

## TABLET, CHEWABLE;ORAL

## AMOXICILLIN

	@ SUN PHARM INDS LTD	125MG		A065021	001	Dec 23, 1999	Feb DISC
	@	250MG		A065021	002	Dec 23, 1999	Feb DISC



TABLET, EXTENDED RELEASE;ORAL  
MOXATAG

+ VERNALIS R AND D LTD 775MG N050813 001 Jan 23, 2008 Jan CAHN

AMOXICILLIN; CLAVULANATE POTASSIUM

## FOR SUSPENSION;ORAL

## AMOXICILLIN AND CLAVULANATE POTASSIUM

AB	AUROBINDO PHARMA LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A201090	001	Dec 20, 2011	Feb	CDFR
AB		400MG/5ML;EQ 57MG BASE/5ML	A201090	002	Dec 20, 2011	Feb	CDFR
AB		600MG/5ML;EQ 42.9MG BASE/5ML	A201091	001	Dec 20, 2011	Feb	CDFR
	@ SUN PHARM INDS LTD	200MG/5ML;EQ 28.5MG BASE/5ML	A065132	001	Mar 19, 2003	Feb	DISC
	@	400MG/5ML;EQ 57MG BASE/5ML	A065132	002	Mar 19, 2003	Feb	DISC
	@	600MG/5ML;EQ 42.9MG BASE/5ML	A065207	002	Jan 30, 2007	Feb	DISC

## TABLET;ORAL

## AMOXICILLIN AND CLAVULANATE POTASSIUM

@ SUN PHARM INDS LTD 875MG;EQ 125MG BASE A065102 001 Sep 17, 2002 Feb DISC

## TABLET, CHEWABLE;ORAL

## AMOXICILLIN AND CLAVULANATE POTASSIUM

@	SUN PHARM INDS LTD	200MG;EQ 28.5MG BASE	A065161	001	Dec 03, 2003	Feb	DISC
@		400MG;EQ 57MG BASE	A065161	002	Dec 03, 2003	Feb	DISC

AMPHETAMINE

## TABLET, ORALLY DISINTEGRATING, EXTENDED RELEASE;ORAL

## ADZENYS XR-ODT

	NEOS THERAPS	EQ 3.1MG BASE	N204326	001	Jan 27, 2016	Jan	NEWA
		EQ 6.3MG BASE	N204326	002	Jan 27, 2016	Jan	NEWA
		EQ 9.4MG BASE	N204326	003	Jan 27, 2016	Jan	NEWA
		EQ 12.5MG BASE	N204326	004	Jan 27, 2016	Jan	NEWA
		EQ 15.7MG BASE	N204326	005	Jan 27, 2016	Jan	NEWA
+		EQ 18.8MG BASE	N204326	006	Jan 27, 2016	May	CRLD
		EQ 18.8MG BASE	N204326	006	Jan 27, 2016	Jan	NEWA

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

## CAPSULE, EXTENDED RELEASE;ORAL

## DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	IMPAX LABS	1.25MG;1.25MG;1.25MG;1.25MG	A076852	001	Feb 16, 2016	Feb	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A076852	002	Feb 16, 2016	Feb	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A076852	003	Feb 16, 2016	Feb	NEWA
AB		5MG;5MG;5MG;5MG	A076852	004	Feb 16, 2016	Feb	NEWA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A076852	005	Feb 16, 2016	Feb	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A076852	006	Feb 16, 2016	Feb	NEWA
AB	TEVA	1.25MG;1.25MG;1.25MG;1.25MG	A077488	001	Apr 29, 2013	Feb	CTNA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A077488	002	Apr 29, 2013	Feb	CTNA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A077488	003	Apr 29, 2013	Feb	CTNA
AB		5MG;5MG;5MG;5MG	A077488	004	Apr 29, 2013	Feb	CTNA
AB		6.25MG;6.25MG;6.25MG;6.25MG	A077488	005	Apr 29, 2013	Feb	CTNA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A077488	006	Apr 29, 2013	Feb	CTNA

## TABLET;ORAL

## DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG;1.25MG;1.25MG;1.25MG	A206340	001	Feb 05, 2016	Jan	NEWA
AB		1.875MG;1.875MG;1.875MG;1.875MG	A206340	002	Feb 05, 2016	Jan	NEWA
AB		2.5MG;2.5MG;2.5MG;2.5MG	A206340	003	Feb 05, 2016	Jan	NEWA
AB		3.125MG;3.125MG;3.125MG;3.125MG	A206340	004	Feb 05, 2016	Jan	NEWA
AB		3.75MG;3.75MG;3.75MG;3.75MG	A206340	005	Feb 05, 2016	Jan	NEWA
AB		5MG;5MG;5MG;5MG	A206340	006	Feb 05, 2016	Jan	NEWA
AB		7.5MG;7.5MG;7.5MG;7.5MG	A206340	007	Feb 05, 2016	Jan	NEWA

AMPHOTERICIN B

## INJECTABLE, LIPID COMPLEX;INJECTION

## AMPHOTEC

@	ALKOPHARMA USA	50MG/VIAL	N050729	001	Nov 22, 1996	Apr	DISC
@		100MG/VIAL	N050729	002	Nov 22, 1996	Apr	DISC

ARIPIPRAZOLE

## &gt;D&gt; INJECTABLE; INTRAMUSCULAR

## &gt;D&gt; ABILIFY

>D>	+	OTSUKA	9.75MG/1.3ML (7.5MG/ML)	N021866	001	Sep 20, 2006	Jun	DISC
>A>		@	9.75MG/1.3ML (7.5MG/ML)	N021866	001	Sep 20, 2006	Jun	DISC

## SOLUTION;ORAL

## ARIPIPRAZOLE

AA	+	AMNEAL PHARMS	1MG/ML	A203906	001	Aug 14, 2015	Feb	CRLD
----	---	---------------	--------	---------	-----	--------------	-----	------

## TABLET;ORAL

## ARIPIPIRAZOLE

>A>	AB	AMNEAL PHARMS	2MG	A204838	001	Jun 17, 2016	Jun NEWA
>A>	AB		5MG	A204838	002	Jun 17, 2016	Jun NEWA
>A>	AB		10MG	A204838	003	Jun 17, 2016	Jun NEWA
>A>	AB		15MG	A204838	004	Jun 17, 2016	Jun NEWA
>A>	AB		20MG	A204838	005	Jun 17, 2016	Jun NEWA
>A>	AB		30MG	A204838	006	Jun 17, 2016	Jun NEWA

## TABLET, ORALLY DISINTEGRATING;ORAL

## ABILIFY

@ OTSUKA

10MG

N021729 002 Jun 07, 2006 May DISC

@

15MG

N021729 003 Jun 07, 2006 May DISC

## ARIPIPIRAZOLE

+ ALEMBIC PHARMS LTD

10MG

A202102 001 Apr 28, 2015 May CRLD

15MG

A202102 002 Apr 28, 2015 May CTEC

ARMODAFINIL

## TABLET;ORAL

## ARMODAFINIL

AB MYLAN PHARMS INC

50MG

A200043 001 Jun 01, 2012 Apr CMFD

AB

150MG

A200043 002 Jun 01, 2012 Apr CMFD

AB

250MG

A200043 003 Jun 01, 2012 Apr CMFD

## NUVIGIL

AB CEPHALON

50MG

N021875 001 Jun 15, 2007 Apr CTEC

AB

150MG

N021875 003 Jun 15, 2007 Apr CTEC

AB

+

250MG

N021875 004 Jun 15, 2007 Apr CTEC

ASCORBIC ACID; BIOTIN; CYANOCOBALAMIN; DEXPANTHENOL; ERGOCALCIFEROL; FOLIC ACID; NIACINAMIDE; PYRIDOXINE; RIBOFLAVIN 5'-PHOSPHATE SODIUM; THIAMINE; VITAMIN A; VITAMIN E

## INJECTABLE;INJECTION

## M.V.I.-12 LYOPHILIZED

@ TELIGENT PHARMA INC

100MG/VIAL;0.06MG/VIAL;0.005MG/VIAL;15MG/VIAL;5MCG/VIAL;0.4MG/VIAL;40MG/VIAL;4MG/VIAL;3.6MG/VIAL;3MG/VIAL;1MG/VIAL;10MG/VIAL

N018933 002 Aug 08, 1985 Jan CAHN

ASENAPINE MALEATE

## TABLET;SUBLINGUAL

## SAPHRIS

FOREST LABS LLC

EQ 2.5 BASE

N022117 003 Mar 12, 2015 Mar NEWA

ASPIRIN; BUTALBITAL; CAFFEINE

## CAPSULE;ORAL

## BUTALBITAL, ASPIRIN AND CAFFEINE

@ NOSTRUM LABS INC

325MG;50MG;40MG

A078149 001 Jun 13, 2007 Jan CAHN

## FIORINAL

AA + ALLERGAN SALES LLC

325MG;50MG;40MG

N017534 005 Apr 16, 1986 Apr CAHN

## TABLET;ORAL

## FIORINAL

@ ALLERGAN SALES LLC

325MG;50MG;40MG

N017534 003 Apr 16, 1986 Apr CAHN

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

## CAPSULE;ORAL

## FIORINAL W/CODEINE

AB + ALLERGAN SALES LLC

325MG;50MG;40MG;30MG

N019429 003 Oct 26, 1990 Apr CAHN

ASPIRIN; CARISOPRODOL

## TABLET;ORAL

## CARISOPRODOL AND ASPIRIN

&gt;D&gt; AB HERITAGE PHARMS INC

325MG;200MG

A089594 001 Mar 31, 1989 Jun CRLD

&gt;A&gt; AB

+

325MG;200MG

A089594 001 Mar 31, 1989 Jun CRLD

AB

INGENUS PHARMS NJ

325MG;200MG

A040832 001 Jan 07, 2010 Jan CAHN

&gt;D&gt;

## SOMA COMPOUND

&gt;D&gt; AB + MEDA PHARMS

325MG;200MG

N012365 005 Jul 11, 1983 Jun DISC

&gt;A&gt;

@

325MG;200MG

N012365 005 Jul 11, 1983 Jun DISC

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

AB		INGENUS PHARMS NJ	325MG;200MG;16MG	A040860	001	Jan 07, 2010	Mar	CMFD
	@		325MG;200MG;16MG	A040860	001	Jan 07, 2010	Jan	CAHN
AB	+	SANDOZ	325MG;200MG;16MG	A040118	001	Apr 16, 1996	Mar	CTEC
	+		325MG;200MG;16MG	A040118	001	Apr 16, 1996	Jan	CRLD
		SOMA COMPOUND W/ CODEINE						
	@	MEDA PHARMS	325MG;200MG;16MG	N012366	002	Jul 11, 1983	Jan	DISC

ASPIRIN; DIPYRIDAMOLE

CAPSULE, EXTENDED RELEASE; ORAL

ASPIRIN AND DIPYRIDAMOLE

	@	AMNEAL PHARMS	25MG;200MG	A206392	001	Mar 08, 2016	Apr	DISC
AB			25MG;200MG	A206392	001	Mar 08, 2016	Feb	NEWA

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

	@	SUN PHARM INDS	325MG;4.5MG;0.38MG	A040260	001	Jul 17, 1998	Mar	CAHN
	@		325MG;4.5MG;0.38MG	A087794	001	May 26, 1982	Mar	CAHN

ATENOLOL

TABLET; ORAL

ATENOLOL

AB		ALVOGEN MALTA	25MG	A073646	001	Jul 31, 1992	Jan	CAHN
AB			50MG	A072303	001	Jul 15, 1988	Jan	CAHN
AB			100MG	A072304	001	Jul 15, 1988	Jan	CAHN
		TENORMIN						
AB		ALVOGEN MALTA	25MG	N018240	004	Apr 09, 1990	Jan	CAHN
AB			50MG	N018240	001		Jan	CAHN
AB	+		100MG	N018240	002		Jan	CAHN

ATENOLOL; CHLORTHALIDONE

TABLET; ORAL

ATENOLOL AND CHLORTHALIDONE

AB		ALVOGEN MALTA	50MG;25MG	A072301	001	May 31, 1990	Jan	CAHN
AB			100MG;25MG	A072302	001	May 31, 1990	Jan	CAHN
AB		SUN PHARM INDS	100MG;25MG	A073582	001	Apr 29, 1993	Mar	CAHN
		TENORETIC 100						
AB	+	ALVOGEN MALTA	100MG;25MG	N018760	001	Jun 08, 1984	Jan	CAHN
		TENORETIC 50						
AB		ALVOGEN MALTA	50MG;25MG	N018760	002	Jun 08, 1984	Jan	CAHN

ATORVASTATIN CALCIUM

TABLET; ORAL

ATORVASTATIN CALCIUM

AB		SCIEGEN PHARMS INC	EQ 10MG BASE	A205519	001	May 19, 2016	May	NEWA
AB			EQ 20MG BASE	A205519	002	May 19, 2016	May	NEWA
AB			EQ 40MG BASE	A205519	003	May 19, 2016	May	NEWA
AB			EQ 80MG BASE	A205519	004	May 19, 2016	May	NEWA

ATROPINE SULFATE; DIPHENOXYLATE HYDROCHLORIDE

TABLET; ORAL

DIPHENOXYLATE HYDROCHLORIDE AND ATROPINE SULFATE

	@	SUN PHARM INDS	0.025MG;2.5MG	A085506	001		Mar	CAHN
--	---	----------------	---------------	---------	-----	--	-----	------

AURANOFIN

CAPSULE; ORAL

RIDAURA

	+	SEBELA IRELAND LTD	3MG	N018689	001	May 24, 1985	Jan	CAHN
--	---	--------------------	-----	---------	-----	--------------	-----	------

AXITINIB

TABLET; ORAL

INLYTA

		PF PRISM CV	1MG	N202324	001	Jan 27, 2012	Apr	CAHN
	+		5MG	N202324	002	Jan 27, 2012	Apr	CAHN

<u>AZACITIDINE</u>									
INJECTABLE; INTRAVENOUS, SUBCUTANEOUS									
AZACITIDINE									
AP	MYLAN INSTITUTIONAL	100MG/VIAL		A204949	001	Apr 28, 2016	Apr	NEWA	
POWDER; IV (INFUSION), SUBCUTANEOUS									
AZACITIDINE									
	ACTAVIS LLC	100MG/VIAL		N208216	001	Apr 29, 2016	Apr	NEWA	
<u>AZATHIOPRINE</u>									
TABLET; ORAL									
IMURAN									
	@ SEBELA IRELAND LTD	25MG		N016324	002		Jan	CAHN	
AB	+	50MG		N016324	001		Jan	CAHN	
<u>AZATHIOPRINE SODIUM</u>									
INJECTABLE; INJECTION									
IMURAN									
	@ SEBELA IRELAND LTD	EQ 100MG BASE/VIAL		N017391	001		Jan	CAHN	
<u>AZILSARTAN KAMEDOXOMIL</u>									
TABLET; ORAL									
EDARBI									
	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL		N200796	001	Feb 25, 2011	Jan	CAHN	
	+	EQ 80MG MEDOXOMIL		N200796	002	Feb 25, 2011	Jan	CAHN	
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE</u>									
TABLET; ORAL									
EDARBYCLOR									
	ARBOR PHARMS LLC	EQ 40MG MEDOXOMIL; 12.5MG		N202331	001	Dec 20, 2011	Jan	CAHN	
	+	EQ 40MG MEDOXOMIL; 25MG		N202331	002	Dec 20, 2011	Jan	CAHN	
<u>AZITHROMYCIN</u>									
FOR SUSPENSION; ORAL									
AZITHROMYCIN									
BX	LUPIN LTD	EQ 100MG BASE/5ML		A065488	001	May 15, 2015	Apr	CTEC	
BX		EQ 200MG BASE/5ML		A065488	002	May 15, 2015	Apr	CTEC	
<u>AZTREONAM</u>									
INJECTABLE; INJECTION									
AZTREONAM									
	@ EUROHLTH INTL SARL	1GM/VIAL		A065286	001	Mar 23, 2011	Mar	DISC	
	@	2GM/VIAL		A065286	002	Mar 23, 2011	Mar	DISC	
<u>BACLOFEN</u>									
INJECTABLE; INTRATHECAL									
BACLOFEN									
AP	SINETICA SA	0.05MG/ML		A091193	001	May 03, 2016	Apr	NEWA	
AP		0.5MG/ML		A091193	002	May 03, 2016	Apr	NEWA	
AP		2MG/ML		A091193	003	May 03, 2016	Apr	NEWA	
LIORESAL									
AP	+	SAOL THERAPS RES LTD	0.05MG/ML	N020075	003	Nov 07, 1996	May	CAHN	
AP	+		0.5MG/ML	N020075	001	Jun 17, 1992	May	CAHN	
AP	+		2MG/ML	N020075	002	Jun 17, 1992	May	CAHN	
TABLET; ORAL									
BACLOFEN									
AB	NORTHSTAR HLTHCARE	10MG		A078401	002	Sep 18, 2009	Jan	NEWA	
<u>BARIUM SULFATE</u>									
FOR SUSPENSION; ORAL									
E-Z-HD									
	+	BRACCO	334GM/BOTTLE	N208036	001	Jan 11, 2016	Jan	NEWA	
SUSPENSION; ORAL									
READI-CAT 2									
	+	BRACCO	2% (9GM/450ML)	N208143	001	Jan 15, 2016	Jan	NEWA	
READI-CAT 2 SMOOTHIES									
		BRACCO	2% (9GM/450ML)	N208143	002	Jan 15, 2016	Jan	NEWA	

BENAZEPRIL HYDROCHLORIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE

@	ACTAVIS LABS FL INC	5MG	A076267	001	Feb 11, 2004	Jan	DISC
@		10MG	A076267	002	Feb 11, 2004	Jan	DISC
@		20MG	A076267	003	Feb 11, 2004	Jan	DISC
@		40MG	A076267	004	Feb 11, 2004	Jan	DISC

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@	ACTAVIS LABS FL INC	5MG;6.25MG	A076342	001	Feb 11, 2004	Jan	DISC
@		10MG;12.5MG	A076342	002	Feb 11, 2004	Jan	DISC
@		20MG;12.5MG	A076342	003	Feb 11, 2004	Jan	DISC
@		20MG;25MG	A076342	004	Feb 11, 2004	Jan	DISC
@	IVAX SUB TEVA PHARMS	5MG;6.25MG	A076348	001	Feb 11, 2004	Mar	DISC
@		10MG;12.5MG	A076348	002	Feb 11, 2004	Mar	DISC
@		20MG;12.5MG	A076348	003	Feb 11, 2004	Mar	DISC
@		20MG;25MG	A076348	004	Feb 11, 2004	Mar	DISC
@	SUN PHARM INDS LTD	5MG;6.25MG	A077483	001	Sep 08, 2005	Mar	DISC
@		10MG;12.5MG	A077483	002	Sep 08, 2005	Mar	DISC
@		20MG;12.5MG	A077483	003	Sep 08, 2005	Mar	DISC
@		20MG;25MG	A077483	004	Sep 08, 2005	Mar	DISC

BENDAMUSTINE HYDROCHLORIDE

POWDER; IV (INFUSION)

BENDAMUSTINE HYDROCHLORIDE

AP	ACCORD HLTHCARE	25MG/VIAL	A205574	001	May 19, 2016	May	NEWA
AP		100MG/VIAL	A205574	002	May 19, 2016	May	NEWA
AP	GLENMARK PHARMS LTD	25MG/VIAL	A204771	001	Mar 24, 2016	Mar	NEWA
AP		100MG/VIAL	A204771	002	Mar 24, 2016	Mar	NEWA
AP	HOSPIRA INC	25MG/VIAL	A204086	001	May 20, 2016	May	NEWA
AP		100MG/VIAL	A204086	002	May 20, 2016	May	NEWA
AP	INNOPHARMA LICENSING	25MG/VIAL	A205476	001	Mar 24, 2016	Mar	NEWA
AP		100MG/VIAL	A205476	002	Mar 24, 2016	Mar	NEWA
	TREANDA						
AP	+ CEPHALON	25MG/VIAL	N022249	002	May 01, 2009	Mar	CFTG
AP	+	100MG/VIAL	N022249	001	Mar 20, 2008	Mar	CFTG

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA	BIONPHARMA INC	100MG	A081297	001	Jan 29, 1993	Jan	CAHN
AA		200MG	A081297	002	Oct 30, 2007	Jan	CAHN

BENZOYL PEROXIDE; ERYTHROMYCIN

GEL; TOPICAL

BENZAMYCIN PAK

+	CUTANEA	5%;3%	N050769	001	Nov 27, 2000	Feb	CAHN
---	---------	-------	---------	-----	--------------	-----	------

BENZPHETAMINE HYDROCHLORIDE

TABLET; ORAL

BENZPHETAMINE HYDROCHLORIDE

@	IMPAX LABS	50MG	A040845	001	Nov 18, 2008	Mar	DISC
---	------------	------	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE

SPRAY; TOPICAL

SERNIVO

+	PROMIUS PHARMA LLC	EQ 0.05% BASE/SPRAY	N208079	001	Feb 05, 2016	Feb	NEWA
---	--------------------	---------------------	---------	-----	--------------	-----	------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

CREAM; TOPICAL

CLOTRIMAZOLE AND BETAMETHASONE DIPROPIONATE

AB	GLENMARK PHARMS	EQ 0.05% BASE;1%	A202894	001	Oct 30, 2015	Mar	CAHN
----	-----------------	------------------	---------	-----	--------------	-----	------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

BETAXOLOL HYDROCHLORIDE

AT	TELIGENT PHARMA INC	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Jan	CAHN
----	---------------------	--------------	---------	-----	--------------	-----	------

BETHANECHOL CHLORIDE

TABLET; ORAL

BETHANECHOL CHLORIDE

@ IMPAX LABS

5MG

A040739 001 Nov 01, 2006 Mar DISC

@

10MG

A040741 001 Nov 01, 2006 Mar DISC

@

25MG

A040740 001 Nov 01, 2006 Mar DISC

@

50MG

A040721 004 Nov 01, 2006 Mar DISC

BIMATOPROST

SOLUTION/DROPS; TOPICAL

BIMATOPROST

AT

SANDOZ INC

0.03%

A202719 001 Apr 19, 2016 Apr NEWA

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE; ORAL

HELIDAC

@ SEBELA IRELAND LTD

262.4MG, N/A, N/A, N/A, 250MG, N/A, N/A, N/A, 500MG

N050719 001 Aug 15, 1996 Jan CAHN

BISOPROLOL FUMARATE

TABLET; ORAL

BISOPROLOL FUMARATE

@ SUN PHARM INDS

5MG

A075474 001 Oct 25, 2002 Mar CAHN

@

10MG

A075474 002 Oct 25, 2002 Mar CAHN

&gt;D&gt;

BOCEPREVIR

&gt;D&gt;

CAPSULE; ORAL

&gt;D&gt;

VICTRELIS

&gt;D&gt;

+ MERCK SHARP DOHME

200MG

N202258 001 May 13, 2011 Jun DISC

&gt;A&gt;

@

200MG

N202258 001 May 13, 2011 Jun DISC

BRIVARACETAM

SOLUTION; INTRAVENOUS

BRIVIACT

+ UCB INC

50MG/5ML (10MG/ML)

N205837 001 Feb 18, 2016 Feb NEWA

+ UCB INC

50MG/5ML (10MG/ML)

N205837 001 May 12, 2016 May CMS1

SOLUTION; ORAL

BRIVIACT

+ UCB INC

10MG/ML

N205838 001 May 12, 2016 May CMS1

+

10MG/ML

N205838 001 Feb 18, 2016 Feb NEWA

TABLET; ORAL

BRIVIACT

UCB INC

10MG

N205836 001 May 12, 2016 May CMS1

10MG

N205836 001 Feb 18, 2016 Feb NEWA

25MG

N205836 002 May 12, 2016 May CMS1

25MG

N205836 002 Feb 18, 2016 Feb NEWA

50MG

N205836 003 May 12, 2016 May CMS1

50MG

N205836 003 Feb 18, 2016 Feb NEWA

75MG

N205836 004 May 12, 2016 May CMS1

75MG

N205836 004 Feb 18, 2016 Feb NEWA

+

100MG

N205836 005 May 12, 2016 May CMS1

+

100MG

N205836 005 Feb 18, 2016 Feb NEWA

BROMFENAC SODIUM

SOLUTION/DROPS; OPHTHALMIC

BROMSITE

+ INSITE VISION INC

EQ 0.075% ACID

N206911 001 Apr 08, 2016 Apr NEWA

BROMOCRIPTINE MESYLATE

CAPSULE; ORAL

BROMOCRIPTINE MESYLATE

AB

+ MYLAN

EQ 5MG BASE

A077226 001 Apr 04, 2005 Jan CRLD

PARLODEL

@ US PHARMS HOLDINGS I

EQ 5MG BASE

N017962 002 Mar 01, 1982 Jan DISC

TABLET; ORAL

BROMOCRIPTINE MESYLATE

AB

+ PADDOCK LLC

EQ 2.5MG BASE

A077646 001 Oct 01, 2008 Jan CRLD

AB

SANDOZ INC

EQ 2.5MG BASE

A074631 001 Jan 13, 1998 Feb CAHN

PARLODEL

AB

US PHARMS HOLDINGS I

EQ 2.5MG BASE

N017962 001 Apr CMFD

@

EQ 2.5MG BASE

N017962 001 Jan DISC

BUDESONIDECAPSULE; ORAL  
BUDESONIDE

AB		ACTAVIS ELIZABETH	3MG	A206623	001	Apr 08, 2016	Mar	NEWA
		ENTOCORT EC						
AB	+	ELAN PHARMA INTL LTD	3MG	N021324	001	Oct 02, 2001	Jan	CAHN
AB	+	PERRIGO PHARMA INTL	3MG	N021324	001	Oct 02, 2001	May	CAHN

SUSPENSION; INHALATION

BUDESONIDE

>D>		@ APOTEX INC	0.25MG/2ML	A078202	001	Mar 30, 2009	Jun	CMFD
>A>	AN		0.25MG/2ML	A078202	001	Mar 30, 2009	Jun	CMFD
>D>		@	0.5MG/2ML	A078202	002	Mar 30, 2009	Jun	CMFD
>A>	AN		0.5MG/2ML	A078202	002	Mar 30, 2009	Jun	CMFD
	AN	TEVA PHARMS USA	1MG/2ML	A204548	001	Mar 08, 2016	Feb	NEWA

BUMETANIDEINJECTABLE; INJECTION  
BUMETANIDE

>A>	AP	+	AMPHASTAR PHARMS INC	0.25MG/ML	A074441	001	Jan 27, 1995	Jun	CAHN
>D>	AP	+	EUROHLTH INTL SARL	0.25MG/ML	A074441	001	Jan 27, 1995	Jun	CAHN
	AP	+		0.25MG/ML	A074441	001	Jan 27, 1995	Apr	CAHN

BUPIVACAINE HYDROCHLORIDEINJECTABLE; INJECTION  
BUPIVACAINE HYDROCHLORIDE

AP		AUROBINDO PHARMA LTD	0.25%	A207183	001	May 13, 2016	May	NEWA
AP			0.5%	A207183	002	May 13, 2016	May	NEWA

BUPRENORPHINE HYDROCHLORIDEIMPLANT; IMPLANTATION  
PROBUPHINE

>A>		+	BRAEBURN PHARMS INC	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	Jun	CAHN
>D>		+	TITAN PHARMS	EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	Jun	CAHN
		+		EQ 80MG BASE/IMPLANT	N204442	001	May 26, 2016	May	NEWA

TABLET; SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE

AB		SUN PHARM INDS LTD	EQ 2MG BASE	A201760	001	Jan 29, 2016	Jan	NEWA
AB			EQ 8MG BASE	A201760	002	Jan 29, 2016	Jan	NEWA

BUPROPION HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL  
BUPROPION HYDROCHLORIDE

AB1		INVAGEN PHARMS	100MG	A206674	001	Feb 09, 2016	Jan	NEWA
AB1			150MG	A206674	002	Feb 09, 2016	Jan	NEWA
AB1			200MG	A206674	003	Feb 09, 2016	Jan	NEWA
AB1		SCIEGEN PHARMS INC	100MG	A205794	001	Mar 01, 2016	Feb	NEWA
AB1			150MG	A205794	002	Mar 01, 2016	Feb	NEWA
AB1			200MG	A205794	003	Mar 01, 2016	Feb	NEWA

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL  
CONTRAVE

		+	OREXIGEN	90MG; 8MG	N200063	001	Sep 10, 2014	Apr	CAHN
--	--	---	----------	-----------	---------	-----	--------------	-----	------

BUSPIRONE HYDROCHLORIDETABLET; ORAL  
BUSPIRONE HYDROCHLORIDE

>D>	AB		EMCURE PHARMS USA	5MG	A204582	001	Sep 18, 2015	Jun	CAHN
>D>	AB			10MG	A204582	002	Sep 18, 2015	Jun	CAHN
>D>	AB			15MG	A204582	003	Sep 18, 2015	Jun	CAHN
>D>	AB			30MG	A204582	004	Sep 18, 2015	Jun	CAHN
>A>	AB		HERITAGE PHARMA	5MG	A204582	001	Sep 18, 2015	Jun	CAHN
>A>	AB			10MG	A204582	002	Sep 18, 2015	Jun	CAHN
>A>	AB			15MG	A204582	003	Sep 18, 2015	Jun	CAHN
>A>	AB			30MG	A204582	004	Sep 18, 2015	Jun	CAHN

BUSULFAN

INJECTABLE; INJECTION  
 BUSULFAN  
 AP LUITPOLD PHARMS INC 6MG/ML A202259 001 Dec 22, 2015 Mar CAHN

BUTOCONAZOLE NITRATE

CREAM; VAGINAL  
 BUTOCONAZOLE NITRATE  
 >D> @ ELAN PHARMA INTL LTD 2% N019881 001 Feb 07, 1997 Jun CAHN  
 >A> @ PERRIGO PHARMA INTL 2% N019881 001 Feb 07, 1997 Jun CAHN

BUTORPHANOL TARTRATE

INJECTABLE; INJECTION  
 BUTORPHANOL TARTRATE  
 @ CLARIS 2MG/ML A075697 001 Oct 23, 2001 Jan CAHN  
 AP EUROHLTH INTL SARL 2MG/ML A075046 001 Aug 12, 1998 Apr CAHN  
 BUTORPHANOL TARTRATE PRESERVATIVE FREE  
 @ CLARIS 1MG/ML A075695 001 Oct 23, 2001 Mar CAHN  
 @ 2MG/ML A075695 002 Oct 23, 2001 Mar CAHN  
 AP EUROHLTH INTL SARL 1MG/ML A075045 001 Aug 12, 1998 Apr CAHN  
 AP 2MG/ML A075045 002 Aug 12, 1998 Apr CAHN

CABERGOLINE

TABLET; ORAL  
 CABERGOLINE  
 @ IMPAX LABS INC 0.5MG A077843 001 Jul 03, 2007 Mar DISC

CABOZANTINIB S-MALATE

TABLET; ORAL  
 CABOMETYX  
 EXELIXIS INC EQ 20MG BASE N208692 001 Apr 25, 2016 Apr NEWA  
 EQ 40MG BASE N208692 002 Apr 25, 2016 Apr NEWA  
 + EQ 60MG BASE N208692 003 Apr 25, 2016 Apr NEWA

CAFFEINE; ERGOTAMINE TARTRATE

SUPPOSITORY; RECTAL  
 MIGERGOT  
 + HORIZON PHARMA 100MG; 2MG A086557 001 Oct 04, 1983 Jan CAHN  
 >A> CALCIFEDIOL  
 >A> CAPSULE, EXTENDED RELEASE; ORAL  
 >A> RAYALDEE  
 >A> + OPKO IRELAND GLOBAL 0.03MG N208010 001 Jun 17, 2016 Jun NEWA

CALCIPOTRIENE

CREAM; TOPICAL  
 CALCIPOTRIENE  
 AB GLENMARK PHARMS 0.005% A205772 001 Jun 09, 2015 Mar CAHN

CALCITRIOL

CAPSULE; ORAL  
 CALCITRIOL  
 AB BIONPHARMA INC 0.25MCG A091174 001 May 24, 2013 Jan CAHN  
 AB 0.5MCG A091174 002 May 24, 2013 Jan CAHN  
 INJECTABLE; INJECTION  
 CALCITRIOL  
 AKORN 0.001MG/ML A078066 001 Jan 29, 2008 Feb CTEC  
 @ ROCKWELL MEDCL 0.001MG/ML A076206 001 Sep 17, 2003 Feb DISC

CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM CHLORIDE; SODIUM CHLORIDE; SODIUM LACTATE

SOLUTION; INTRAPERITONEAL  
 DELFLEX W/ DEXTROSE 1.5% IN PLASTIC CONTAINER  
 @ FRESENIUS MEDCL 25.7MG/100ML; 1.5GM/100ML; 15.2MG/10 N018379 002 Feb DISC  
 OML; 567MG/100ML; 392MG/100ML  
 DELFLEX W/ DEXTROSE 2.5% IN PLASTIC CONTAINER  
 @ FRESENIUS MEDCL 25.7MG/100ML; 2.5GM/100ML; 15.2MG/10 N018379 003 Feb DISC  
 OML; 567MG/100ML; 392MG/100ML  
 DELFLEX W/ DEXTROSE 3.5% IN PLASTIC CONTAINER  
 @ FRESENIUS MEDCL 25.7MG/100ML; 3.5GM/100ML; 15.2MG/10 N018379 007 Jun 24, 1988 Feb DISC  
 OML; 567MG/100ML; 392MG/100ML



## SOLUTION;INTRAPERITONEAL

DELFLEX W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N018379	001			Feb	DISC
--------------------	--	---------	-----	--	--	-----	------

DELFLEX-LM W/ DEXTROSE 1.5% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML; 1.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	004	Jul 07, 1982		Feb	DISC
--------------------	---	---------	-----	--------------	--	-----	------

DELFLEX-LM W/ DEXTROSE 2.5% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML; 2.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	005	Jul 07, 1982		Feb	DISC
--------------------	---	---------	-----	--------------	--	-----	------

DELFLEX-LM W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	008	Jun 24, 1988		Feb	DISC
--------------------	---	---------	-----	--------------	--	-----	------

DELFLEX-LM W/ DEXTROSE 4.25% IN PLASTIC CONTAINER

@ FRESSENIUS MEDCL	25.7MG/100ML; 4.25GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N018379	006	Jul 07, 1982		Feb	DISC
--------------------	--	---------	-----	--------------	--	-----	------

DIANEAL PD-1 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML; 3.5GM/100ML; 15.2MG/100ML; 567MG/100ML; 392MG/100ML	N017512	010	Nov 18, 1985		Feb	CTEC
-----------------	---	---------	-----	--------------	--	-----	------

DIANEAL PD-2 W/ DEXTROSE 3.5% IN PLASTIC CONTAINER

BAXTER HLTHCARE	25.7MG/100ML; 3.5GM/100ML; 5.08MG/100ML; 538MG/100ML; 448MG/100ML	N017512	011	Nov 18, 1985		Feb	CTEC
-----------------	---	---------	-----	--------------	--	-----	------

CAPTOPRIL

TABLET;ORAL

CAPTOPRIL

@ APOTEX	12.5MG	A074737	001	Oct 28, 1998		Mar	DISC
@	25MG	A074737	002	Oct 28, 1998		Mar	DISC
@	50MG	A074737	003	Oct 28, 1998		Mar	DISC
@	100MG	A074737	004	Oct 28, 1998		Mar	DISC
>A> AB	HIKMA INTL PHARMS	12.5MG	A074505	001	Feb 13, 1996	Jun	CAHN
>A> AB		25MG	A074505	002	Feb 13, 1996	Jun	CAHN
>A> AB		50MG	A074505	003	Feb 13, 1996	Jun	CAHN
>A> AB		100MG	A074505	004	Feb 13, 1996	Jun	CAHN
>D> AB	HIKMA PHARMS	12.5MG	A074505	001	Feb 13, 1996	Jun	CAHN
>D> AB		25MG	A074505	002	Feb 13, 1996	Jun	CAHN
>D> AB		50MG	A074505	003	Feb 13, 1996	Jun	CAHN
>D> AB		100MG	A074505	004	Feb 13, 1996	Jun	CAHN
@ SANDOZ	12.5MG	A074363	001	Nov 09, 1995		Jan	DISC
@	25MG	A074363	002	Nov 09, 1995		Jan	DISC
@	50MG	A074363	003	Nov 09, 1995		Jan	DISC
@	100MG	A074363	004	Nov 09, 1995		Jan	DISC
@ STASON	12.5MG	A074677	004	May 30, 1997		Mar	DISC
@	25MG	A074677	002	May 30, 1997		Mar	DISC
@	50MG	A074677	001	May 30, 1997		Mar	DISC
@	100MG	A074677	003	May 30, 1997		Mar	DISC

CARBAMAZEPINE

CAPSULE, EXTENDED RELEASE;ORAL

CARBAMAZEPINE

AB	MYLAN IRELAND LTD	100MG	A076697	001	May 20, 2011	Jan	CAHN
AB		200MG	A076697	002	May 20, 2011	Jan	CAHN
AB		300MG	A076697	003	May 20, 2011	Jan	CAHN

CARBIDOPA

TABLET;ORAL

CARBIDOPA

AB	EDENBRIDGE PHARMS	25MG	A205304	001	Feb 17, 2016	Feb	NEWA
----	-------------------	------	---------	-----	--------------	-----	------

CARBIDOPA; LEVODOPA

TABLET;ORAL

CARBIDOPA AND LEVODOPA

@ IDT AUSTRALIA LTD	10MG;100MG	A073586	001	Jun 29, 1995		May	CAHN
@	25MG;100MG	A073587	001	Jun 29, 1995		May	CAHN
@	25MG;250MG	A073620	001	Jun 29, 1995		May	CAHN

CARBINOXAMINE MALEATE

TABLET;ORAL

CARBINOXAMINE MALEATE

MIKART INC	6MG	A207484	001	May 31, 2016		May	NEWA
------------	-----	---------	-----	--------------	--	-----	------

CARBOPLATIN

INJECTABLE; IV (INFUSION)		CARBOPLATIN							
	@	ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Apr	DISC	
	@		150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Apr	DISC	
	@		450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Apr	DISC	
	@		600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Apr	DISC	
AP		SANDOZ INC	50MG/5ML (10MG/ML)	A078280	001	May 08, 2008	Feb	CAHN	
AP			150MG/15ML (10MG/ML)	A078280	002	May 08, 2008	Feb	CAHN	
AP			450MG/45ML (10MG/ML)	A078280	003	May 08, 2008	Feb	CAHN	
AP		SANJA PHARMS CO	50MG/5ML (10MG/ML)	A205487	001	Mar 28, 2016	Mar	NEWA	
AP			150MG/15ML (10MG/ML)	A205487	002	Mar 28, 2016	Mar	NEWA	
AP			450MG/45ML (10MG/ML)	A205487	003	Mar 28, 2016	Mar	NEWA	

CARFILZOMIB

POWDER; INTRAVENOUS		KYPROLIS							
>A>		ONYX THERAP	30MG/VIAL	N202714	002	Jun 03, 2016	Jun	NEWA	
	+		60MG/VIAL	N202714	001	Jul 20, 2012	Feb	CAHN	

CARISOPRODOL

TABLET; ORAL		CARISOPRODOL							
AA		INGENUS PHARMS NJ	350MG	A040823	001	Oct 22, 2008	Jan	CAHN	
AB		STRIDES PHARMA	250MG	A205513	001	Nov 12, 2015	May	CAHN	
AA			350MG	A205513	002	Nov 12, 2015	May	CAHN	

CARVEDILOL

TABLET; ORAL		COREG							
AB		SMITHKLINE BEECHAM	3.125MG	N020297	004	May 29, 1997	May	CAHN	
AB			6.25MG	N020297	003	Sep 14, 1995	May	CAHN	
AB	+		12.5MG	N020297	002	Sep 14, 1995	May	CAHN	
AB			25MG	N020297	001	Sep 14, 1995	May	CAHN	

CARVEDILOL PHOSPHATE

CAPSULE, EXTENDED RELEASE; ORAL		COREG CR							
		SMITHKLINE BEECHAM	10MG	N022012	001	Oct 20, 2006	May	CAHN	
			20MG	N022012	002	Oct 20, 2006	May	CAHN	
	+		40MG	N022012	003	Oct 20, 2006	May	CAHN	
			80MG	N022012	004	Oct 20, 2006	May	CAHN	

CEFADROXIL/CEFADROXIL HEMIHYDRATE

FOR SUSPENSION; ORAL		CEFADROXIL							
	@	SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065115	001	Mar 26, 2003	Feb	DISC	
	@		EQ 250MG BASE/5ML	A065115	002	Mar 26, 2003	Feb	DISC	
	@		EQ 500MG BASE/5ML	A065115	003	Mar 26, 2003	Feb	DISC	

CEFAZOLIN SODIUM

INJECTABLE; INJECTION		CEFAZOLIN SODIUM							
AP		HOSPIRA INC	EQ 1GM BASE/VIAL	A201654	001	Feb 03, 2016	Jan	NEWA	

CEFDITOREN PIVOXIL

TABLET; ORAL		SPECTRACEF							
	@	VANSEN PHARMA	200MG	N021222	001	Aug 29, 2001	Apr	DISC	
	@		400MG	N021222	002	Jul 21, 2008	Apr	DISC	

CEFEPIME HYDROCHLORIDE

INJECTABLE; INJECTION		CEFEPIME HYDROCHLORIDE							
AP		QILU PHARM CO LTD	EQ 500MG BASE/VIAL	A203704	001	Feb 01, 2016	Jan	NEWA	
AP			EQ 1GM BASE/VIAL	A203704	002	Feb 01, 2016	Jan	NEWA	
AP			EQ 2GM BASE/VIAL	A203704	003	Feb 01, 2016	Jan	NEWA	

CEFOTAXIME SODIUMINJECTABLE; INJECTION  
CEFOTAXIME SODIUM

AP	HOSPIRA INC	EQ 1GM BASE/VIAL	A203132	001	Feb 19, 2016	Feb	NEWA
AP		EQ 2GM BASE/VIAL	A203132	002	Feb 19, 2016	Feb	NEWA
	CLAFORAN						
AP	+ US PHARM HOLDINGS	EQ 500MG BASE/VIAL	N050547	001		Jan	CAHN
AP	+	EQ 1GM BASE/VIAL	N050547	002		Jan	CAHN
AP	+	EQ 2GM BASE/VIAL	N050547	003		Jan	CAHN
AP	+	EQ 10GM BASE/VIAL	N050547	004	Dec 29, 1983	Jan	CAHN
>D>	CLAFORAN IN DEXTROSE 5% IN PLASTIC CONTAINER						
>D>	+ SANOFI AVENTIS US	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jun	DISC
>A>	@ US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	002	May 20, 1985	Jun	DISC
>D>	+	EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jun	DISC
>A>	@	EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jun	DISC
	+	EQ 40MG BASE/ML	N050596	004	May 20, 1985	Jan	CAHN
	CLAFORAN IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
	@ US PHARM HOLDINGS	EQ 20MG BASE/ML	N050596	001	May 20, 1985	Jan	CAHN
	@	EQ 40MG BASE/ML	N050596	003	May 20, 1985	Jan	CAHN

CEFOTETAN DISODIUMINJECTABLE; INJECTION  
CEFOTAN

	@ TELIGENT PHARMA INC	EQ 1GM BASE/VIAL	A063293	001	Apr 29, 1993	Jan	CAHN
AP		EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Feb	CMFD
	@	EQ 1GM BASE/VIAL	N050588	001	Dec 27, 1985	Jan	CAHN
	@	EQ 2GM BASE/VIAL	A063293	002	Apr 29, 1993	Jan	CAHN
AP		EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Feb	CMFD
	@	EQ 2GM BASE/VIAL	N050588	002	Dec 27, 1985	Jan	CAHN
	@	EQ 10GM BASE/VIAL	N050588	003	Apr 25, 1988	Jan	CAHN
	CEFOTETAN AND DEXTROSE IN DUPLEX CONTAINER						
>D>	+ B BRAUN	EQ 1GM BASE/VIAL	\$065430	001	Aug 09, 2007	Jun	CMS2
>A>	+	EQ 1GM BASE/VIAL	N065430	001	Aug 09, 2007	Jun	CMS2
>D>	+	EQ 2GM BASE/VIAL	A065430	002	Aug 09, 2007	Jun	CMS2
>A>	+	EQ 2GM BASE/VIAL	N065430	002	Aug 09, 2007	Jun	CMS2

CEFOXITIN SODIUMINJECTABLE; INJECTION  
CEFOXITIN

AP	ACS DOBFAR SPA	EQ 1GM BASE/VIAL	A065467	001	Aug 31, 2011	May	CAHN
AP		EQ 2GM BASE/VIAL	A065467	002	Aug 31, 2011	May	CAHN
AP		EQ 10GM BASE/VIAL	A065464	001	Aug 31, 2011	May	CAHN

CEFPODOXIME PROXETILFOR SUSPENSION; ORAL  
CEFPODOXIME PROXETIL

	@ SUN PHARM INDS LTD	EQ 50MG BASE/5ML	A065082	001	May 31, 2002	Feb	DISC
	@	EQ 100MG BASE/5ML	A065082	002	May 31, 2002	Feb	DISC

TABLET; ORAL  
CEFPODOXIME PROXETIL

	@ SUN PHARM INDS LTD	EQ 100MG BASE	A065083	001	Aug 20, 2003	Feb	DISC
	@	EQ 200MG BASE	A065083	002	Aug 20, 2003	Feb	DISC

>D> CEFTIBUTEN DIHYDRATE>D> CAPSULE; ORAL  
>D> CEDAX

>D>	+ PERNIX THERAP	EQ 400MG BASE	N050685	002	Dec 20, 1995	Jun	DISC
>A>	@	EQ 400MG BASE	N050685	002	Dec 20, 1995	Jun	DISC
>D>	FOR SUSPENSION; ORAL						
>D>	CEDAX						
>D>	+ PERNIX THERAP	EQ 90MG BASE/5ML	N050686	001	Dec 20, 1995	Jun	DISC
>A>	@	EQ 90MG BASE/5ML	N050686	001	Dec 20, 1995	Jun	DISC
>D>	+	EQ 180MG BASE/5ML	N050686	002	Dec 20, 1995	Jun	DISC
>A>	@	EQ 180MG BASE/5ML	N050686	002	Dec 20, 1995	Jun	DISC

CEFTRIAXONE SODIUMINJECTABLE; INJECTION  
CEFTRIAXONE

	@ HOSPIRA INC	EQ 1GM BASE/VIAL	A065231	001	Aug 02, 2005	Apr	DISC
	@	EQ 1GM BASE/VIAL	A202563	001	Aug 20, 2012	Apr	DISC
	@	EQ 2GM BASE/VIAL	A065231	002	Aug 02, 2005	Apr	DISC

INJECTABLE; INJECTION  
CEFTRIAZONE

@	EQ 2GM BASE/VIAL	A202563	002	Aug 20, 2012	Apr	DISC
ROCEPHIN						
@ HOFFMANN LA ROCHE	EQ 500MG BASE/VIAL	A063239	002	Aug 13, 1993	Apr	DISC
@	EQ 1GM BASE/VIAL	A063239	003	Aug 13, 1993	Apr	DISC

INJECTABLE; INTRAMUSCULAR, INTRAVENOUS  
CEFTRIAZONE

>D> AP	BEDFORD	EQ 250MG BASE/VIAL	A065465	001	Aug 18, 2008	Jun	DISC
>A>	@	EQ 250MG BASE/VIAL	A065465	001	Aug 18, 2008	Jun	DISC
>D> AP		EQ 500MG BASE/VIAL	A065465	002	Aug 18, 2008	Jun	DISC
>A>	@	EQ 500MG BASE/VIAL	A065465	002	Aug 18, 2008	Jun	DISC
>D> AP		EQ 1GM BASE/VIAL	A065465	003	Aug 18, 2008	Jun	DISC
>A>	@	EQ 1GM BASE/VIAL	A065465	003	Aug 18, 2008	Jun	DISC
>D> AP		EQ 2GM BASE/VIAL	A065465	004	Aug 18, 2008	Jun	DISC
>A>	@	EQ 2GM BASE/VIAL	A065465	004	Aug 18, 2008	Jun	DISC
>A> AP	QILU PHARM CO LTD	EQ 250MG BASE/VIAL	A203702	001	Jun 29, 2016	Jun	NEWA
>A> AP		EQ 500MG BASE/VIAL	A203702	002	Jun 29, 2016	Jun	NEWA
>A> AP		EQ 1GM BASE/VIAL	A203702	003	Jun 29, 2016	Jun	NEWA
>A> AP		EQ 2GM BASE/VIAL	A203702	004	Jun 29, 2016	Jun	NEWA

CEFUROXIME AXETILFOR SUSPENSION; ORAL  
CEFTIN

GLAXOSMITHKLINE	EQ 125MG BASE/5ML	N050672	001	Jun 30, 1994	Feb	CTEC
+	EQ 250MG BASE/5ML	N050672	002	Apr 29, 1997	Feb	CTEC
CEFUROXIME AXETIL						
@ SUN PHARM INDS LTD	EQ 125MG BASE/5ML	A065323	001	Feb 05, 2008	Feb	DISC
@	EQ 250MG BASE/5ML	A065323	002	Feb 05, 2008	Feb	DISC

## TABLET; ORAL

CEFUROXIME AXETIL						
@ SUN PHARM INDS LTD	EQ 125MG BASE	A065118	001	Apr 25, 2003	Feb	DISC
@	EQ 250MG BASE	A065118	002	Apr 25, 2003	Feb	DISC
@	EQ 500MG BASE	A065118	003	Apr 25, 2003	Feb	DISC

CEFUROXIME SODIUMINJECTABLE; INJECTION  
ZINACEF

AP	+	IGI LABS INC	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Jan	CAHN
AP	+		EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Jan	CAHN
ZINACEF IN PLASTIC CONTAINER								
@		IGI LABS INC	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	Jan	CAHN
+			EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	Jan	CAHN

## INJECTABLE; INTRAMUSCULAR, INTRAVENOUS

AB	+	IGI LABS INC	EQ 750MG BASE/VIAL	N050558	002	Oct 19, 1983	Jan	CAHN
----	---	--------------	--------------------	---------	-----	--------------	-----	------

CELECOXIBCAPSULE; ORAL  
CELECOXIB

AB		AUROBINDO PHARMA LTD	50MG	A206827	001	Feb 01, 2016	Jan	NEWA
AB			100MG	A206827	002	Feb 01, 2016	Jan	NEWA
AB			200MG	A206827	003	Feb 01, 2016	Jan	NEWA
AB			400MG	A206827	004	Feb 01, 2016	Jan	NEWA
AB		MACLEODS PHARMS LTD	50MG	A204590	001	Mar 16, 2016	Feb	NEWA
AB			100MG	A204590	002	Mar 16, 2016	Feb	NEWA
AB			200MG	A204590	003	Mar 16, 2016	Feb	NEWA
AB			400MG	A204590	004	Mar 16, 2016	Feb	NEWA

CEPHALEXINCAPSULE; ORAL  
CEPHALEXIN

@	SUN PHARM INDS LTD	EQ 250MG BASE	A065007	001	Sep 16, 1999	Feb	DISC
@		EQ 500MG BASE	A065007	002	Sep 16, 1999	Feb	DISC

## FOR SUSPENSION; ORAL

KEFLEX								
@	PRAGMA PHARMS LLC	EQ 100MG BASE/ML	N050406	003		Mar	CAHN	
@		EQ 125MG BASE/5ML	N050406	001		Mar	CAHN	
@		EQ 250MG BASE/5ML	N050406	002		Mar	CAHN	

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

AA	NOSTRUM LABS INC	5MG/5ML	A090191	001	Nov 12, 2009	Mar	CAHN
	@ WOCKHARDT	5MG/5ML	A078757	001	Aug 28, 2009	Apr	DISC

CHLORHEXIDINE GLUCONATE

SOLUTION;DENTAL

PERIOGARD

AT	COLGATE-PALMOLIVE CO	0.12%	A203212	001	Jan 28, 2016	Jan	NEWA
----	----------------------	-------	---------	-----	--------------	-----	------

CHLOROQUINE PHOSPHATE

TABLET;ORAL

CHLOROQUINE PHOSPHATE

@ IMPAX LABS

EQ 150MG BASE

A080880 001

Mar DISC

@

EQ 300MG BASE

A040516 001 Aug 29, 2003

Mar DISC

CHLORPHENIRAMINE MALEATE

TABLET;ORAL

CHLORPHENIRAMINE MALEATE

@ AUROLIFE PHARMA LLC

4MG

A080961 001

Mar CAHN

&gt;D&gt; @ MUTUAL PHARM

4MG

A080700 001

Jun CAHN

&gt;A&gt; @ SUN PHARM INDS

4MG

A080700 001

Jun CAHN

>D> CHLORPHENIRAMINE MALEATE; CODEINE PHOSPHATE

&gt;D&gt; TABLET, EXTENDED RELEASE;ORAL

&gt;D&gt; CODEINE PHOSPHATE AND CHLORPHENIRAMINE MALEATE

&gt;D&gt; SPRIASO LLC

8MG;54.3MG

N206323 001 Jun 22, 2015

Jun DISC

&gt;A&gt; @

8MG;54.3MG

N206323 001 Jun 22, 2015

Jun DISC

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE,CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	MAYNE PHARMA INC	4MG/5ML;5MG/5ML;60MG/5ML	A205657	001	Aug 03, 2015	Feb	CAHN
----	------------------	--------------------------	---------	-----	--------------	-----	------

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

@ AUROLIFE PHARMA LLC

100MG

A088725 001 Aug 31, 1984

Mar CAHN

@

250MG

A088726 001 Aug 31, 1984

Mar CAHN

CHLORTHALIDONE

TABLET;ORAL

CHLORTHALIDONE

AB MYLAN

25MG

A086831 002

Jan CTEC

AB SUN PHARM INDS

25MG

A089286 002 Jul 21, 1986

Jan NEWA

CHLORZOXAZONE

TABLET;ORAL

CHLORZOXAZONE

@ AUROLIFE PHARMA LLC

250MG

A089852 001 May 04, 1988

Feb CAHN

@

500MG

A089853 001 May 04, 1988

Feb CAHN

+ MIKART

750MG

A040861 002 Jun 01, 2010

Apr CRLD

&gt;A&gt; + MIKART INC

250MG

A207483 001 Jun 24, 2016

Jun NEWA

@ SUN PHARM INDS

500MG

A089970 001 Sep 27, 1990

Mar CAHN

CICLESONIDE

AEROSOL, METERED;INHALATION

ALVESCO

+ TAKEDA GMBH

0.08MG/INH

N021658 002 Jan 10, 2008

Jan CRLD

CILASTATIN SODIUM; IMIPENEM

POWDER;INTRAMUSCULAR

PRIMAXIN

@ MERCK

EQ 500MG BASE/VIAL;500MG/VIAL

N050630 001 Dec 14, 1990

May DISC

CILOSTAZOL

TABLET; ORAL

CILOSTAZOL

>D>	@	MUTUAL PHARM	50MG	A 077208	002	Mar 29, 2006	Jun	CAHN	
>D>	@		100MG	A 077208	001	Mar 29, 2006	Jun	CAHN	
>A>	@	SUN PHARM INDS	50MG	A 077208	002	Mar 29, 2006	Jun	CAHN	
>A>	@		100MG	A 077208	001	Mar 29, 2006	Jun	CAHN	
>D>	AB	TEVA	50MG	A 077027	001	Nov 24, 2004	Jun	CRLD	
>A>	AB	+	50MG	A 077027	001	Nov 24, 2004	Jun	CRLD	
>D>	AB		100MG	A 077027	002	Nov 24, 2004	Jun	CRLD	
>A>	AB	+	100MG	A 077027	002	Nov 24, 2004	Jun	CRLD	
>D>		PLETAL							
>D>	AB	+	OTSUKA	50MG	N 020863	001	Jan 15, 1999	Jun	DISC
>A>		@	50MG	N 020863	001	Jan 15, 1999	Jun	DISC	
>D>	AB	+	100MG	N 020863	002	Jan 15, 1999	Jun	DISC	
>A>		@	100MG	N 020863	002	Jan 15, 1999	Jun	DISC	

CIPROFLOXACIN HYDROCHLORIDE

TABLET; ORAL

CIPROFLOXACIN HYDROCHLORIDE

@	IDT AUSTRALIA LTD	EQ 100MG BASE	A 075939	001	Mar 03, 2005	May	CAHN
@		EQ 250MG BASE	A 075939	002	Jun 09, 2004	May	CAHN
@		EQ 500MG BASE	A 075939	003	Jun 09, 2004	May	CAHN
@		EQ 750MG BASE	A 075939	004	Jun 09, 2004	May	CAHN

CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE

SOLUTION/DROPS; OTIC

OTOVEL

+ LABORATORIOS SALVAT EQ 0.3% BASE; 0.025%

N 208251 001 Apr 29, 2016 Apr NEWA

CIPROFLOXACIN; CIPROFLOXACIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

CIPROFLOXACIN EXTENDED RELEASE

@	ACTAVIS LABS FL INC	212.6MG; EQ 287.5MG BASE	A 077417	001	Nov 30, 2010	Jan	DISC
@		425.2MG; EQ 574.9MG BASE	A 077809	001	Nov 30, 2010	Jan	DISC

CITALOPRAM HYDROBROMIDE

TABLET; ORAL

CITALOPRAM HYDROBROMIDE

@	SUN PHARM INDS	EQ 10MG BASE	A 077052	001	Jul 03, 2006	Mar	CAHN
@		EQ 20MG BASE	A 077052	002	Jul 03, 2006	Mar	CAHN
@		EQ 40MG BASE	A 077052	003	Jul 03, 2006	Mar	CAHN

CLARITHROMYCIN

TABLET, EXTENDED RELEASE; ORAL

CLARITHROMYCIN

AB	ALLIED PHARMA INC	500MG	A 203243	001	Feb 29, 2016	Feb	NEWA	
	@	IDT AUSTRALIA LTD	500MG	A 065250	001	Aug 25, 2005	May	CAHN

CLINDAMYCIN PALMITATE HYDROCHLORIDE

FOR SOLUTION; ORAL

CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA MYLAN PHARMS INC EQ 75MG BASE/5ML

A 203063 001 May 25, 2016 May NEWA

CLINDAMYCIN PHOSPHATE

CREAM; VAGINAL

CLINDESSE

>D>	+	ELAN PHARMA INTL LTD	EQ 2% BASE	N 050793	001	Nov 30, 2004	Jun	CAHN
>A>	+	PERRIGO PHARMA INTL	EQ 2% BASE	N 050793	001	Nov 30, 2004	Jun	CAHN

INJECTABLE; INJECTION

CLINDAMYCIN PHOSPHATE

AP EUROHLTH INTL SARL EQ 150MG BASE/ML

A 065206 001 Sep 24, 2004 Apr CAHN

CLINDAMYCIN PHOSPHATE; TRETINOIN

GEL; TOPICAL

VELTIN

BX + AQUA PHARMS LLC 1.2%; 0.025%

N 050803 001 Jul 16, 2010 Jan CAHN

CLOBETASOL PROPIONATE

OINTMENT;TOPICAL

AB	+	FOUGERA PHARMS	0.05%	A074407	001	Feb 23, 1996	Mar	CRLD
		TEMOVATE						
	@	FOUGERA PHARMS	0.05%	N019323	001	Dec 27, 1985	Mar	DISC

CLOMIPRAMINE HYDROCHLORIDE

CAPSULE;ORAL

ANAFRANIL

AB	+	MALLINCKRODT LLC	25MG	N019906	001	Dec 29, 1989	Jan	CRLD
AB			50MG	N019906	002	Dec 29, 1989	Jan	CRLD

CLONIDINE HYDROCHLORIDE

TABLET;ORAL

CLONIDINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC 0.1MG  
 @ 0.2MG  
 @ 0.3MG

A070887 001 Aug 31, 1988 Feb CAHN  
 A070886 001 Aug 31, 1988 Feb CAHN  
 A071294 001 Aug 31, 1988 Feb CAHN

CLOPIDOGREL BISULFATE

TABLET;ORAL

CLOPIDOGREL BISULFATE

>D>	AB	ACTAVIS TOTOWA	EQ 75MG BASE	A090307	001	May 28, 2013	Jun	DISC
>A>		@	EQ 75MG BASE	A090307	001	May 28, 2013	Jun	DISC
	AB	SUN PHARM INDS	EQ 75MG BASE	A078133	001	Jun 10, 2013	Mar	CAHN

CLORAZEPATE DIPOTASSIUM

CAPSULE;ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC 3.75MG  
 @ 7.5MG  
 @ 15MG

A072219 001 Aug 26, 1988 Apr CAHN  
 A072220 001 Aug 26, 1988 Feb CAHN  
 A072112 001 Aug 26, 1988 Feb CAHN

TABLET;ORAL

CLORAZEPATE DIPOTASSIUM

@ AUROLIFE PHARMA LLC 3.75MG  
 @ 7.5MG  
 @ 15MG

A072512 001 May 11, 1990 Mar CAHN  
 A072513 001 May 11, 1990 Mar CAHN  
 A072514 001 May 11, 1990 Feb CAHN

TRANXENE

>D>	AB	RECORDATI RARE	3.75MG	N017105	006		Jun	DISC
>A>		@	3.75MG	N017105	006		Jun	DISC

CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE

AA		NOSTRUM LABS INC	10MG/5ML;6.25MG/5ML	A090180	001	Mar 17, 2010	Feb	CAHN
----	--	------------------	---------------------	---------	-----	--------------	-----	------

COLCHICINE

CAPSULE;ORAL

MITIGARE

+ HIKMA INTL PHARMS 0.6MG

N204820 001 Sep 26, 2014 Mar CRLD

COLCHICINE; PROBENECID

TABLET;ORAL

PROBENECID AND COLCHICINE

AB		INGENUS PHARMS NJ	0.5MG;500MG	A040618	001	May 13, 2008	Jan	CAHN
----	--	-------------------	-------------	---------	-----	--------------	-----	------

COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE

SUSPENSION/DROPS;OTIC

COLY-MYCIN S

+ ENDO PHARMS INC EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG  
BASE/ML;0.5MG/ML

N050356 001 Feb CAHN

CORTICOTROPIN

INJECTABLE;INJECTION

PURIFIED CORTROPHIN GEL

@ ANI PHARMS 40 UNITS/ML  
 @ 80 UNITS/ML

N008975 001 Feb CAHN  
 N008975 002 Feb CAHN

CORTICOTROPIN-ZINC HYDROXIDEINJECTABLE; INJECTION  
CORTROPHIN-ZINC

@ ANI PHARMS	40 UNITS/ML	N009854	001			Feb	CAHN
--------------	-------------	---------	-----	--	--	-----	------

CROFELEMERTABLET, DELAYED RELEASE; ORAL  
FULYZAQ

>A>	+	NAPO PHARMS INC	125MG	N202292	001	Dec 31, 2012	Jun	CAHN
>D>	+	SALIX PHARMS	125MG	N202292	001	Dec 31, 2012	Jun	CAHN

CYANOCOBALAMININJECTABLE; INJECTION  
CYANOCOBALAMIN

AP		SOMERSET THERAPS LLC	1MG/ML	A206503	001	Dec 11, 2015	Mar	CAHN
		SPRAY, METERED; NASAL						
		NASCOBAL						
	+	ENDO PHARMS INC	0.5MG/SPRAY	N021642	001	Jan 31, 2005	Feb	CAHN

CYCLOPHOSPHAMIDEINJECTABLE; INJECTION  
CYTOXAN (LYOPHILIZED)

@ BAXTER HLTHCARE	500MG/VIAL	N012142	003				Mar	DISC
@	1GM/VIAL	N012142	004	Aug 30, 1982			Mar	DISC
@	2GM/VIAL	N012142	005	Aug 30, 1982			Mar	DISC

CYPROHEPTADINE HYDROCHLORIDE

TABLET; ORAL

CYPROHEPTADINE HYDROCHLORIDE

AA		INGENUS PHARMS NJ	4MG	A205087	001	Sep 23, 2015	Jan	CAHN
----	--	-------------------	-----	---------	-----	--------------	-----	------

CYTARABINEINJECTABLE; INJECTION  
CYTARABINE

AP		MYLAN PHARMS INC	20MG/ML	A200915	001	Dec 13, 2011	Mar	CAHN
AP			20MG/ML	A200916	001	Dec 13, 2011	Mar	CAHN

DACLATASVIR DIHYDROCHLORIDE

TABLET; ORAL

DAKLINZA

		BRISTOL-MYERS SQUIBB	EQ 90MG BASE	N206843	003	Apr 13, 2016	Apr	NEWA
--	--	----------------------	--------------	---------	-----	--------------	-----	------

DACTINOMYCININJECTABLE; INJECTION  
DACTINOMYCIN

@ EUROHLTH INTL SARL	0.5MG/VIAL	A090304	001	Mar 16, 2010			Feb	DISC
----------------------	------------	---------	-----	--------------	--	--	-----	------

DALBAVANCIN HYDROCHLORIDEPOWDER; IV (INFUSION)  
DALVANCE

+	DURATA THERAPS INTL	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	Jan	CDFR
---	---------------------	--------------------	---------	-----	--------------	-----	------

DANTROLENE SODIUMFOR SUSPENSION; INTRAVENOUS  
RYANODEX

>D>		EAGLE PHARMS	250MG/VIAL	N205579	001	Jul 22, 2014	Jun	CRLD
>A>	+		250MG/VIAL	N205579	001	Jul 22, 2014	Jun	CRLD

INJECTABLE; INJECTION  
DANTROLENE SODIUM

AP		MYLAN INSTITUTIONAL	20MG/VIAL	A205239	001	Feb 18, 2016	Feb	NEWA
----	--	---------------------	-----------	---------	-----	--------------	-----	------

DAPSONEGEL; TOPICAL  
ACZONE

+	ALLERGAN INC	7.5%	N207154	001	Feb 24, 2016	Feb	NEWA
---	--------------	------	---------	-----	--------------	-----	------

TABLET; ORAL

DAPSONE

AB		ALVOGEN	25MG	A205429	001	Jan 07, 2016	Mar	CAHN
AB			100MG	A205429	002	Jan 07, 2016	Mar	CAHN
AB		NORTH CREEK PHARMS	25MG	A204074	001	May 10, 2016	Apr	NEWA



TABLET;ORAL

## DAPSONE

AB		100MG	A204074	002	May 10, 2016	Apr	NEWA
AB	NOSTRUM LABS INC	25MG	A203887	001	May 06, 2016	Apr	NEWA
AB		100MG	A203887	002	May 06, 2016	Apr	NEWA

DAPTOMYCIN

## POWDER; INTRAVENOUS

## CUBICIN

AP	+ CUBIST	500MG/VIAL	N021572	002	Sep 12, 2003	Jan	CDFR
	DAPTOMYCIN						
>A> AP	CRANE PHARMS LLC	500MG/VIAL	A206005	001	Jun 15, 2016	Jun	NEWA
AP	HOSPIRA INC	500MG/VIAL	A202857	001	Sep 12, 2014	Jan	CDFR
AP	TEVA PARENTERAL	500MG/VIAL	A091039	001	Mar 25, 2016	Mar	NEWA
	POWDER; IV (INFUSION)						
	CUBICIN						
	@ CUBIST	250MG/VIAL	N021572	001	Sep 12, 2003	Jan	CDFR

DARIFENACIN HYDROBROMIDE

## TABLET, EXTENDED RELEASE;ORAL

## ENABLEX

AB	APIL	EQ 7.5MG BASE	N021513	001	Dec 22, 2004	Jan	CAHN
AB	+	EQ 15MG BASE	N021513	002	Dec 22, 2004	Jan	CAHN

DASATINIB

## TABLET;ORAL

## DASATINIB

AB	APOTEX INC	20MG	A202103	001	Jun 10, 2016	May	NEWA
AB		50MG	A202103	002	Jun 10, 2016	May	NEWA
AB		70MG	A202103	003	Jun 10, 2016	May	NEWA
AB		100MG	A202103	004	Jun 10, 2016	May	NEWA
	SPRYCEL						
AB	BRISTOL MYERS SQUIBB	20MG	N021986	001	Jun 28, 2006	May	CFTG
AB		50MG	N021986	002	Jun 28, 2006	May	CFTG
AB		70MG	N021986	003	Jun 28, 2006	May	CFTG
AB	+	100MG	N021986	004	May 30, 2008	May	CFTG

DAUNORUBICIN CITRATE

## INJECTABLE, LIPOSOMAL; INJECTION

## DAUNOXOME

## @ GALEN (UK)

EQ 2MG BASE/ML

N050704 002 Apr 08, 1996 May DISC

DEFERASIROX

## TABLET, FOR SUSPENSION;ORAL

## DEFERASIROX

AB	ACTAVIS ELIZABETH	125MG	A203560	001	Jan 26, 2016	Jan	NEWA
AB		250MG	A203560	002	Jan 26, 2016	Jan	NEWA
AB		500MG	A203560	003	Jan 26, 2016	Jan	NEWA
	EXJADE						
AB	NOVARTIS	125MG	N021882	001	Nov 02, 2005	Jan	CFTG
AB		250MG	N021882	002	Nov 02, 2005	Jan	CFTG
AB	+	500MG	N021882	003	Nov 02, 2005	Jan	CFTG

DEFIBROTIDE SODIUM

## SOLUTION; IV (INFUSION)

## DEFITELIO

+ GENTIUM SPA 200MG/2.5ML (80MG/ML)

N208114 001 Mar 30, 2016 Mar NEWA

DEMECLOCYCLINE HYDROCHLORIDE

## TABLET;ORAL

## DEMECLOCYCLINE HYDROCHLORIDE

## @ IMPAX LABS

150MG

A065094 001 Mar 22, 2004 Mar DISC

## @

300MG

A065094 002 Mar 22, 2004 Mar DISC

DESIPRAMINE HYDROCHLORIDE

## TABLET;ORAL

## DESIPRAMINE HYDROCHLORIDE

AB	AMNEAL PHARMS CO	10MG	A208105	001	Mar 17, 2016	Mar	NEWA
AB		25MG	A208105	002	Mar 17, 2016	Mar	NEWA
AB		50MG	A208105	003	Mar 17, 2016	Mar	NEWA
AB		75MG	A208105	004	Mar 17, 2016	Mar	NEWA
AB		100MG	A208105	005	Mar 17, 2016	Mar	NEWA

## TABLET;ORAL

## DESIPRAMINE HYDROCHLORIDE

AB		150MG	A208105	006	Mar 17, 2016	Mar	NEWA
>A>	AB	HERITAGE PHARMS INC 10MG	A207433	001	May 05, 2016	Jun	CAHN
>A>	AB	25MG	A207433	002	May 05, 2016	Jun	CAHN
>A>	AB	50MG	A207433	003	May 05, 2016	Jun	CAHN
>A>	AB	75MG	A207433	004	May 05, 2016	Jun	CAHN
>A>	AB	100MG	A207433	005	May 05, 2016	Jun	CAHN
>A>	AB	150MG	A207433	006	May 05, 2016	Jun	CAHN
>D>	AB	INDICUS PHARMA 10MG	A207433	001	May 05, 2016	Jun	CAHN
	AB	10MG	A207433	001	May 05, 2016	Apr	NEWA
>D>	AB	25MG	A207433	002	May 05, 2016	Jun	CAHN
	AB	25MG	A207433	002	May 05, 2016	Apr	NEWA
>D>	AB	50MG	A207433	003	May 05, 2016	Jun	CAHN
	AB	50MG	A207433	003	May 05, 2016	Apr	NEWA
>D>	AB	75MG	A207433	004	May 05, 2016	Jun	CAHN
	AB	75MG	A207433	004	May 05, 2016	Apr	NEWA
>D>	AB	100MG	A207433	005	May 05, 2016	Jun	CAHN
	AB	100MG	A207433	005	May 05, 2016	Apr	NEWA
>D>	AB	150MG	A207433	006	May 05, 2016	Jun	CAHN
	AB	150MG	A207433	006	May 05, 2016	Apr	NEWA
		NORPRAMIN					
AB		US PHARM HOLDINGS 10MG	N014399	007	Feb 11, 1982	Jan	CAHN
AB		25MG	N014399	001		Jan	CAHN
AB		50MG	N014399	003		Jan	CAHN
AB		75MG	N014399	004		Jan	CAHN
AB	+	100MG	N014399	005		Jan	CAHN
AB		150MG	N014399	006		Jan	CAHN

DESLORATADINE

## SOLUTION;ORAL

## DESLORATADINE

AA		TARO 0.5MG/ML	A202936	001	May 26, 2016	May	NEWA
----	--	---------------	---------	-----	--------------	-----	------

DESMOPRESSIN ACETATE

## TABLET;ORAL

## DESMOPRESSIN ACETATE

>D>		FERRING 0.1MG	N021795	001	May 08, 2008	Jun	DISC
>A>		@ 0.1MG	N021795	001	May 08, 2008	Jun	DISC
>D>		+ 0.2MG	N021795	002	May 08, 2008	Jun	DISC
>A>		@ 0.2MG	N021795	002	May 08, 2008	Jun	DISC

DESONIDE

## CREAM;TOPICAL

## DESONIDE

AB		G AND W LABS INC 0.05%	A074027	001	Sep 28, 1992	Jan	CAHN
----	--	------------------------	---------	-----	--------------	-----	------

DESOXIMETASONE

## OINTMENT;TOPICAL

## DESOXIMETASONE

AB		NOVEL LABS INC 0.25%	A206792	001	May 10, 2016	Apr	NEWA
AB		PERRIGO ISRAEL 0.25%	A077770	001	Apr 20, 2015	May	CAHN
AB		TELLIGENT PHARMA INC 0.25%	A208101	001	Feb 25, 2016	Feb	NEWA

DESVENLAFAXINE SUCCINATE

## TABLET, EXTENDED RELEASE;ORAL

## DESVENLAFAXINE SUCCINATE

AB		ROXANE EQ 50MG BASE	A204082	001	Feb 16, 2016	Feb	NEWA
AB		EQ 100MG BASE	A204083	001	Feb 16, 2016	Feb	NEWA

DEXAMETHASONE

## TABLET;ORAL

## DEXAMETHASONE

	@	IDT AUSTRALIA LTD 0.75MG	A080399	001		May	CAHN
	@	SUN PHARM INDS 0.25MG	A084013	001		Mar	CAHN
	@	0.25MG	A084764	001		Mar	CAHN
	@	0.5MG	A084084	001		Mar	CAHN
	@	0.5MG	A084766	001		Mar	CAHN
	@	0.75MG	A084081	001		Mar	CAHN
	@	0.75MG	A084765	001		Mar	CAHN
	@	1.5MG	A084086	001		Mar	CAHN
	@	1.5MG	A084763	001		Mar	CAHN

DEXAMETHASONE SODIUM PHOSPHATE

INJECTABLE; INJECTION  
DEXAMETHASONE SODIUM PHOSPHATE PRESERVATIVE FREE

AP + FRESENIUS KABI USA EQ 10MG PHOSPHATE/ML A040491 001 Apr 11, 2003 Mar CTNA

DEXLANSOPRAZOLE

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE; ORAL  
DEXILANT SOLUTAB

+ TAKEDA PHARMS USA 30MG N208056 001 Jan 26, 2016 Jan NEWA

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE; INJECTION  
DEXMEDETOMIDINE HYDROCHLORIDE

AP ACCORD HLTHCARE INC EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A204023 001 Feb 09, 2016 Jan NEWA

AP AUROBINDO PHARMA LTD EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A205867 001 Mar 17, 2016 Mar NEWA

AP SANDOZ INC EQ 200MCG BASE/2ML (EQ 100MCG BASE/ML) A091465 001 Jun 14, 2016 May NEWA

PRECEDEX

+ HOSPIRA EQ 80MCG BASE/20ML (EQ 4MCG BASE/ML) N021038 004 Nov 14, 2014 Feb CRLD

DEXMETHYLPHENIDATE HYDROCHLORIDE

TABLET; ORAL  
DEXMETHYLPHENIDATE HYDROCHLORIDE

AB SUN PHARM INDS 2.5MG A201231 001 Sep 24, 2015 Feb CAHN

AB 5MG A201231 002 Sep 24, 2015 Feb CAHN

AB 10MG A201231 003 Sep 24, 2015 Feb CAHN

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE; INJECTION  
TOTECT

+ CLINIGEN HLTHCARE EQ 500MG BASE/VIAL N022025 001 Sep 06, 2007 Mar CAHN

DEXTROAMPHETAMINE SULFATE

CAPSULE, EXTENDED RELEASE; ORAL  
DEXTROAMPHETAMINE SULFATE

AB MYLAN PHARMS INC 5MG A206735 001 Jan 27, 2016 Jan NEWA

AB 10MG A206735 002 Jan 27, 2016 Jan NEWA

AB 15MG A206735 003 Jan 27, 2016 Jan NEWA

TABLET; ORAL

DEXTROAMPHETAMINE SULFATE

AA NESHER PHARMS 5MG A206588 001 Mar 28, 2016 Mar NEWA

AA 10MG A206588 002 Mar 28, 2016 Mar NEWA

AA NOVEL LABS INC 5MG A204330 001 Mar 16, 2016 Feb NEWA

AA 10MG A204330 002 Mar 16, 2016 Feb NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL  
PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

@ ANI PHARMS 15MG/5ML; 6.25MG/5ML N011265 002 Apr 02, 1984 Feb CMS1

DEXTROSE; MAGNESIUM CHLORIDE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION  
DEXTROSE 5% AND ELECTROLYTE NO. 48 IN PLASTIC CONTAINER

BAXTER HLTHCARE 5GM/100ML; 31MG/100ML; 141MG/100ML; 20MG/100ML; 12MG/100ML; 260MG/100ML N017484 001 Feb CMS1

DEXTROSE; POTASSIUM CHLORIDE; POTASSIUM PHOSPHATE, MONOBASIC; SODIUM CHLORIDE; SODIUM LACTATE

INJECTABLE; INJECTION  
DEXTROSE 5% AND ELECTROLYTE NO. 75 IN PLASTIC CONTAINER

@ BAXTER HLTHCARE 5GM/100ML; 205MG/100ML; 100MG/100ML; 120MG/100ML; 220MG/100ML N018840 001 Jun 29, 1983 Feb CMS1

DIAZEPAM

INJECTABLE; INJECTION  
DIAZEPAM

@ EUROHLTH INTL SARL 5MG/ML A070313 001 Dec 16, 1985 Jan CAHN

	SOLUTION;ORAL						
>A>	DIAZEPAM						
>A> AA	LANNETT HOLDINGS INC	5MG/5ML	A206477	001	Jun 24, 2016	Jun	NEWA
>D>	+ ROXANE	5MG/5ML	A070928	001	Apr 03, 1987	Jun	CFTG
>A> AA	+	5MG/5ML	A070928	001	Apr 03, 1987	Jun	CFTG
	TABLET;ORAL						
	DIAZEPAM						
	DAVA PHARMS INC	2MG	A070228	002	Sep 26, 1985	Jan	NEWA
		5MG	A070228	003	Sep 26, 1985	Jan	NEWA
	<u>DICLOFENAC POTASSIUM</u>						
	CAPSULE;ORAL						
	DICLOFENAC POTASSIUM						
AB	BIONPHARMA INC	25MG	A204648	001	Feb 23, 2016	Feb	NEWA
	ZIPSOR						
AB	+ DEPOMED INC	25MG	N022202	001	Jun 16, 2009	Feb	CFTG
	FOR SOLUTION;ORAL						
	CAMBIA						
AB	+ DEPOMED INC	50MG	N022165	001	Jun 17, 2009	Apr	CFTG
	DICLOFENAC POTASSIUM						
AB	PAR FORM	50MG	A202964	001	May 02, 2016	Apr	NEWA
	TABLET;ORAL						
	CATAFLAM						
	@ NOVARTIS	50MG	N020142	002	Nov 24, 1993	Mar	DISC
	DICLOFENAC POTASSIUM						
>D>	@ MUTUAL PHARM	50MG	A075470	001	Feb 21, 2002	Jun	CAHN
AB	+ MYLAN	50MG	A075463	001	Jul 26, 1999	Mar	CRLD
>A>	@ SUN PHARM INDS	50MG	A075470	001	Feb 21, 2002	Jun	CAHN
	<u>DICLOFENAC SODIUM</u>						
	GEL;TOPICAL						
	DICLOFENAC SODIUM						
AB	AMNEAL PHARMS	1%	A208077	001	Mar 18, 2016	Mar	NEWA
AB	TARO	3%	A206298	001	Apr 28, 2016	Apr	NEWA
	VOLTAREN						
AB	+ GLAXOSMITHKLINE CONS	1%	N022122	001	Oct 17, 2007	Mar	CFTG
	SOLUTION;TOPICAL						
	DICLOFENAC SODIUM						
AT	TELIGENT PHARMA INC	1.5%	A202769	001	Jul 08, 2015	May	CAHN
	SOLUTION/DROPS;OPHTHALMIC						
	DICLOFENAC SODIUM						
AT	RISING PHARMS INC	0.1%	A078553	001	Dec 28, 2007	Jan	CAHN
	TABLET, EXTENDED RELEASE;ORAL						
	DICLOFENAC SODIUM						
AB	+ ACTAVIS ELIZABETH	100MG	A075910	001	Jan 07, 2002	Feb	CRLD
	VOLTAREN-XR						
	@ NOVARTIS	100MG	N020254	001	Mar 08, 1996	Feb	DISC
	<u>DICLOFENAC SODIUM; MISOPROSTOL</u>						
	TABLET, DELAYED RELEASE;ORAL						
	DICLOFENAC SODIUM AND MISOPROSTOL						
AB	EXELA PHARMA SCS LLC	50MG;0.2MG	A200540	001	Mar 14, 2014	Mar	CAHN
AB		75MG;0.2MG	A200540	002	Mar 14, 2014	Mar	CAHN
	<u>DICYCLOMINE HYDROCHLORIDE</u>						
	CAPSULE;ORAL						
	DICYCLOMINE HYDROCHLORIDE						
	@ SUN PHARM INDS	10MG	A084505	001	Oct 21, 1986	Mar	CAHN
	INJECTABLE;INJECTION						
	DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE FREE)						
AP	EUROHLTH INTL SARL	10MG/ML	A040465	001	Jun 30, 2003	Mar	CMS1
	SYRUP;ORAL						
	BENTYL						
	@ APTALIS PHARMA US	10MG/5ML	N007961	002	Oct 15, 1984	Jan	DISC
	DICYCLOMINE HYDROCHLORIDE						
	+ MIKART	10MG/5ML	A040169	001	Mar 24, 2005	Jan	CRLD
	TABLET;ORAL						
	DICYCLOMINE HYDROCHLORIDE						
	@ SUN PHARM INDS	20MG	A084600	001	Jul 29, 1985	Mar	CAHN

DIENOGEST; ESTRADIOL VALERATE

TABLET; ORAL

ESTRADIOL VALERATE AND DIENOGEST

AB		WATSON LABS INC	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M	A 202349	001	May 06, 2016	Apr	NEWA
			G, N/A					
		NATAZIA						
AB	+	BAYER HLTHCARE	N/A, 2MG, 3MG, N/A, N/A; 3MG, 2MG, 2MG, 1M	N 022252	001	May 06, 2010	Apr	CFTG
			G, N/A					

DIETHYLPROPION HYDROCHLORIDE

TABLET; ORAL

DIETHYLPROPION HYDROCHLORIDE

		@ COREPHARMA	25MG	A 040828	001	Nov 05, 2008	Mar	DISC
		TENUATE						
AA	+	ACTAVIS LABS UT INC	25MG	N 011722	002		Apr	CAHN
AA	+	ALLERGAN SALES LLC	25MG	N 011722	002		Mar	CAHN
		TABLET, EXTENDED RELEASE; ORAL						
		TENUATE DOSPAN						
AB	+	ACTAVIS LABS UT INC	75MG	N 012546	001		Apr	CAHN
AB	+	ALLERGAN SALES LLC	75MG	N 012546	001		Mar	CAHN

DIFLUNISAL

TABLET; ORAL

DIFLUNISAL

		@ IDT AUSTRALIA LTD	500MG	A 074604	001	Jun 10, 1996	May	CAHN
--	--	---------------------	-------	----------	-----	--------------	-----	------

DIGOXIN

INJECTABLE; INJECTION

LANOXIN

>D>	AP	+	COVIS INJECTABLES	0.25MG/ML	N 009330	002		Jun	CAHN
>A>	AP	+	COVIS PHARMA SARL	0.25MG/ML	N 009330	002		Jun	CAHN
			LANOXIN PEDIATRIC						
>D>		+	COVIS INJECTABLES	0.1MG/ML	N 009330	004		Jun	CAHN
>A>		+	COVIS PHARMA SARL	0.1MG/ML	N 009330	004		Jun	CAHN

DIHYDROERGOTAMINE MESYLATE

INJECTABLE; INJECTION

DIHYDROERGOTAMINE MESYLATE

AP		EUROHLTH INTL SARL	1MG/ML	A 040453	001	Jun 09, 2003	Apr	CAHN
----	--	--------------------	--------	----------	-----	--------------	-----	------

DILTIAZEM HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE; ORAL

DILTIAZEM HYDROCHLORIDE

		@ ACTAVIS LABS FL INC	120MG	A 074852	001	Oct 10, 1997	Jan	DISC
		@	180MG	A 074852	002	Oct 10, 1997	Jan	DISC
		@	240MG	A 074852	003	Oct 10, 1997	Jan	DISC
AB3		VALEANT PHARMS NORTH	120MG	A 075116	001	Dec 23, 1999	Jan	CAHN
AB3			180MG	A 075116	002	Dec 23, 1999	Jan	CAHN
AB3			240MG	A 075116	003	Dec 23, 1999	Jan	CAHN
AB3			300MG	A 075116	004	Dec 23, 1999	Jan	CAHN

INJECTABLE; INJECTION

DILTIAZEM HYDROCHLORIDE

>A>	AP	+	AMPHASTAR PHARMS INC	5MG/ML	A 074617	001	Feb 28, 1996	Jun	CAHN
>D>	AP	+	EUROHLTH INTL SARL	5MG/ML	A 074617	001	Feb 28, 1996	Jun	CAHN
	AP	+		5MG/ML	A 074617	001	Feb 28, 1996	Apr	CAHN

DINOPROSTONE

INSERT, EXTENDED RELEASE; VAGINAL

CERVIDIL

		+	FERRING PHARMS INC	10MG	N 020411	001	Mar 30, 1995	Jan	CAHN
--	--	---	--------------------	------	----------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIPHENHYDRAMINE HYDROCHLORIDE

>A>		@ HIKMA INTL PHARMS	50MG	A 083567	001		Jun	CAHN
>D>		@ HIKMA PHARMS	50MG	A 083567	001		Jun	CAHN
		@	50MG	A 083567	001		Feb	CAHN
>D>		@ MUTUAL PHARM	50MG	A 089489	001	Jan 02, 1987	Jun	CAHN
		@ SUN PHARM INDS	25MG	A 089488	001	Jan 02, 1987	Mar	CAHN
>A>		@	50MG	A 089489	001	Jan 02, 1987	Jun	CAHN

DIPYRIDAMOLEINJECTABLE; INJECTION  
DIPYRIDAMOLE

>A>	AP	+	AMPHASTAR PHARMS INC	5MG/ML	A 074939	001	Apr 13, 1998	Jun	CAHN
>D>	AP	+	EUROHLTH INTL SARL	5MG/ML	A 074939	001	Apr 13, 1998	Jun	CAHN
	AP	+		5MG/ML	A 074939	001	Apr 13, 1998	Apr	CAHN

TABLET; ORAL

DIPYRIDAMOLE

	@	IDT AUSTRALIA LTD	25MG	A 086944	002	Apr 16, 1991	May	CAHN
	@		50MG	A 087562	001	Feb 25, 1992	May	CAHN
	@		75MG	A 087561	001	Feb 25, 1992	May	CAHN

DISOPYRAMIDE PHOSPHATE

CAPSULE; ORAL

DISOPYRAMIDE PHOSPHATE

	@	AUROLIFE PHARMA LLC	EQ 100MG BASE	A 070470	001	Dec 10, 1985	Feb	CAHN
	@		EQ 150MG BASE	A 070471	001	Dec 10, 1985	Feb	CAHN
	@	SUN PHARM INDS	EQ 100MG BASE	A 070351	001	Dec 17, 1985	Mar	CAHN
	@		EQ 150MG BASE	A 070352	001	Dec 17, 1985	Mar	CAHN

DISULFIRAM

TABLET; ORAL

DISULFIRAM

AB		ALVOGEN MALTA	250MG	A 091681	001	Aug 08, 2013	Jan	CAHN
----	--	---------------	-------	----------	-----	--------------	-----	------

DIVALPROEX SODIUM

TABLET, EXTENDED RELEASE; ORAL

DIVALPROEX SODIUM

	@	IMPAX LABS	EQ 250MG VALPROIC ACID	A 078791	001	May 06, 2009	Feb	DISC
	@		EQ 500MG VALPROIC ACID	A 078791	002	Aug 04, 2009	Feb	DISC

DOBUTAMINE HYDROCHLORIDE

INJECTABLE; INJECTION

DOBUTAMINE HYDROCHLORIDE

	@	TELIGENT PHARMA INC	EQ 12.5MG BASE/ML	A 074098	001	Feb 21, 1995	Jan	CAHN
--	---	---------------------	-------------------	----------	-----	--------------	-----	------

DOCETAXEL

INJECTABLE; INJECTION

DOCETAXEL

>A>		HOSPIRA INC	20MG/ML (20MG/ML)	N 022234	004	Jun 23, 2016	Jun	NEWA
>A>			80MG/4ML (20MG/ML)	N 022234	005	Jun 23, 2016	Jun	NEWA
>A>			120MG/6ML (20MG/ML)	N 022234	006	Jun 23, 2016	Jun	NEWA

SOLUTION; IV (INFUSION)

DOCETAXEL

		EAGLE PHARMS	20MG/ML (20MG/ML)	N 205934	001	Dec 22, 2015	Jan	CAHN
			80MG/4ML (20MG/ML)	N 205934	002	Dec 22, 2015	Jan	CAHN
			160MG/8ML (20MG/ML)	N 205934	003	Dec 22, 2015	Jan	CAHN

DOFETILIDE

CAPSULE; ORAL

DOFETILIDE

AB		TIGER PHARMS LLC	0.125MG	A 207058	001	Jun 06, 2016	May	NEWA
AB			0.25MG	A 207058	002	Jun 06, 2016	May	NEWA
AB			0.5MG	A 207058	003	Jun 06, 2016	May	NEWA

TIKOSYN

AB		PFIZER	0.125MG	N 020931	001	Oct 01, 1999	May	CFTG
AB			0.25MG	N 020931	002	Oct 01, 1999	May	CFTG
AB	+		0.5MG	N 020931	003	Oct 01, 1999	May	CFTG

DOLASETRON MESYLATE

INJECTABLE; INJECTION

ANZEMET

	+	US PHARM HOLDINGS	12.5MG/0.625ML (20MG/ML)	N 020624	002	Sep 11, 1997	Jan	CAHN
	+		12.5MG/0.625ML (20MG/ML)	N 020624	002	Sep 11, 1997	Jan	CAHN
	+		100MG/5ML (20MG/ML)	N 020624	001	Sep 11, 1997	Jan	CAHN
>D>	+		500MG/25ML (20MG/ML)	N 020624	003	Dec 11, 2001	Jun	DISC
>A>	@		500MG/25ML (20MG/ML)	N 020624	003	Dec 11, 2001	Jun	DISC
	+		500MG/25ML (20MG/ML)	N 020624	003	Dec 11, 2001	Jan	CAHN

## TABLET;ORAL

## ANZEMET

	US PHARM HOLDINGS	50MG	N020623	001	Sep 11, 1997	Jan CAHN
+		100MG	N020623	002	Sep 11, 1997	Jan CAHN

DOLUTEGRAVIR SODIUM

## TABLET;ORAL

## TIVICAY

>A>	VIIV HLTHCARE	EQ 10MG BASE	N204790	002	Jun 09, 2016	Jun NEWA
>A>		EQ 25MG BASE	N204790	003	Jun 09, 2016	Jun NEWA

DONEPEZIL HYDROCHLORIDE

## TABLET;ORAL

## DONEPEZIL HYDROCHLORIDE

AB	DEXCEL PHARMA	23MG	A203713	001	Feb 19, 2016	Feb NEWA
AB	INDICUS PHARMA	23MG	A203419	001	Apr 12, 2016	Mar NEWA
>D> AB	OSMOTICA PHARM CORP	23MG	A203114	001	Jan 26, 2016	Jun CAHN
AB		23MG	A203114	001	Jan 26, 2016	Jan NEWA
>A> AB	OSMOTICA PHARM US	23MG	A203114	001	Jan 26, 2016	Jun CAHN
>A> AB	UNICHEM LABS LTD	5MG	A203656	001	Jun 23, 2016	Jun NEWA
>A> AB		10MG	A203656	002	Jun 23, 2016	Jun NEWA

## TABLET, ORALLY DISINTEGRATING;ORAL

## DONEPEZIL HYDROCHLORIDE

@	SUN PHARM INDS	5MG	A077975	002	Dec 11, 2009	Mar CAHN
@		10MG	A077975	001	Dec 11, 2009	Mar CAHN

DOXAPRAM HYDROCHLORIDE

## INJECTABLE;INJECTION

## DOXAPRAM HYDROCHLORIDE

>A> AP	AMPHASTAR PHARMS INC	20MG/ML	A076266	001	Jan 10, 2003	Jun CAHN
>D> AP	EUROHLTH INTL SARL	20MG/ML	A076266	001	Jan 10, 2003	Jun CAHN
AP		20MG/ML	A076266	001	Jan 10, 2003	Apr CAHN

DOXAZOSIN MESYLATE

## TABLET;ORAL

## DOXAZOSIN MESYLATE

@	IDT AUSTRALIA LTD	EQ 1MG BASE	A075432	001	Oct 18, 2000	Mar CAHN
@		EQ 2MG BASE	A075432	002	Oct 18, 2000	Mar CAHN
@		EQ 4MG BASE	A075432	003	Oct 18, 2000	Mar CAHN
@		EQ 8MG BASE	A075432	004	Oct 18, 2000	Mar CAHN

DOXEPIN HYDROCHLORIDE

## CAPSULE;ORAL

## DOXEPIN HYDROCHLORIDE

@	SUN PHARM INDS	EQ 25MG BASE	A071502	001	Feb 18, 1988	Mar CAHN
@		EQ 50MG BASE	A071653	001	Feb 18, 1988	Mar CAHN
@		EQ 75MG BASE	A071654	001	Feb 18, 1988	Mar CAHN
@		EQ 100MG BASE	A071521	001	Feb 18, 1988	Mar CAHN

## TABLET;ORAL

## DOXEPIN HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 3MG BASE	A202337	001	Jan 20, 2016	Jan NEWA
AB		EQ 6MG BASE	A202337	002	Jan 20, 2016	Jan NEWA

DOXERCALCIFEROL

## INJECTABLE;INJECTION

## DOXERCALCIFEROL

AP	AKORN INC	2MCG/ML (2MCG/ML)	A203929	002	Mar 28, 2016	Mar NEWA
AP	GENZYME CORP	2MCG/ML (2MCG/ML)	N021027	002	Apr 06, 2000	Mar CFTG

DOXORUBICIN HYDROCHLORIDE

## INJECTABLE;INJECTION

## DOXORUBICIN HYDROCHLORIDE

AP	ACTAVIS INC	2MG/ML	A203622	001	Jun 27, 2014	May CRLD
AP		200MG/100ML	A203622	002	Jun 27, 2014	May CRLD
AP	+ PHARMACIA AND UPJOHN	2MG/ML	N050629	001	Dec 23, 1987	May CRLD
AP	+	200MG/100ML	N050629	002	May 03, 1988	May CRLD

DOXYCYCLINE

## CAPSULE;ORAL

## DOXYCYCLINE

AB	G AND W LABS INC	EQ 50MG BASE	A204446	001	May 28, 2015	Mar	CAHN
AB		EQ 75MG BASE	A204446	002	May 28, 2015	Mar	CAHN
AB		EQ 100MG BASE	A204446	003	May 28, 2015	Mar	CAHN
AB	ZYDUS PHARMS USA INC	EQ 50MG BASE	A205115	001	Feb 18, 2016	Feb	NEWA
AB		EQ 75MG BASE	A205115	002	Feb 18, 2016	Feb	NEWA
AB		EQ 100MG BASE	A205115	003	Feb 18, 2016	Feb	NEWA

## TABLET;ORAL

## DOXYCYCLINE

>D>	@ MUTUAL PHARM	EQ 50MG BASE	A065471	001	Apr 17, 2009	Jun	CAHN
>D>	@	EQ 75MG BASE	A065471	002	Apr 17, 2009	Jun	CAHN
>D>	@	EQ 100MG BASE	A065471	003	Apr 17, 2009	Jun	CAHN
>A>	@ SUN PHARM INDS	EQ 50MG BASE	A065471	001	Apr 17, 2009	Jun	CAHN
>A>	@	EQ 75MG BASE	A065471	002	Apr 17, 2009	Jun	CAHN
>A>	@	EQ 100MG BASE	A065471	003	Apr 17, 2009	Jun	CAHN

DOXYCYCLINE HYCLATE

## CAPSULE;ORAL

## ACTICLATE CAP

+	AQUA PHARMS	EQ 75MG BASE	N208253	001	Apr 26, 2016	Apr	NEWA
---	-------------	--------------	---------	-----	--------------	-----	------

## DOXYCYCLINE HYCLATE

>A>	AB	AMNEAL PHARMS	EQ 100MG BASE	A207289	001	Jun 27, 2016	Jun	NEWA
	AB	SUN PHARM INDS	EQ 100MG BASE	A062676	001	Jul 10, 1986	Mar	CAHN

## TABLET;ORAL

## DOXYCYCLINE HYCLATE

		@ COREPHARMA	EQ 20MG BASE	A065182	001	May 13, 2005	Mar	DISC
	AB	SUN PHARM INDS	EQ 20MG BASE	A065134	001	May 13, 2005	Mar	CAHN
	AB		EQ 100MG BASE	A062677	001	Jul 10, 1986	Mar	CAHN
		@ VINTAGE PHARMS	EQ 100MG BASE	A062538	001	Apr 07, 1986	Mar	DISC

## TABLET, DELAYED RELEASE;ORAL

## DORYX

AB	MAYNE PHARMA	EQ 80MG BASE	N050795	004	Apr 11, 2013	Apr	CFTG	
AB	+	EQ 200MG BASE	N050795	005	Apr 11, 2013	May	CFTG	
		DOXYCYCLINE HYCLATE						
		@ IMPAX LABS INC	EQ 75MG BASE	A090505	001	Dec 28, 2010	Mar	DISC
		@	EQ 100MG BASE	A090505	002	Dec 28, 2010	Mar	DISC
	AB	MYLAN	EQ 50MG BASE	A090431	003	May 23, 2016	May	NEWA
	AB		EQ 80MG BASE	A090431	004	Apr 29, 2016	Apr	NEWA
	AB		EQ 200MG BASE	A090431	005	May 19, 2016	May	NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

## TABLET;ORAL

## MELAMISA

AB	NOVAST LABS LTD	3MG;0.02MG	A202016	001	Jan 26, 2016	Jan	NEWA
----	-----------------	------------	---------	-----	--------------	-----	------

## TABLET;ORAL-28

## DROSPIRENONE AND ETHINYL ESTRADIOL

AB	GLENMARK PHARMS LTD	3MG;0.03MG	A204848	001	Mar 25, 2016	Mar	NEWA
----	---------------------	------------	---------	-----	--------------	-----	------

DUTASTERIDE

## CAPSULE;ORAL

## DUTASTERIDE

AB	AUROLIFE PHARMA LLC	0.5MG	A202660	001	Nov 20, 2015	Apr	CAHN
AB	BIONPHARMA INC	0.5MG	A200899	001	Nov 20, 2015	Jan	CAHN
AB	INTERGEL PHARMS INC	0.5MG	A206373	001	Mar 17, 2016	Feb	NEWA
AB	MYLAN PHARMS INC	0.5MG	A203241	001	Jun 14, 2016	May	NEWA
AB	STRIDES PHARMA	0.5MG	A204262	001	Nov 20, 2015	Mar	CAHN

>D> DYPHYLLINE

## &gt;D&gt; TABLET;ORAL

## &gt;D&gt; LUFYLLIN

>D>		MEDA PHARMS	200MG	A084566	001		Jun	DISC
>A>		@	200MG	A084566	001		Jun	DISC
>D>	+		400MG	A084566	002		Jun	DISC
>A>		@	400MG	A084566	002		Jun	DISC



ECONAZOLE NITRATE

CREAM; TOPICAL  
 ECONAZOLE NITRATE  
 AB TELIGENT PHARMA INC 1% A076574 001 Dec 17, 2004 May CAHN

EDROPHONIUM CHLORIDE

INJECTABLE; INJECTION  
 TENSILON  
 @ TELIGENT PHARMA INC 10MG/ML N007959 001 Jan CAHN  
 TENSILON PRESERVATIVE FREE  
 @ TELIGENT PHARMA INC 10MG/ML N007959 002 Jan CAHN

EFAVIRENZ

TABLET; ORAL  
 EFAVIRENZ  
 >D> AB MYLAN LABS LTD 600MG A091471 001 Feb 17, 2016 Jun CAHN  
 AB 600MG A091471 001 Feb 17, 2016 Feb NEWA  
 >A> AB MYLAN PHARMS INC 600MG A091471 001 Feb 17, 2016 Jun CAHN  
 SUSTIVA  
 AB + BRISTOL MYERS SQUIBB 600MG N021360 002 Feb 01, 2002 Feb CFTG

ELBASVIR; GRAZOPREVIR

TABLET; ORAL  
 ZEPATIER  
 + MERCK SHARP DOHME 50MG;100MG N208261 001 Jan 28, 2016 Jan NEWA

ELUXADOLINE

TABLET; ORAL  
 VIBERZI  
 ALLERGAN HOLDINGS 75MG N206940 001 May 27, 2015 May CAHN  
 + 100MG N206940 002 May 27, 2015 May CAHN

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL  
 ODEFSEY  
 + GILEAD SCIENCES INC 200MG;EQ 25MG BASE;EQ 25MG BASE N208351 001 Mar 01, 2016 Apr CAIN

EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL  
 ODEFSEY  
 + GILEAD SCIENCES INC 200MG;EQ 25MG BASE;EQ 25MG BASE N208351 001 Mar 01, 2016 Mar NEWA

EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE

TABLET; ORAL  
 DESCOVY  
 + GILEAD SCIENCES INC 200MG;EQ 25MG BASE N208215 001 Apr 04, 2016 Apr NEWA

EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE

TABLET; ORAL  
 TRUVADA  
 GILEAD 100MG;150MG N021752 002 Mar 10, 2016 Mar NEWA  
 133MG;200MG N021752 003 Mar 10, 2016 Mar NEWA  
 167MG;250MG N021752 004 Mar 10, 2016 Mar NEWA

ENALAPRILAT

INJECTABLE; INJECTION  
 ENALAPRILAT  
 >A> AP + AMPHASTAR PHARMS INC 1.25MG/ML A075634 001 Aug 22, 2000 Jun CAHN  
 >D> AP + EUROHLTH INTL SARL 1.25MG/ML A075634 001 Aug 22, 2000 Jun CAHN  
 AP + 1.25MG/ML A075634 001 Aug 22, 2000 Apr CAHN

EPHEDRINE SULFATE

SOLUTION; INTRAVENOUS  
 AKOVAZ  
 + FLAMEL IRELAND LTD 50MG/ML N208289 001 Apr 29, 2016 Apr NEWA

EPINASTINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
 EPINASTINE HYDROCHLORIDE  
 AT SOMERSET THERAPS LLC 0.05% A090951 001 Oct 31, 2011 Mar CAHN

EPINEPHRINE

INJECTABLE; INJECTION  
 SUS-PHRINE SULFITE FREE  
 @ FOREST LABS 1.5MG/AMP N007942 003 Feb 05, 1999 Mar CMS1  
 @ 5MG/ML N007942 001 Mar CMS1  
 INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS  
 AUVI-Q  
 BX + KALEO INC EQ 0.15MG/DELIVERY N201739 002 Aug 10, 2012 Mar CAHN  
 BX EQ 0.3MG/DELIVERY N201739 001 Aug 10, 2012 Mar CAHN  
 TWINJECT 0.15  
 @ AMEDRA PHARMS EQ 0.15MG/DELIVERY N020800 002 May 28, 2004 May DISC  
 TWINJECT 0.3  
 @ AMEDRA PHARMS EQ 0.3MG/DELIVERY N020800 001 May 30, 2003 May DISC

EPINEPHRINE HYDROCHLORIDE

SOLUTION; IV (INFUSION), INTRAOCULAR, INTRAMUSCULAR, SUBCUTANEOUS  
 EPINEPHRINE  
 BELCHER PHARMS LLC EQ 1MG BASE/ML (EQ 1MG BASE/ML) N205029 001 Jul 29, 2014 Feb CDFR

ERGOCALCIFEROL

CAPSULE; ORAL  
 DRISDOL  
 AA + US PHARM HOLDINGS 50,000 IU N003444 001 Jan CAHN  
 VITAMIN D  
 AA BIONPHARMA INC 50,000 IU A080704 001 Jan CAHN

ERGOLOID MESYLATES

TABLET; ORAL  
 ERGOLOID MESYLATES  
 AB SUN PHARM INDS 1MG A081113 001 Oct 31, 1991 Mar CAHN  
 TABLET; SUBLINGUAL  
 ERGOLOID MESYLATES  
 >D> @ MUTUAL PHARM 0.5MG A087407 001 Jun CAHN  
 >D> @ 1MG A087552 001 Jun CAHN  
 >A> @ SUN PHARM INDS 0.5MG A087407 001 Jun CAHN  
 >A> @ 1MG A087552 001 Jun CAHN

ERYTHROMYCIN

SOLUTION; TOPICAL  
 C-SOLVE-2  
 @ FOUGERA PHARMS 2% A062468 001 Jul 03, 1985 Feb DISC  
 ERYTHRO-STATIN  
 @ HI TECH PHARMA 2% A064101 001 Oct 22, 1996 Feb DISC  
 ERYTHROMYCIN  
 AT + FOUGERA PHARMS 2% A064187 001 Sep 30, 1997 Jan CRLD  
 AT PERRIGO NEW YORK 2% A063038 001 Jan 11, 1991 Jan CRLD

ESCITALOPRAM OXALATE

SOLUTION; ORAL  
 ESCITALOPRAM OXALATE  
 AA MACLEODS PHARMS LTD EQ 5MG BASE/5ML A202754 001 Mar 31, 2016 Mar NEWA

ESMOLOL HYDROCHLORIDE

SOLUTION; INTRAVENOUS  
 ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER  
 + HQ SPCLT PHARMA 2GM/100ML (20MG/ML) N205703 002 Apr 07, 2016 Apr NEWA  
 ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER  
 >D> HQ SPCLT PHARMA 2.5GM/250ML (10MG/ML) N205703 001 Apr 07, 2016 Jun CRLD  
 >A> + 2.5GM/250ML (10MG/ML) N205703 001 Apr 07, 2016 Jun CRLD  
 2.5GM/250ML (10MG/ML) N205703 001 Apr 07, 2016 Apr NEWA

ESOMEPRAZOLE MAGNESIUM

CAPSULE, DELAYED REL PELLETS;ORAL  
ESOMEPRAZOLE MAGNESIUM

AB	AUROBINDO PHARMA LTD	EQ 20MG BASE	A205606	001	Apr 21, 2016	Apr	NEWA
AB		EQ 40MG BASE	A205606	002	Apr 21, 2016	Apr	NEWA
BX	HETERO LABS LTD III	EQ 20MG BASE	A202784	001	Sep 21, 2015	Apr	CTEC
BX		EQ 40MG BASE	A202784	002	Sep 21, 2015	Apr	CTEC

ESTRADIOL

CREAM;VAGINAL  
ESTRACE

+	ALLERGAN SALES LLC	0.01%	A086069	001	Jan 31, 1984	Apr	CAHN
---	--------------------	-------	---------	-----	--------------	-----	------

FILM, EXTENDED RELEASE;TRANSDERMAL  
ALORA

BX	ALLERGAN SALES LLC	0.025MG/24HR	N020655	004	Apr 05, 2002	Mar	CAHN
BX		0.05MG/24HR	N020655	001	Dec 20, 1996	Mar	CAHN
BX		0.075MG/24HR	N020655	002	Dec 20, 1996	Mar	CAHN
BX		0.1MG/24HR	N020655	003	Dec 20, 1996	Mar	CAHN

ESTRADIOL ACETATE

INSERT, EXTENDED RELEASE;VAGINAL  
FEMRING

	APIL	EQ 0.05MG BASE/24HR	N021367	001	Mar 20, 2003	Jan	CAHN
+		EQ 0.1MG BASE/24HR	N021367	002	Mar 20, 2003	Jan	CAHN

TABLET;ORAL  
FEMTRACE

	APIL	0.45MG	N021633	001	Aug 20, 2004	Jan	CAHN
		0.9MG	N021633	002	Aug 20, 2004	Jan	CAHN
+		1.8MG	N021633	003	Aug 20, 2004	Jan	CAHN

ESTRADIOL HEMIHYDRATE

EMULSION;TOPICAL  
ESTRASORB

>A>	+	EXELTIS USA INC	0.25%	N021371	001	Oct 09, 2003	Jun	CAHN
>D>	+	MEDICIS	0.25%	N021371	001	Oct 09, 2003	Jun	CAHN

ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL

>A>	AMABELZ							
>A>	AB	LUPIN LTD	0.5MG;0.1MG	A203339	001	Jun 20, 2016	Jun	NEWA
>A>	AB		1MG;0.5MG	A203339	002	Jun 20, 2016	Jun	NEWA

ESTROGENS, CONJUGATED SYNTHETIC A

>D> TABLET;ORAL

>D> CENESTIN

>D>	TEVA BRANDED PHARM	0.3MG	N020992	001	Jun 21, 2002	Jun	DISC
>A>	@	0.3MG	N020992	001	Jun 21, 2002	Jun	DISC
>D>		0.45MG	N020992	005	Feb 05, 2004	Jun	DISC
>A>	@	0.45MG	N020992	005	Feb 05, 2004	Jun	DISC
>D>		0.625MG	N020992	002	Mar 24, 1999	Jun	DISC
>A>	@	0.625MG	N020992	002	Mar 24, 1999	Jun	DISC
>D>		0.9MG	N020992	003	Mar 24, 1999	Jun	DISC
>A>	@	0.9MG	N020992	003	Mar 24, 1999	Jun	DISC
>D>	+	1.25MG	N020992	004	Mar 13, 2000	Jun	DISC
>A>	@	1.25MG	N020992	004	Mar 13, 2000	Jun	DISC

ESTROGENS, CONJUGATED SYNTHETIC B

TABLET;ORAL

ENJUWIA

>D>	TEVA WOMENS	0.625MG	N021443	003	May 10, 2004	Jun	DISC
>A>	@	0.625MG	N021443	003	May 10, 2004	Jun	DISC

ETHACRYNIC ACID

TABLET;ORAL

EDECIN

>D>	+	ATON	25MG	N016092	001		Jun	CFTG
>A>	AB	+	25MG	N016092	001		Jun	CFTG
>A>		ETHACRYNIC ACID						
>A>	AB	EDENBRIDGE PHARMS	25MG	A205609	001	Jun 30, 2016	Jun	NEWA

ETHINYL ESTRADIOL; ETHYNODIOL DIACETATE

TABLET;ORAL-28

ETHYNODIOL DIACETATE AND ETHINYL ESTRADIOL

AB	JAI PHARMA LTD	0.05MG;1MG	A204704	001	Feb 09, 2016	Jan	NEWA
AB	+ ZOVIA 1/50E-28						
AB	+ WATSON LABS	0.05MG;1MG	A072723	001	Dec 30, 1991	Jan	CTEC

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL

FAYOSIM

AB	LUPIN LTD	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	A205943	001	Mar 29, 2016	Mar	NEWA
AB	+ QUARTETTE						
AB	+ TEVA BRANDED PHARM	0.02MG,0.15MG;0.025MG,0.15MG;0.03MG,0.15MG;0.01MG,N/A	N204061	001	Mar 28, 2013	Mar	CFTG

TABLET;ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB1	AMNEAL PHARMS	0.02MG;0.1MG	A201108	001	Feb 05, 2014	May	CAHN
-----	---------------	--------------	---------	-----	--------------	-----	------

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21

BREVICON 21-DAY

	@ ALLERGAN SALES LLC	0.035MG;0.5MG	N017566	001		Apr	CAHN
AB	NORINYL 1+35 21-DAY						
AB	ALLERGAN SALES LLC	0.035MG;1MG	N017565	001		Mar	CAHN

TABLET;ORAL-28

BREVICON 28-DAY

AB	ALLERGAN SALES LLC	0.035MG;0.5MG	N017743	001		Mar	CAHN
AB	NORINYL 1+35 28-DAY						
AB	ALLERGAN SALES LLC	0.035MG;1MG	N017565	002		Mar	CAHN

TABLET, CHEWABLE;ORAL

FEMCON FE

AB	+ APIL	0.035MG;0.4MG	N021490	001	Nov 14, 2003	Jan	CAHN
	NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB	+ APIL	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Jan	CAHN
AB	LUPIN LTD	0.035MG;0.4MG	A091332	001	Mar 23, 2016	Mar	NEWA

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

CAPSULE;ORAL

NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

	@ APIL	0.02MG;1MG	N204426	001	Apr 19, 2013	Apr	CAHN
--	--------	------------	---------	-----	--------------	-----	------

TABLET;ORAL

FEMHRT

AB	APIL	0.0025MG;0.5MG	N021065	001	Jan 14, 2005	Jan	CAHN
	@	0.005MG;1MG	N021065	002	Oct 15, 1999	Jan	CAHN
	LERIBANE						
AB	NOVAST LABS LTD	0.0025MG;0.5MG	A203435	002	Jun 03, 2016	May	NEWA
AB		0.005MG;1MG	A203435	001	Jun 03, 2016	May	NEWA

LO LOESTRIN FE

AB	+ APIL	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	May	CFTG
	+ APIL	0.01MG,0.01MG;1MG,N/A	N022501	001	Oct 21, 2010	Jan	CAHN
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND ETHINYL ESTRADIOL AND FERROUS FUMARATE						
AB	JAI PHARMA LTD	0.01MG,0.01MG;1MG,N/A	A205049	001	May 31, 2016	May	NEWA

TABLET;ORAL-21

ESTROSTEP 21

	@ APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	001	Oct 09, 1996	Jan	CAHN
	LOESTRIN 21 1.5/30						
AB	APIL	0.03MG;1.5MG	N017875	001		Apr	CAHN
	LOESTRIN 21 1/20						
AB	APIL	0.02MG;1MG	N017876	001		Apr	CAHN
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL						
AB	GLENMARK PHARMS LTD	0.02MG;1MG	A206969	001	Jan 20, 2016	Jan	NEWA

TABLET;ORAL-28

ESTROSTEP FE

AB	+ APIL	0.02MG,0.03MG,0.035MG;1MG,1MG,1MG	N020130	002	Oct 09, 1996	Jan	CAHN
	LOESTRIN FE 1.5/30						
AB	+ APIL	0.03MG;1.5MG	N017355	001		Apr	CAHN
	LOESTRIN FE 1/20						
AB	APIL	0.02MG;1MG	N017354	001		Apr	CAHN

## TABLET, CHEWABLE;ORAL

	MIBELAS 24 FE						
AB	LUPIN ATLANTIS	0.02MG;1MG	A206287	001	May 24, 2016	May	NEWA
	MINASTRIN 24 FE						
AB	+ APIL	0.02MG;1MG	N203667	001	May 08, 2013	May	CFTG
		0.02MG;1MG	N203667	001	May 08, 2013	Jan	CAHN
	TABLET, CHEWABLE, TABLET;ORAL						
	LO MINASTRIN FE						
	+ APIL	0.01MG,0.01MG,N/A;1MG,N/A,N/A	N204654	001	Jul 24, 2013	Jan	CAHN

ETHINYL ESTRADIOL; NORGESTIMATE

## TABLET;ORAL-28

>A>	MILI						
>A>	AUROBINDO PHARMA LTD	0.035MG;0.25MG	A205449	001	Jul 07, 2016	Jun	NEWA
	NORGESTIMATE AND ETHINYL ESTRADIOL						
AB	AMNEAL PHARMS	0.035MG;0.25MG	A203865	001	Oct 27, 2015	May	CAHN
>A>	GLENMARK PHARMS	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A204057	001	Feb 23, 2016	Jun	CAHN
		15MG,0.25MG					
>D>	GLENMARK PHARMS LTD	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A204057	001	Feb 23, 2016	Jun	CAHN
		15MG,0.25MG					
AB		0.025MG,0.025MG,0.025MG;0.18MG,0.2	A204057	001	Feb 23, 2016	Feb	NEWA
		15MG,0.25MG					
AB	HAUPT PHARMA	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A203873	001	May 12, 2016	May	NEWA
		15MG,0.25MG					
AB	JAI PHARMA LTD	0.035MG, 0.035MG, 0.035MG;0.18MG,	A201897	001	Jan 27, 2016	Jan	NEWA
		0.215MG, 0.25MG					
AB		0.035MG;0.25MG	A201896	001	Jan 27, 2016	Jan	NEWA
AB	LUPIN LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A205588	001	Apr 26, 2016	Apr	NEWA
		15MG,0.25MG					
>A>	TRI-MILI						
>A>	AUROBINDO PHARMA LTD	0.035MG,0.035MG,0.035MG;0.18MG,0.2	A205441	001	Jul 06, 2016	Jun	NEWA
		15MG,0.25MG					

ETHINYL ESTRADIOL; NORGESTREL

## TABLET;ORAL-21

	LO/OVRAL						
>A>	@ PELAGIUS	0.03MG;0.3MG	N017612	001		Jun	CAHN
>D>	@ WYETH PHARMS INC	0.03MG;0.3MG	N017612	001		Jun	CAHN
	TABLET;ORAL-28						
	LO/OVRAL-28						
>D>	AB WYETH PHARMS	0.03MG;0.3MG	N017802	001		Jun	DISC
>A>	@	0.03MG;0.3MG	N017802	001		Jun	DISC
>A>	NORGESTREL AND ETHINYL ESTRADIOL						
>A>	AB JAI PHARMA LTD	0.03MG;0.3MG	A201828	001	Jun 21, 2016	Jun	NEWA

ETHOSUXIMIDE

## CAPSULE;ORAL

	ETHOSUXIMIDE						
AB	BIONPHARMA INC	250MG	A040430	001	Oct 28, 2002	Jan	CAHN

ETIDRONATE DISODIUM

## TABLET;ORAL

	DIDRONEL						
AB	APIL	200MG	N017831	001		Apr	CAHN
AB	+	400MG	N017831	002		Apr	CAHN

ETODOLAC

## CAPSULE;ORAL

	ETODOLAC						
	@ IDT AUSTRALIA LTD	200MG	A074840	001	Aug 29, 1997	May	CAHN
	@	300MG	A074840	002	Aug 29, 1997	May	CAHN
	@ LEHIGH VALLEY	300MG	A074929	001	Jan 30, 1998	Feb	CAHN

ETOMIDATE

## INJECTABLE;INJECTION

	ETOMIDATE						
AP	EUROHLTH INTL SARL	2MG/ML	A074593	001	Nov 04, 1996	Apr	CAHN
AP	HIKMA FARMACEUTICA	2MG/ML	A202354	001	Feb 25, 2016	Feb	NEWA

EXEMESTANETABLET; ORAL  
EXEMESTANE

AB	ALVOGEN MALTA	25MG	A200898	001	Jul 28, 2014	Jan CAHN
----	---------------	------	---------	-----	--------------	----------

EXENATIDE SYNTHETICFOR SUSPENSION, EXTENDED RELEASE; SUBCUTANEOUS  
BYDUREON PEN

+	ASTRAZENECA AB	2MG	N022200	002	Feb 28, 2014	Feb NEWA
---	----------------	-----	---------	-----	--------------	----------

FAMOTIDINEINJECTABLE; INJECTION  
FAMOTIDINE

>A>	AP	AMPHASTAR PHARMS INC	10MG/ML	A075651	001	Apr 16, 2001	Jun CAHN
>A>	AP		10MG/ML	A075684	001	Apr 16, 2001	Jun CAHN
>D>	AP	EUROHLTH INTL SARL	10MG/ML	A075651	001	Apr 16, 2001	Jun CAHN
	AP		10MG/ML	A075651	001	Apr 16, 2001	Apr CAHN
>D>	AP		10MG/ML	A075684	001	Apr 16, 2001	Jun CAHN
	AP		10MG/ML	A075684	001	Apr 16, 2001	Apr CAHN
		FAMOTIDINE PRESERVATIVE FREE					
>A>	AP	AMPHASTAR PHARMS INC	10MG/ML	A075622	001	Apr 16, 2001	Jun CAHN
>A>	AP		10MG/ML	A075825	001	Apr 17, 2001	Jun CAHN
>D>	AP	EUROHLTH INTL SARL	10MG/ML	A075622	001	Apr 16, 2001	Jun CAHN
	AP		10MG/ML	A075622	001	Apr 16, 2001	Apr CAHN
>D>	AP		10MG/ML	A075825	001	Apr 17, 2001	Jun CAHN
	AP		10MG/ML	A075825	001	Apr 17, 2001	Apr CAHN

TABLET; ORAL

FAMOTIDINE

@	SUN PHARM INDS	20MG	A075639	002	Dec 12, 2001	Mar CAHN
@		40MG	A075639	001	Dec 12, 2001	Mar CAHN

FELODIPINETABLET, EXTENDED RELEASE; ORAL  
FELODIPINE

AB	SUN PHARM INDS	2.5MG	A075896	001	Nov 02, 2004	Mar CAHN
AB		5MG	A075896	002	Nov 02, 2004	Mar CAHN
AB		10MG	A075896	003	Nov 02, 2004	Mar CAHN

FENOFIBRATETABLET; ORAL  
FENOFIBRATE

AB	AUROBINDO PHARMA LTD	48MG	A205118	001	May 05, 2016	Apr NEWA	
AB		145MG	A205118	002	May 05, 2016	Apr NEWA	
>A>	AB	HETERO LABS LTD III	48MG	A204598	001	Jul 12, 2016	Jun NEWA
>A>	AB		145MG	A204598	002	Jul 12, 2016	Jun NEWA
>A>	AB	MYLAN	40MG	A204475	001	Jun 23, 2016	Jun NEWA
>A>	AB		120MG	A204475	002	Jun 23, 2016	Jun NEWA
		FENOGLIDE					
>D>		SANTARUS INC	40MG	N022118	001	Aug 10, 2007	Jun CFTG
>A>	AB		40MG	N022118	001	Aug 10, 2007	Jun CFTG
>D>	+		120MG	N022118	002	Aug 10, 2007	Jun CFTG
>A>	AB	+	120MG	N022118	002	Aug 10, 2007	Jun CFTG

FENOFIBRIC ACIDTABLET; ORAL  
FIBRICOR

>D>		ARALENZ PHARMS	35MG	N022418	001	Aug 14, 2009	Jun CAHN
			35MG	N022418	001	Aug 14, 2009	Apr CAHN
>D>	+		105MG	N022418	002	Aug 14, 2009	Jun CAHN
	+		105MG	N022418	002	Aug 14, 2009	Apr CAHN
>A>		ARALEZ PHARMS INC	35MG	N022418	001	Aug 14, 2009	Jun CAHN
>A>	+		105MG	N022418	002	Aug 14, 2009	Jun CAHN

FENOPROFEN CALCIUM

CAPSULE; ORAL

FENOPROFEN CALCIUM

@	AUROLIFE PHARMA LLC	EQ 200MG BASE	A072394	001	Oct 17, 1988	Mar CAHN
@		EQ 300MG BASE	A072395	001	Oct 17, 1988	Feb CAHN

TABLET; ORAL

FENOPROFEN CALCIUM

@	AUROLIFE PHARMA LLC	EQ 600MG BASE	A072396	001	Oct 17, 1988	Feb CAHN
---	---------------------	---------------	---------	-----	--------------	----------

	TABLET;ORAL								
	FENOPROFEN CALCIUM								
	@ SUN PHARM INDS	EQ 600MG BASE	A072902	001	Dec 21, 1990	Mar	CAHN		
	<u>FENTANYL</u>								
	FILM, EXTENDED RELEASE;TRANSDERMAL								
	FENTANYL-12								
AB	AVEVA	12.5MCG/HR	A077449	005	Sep 11, 2015	Jan	NEWA		
	<u>FERRIC PYROPHOSPHATE CITRATE</u>								
	FOR SOLUTION;INTRAVENOUS								
	TRIFERIC								
	+ ROCKWELL MEDICAL INC	272MG IRON/PACKET	N208551	001	Apr 25, 2016	Apr	NEWA		
	<u>FESOTERODINE FUMARATE</u>								
	TABLET, EXTENDED RELEASE;ORAL								
	FESOTERODINE FUMARATE								
	@ ALKEM LABS LTD	4MG	A204827	001	Dec 10, 2015	Jan	DISC		
	@	8MG	A204827	002	Dec 10, 2015	Jan	DISC		
	<u>FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE</u>								
	TABLET, EXTENDED RELEASE;ORAL								
	FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE								
	@ BARR	60MG;120MG	A076236	001	Apr 14, 2005	Mar	DISC		
	@ IMPAX PHARMS	60MG;120MG	A076298	001	Nov 12, 2010	Mar	DISC		
	<u>FLAVOXATE HYDROCHLORIDE</u>								
	TABLET;ORAL								
	FLAVOXATE HYDROCHLORIDE								
	@ IMPAX PHARMS	100MG	A076234	001	Aug 28, 2003	Mar	DISC		
	<u>FLECAINIDE ACETATE</u>								
	TABLET;ORAL								
	FLECAINIDE ACETATE								
	@ IDT AUSTRALIA LTD	50MG	A076030	001	Oct 28, 2002	May	CAHN		
	@	100MG	A076030	002	Oct 28, 2002	May	CAHN		
	@	150MG	A076030	003	Oct 28, 2002	May	CAHN		
	<u>FLUCICLOVINE F-18</u>								
	SOLUTION;INTRAVENOUS								
	AXUMIN								
	+ BLUE EARTH	9-221mCi/ML	N208054	001	May 27, 2016	May	NEWA		
	<u>FLUCONAZOLE</u>								
	FOR SUSPENSION;ORAL								
	FLUCONAZOLE								
	@ SUN PHARM INDS LTD	50MG/5ML	A076332	001	Jul 29, 2004	Feb	DISC		
	@	200MG/5ML	A076332	002	Jul 29, 2004	Feb	DISC		
	INJECTABLE;INJECTION								
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9%								
	EUROHLTH INTL SARL	100MG/50ML (2MG/ML)	A076087	002	Sep 26, 2008	Apr	CAHN		
AP		200MG/100ML (2MG/ML)	A076087	001	Jul 29, 2004	Apr	CAHN		
AP		400MG/200ML (2MG/ML)	A076087	003	Jul 29, 2004	Apr	CAHN		
	@ TEVA PHARMS USA	200MG/100ML (2MG/ML)	A076653	001	Jul 29, 2004	Jan	DISC		
	@	400MG/200ML (2MG/ML)	A076653	002	Jul 29, 2004	Jan	DISC		
	FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER								
AP	ACS DOBFAR INFO SA	200MG/100ML (2MG/ML)	A079104	001	Jul 30, 2009	Mar	CMS1		
AP		400MG/200ML (2MG/ML)	A079104	002	Jul 30, 2009	Mar	CMS1		
>D>	AP	BEDFORD LABS	200MG/100ML (2MG/ML)	A078107	001	Jul 30, 2008	Jun	CAHN	
>D>	AP		400MG/200ML (2MG/ML)	A078107	002	Jul 30, 2008	Jun	CAHN	
>A>	AP	EUROHLTH INTL SARL	200MG/100ML (2MG/ML)	A078107	001	Jul 30, 2008	Jun	CAHN	
>A>	AP		400MG/200ML (2MG/ML)	A078107	002	Jul 30, 2008	Jun	CAHN	
	TABLET;ORAL								
	FLUCONAZOLE								
	@ IDT AUSTRALIA LTD	50MG	A076086	001	Jul 29, 2004	May	CAHN		
	@	100MG	A076086	002	Jul 29, 2004	May	CAHN		
	@	150MG	A076086	003	Jul 29, 2004	May	CAHN		
	@	200MG	A076086	004	Jul 29, 2004	May	CAHN		

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS		FLUDEOXYGLUCOSE F18					
AP	KREITCHMAN PET CTR	10-100mCi/ML	A203942	001	Apr 11, 2016	Mar	NEWA
AP	+ QUEEN HAMAMATSU PET	10-100mCi/ML	A203771	001	Aug 31, 2015	Mar	CTEC
AP	ZEVACOR PHARMA INC	20-300mCi/ML	A203591	001	Aug 31, 2015	Feb	CAHN

FLUMAZENIL

INJECTABLE; INJECTION		FLUMAZENIL					
AP	EUROHLTH INTL SARL	0.5MG/5ML (0.1MG/ML)	A076256	002	Oct 12, 2004	Apr	CAHN
AP		1MG/10ML (0.1MG/ML)	A076256	001	Oct 12, 2004	Apr	CAHN

FLUOCINOLONE ACETONIDE

OIL; TOPICAL		FLUOCINOLONE ACETONIDE					
AT	LYNE	0.01%	A090982	001	Apr 25, 2016	Apr	NEWA
AT		0.01%	A203377	001	Apr 25, 2016	Apr	NEWA
AT	TARO	0.01%	A202368	001	May 19, 2016	May	NEWA
AT		0.01%	A209336	001	May 19, 2016	May	NEWA
OIL/DROPS; OTIC		FLUOCINOLONE ACETONIDE					
AT	LYNE	0.01%	A203378	001	Apr 25, 2016	Apr	NEWA

FLUOROURACIL

INJECTABLE; INJECTION		FLUOROURACIL					
AP	SAGENT PHARMS	2.5GM/50ML (50MG/ML)	A203609	001	Feb 17, 2016	Feb	NEWA
AP		5GM/100ML (50MG/ML)	A203609	002	Feb 17, 2016	Feb	NEWA
	@ SPECTRUM PHARMS	500MG/10ML (50MG/ML)	N012209	001		Jan	CAHN

FLUOXETINE HYDROCHLORIDE

CAPSULE; ORAL		FLUOXETINE					
	@ SUN PHARM INDS	EQ 10MG BASE	A075787	001	Jan 29, 2002	Mar	CAHN
	@	EQ 20MG BASE	A075787	002	Jan 29, 2002	Mar	CAHN
TABLET; ORAL		FLUOXETINE HYDROCHLORIDE					
	+ EDMONT PHARMS LLC	EQ 60MG BASE	N202133	001	Oct 06, 2011	Mar	CRLD
	SARAFEM						
AB1	APIL	EQ 10MG BASE	N021860	001	May 19, 2006	Jan	CAHN
AB1		EQ 15MG BASE	N021860	002	May 19, 2006	Jan	CAHN
AB1	+	EQ 20MG BASE	N021860	003	May 19, 2006	Jan	CAHN

FLURANDRENOLIDE

CREAM; TOPICAL		CORDRAN SP					
AT	+ AQUA PHARMS	0.05%	N012806	002		Mar	CFTG
FLURANDRENOLIDE		CORDRAN					
AT	TELIGENT PHARMA INC	0.05%	A205342	001	Apr 13, 2016	Mar	NEWA
TAPE; TOPICAL		CORDRAN					
	+ ALLERGAN SALES LLC	0.004MG/SQ CM	N016455	001		Apr	CAHN

FLURANDRENOLIDE; NEOMYCIN SULFATE

CREAM; TOPICAL		CORDRAN N					
	@ LILLY	0.05%;EQ 3.5MG BASE/GM	N050346	001		Mar	CMS1
OINTMENT; TOPICAL		CORDRAN N					
	@ LILLY	0.05%;EQ 3.5MG BASE/GM	N050345	001		Mar	CMS1

FLURAZEPAM HYDROCHLORIDE

CAPSULE; ORAL		FLURAZEPAM HYDROCHLORIDE					
	@ AUROLIFE PHARMA LLC	15MG	A071716	001	Jul 31, 1991	Feb	CAHN
	@	30MG	A071717	001	Jul 31, 1991	Feb	CAHN
	@ HIKMA INTL PHARMS	15MG	A071107	001	Dec 08, 1986	May	CAHN
	@ SUN PHARM INDS	15MG	A070454	001	Aug 04, 1986	Mar	CAHN
	@	30MG	A070455	001	Aug 04, 1986	Mar	CAHN



FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

@	AUROLIFE PHARMA LLC	50MG	A074448	001	Jul 28, 1995	Feb	CAHN
@		100MG	A074448	002	Jul 28, 1995	Feb	CAHN

FLUTICASONE FUROATE

POWDER; INHALATION

ARNUITY ELLIPTA

+	GLAXOSMITHKLINE	0.1MG/INH	N205625	001	Aug 20, 2014	Mar	CRLD
---	-----------------	-----------	---------	-----	--------------	-----	------

FLUTICASONE FUROATE; VILANTEROL TRIFENATATE

POWDER; INHALATION

BREQ ELLIPTA

+	GLAXO GRP LTD	0.2MG/INH;EQ 0.025MG BASE/INH	N204275	002	Apr 30, 2015	Mar	CRLD
---	---------------	-------------------------------	---------	-----	--------------	-----	------

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

FLONASE

>D>									
>D>	AB	+	GLAXOSMITHKLINE	0.05MG/SPRAY	N020121	001	Oct 19, 1994	Jun	DISC
>A>			@	0.05MG/SPRAY	N020121	001	Oct 19, 1994	Jun	DISC

FLUVASTATIN SODIUM

TABLET, EXTENDED RELEASE; ORAL

FLUVASTATIN SODIUM

AB	MYLAN PHARMS INC	EQ 80MG BASE	A202458	001	Sep 11, 2015	May	CPOT	
AB	TEVA PHARMS USA	EQ 80MG BASE	A079011	001	Jan 27, 2016	May	CPOT	
AB		80MG	A079011	001	Jan 27, 2016	Jan	NEWA	
	LESCOL XL							
AB	+	NOVARTIS	EQ 80MG BASE	N021192	001	Oct 06, 2000	May	CPOT

FLUVOXAMINE MALEATE

TABLET; ORAL

FLUVOXAMINE MALEATE

@	NOSTRUM LABS INC	25MG	A075900	001	Feb 23, 2006	Feb	CAHN
@		50MG	A075900	002	Feb 23, 2006	Feb	CAHN
@		100MG	A075900	003	Feb 23, 2006	Feb	CAHN
@	SUN PHARM INDS	25MG	A076125	001	Apr 29, 2002	Mar	CAHN
@		50MG	A076125	002	Apr 29, 2002	Mar	CAHN
@		100MG	A076125	003	Apr 29, 2002	Mar	CAHN

FOLIC ACID

INJECTABLE; INJECTION

FOLVITE

@	WYETH PHARMS INC	5MG/ML	N005897	008			May	CAHN
---	------------------	--------	---------	-----	--	--	-----	------

TABLET; ORAL

FOLIC ACID

@	SUN PHARM INDS	1MG	A040582	001	Jul 18, 2005	Mar	CAHN	
@	WYETH PHARMS INC	1MG	N005897	004			May	CAHN

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS

FOLLISTIM AQ

>D>	+	ORGANON USA INC	75 IU/0.5ML	N021273	001	Aug 26, 2005	Jun	DISC
>A>		@	75 IU/0.5ML	N021273	001	Aug 26, 2005	Jun	DISC
>D>	+		150 IU/0.5ML	N021273	002	Aug 26, 2005	Jun	DISC
>A>		@	150 IU/0.5ML	N021273	002	Aug 26, 2005	Jun	DISC

FORMOTEROL FUMARATE; GLYCOPYRROLATE

AEROSOL, METERED; INHALATION

BEVESPI AEROSPHERE

+	PEARL THERAPS INC	0.0048MG/INH;0.0090MG/INH	N208294	001	Apr 25, 2016	Apr	NEWA
---	-------------------	---------------------------	---------	-----	--------------	-----	------

FOSAMPRENAVIR CALCIUM

TABLET; ORAL

FOSAMPRENAVIR CALCIUM

AB	MYLAN PHARMS INC	EQ 700MG BASE	A204060	001	Apr 15, 2016	Apr	NEWA	
	LEXIVA							
AB	+	VIIV HLTHCARE	EQ 700MG BASE	N021548	001	Oct 20, 2003	Apr	CFTG

FOSAPREPITANT DIMEGLUMINEPOWDER; INTRAVENOUS  
EMEND

AP	+	MERCK AND CO INC	EQ 150MG BASE/VIAL	N022023	002	Nov 12, 2010	May CFTG
AP		FOSAPREPITANT DIMEGLUMINE					
AP		FRESENIUS KABI USA	EQ 150MG BASE/VIAL	A206197	001	Jun 09, 2016	May NEWA

FOSINOPRIL SODIUMTABLET; ORAL  
FOSINOPRIL SODIUM

@	ACTAVIS LABS FL INC	10MG	A076620	001	Oct 15, 2004	Jan DISC
@		20MG	A076620	002	Oct 15, 2004	Jan DISC
@		40MG	A076620	003	Oct 15, 2004	Jan DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDETABLET; ORAL  
FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

@	ACTAVIS LABS FL INC	10MG;12.5MG	A076608	001	Dec 03, 2004	Jan DISC
@		20MG;12.5MG	A076608	002	Dec 03, 2004	Jan DISC
@	SUN PHARM INDS LTD	10MG;12.5MG	A076739	001	Dec 17, 2004	Feb DISC
@		20MG;12.5MG	A076739	002	Dec 17, 2004	Feb DISC

FOSPHENYTOIN SODIUMINJECTABLE; INJECTION  
FOSPHENYTOIN SODIUM

>D>	AP	BEDFORD	EQ 50MG PHENYTOIN NA/ML	A077481	001	Aug 06, 2007	Jun CAHN
>A>	AP	EUROHLTH INTL SARL	EQ 50MG PHENYTOIN NA/ML	A077481	001	Aug 06, 2007	Jun CAHN

FROVATRIPTAN SUCCINATETABLET; ORAL  
FROVATRIPTAN SUCCINATE

AB		GLENMARK PHARMS LTD	EQ 2.5MG BASE	A204730	001	Mar 11, 2016	Feb NEWA
----	--	---------------------	---------------	---------	-----	--------------	----------

FUROSEMIDEINJECTABLE; INJECTION  
FUROSEMIDE

AP		CLARIS	10MG/ML	A202747	001	Jan 27, 2014	May CAHN
		@ EUROHLTH INTL SARL	10MG/ML	A071439	001	Sep 14, 1990	Jan CAHN
		@ LUITPOLD	10MG/ML	N018579	001	Nov 30, 1983	Feb DISC

TABLET; ORAL

		FUROSEMIDE					
		@ SUN PHARM INDS	20MG	A070043	001	Sep 26, 1985	Mar CAHN
		@	80MG	A070100	001	Jan 26, 1988	Mar CAHN

AB		US PHARM HOLDINGS	20MG	N016273	002		Jan CAHN
AB			40MG	N016273	001		Jan CAHN
AB	+		80MG	N016273	003		Jan CAHN

GABAPENTINCAPSULE; ORAL  
GABAPENTIN

AB		SCIEGEN PHARMS INC	100MG	A204989	001	Feb 18, 2016	Feb NEWA
AB			300MG	A204989	002	Feb 18, 2016	Feb NEWA
AB			400MG	A204989	003	Feb 18, 2016	Feb NEWA
		@ SUN PHARM INDS	100MG	A076537	001	Jun 30, 2005	Mar CAHN
		@	300MG	A076537	002	Jun 30, 2005	Mar CAHN
		@	400MG	A076537	003	Jun 30, 2005	Mar CAHN

SOLUTION; ORAL  
GABAPENTIN

AA		TRIS PHARMA INC	250MG/5ML	A091286	001	Mar 14, 2016	Feb NEWA
----	--	-----------------	-----------	---------	-----	--------------	----------

TABLET; ORAL

		GABAPENTIN					
AB		SCIEGEN PHARMS INC	600MG	A205101	001	Feb 04, 2016	Jan NEWA
AB			800MG	A205101	002	Feb 04, 2016	Jan NEWA

GALANTAMINE HYDROBROMIDECAPSULE, EXTENDED RELEASE;ORAL  
GALANTAMINE HYDROBROMIDE

@	IMPAX LABS	EQ 8MG BASE	A 078484	001	May 27, 2009	Feb	DISC
@		EQ 16MG BASE	A 078484	002	May 27, 2009	Feb	DISC
@		EQ 24MG BASE	A 078484	003	May 27, 2009	Feb	DISC

SOLUTION;ORAL

GALANTAMINE HYDROBROMIDE

+	ROXANE	4MG/ML	A 078185	001	Jan 30, 2009	May	CRLD
	RAZADYNE						
@	JANSSEN PHARMS	4MG/ML	N 021224	001	Jun 22, 2001	May	DISC

GATIFLOXACIN

SOLUTION/DROPS;OPHTHALMIC

GATIFLOXACIN

>A>	AT	ALCON RES LTD	0.5%	A 204227	001	Jul 11, 2016	Jun	NEWA
-----	----	---------------	------	----------	-----	--------------	-----	------

GEMCITABINE HYDROCHLORIDE

INJECTABLE;INJECTION

GEMCITABINE HYDROCHLORIDE

AP		ACTAVIS INC	200MG/5.26ML (38MG/ML)	A 204549	001	Apr 11, 2016	Mar	NEWA
AP			1GM/26.3ML (38MG/ML)	A 204549	002	Apr 11, 2016	Mar	NEWA
AP			2GM/52.6ML (38MG/ML)	A 204549	003	Apr 11, 2016	Mar	NEWA
AP	+	HOSPIRA INC	200MG/5.26ML (38MG/ML)	N 200795	001	Aug 04, 2011	Mar	CFTG
AP	+		1GM/26.3ML (38MG/ML)	N 200795	002	Aug 04, 2011	Mar	CFTG
AP	+		2GM/52.6ML (38MG/ML)	N 200795	003	Aug 04, 2011	Mar	CFTG

GEMFIBROZIL

TABLET;ORAL

GEMFIBROZIL

>A>	AB	CADILA PHARMS LTD	600MG	A 203266	001	Jun 17, 2016	Jun	NEWA
-----	----	-------------------	-------	----------	-----	--------------	-----	------

GLIMEPIRIDE

TABLET;ORAL

GLIMEPIRIDE

@	ACTAVIS LABS FL INC	1MG	A 076995	001	Apr 27, 2010	Jan	DISC
@		2MG	A 076995	002	Apr 27, 2010	Jan	DISC
@		4MG	A 076995	003	Apr 27, 2010	Jan	DISC

GLIMEPIRIDE; ROSIGLITAZONE MALEATE

TABLET;ORAL

ROSIGLITAZONE MALEATE AND GLIMEPIRIDE

+	TEVA PHARMS USA	1MG;4MG	A 078709	001	Apr 01, 2016	Mar	NEWA
		2MG;4MG	A 078709	002	Apr 01, 2016	Mar	NEWA
		2MG;8MG	A 078709	004	Apr 01, 2016	Mar	NEWA
		4MG;4MG	A 078709	003	Apr 01, 2016	Mar	NEWA
		4MG;8MG	A 078709	005	Apr 01, 2016	Mar	NEWA

GLYBURIDE

TABLET;ORAL

GLYBURIDE

AB1		PHARMADAX INC	1.25MG	A 203581	001	Apr 14, 2016	Apr	NEWA
AB1			2.5MG	A 203581	002	Apr 14, 2016	Apr	NEWA
AB1			5MG	A 203581	003	Apr 14, 2016	Apr	NEWA
AB1		ZYDUS PHARMS USA INC	1.25mg	A 206749	001	May 10, 2016	Apr	NEWA
AB1			2.5mg	A 206749	002	May 10, 2016	Apr	NEWA
AB1			5MG	A 206749	003	May 10, 2016	Apr	NEWA

GLYBURIDE; METFORMIN HYDROCHLORIDE

TABLET;ORAL

GLYBURIDE AND METFORMIN HYDROCHLORIDE

@	COREPHARMA	1.25MG;250MG	A 076731	001	Nov 19, 2004	Jan	DISC	
@		2.5MG;500MG	A 076731	002	Nov 19, 2004	Jan	DISC	
@		5MG;500MG	A 076731	003	Nov 19, 2004	Jan	DISC	
AB		ZYDUS PHARMS USA INC	1.25MG;250MG	A 206748	001	Feb 29, 2016	Feb	NEWA
AB			2.5MG;500MG	A 206748	002	Feb 29, 2016	Feb	NEWA
AB			5MG;500MG	A 206748	003	Feb 29, 2016	Feb	NEWA

GLYCOPYRROLATEINJECTABLE; INJECTION  
GLYCOPYRROLATE

AP	+	HIKMA FARMACEUTICA	0.2MG/ML	A090963	001	Sep 21, 2011	Feb	CRLD
		ROBINUL						
	@	EUROHLTH INTL SARL	0.2MG/ML	N017558	001		Feb	DISC

TABLET; ORAL

GLYCOPYRROLATE

	@	HIKMA INTL PHARMS	1MG	A040836	001	Mar 05, 2009	May	CAHN
	@		2MG	A040836	002	Mar 05, 2009	May	CAHN
>A>	AA	NATCO PHARMA LTD	1MG	A091413	001	Jun 20, 2016	Jun	NEWA
>A>	AA		2MG	A091413	002	Jun 20, 2016	Jun	NEWA
	AA	RISING PHARMS INC	1MG	A040821	001	Dec 29, 2008	Jan	CAHN
	AA		2MG	A040821	002	Dec 29, 2008	Jan	CAHN
		ROBINUL						
AA	+	CASPER PHARMA LLC	1MG	N012827	001		Jan	CAHN
		ROBINUL FORTE						
AA	+	CASPER PHARMA LLC	2MG	N012827	002		Jan	CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE; INJECTION

GRANISETRON HYDROCHLORIDE

>A>	AP	AUROBINDO PHARMA LTD	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A204238	001	Jul 06, 2016	Jun	NEWA
>A>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A204238	002	Jul 06, 2016	Jun	NEWA
>D>	AP	BEDFORD LABS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A077913	001	Jun 26, 2008	Jun	CAHN
>D>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077186	001	Jun 30, 2008	Jun	CAHN
>D>	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077187	001	Jun 30, 2008	Jun	CAHN
	AP	BIONPHARMA INC	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Jan	CAHN
	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Jan	CAHN
	@	CLARIS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078197	001	Dec 31, 2007	May	CAHN
>A>	AP	EUROHLTH INTL SARL	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A077913	001	Jun 26, 2008	Jun	CAHN
>A>	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A077186	001	Jun 30, 2008	Jun	CAHN
>A>	AP		EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A077187	001	Jun 30, 2008	Jun	CAHN
	AP	HIKMA FARMACEUTICA	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078629	001	Dec 23, 2009	Jan	CMS1
	AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078629	002	Dec 23, 2009	Jan	CMS1
		GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE						
	AP	BIONPHARMA INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Jan	CAHN
		TABLET; ORAL						
		GRANISETRON HYDROCHLORIDE						
	@	COREPHARMA	EQ 1MG BASE	A078260	001	Dec 31, 2007	Mar	DISC

GUAIFENESIN; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION; ORAL

HYCOFENIX

+	MISSION PHARMACAL CO	200MG/5ML; 2.5MG/5ML; 30MG/5ML	N022279	001	May 14, 2015	Apr	CAHN
---	----------------------	--------------------------------	---------	-----	--------------	-----	------

GUANFACINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

GUANFACINE HYDROCHLORIDE

@	IMPAX LABS INC	EQ 1MG BASE	A202238	001	Oct 20, 2015	Mar	DISC
@		EQ 2MG BASE	A202238	002	Oct 20, 2015	Mar	DISC
@		EQ 3MG BASE	A202238	003	Oct 20, 2015	Mar	DISC
@		EQ 4MG BASE	A202238	004	Oct 20, 2015	Mar	DISC

HALOBETASOL PROPIONATE

LOTION; TOPICAL

ULTRAVATE

>D>	+	FERNDALE LABS INC	0.05%	N208183	001	Nov 06, 2015	Jun	CAHN
>A>	+	SUN PHARM INDS	0.05%	N208183	001	Nov 06, 2015	Jun	CAHN

HALOPERIDOL

TABLET; ORAL

HALOPERIDOL

	@	CYCLE PHARMS LTD	2MG	A071130	001	Feb 17, 1987	Jan	CAHN
>D>	@	MUTUAL PHARM	0.5MG	A071156	001	Jan 02, 1987	Jun	CAHN
>D>	@		1MG	A071157	001	Jan 02, 1987	Jun	CAHN
>A>	@	SUN PHARM INDS	0.5MG	A071156	001	Jan 02, 1987	Jun	CAHN
>A>	@		1MG	A071157	001	Jan 02, 1987	Jun	CAHN

## TABLET;ORAL

## HALOPERIDOL

@	2MG	A071172	001	Jan 02, 1987	Mar CAHN
@	5MG	A071212	001	Jan 07, 1988	Mar CAHN
@	10MG	A071173	001	Jan 07, 1988	Mar CAHN
@	20MG	A071177	001	Jan 07, 1988	Mar CAHN
@ VINTAGE	0.5MG	A071235	002	Nov 03, 1986	Jan CMS1
@	1MG	A071235	003	Nov 03, 1986	Jan CMS1
@	5MG	A071235	004	Nov 03, 1986	Jan CMS1
@	10MG	A071235	005	Jul 20, 1987	Jan CMS1

HEPARIN SODIUM

## INJECTABLE;INJECTION

## HEPARIN SODIUM

AP	FRESENIUS KABI USA	5,000 UNITS/ML	A206552	001	Jun 10, 2016	May NEWA
----	--------------------	----------------	---------	-----	--------------	----------

HEXACHLOROPHENE

## EMULSION;TOPICAL

## PHISOHEX

@ SANOFI AVENTIS US	3%	N006882	001		May DISC
---------------------	----	---------	-----	--	----------

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

## TABLET;ORAL

## HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

@ ACTAVIS ELIZABETH	1.5MG;5MG	A040295	001	Dec 01, 2000	Jan CMS1
---------------------	-----------	---------	-----	--------------	----------

HYDRALAZINE HYDROCHLORIDE

## INJECTABLE;INJECTION

## HYDRALAZINE HYDROCHLORIDE

AP	MYLAN INSTITUTIONAL	20MG/ML	A204680	001	Apr 28, 2016	Apr NEWA
----	---------------------	---------	---------	-----	--------------	----------

## TABLET;ORAL

## HYDRALAZINE HYDROCHLORIDE

@ ACTAVIS GRP PTC	10MG	A091679	001	Mar 04, 2013	Apr DISC	
@	25MG	A091679	002	Mar 04, 2013	Apr DISC	
@	50MG	A091679	003	Mar 04, 2013	Apr DISC	
@	100MG	A091679	004	Mar 04, 2013	Apr DISC	
>D>	@ MUTUAL PHARM	100MG	A088729	001	Apr 11, 1985	Jun CAHN
>A>	@ SUN PHARM INDS	10MG	A089359	001	Jul 25, 1986	Mar CAHN
	@	100MG	A088729	001	Apr 11, 1985	Jun CAHN

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

## TABLET;ORAL

## HYDRALAZINE AND HYDROCHLOROTHIAZIDE

@ WATSON LABS	25MG;15MG	A085827	001		Feb CMS1
---------------	-----------	---------	-----	--	----------

HYDRALAZINE HYDROCHLORIDE; HYDROCHLOROTHIAZIDE; RESERPINE

## TABLET;ORAL

## RESERPINE, HYDRALAZINE HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

@ SUN PHARM INDS	25MG;15MG;0.1MG	A088570	001	Apr 10, 1984	Mar CAHN
------------------	-----------------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE

## CAPSULE;ORAL

## MICROZIDE

AB	+ ALLERGAN SALES LLC	12.5MG	N020504	001	Dec 27, 1996	Apr CAHN
----	----------------------	--------	---------	-----	--------------	----------

## TABLET;ORAL

## HYDROCHLOROTHIAZIDE

@ AUROLIFE PHARMA LLC	25MG	A083899	001		Feb CAHN
@	50MG	A085219	001		Feb CAHN
@ HIKMA INTL PHARMS	25MG	A084878	002	Jul 12, 2006	May CAHN
AB		A084878	001		May CAHN
@ SUN PHARM INDS	25MG	A083972	001		Mar CAHN
@	50MG	A083972	002		Mar CAHN
@	100MG	A083972	003		Mar CAHN
ORETIC					
@ ABBVIE	50MG	N011971	002		Jan DISC

HYDROCHLOROTHIAZIDE; IRBESARTAN

TABLET; ORAL

IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB	AUROBINDO PHARMA LTD	25MG;300MG	A203630	003	Mar 31, 2016	Mar	NEWA
AB	INTL SPECLT CHEMS	12.5MG;150MG	A203036	001	Jan 15, 2016	Jan	NEWA
AB		12.5MG;300MG	A203036	002	Jan 15, 2016	Jan	NEWA
AB		25MG;300MG	A203036	003	Jan 15, 2016	Mar	CTEC
AB		25MG;300MG	A203036	003	Jan 15, 2016	Jan	NEWA

HYDROCHLOROTHIAZIDE; LISINOPRIL

TABLET; ORAL

ZESTORETIC

AB	ALVOGEN MALTA	12.5MG;10MG	N019888	003	Nov 18, 1993	Jan	CAHN
AB	+	12.5MG;20MG	N019888	001	Sep 20, 1990	Jan	CAHN
AB	+	25MG;20MG	N019888	002	Jul 20, 1989	Jan	CAHN

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

AB	SUN PHARM INDS	25MG;25MG	A089534	001	Jul 02, 1987	Mar	CAHN
----	----------------	-----------	---------	-----	--------------	-----	------

HYDROCHLOROTHIAZIDE; VALSARTAN

TABLET; ORAL

VALSARTAN AND HYDROCHLOROTHIAZIDE

AB	PRINSTON INC	12.5MG;80MG	A206083	001	Feb 08, 2016	Jan	NEWA
AB		12.5MG;160MG	A206083	002	Feb 08, 2016	Jan	NEWA
AB		12.5MG;320MG	A206083	003	Feb 08, 2016	Jan	NEWA
AB		25MG;160MG	A206083	004	Feb 08, 2016	Jan	NEWA
AB		25MG;320MG	A206083	005	Feb 08, 2016	Jan	NEWA

HYDROCODONE BITARTRATE; IBUPROFEN

TABLET; ORAL

HYDROCODONE BITARTRATE AND IBUPROFEN

AB	@ ACTAVIS LABS FL INC	5MG;200MG	A077454	001	Jun 23, 2010	Jan	DISC
AB	AUROLIFE PHARMA LLC	7.5MG;200MG	A204575	001	Jun 02, 2016	May	NEWA

HYDROCORTISONE

TABLET; ORAL

HYDROCORTISONE

AB	PHARMACEUTICS INTL	5MG	A207029	001	Apr 26, 2016	Apr	NEWA
AB		10MG	A207029	002	Apr 26, 2016	Apr	NEWA
AB		20MG	A207029	003	Apr 26, 2016	Apr	NEWA

HYDROCORTISONE VALERATE

CREAM; TOPICAL

WESTCORT

>D>	@ RANBAXY	0.2%	N017950	001		Jun	CAHN
>A>	@ SUN PHARM INDS LTD	0.2%	N017950	001		Jun	CAHN

HYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE

SUSPENSION/DROPS; OTIC

PEDIOTIC

@ MONARCH PHARMS 1%;EQ 3.5MG BASE/ML;10,000 UNITS/ML

A062822	001	Sep 29, 1987	Jan	DISC
---------	-----	--------------	-----	------

HYDROMORPHONE HYDROCHLORIDE

TABLET; ORAL

HYDROMORPHONE HYDROCHLORIDE

AB	AUROLIFE PHARMA LLC	2MG	A205814	001	May 13, 2016	May	NEWA
AB		4MG	A205814	002	May 13, 2016	May	NEWA
AB		8MG	A205814	003	May 13, 2016	May	NEWA

TABLET, EXTENDED RELEASE; ORAL

EXALGO

>D>	+	MALLINCKRODT INC	32MG	N021217	004	Aug 24, 2012	Jun	CFTG
>A>	AB	+	32MG	N021217	004	Aug 24, 2012	Jun	CFTG

HYDROMORPHONE HYDROCHLORIDE

>A>	AB	ACTAVIS LABS FL INC	32MG	A202144	004	Jun 30, 2016	Jun	NEWA
>A>	AB	OSMOTICA	8MG	A205629	001	Jul 07, 2016	Jun	NEWA
>A>	AB		12MG	A205629	002	Jul 07, 2016	Jun	NEWA
>A>	AB		16MG	A205629	003	Jul 07, 2016	Jun	NEWA
>A>	AB		32MG	A205629	004	Jul 07, 2016	Jun	NEWA

HYDROXOCOBALAMININJECTABLE; INJECTION  
CYANOKIT

	@ SERB SA	2.5GM/VIAL (5GM/KIT)	N022041	002	Dec 15, 2006	Jan	CAHN
	+	5GM/VIAL (5GM/KIT)	N022041	001	Apr 08, 2011	Jan	CAHN

HYDROXYCHLOROQUINE SULFATETABLET; ORAL  
HYDROXYCHLOROQUINE SULFATE

AB	WATSON LABS	200MG	A040133	001	Nov 30, 1995	Feb	CMFD
----	-------------	-------	---------	-----	--------------	-----	------

HYDROXYPROGESTERONE CAPROATEINJECTABLE; INJECTION  
HYDROXYPROGESTERONE CAPROATE

	+	ASPEN GLOBAL INC	250MG/ML	A200271	001	Aug 24, 2015	Jan	CAHN
--	---	------------------	----------	---------	-----	--------------	-----	------

SOLUTION; INTRAMUSCULAR  
MAKENA

>A>	+	AMAG PHARMA USA	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Jun	CAHN
>A>	+		1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	Jun	CAHN
>D>	+	LUMARA HEALTH INC	250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Jun	CAHN
	+		250MG/ML (250MG/ML)	N021945	002	Feb 19, 2016	Feb	NEWA
>D>	+		1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	Jun	CAHN

HYDROXYZINE HYDROCHLORIDETABLET; ORAL  
HYDROXYZINE HYDROCHLORIDE

	@ AUROLIFE PHARMA LLC	10MG	A087869	001	Dec 20, 1982	Feb	CAHN	
	@	25MG	A087870	001	Dec 20, 1982	Feb	CAHN	
	@	50MG	A087871	001	Dec 20, 1982	Feb	CAHN	
AB	ECI PHARMS LLC	10MG	A040804	001	Jun 30, 2008	May	CAHN	
AB		25MG	A040804	002	Jun 30, 2008	May	CAHN	
AB		50MG	A040804	003	Jun 30, 2008	May	CAHN	
>A>	AB	ELITE LABS INC	10MG	A040604	002	Dec 28, 2004	Jun	NEWA
>A>	AB		25MG	A040604	003	Dec 28, 2004	Jun	NEWA
	@ SUN PHARM INDS	10MG	A089381	001	May 19, 1986	Mar	CAHN	
	@	25MG	A089382	001	May 19, 1986	Mar	CAHN	
	@	50MG	A089383	001	May 19, 1986	Mar	CAHN	
	@	100MG	A087862	001	Apr 18, 1983	Mar	CAHN	

IBANDRONATE SODIUMINJECTABLE; INTRAVENOUS  
IBANDRONATE SODIUM

AP	ACCORD HLTHCARE	EQ 3MG BASE/3ML	A206058	001	Feb 05, 2016	Jan	NEWA
----	-----------------	-----------------	---------	-----	--------------	-----	------

TABLET; ORAL  
IBANDRONATE SODIUM

AB	AUROBINDO PHARMA LTD	EQ 150MG BASE	A204502	001	Mar 11, 2016	Feb	NEWA
AB	SUN PHARM INDS	EQ 150MG BASE	A078996	001	Aug 15, 2012	Mar	CAHN

IBUPROFENTABLET; ORAL  
IBUPROFEN

	@ AUROLIFE PHARMA LLC	300MG	A070734	001	Jun 12, 1986	Feb	CAHN
	@	400MG	A070735	001	Jun 12, 1986	Feb	CAHN
	@	600MG	A070736	001	Jun 12, 1986	Feb	CAHN
	@	800MG	A071938	001	Jan 14, 1988	Mar	CAHN
AB	STRIDES PHARMA	400MG	A078329	001	Feb 05, 2009	May	CAHN
AB		600MG	A078329	002	Feb 05, 2009	May	CAHN
AB		800MG	A078329	003	Feb 05, 2009	May	CAHN
	@ SUN PHARM INDS	400MG	A070079	001	Jul 24, 1985	Mar	CAHN
	@	600MG	A070080	001	Jul 24, 1985	Mar	CAHN
	@	800MG	A071448	001	Feb 18, 1987	Mar	CAHN

IBUPROFEN LYSINEINJECTABLE; INTRAVENOUS  
IBUPROFEN LYSINE

AP	EXELA PHARMA SCIENCE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	A202402	001	Mar 30, 2016	Mar	NEWA
----	----------------------	------------------------------------	---------	-----	--------------	-----	------

NEOPROFEN

AP	+	RECORDATI RARE	EQ 20MG BASE/2ML (EQ 10MG BASE/ML)	N021903	001	Apr 13, 2006	Mar	CFTG
----	---	----------------	------------------------------------	---------	-----	--------------	-----	------

IMIPRAMINE HYDROCHLORIDE

TABLET; ORAL

IMIPRAMINE HYDROCHLORIDE

AB	SUN PHARM INDS	10MG	A 081048	001	Jun 05, 1990	Mar	CAHN
AB		25MG	A 081049	001	Jun 05, 1990	Mar	CAHN
AB		50MG	A 081050	001	Jun 05, 1990	Mar	CAHN

IMIPRAMINE PAMOATE

CAPSULE; ORAL

IMIPRAMINE PAMOATE

AB	+ ROXANE	EQ 75MG HCL	A 091099	001	Apr 16, 2010	Feb	CRLD
	TOFRANIL-PM						
	@ MALLINCKRODT INC	EQ 75MG HCL	N 017090	001		Feb	DISC
	@	EQ 100MG HCL	N 017090	004		Feb	DISC
	@	EQ 125MG HCL	N 017090	003		Feb	DISC
	@	EQ 150MG HCL	N 017090	002		Feb	DISC

INDIUM IN-111 CHLORIDE

INJECTABLE; INJECTION

INDIUM IN 111 CHLORIDE

+	MALLINKRODT NUCLEAR	5mCi/0.5ML	N 019841	001	Sep 27, 1994	Jan	CAHN
---	---------------------	------------	----------	-----	--------------	-----	------

INDIUM IN-111 OXYQUINOLINE

INJECTABLE; INJECTION

INDIUM IN 111 OXYQUINOLINE

+	GE HEALTHCARE	1mCi/ML	N 019044	001	Dec 24, 1985	Mar	CMS1
---	---------------	---------	----------	-----	--------------	-----	------

INDIUM IN-111 PENTETREOTIDE KIT

INJECTABLE; INJECTION

OCTREOSCAN

+	MALLINKRODT NUCLEAR	3mCi/ML	N 020314	001	Jun 02, 1994	Jan	CAHN
---	---------------------	---------	----------	-----	--------------	-----	------

INDOCYANINE GREEN

INJECTABLE; INJECTION

INDOCYANINE GREEN

AP	DIAGNOSTIC GREEN	25MG/VIAL	A 040811	001	Nov 21, 2007	Jan	CAHN
----	------------------	-----------	----------	-----	--------------	-----	------

INDOMETHACIN SODIUM

INJECTABLE; INJECTION

INDOMETHACIN SODIUM

AP	HOSPIRA INC	EQ 1MG BASE/VIAL	A 204118	001	Apr 19, 2016	Apr	NEWA
----	-------------	------------------	----------	-----	--------------	-----	------

INSULIN DETEMIR RECOMBINANT

INJECTABLE; SUBCUTANEOUS

LEVEMIR FLEXPEN

@	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N 021536	002	Jun 16, 2005	Feb	DISC
---	------------------	------------------------------	----------	-----	--------------	-----	------

INSULIN HUMAN

SOLUTION; SUBCUTANEOUS

HUMULIN R

+	LILLY	10000 UNITS/20ML (500 UNITS/ML)	N 018780	004	Mar 31, 1994	Jan	CAIN
---	-------	---------------------------------	----------	-----	--------------	-----	------

+	LILLY	1500 UNITS/3ML (500 UNITS/ML)	N 018780	002	Dec 29, 2015	Jan	NEWA
---	-------	-------------------------------	----------	-----	--------------	-----	------

INSULIN RECOMBINANT HUMAN

POWDER; INHALATION

AFREZZA

+	MANNKIND	4 UNITS/INH	N 022472	001	Jun 27, 2014	Mar	CAHN
---	----------	-------------	----------	-----	--------------	-----	------

		8 UNITS/INH	N 022472	002	Jun 27, 2014	Mar	CAHN
--	--	-------------	----------	-----	--------------	-----	------

		12 UNITS/INH	N 022472	003	Apr 17, 2015	Mar	CAHN
--	--	--------------	----------	-----	--------------	-----	------

>D> IOXILAN

&gt;D&gt; INJECTABLE; INJECTION

&gt;D&gt; OXILAN-300

>D>	GUERBET	62%	N 020316	001	Dec 21, 1995	Jun	DISC
-----	---------	-----	----------	-----	--------------	-----	------

>A>	@	62%	N 020316	001	Dec 21, 1995	Jun	DISC
-----	---	-----	----------	-----	--------------	-----	------

>D>	OXILAN-350						
-----	------------	--	--	--	--	--	--

>D>	GUERBET	73%	N 020316	002	Dec 21, 1995	Jun	DISC
-----	---------	-----	----------	-----	--------------	-----	------

>A>	@	73%	N 020316	002	Dec 21, 1995	Jun	DISC
-----	---	-----	----------	-----	--------------	-----	------



IRBESARTANTABLET; ORAL  
IRBESARTAN

AB	HISUN PHARM HANGZHOU	75MG	A206194	001	Jun 14, 2016	May	NEWA
AB		150MG	A206194	002	Jun 14, 2016	May	NEWA
AB		300MG	A206194	003	Jun 14, 2016	May	NEWA

IRINOTECAN HYDROCHLORIDEINJECTABLE; INJECTION  
CAMPOTOSAR

AP	+	PFIZER INC	300MG/15ML (20MG/ML)	N020571	003	Aug 05, 2010	Apr	CTEC
		IRINOTECAN HYDROCHLORIDE						
>D>	AP	BEDFORD LABS	40MG/2ML (20MG/ML)	A078753	001	Dec 24, 2008	Jun	CAHN
>D>	AP		100MG/5ML (20MG/ML)	A078753	002	Dec 24, 2008	Jun	CAHN
>A>	AP	EUROHLTH INTL SARL	40MG/2ML (20MG/ML)	A078753	001	Dec 24, 2008	Jun	CAHN
>A>	AP		100MG/5ML (20MG/ML)	A078753	002	Dec 24, 2008	Jun	CAHN
	AP	QILU PHARM CO LTD	40MG/2ML (20MG/ML)	A203380	001	May 03, 2016	Apr	NEWA
	AP		100MG/5ML (20MG/ML)	A203380	002	May 03, 2016	Apr	NEWA
	AP		300MG/15ML (20MG/ML)	A203380	003	May 03, 2016	Apr	NEWA
	AP	SANDOZ INC	40MG/2ML (20MG/ML)	A090137	001	Nov 12, 2009	Jan	CAHN
	AP		100MG/5ML (20MG/ML)	A090137	002	Nov 12, 2009	Jan	CAHN

IRON DEXTRANINJECTABLE; INJECTION  
INFED

BP	+	ALLERGAN SALES LLC	EQ 50MG IRON/ML	N017441	001		Apr	CAHN
----	---	--------------------	-----------------	---------	-----	--	-----	------

ISONIAZIDTABLET; ORAL  
ISONIAZID

>D>		@ MIKART	100MG	A040090	001	Jun 26, 1997	Jun	CMFD
>A>	AA		100MG	A040090	001	Jun 26, 1997	Jun	CMFD
>D>		@	300MG	A040090	002	Jun 26, 1997	Jun	CMFD
>A>	AA		300MG	A040090	002	Jun 26, 1997	Jun	CMFD
		@ SUN PHARM INDS	100MG	A080136	001		Mar	CAHN
		@	300MG	A083633	001		Mar	CAHN

ISOSORBIDE DINITRATECAPSULE, EXTENDED RELEASE; ORAL  
DILATRATE-SR

+ AUXILIUM PHARMS INC 40MG

N019790 001 Sep 02, 1988 Mar CAHN

TABLET; ORAL

ISOSORBIDE DINITRATE

>D>		@ MUTUAL PHARM	10MG	A086169	001	Sep 19, 1986	Jun	CAHN
>D>		@	20MG	A086167	001	Sep 19, 1986	Jun	CAHN
>D>		@	30MG	A087564	001	Sep 18, 1986	Jun	CAHN
		@ SUN PHARM INDS	5MG	A086166	002	Sep 19, 1986	Mar	CAHN
>A>		@	10MG	A086169	001	Sep 19, 1986	Jun	CAHN
>A>		@	20MG	A086167	001	Sep 19, 1986	Jun	CAHN
>A>		@	30MG	A087564	001	Sep 18, 1986	Jun	CAHN

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

>D>		@ MUTUAL PHARM	2.5MG	A084204	001	Sep 18, 1986	Jun	CAHN
>D>		@	5MG	A086168	001	Sep 18, 1986	Jun	CAHN
>D>		@	10MG	A087545	001	Sep 18, 1986	Jun	CAHN
>A>		@ SUN PHARM INDS	2.5MG	A084204	001	Sep 18, 1986	Jun	CAHN
>A>		@	5MG	A086168	001	Sep 18, 1986	Jun	CAHN
>A>		@	10MG	A087545	001	Sep 18, 1986	Jun	CAHN

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE DINITRATE

@ COREPHARMA 40MG  
+ SUN PHARM INDS INC 40MGA040723 001 Mar 17, 2008 Mar DISC  
A040009 001 Dec 30, 1998 Mar CTECISOSULFAN BLUEINJECTABLE; INJECTION  
ISOSULFAN BLUE

AP	AUROBINDO PHARMA LTD	1%	A206831	001	Feb 02, 2016	Jan	NEWA	
AP	+	MYLAN INSTITUTIONAL	1%	A090874	001	Jul 20, 2010	Jan	CTEC

<u>ITRACONAZOLE</u>							
CAPSULE; ORAL							
ITRACONAZOLE							
AB	ACCORD HLTHCARE	100MG	A205991	001	May 26, 2016	May	NEWA
SOLUTION; ORAL							
ITRACONAZOLE							
	@ AMNEAL PHARMS	10MG/ML	A205573	001	Oct 30, 2015	Apr	DISC
	SPORANOX						
	+ JANSSEN PHARMS	10MG/ML	N020657	001	Feb 21, 1997	Apr	CTEC
<u>IVERMECTIN</u>							
LOTION; TOPICAL							
SKLICE							
	+ ARBOR PHARMS LLC	0.5%	N202736	001	Feb 07, 2012	May	CAHN
<u>KETOCONAZOLE</u>							
TABLET; ORAL							
KETOCONAZOLE							
	@ SUN PHARM INDS	200MG	A075314	001	Jun 15, 1999	Jan	CAHN
<u>KETOPROFEN</u>							
CAPSULE; ORAL							
KETOPROFEN							
	@ AUROLIFE PHARMA LLC	50MG	A074024	001	Dec 29, 1995	Feb	CAHN
	@	75MG	A074024	002	Dec 29, 1995	Feb	CAHN
<u>KETOROLAC TROMETHAMINE</u>							
INJECTABLE; INJECTION							
KETOROLAC TROMETHAMINE							
	@ EUROHLTH INTL SARL	15MG/ML	A075222	001	Apr 26, 1999	Apr	CAHN
	@	30MG/ML	A075222	002	Apr 26, 1999	Apr	CAHN
	@	30MG/ML	A075228	001	Apr 26, 1999	May	CAHN
<u>LABETALOL HYDROCHLORIDE</u>							
INJECTABLE; INJECTION							
LABETALOL HYDROCHLORIDE							
AP	SAGENT STRIDES	5MG/ML	A079134	001	Feb 03, 2010	Jan	CTNA
TRANDATE							
	@ SEBELA IRELAND LTD	5MG/ML	N019425	001	Dec 31, 1985	Jan	CAHN
TABLET; ORAL							
LABETALOL HYDROCHLORIDE							
AB	NOSTRUM LABS INC	100MG	A075215	001	Jul 29, 1999	Jan	CAHN
AB		200MG	A075215	002	Jul 29, 1999	Jan	CAHN
AB		300MG	A075215	003	Jul 29, 1999	Jan	CAHN
<u>LACOSAMIDE</u>							
SOLUTION; ORAL							
LACOSAMIDE							
AA	AMNEAL PHARMS	10MG/ML	A204839	001	Apr 28, 2016	Apr	NEWA
VIMPAT							
AA	+ UCB INC	10MG/ML	N022255	001	Apr 20, 2010	Apr	CFTG
TABLET; ORAL							
LACOSAMIDE							
AB	ACTAVIS LABS FL INC	50MG	A204855	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A204855	002	Apr 28, 2016	Apr	NEWA
AB		150MG	A204855	003	Apr 28, 2016	Apr	NEWA
AB		200MG	A204855	004	Apr 28, 2016	Apr	NEWA
AB	ALEMBIC PHARMS LTD	50MG	A204974	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A204974	002	Apr 28, 2016	Apr	NEWA
AB		150MG	A204974	003	Apr 28, 2016	Apr	NEWA
AB		200MG	A204974	004	Apr 28, 2016	Apr	NEWA
AB	AUROBINDO PHARMA LTD	50MG	A204994	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A204994	002	Apr 28, 2016	Apr	NEWA
AB		150MG	A204994	003	Apr 28, 2016	Apr	NEWA
AB		200MG	A204994	004	Apr 28, 2016	Apr	NEWA
AB	MSN LABS PVT LTD	50MG	A204921	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A204921	002	Apr 28, 2016	Apr	NEWA
AB		150MG	A204921	003	Apr 28, 2016	Apr	NEWA
AB		200MG	A204921	004	Apr 28, 2016	Apr	NEWA
AB	MYLAN PHARMS INC	50MG	A205026	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A205026	002	Apr 28, 2016	Apr	NEWA

TABLET;ORAL  
LACOSAMIDE

AB		150MG	A205026	003	Apr 28, 2016	Apr	NEWA
AB		200MG	A205026	004	Apr 28, 2016	Apr	NEWA
AB	SUN PHARMA GLOBAL	50MG	A205031	001	Apr 28, 2016	Apr	NEWA
AB		100MG	A205031	002	Apr 28, 2016	Apr	NEWA
AB		150MG	A205031	003	Apr 28, 2016	Apr	NEWA
AB		200MG	A205031	004	Apr 28, 2016	Apr	NEWA
<u>VIMPAT</u>							
AB	UCB INC	50MG	N022253	001	Oct 28, 2008	Apr	CFTG
AB		100MG	N022253	002	Oct 28, 2008	Apr	CFTG
AB		150MG	N022253	003	Oct 28, 2008	Apr	CFTG
AB	+	200MG	N022253	004	Oct 28, 2008	Apr	CFTG

LAMIVUDINE

TABLET;ORAL  
LAMIVUDINE

AB	MYLAN PHARMS INC	150MG	A204528	001	Mar 04, 2016	Feb	NEWA
AB		300MG	A204528	002	Mar 04, 2016	Feb	NEWA

LAMOTRIGINE

TABLET;ORAL  
LAMOTRIGINE

>D>	AB	CADISTA PHARMS	25MG	A079132	001	Jan 27, 2009	Jun	CAHN
>D>	AB		100MG	A079132	002	Jan 27, 2009	Jun	CAHN
>D>	AB		150MG	A079132	003	Jan 27, 2009	Jun	CAHN
>D>	AB		200MG	A079132	004	Jan 27, 2009	Jun	CAHN
>A>	AB	JUBILANT CADISTA	25MG	A079132	001	Jan 27, 2009	Jun	CAHN
>A>	AB		100MG	A079132	002	Jan 27, 2009	Jun	CAHN
>A>	AB		150MG	A079132	003	Jan 27, 2009	Jun	CAHN
>A>	AB		200MG	A079132	004	Jan 27, 2009	Jun	CAHN

TABLET, EXTENDED RELEASE;ORAL  
LAMICTAL XR

AB	+	GLAXOSMITHKLINE LLC	200MG	N022115	004	May 29, 2009	Jan	CRLD
----	---	---------------------	-------	---------	-----	--------------	-----	------

TABLET, ORALLY DISINTEGRATING;ORAL  
LAMOTRIGINE

>A>	AB	SCIEGEN PHARMS INC	25MG	A206382	001	Jun 17, 2016	Jun	NEWA
>A>	AB		50MG	A206382	002	Jun 17, 2016	Jun	NEWA
>A>	AB		100MG	A206382	003	Jun 17, 2016	Jun	NEWA
>A>	AB		200MG	A206382	004	Jun 17, 2016	Jun	NEWA

LATANOPROST

SOLUTION/DROPS;OPHTHALMIC  
LATANOPROST

AT	FDC LTD	0.005%	A202442	001	Apr 22, 2016	Apr	NEWA
----	---------	--------	---------	-----	--------------	-----	------

LETROZOLE

TABLET;ORAL  
LETROZOLE

AB	HIKMA PHARMS	2.5MG	A203796	001	Jun 03, 2016	May	NEWA
AB	KREMERS URBAN PHARMS	2.5MG	A091098	001	Jun 03, 2011	Jan	CAHN

LEUCOVORIN CALCIUM

TABLET;ORAL  
LEUCOVORIN CALCIUM

>D>	AB	@ IDT AUSTRALIA LTD	EQ 15MG BASE	A075327	001	Mar 24, 1999	May	CAHN
>A>	AB	ROXANE	EQ 15MG BASE	A072735	001	Feb 22, 1993	Jun	CTEC
>A>	AB		EQ 15MG BASE	A072735	001	Feb 22, 1993	Jun	CTEC

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION  
LEVALBUTEROL HYDROCHLORIDE

AN	RITEDOSE CORP	EQ 0.0103% BASE	A203653	001	Mar 22, 2016	Mar	NEWA
AN		EQ 0.021% BASE	A203653	002	Mar 22, 2016	Mar	NEWA
AN		EQ 0.042% BASE	A203653	003	Mar 22, 2016	Mar	NEWA

LEVETIRACETAM

INJECTABLE;IV (INFUSION)  
LEVETIRACETAM

AP	AUROBINDO PHARMA LTD	500MG/5ML (100MG/ML)	A204312	001	Feb 01, 2016	Jan	NEWA
AP	JUBILANT LIFE	500MG/5ML (100MG/ML)	A206838	001	Jun 02, 2016	May	NEWA

## TABLET, EXTENDED RELEASE;ORAL

## LEVETIRACETAM

AB	INTELLIPHARMACEUTICS	500MG	A204511	001	Feb 23, 2016	Feb	NEWA
AB		750MG	A204511	002	Feb 23, 2016	Feb	NEWA
AB	LOTUS PHARM CO LTD	500MG	A202095	002	Jun 06, 2016	May	NEWA
AB		750MG	A202095	001	Jun 06, 2016	May	NEWA
AB	SUN PHARM INDS	500MG	A091285	001	Sep 12, 2011	Mar	CAHN
AB		750MG	A091285	002	Sep 12, 2011	Mar	CAHN

## TABLET, FOR SUSPENSION;ORAL

## SPRITAM

	APRECIA PHARMS CO	250MG	N207958	001	Jul 31, 2015	Feb	CDFR
		500MG	N207958	002	Jul 31, 2015	Feb	CDFR
		750MG	N207958	003	Jul 31, 2015	Feb	CDFR
+		1GM	N207958	004	Jul 31, 2015	Mar	CRLD
		1GM	N207958	004	Jul 31, 2015	Feb	CDFR

LEVOFLOXACIN

## INJECTABLE;INJECTION

>D>	LEVAQUIN IN DEXTROSE 5% IN PLASTIC CONTAINER								
>D>	AP	+	JANSSEN PHARMS	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jun	DISC
>A>			@	EQ 250MG/50ML (EQ 5MG/ML)	N020635	002	Dec 20, 1996	Jun	DISC
>D>	AP	+		EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jun	DISC
>A>			@	EQ 500MG/100ML (EQ 5MG/ML)	N020635	003	Dec 20, 1996	Jun	DISC
>D>	AP	+		EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jun	DISC
>A>			@	EQ 750MG/150ML (EQ 5MG/ML)	N020635	005	Dec 20, 1996	Jun	DISC
				LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER					
AP	AUROBINDO PHARMA LTD	EQ 250MG/50ML (EQ 5MG/ML)	A206919	001	Feb 10, 2016	Jan	NEWA		
AP		EQ 500MG/100ML (EQ 5MG/ML)	A206919	002	Feb 10, 2016	Jan	NEWA		
AP		EQ 750MG/150ML (EQ 5MG/ML)	A206919	003	Feb 10, 2016	Jan	NEWA		

## SOLUTION/DROPS;OPHTHALMIC

## LEVOFLOXACIN

AT	+	RISING PHARMS INC	0.5%	A077700	001	Dec 20, 2010	Jan	CAHN
----	---	-------------------	------	---------	-----	--------------	-----	------

LEVOLEUCOVORIN CALCIUM

## POWDER;IV (INFUSION)

## FUSILEV

>D>	+	SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Jun	CFTG	
>A>	AP	+	EQ 50MG BASE/VIAL	N020140	001	Mar 07, 2008	Jun	CFTG	
>A>			LEVOLEUCOVORIN CALCIUM						
>A>	AP		EUROHLTH INTL SARL	EQ 50MG BASE/VIAL	A206263	001	Jun 16, 2016	Jun	NEWA

LEVONORGESTREL

## TABLET;ORAL

## LEVONORGESTREL

+	PERRIGO R AND D	0.75MG	A090740	001	Dec 30, 2010	Apr	CRLD
	@ WATSON LABS	0.75MG	A078665	001	Aug 28, 2009	Apr	DISC
	PLAN B						
	@ TEVA BRANDED PHARM	0.75MG	N021045	002	Aug 24, 2006	Apr	DISC

LEVOTHYROXINE SODIUM

## POWDER;INTRAVENOUS

## LEVOTHYROXINE SODIUM

>A>	AP		FERA PHARMS LLC	100MCG/VIAL	A206163	001	Jun 29, 2016	Jun	NEWA
>A>	AP			500MCG/VIAL	A206163	002	Jun 29, 2016	Jun	NEWA
>D>	+	FRESENIUS KABI USA	100MCG/VIAL	N202231	001	Jun 24, 2011	Jun	CFTG	
>A>	AP	+		100MCG/VIAL	N202231	001	Jun 24, 2011	Jun	CFTG
>D>	+			500MCG/VIAL	N202231	003	Jun 24, 2011	Jun	CFTG
>A>	AP	+		500MCG/VIAL	N202231	003	Jun 24, 2011	Jun	CFTG

LEVOTHYROXINE SODIUM \*\*

\*\*See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium

## TABLET;ORAL

## LEVOTHROID

@	LLOYD	0.025MG	N021116	001	Oct 24, 2002	May	DISC
@		0.05MG	N021116	002	Oct 24, 2002	May	DISC
@		0.075MG	N021116	003	Oct 24, 2002	May	DISC
@		0.088MG	N021116	010	Oct 24, 2002	May	DISC
@		0.1MG	N021116	004	Oct 24, 2002	May	DISC
@		0.112MG	N021116	011	Oct 24, 2002	May	DISC
@		0.125MG	N021116	005	Oct 24, 2002	May	DISC
@		0.137MG	N021116	012	Dec 07, 2004	May	DISC
@		0.15MG	N021116	006	Oct 24, 2002	May	DISC

## TABLET;ORAL

## LEVOTHROID

	@	0.175MG		N021116	007	Oct 24, 2002	May	DISC
	@	0.2MG		N021116	008	Oct 24, 2002	May	DISC
	@	0.3MG		N021116	009	Oct 24, 2002	May	DISC
			LEVOTHYROXINE SODIUM					
AB1,	MYLAN	0.3MG		A076187	011	Jun 05, 2002	May	CRLD
AB2,								
AB3,								
AB4,	+							

LIDOCAINE

## OINTMENT;TOPICAL

## LIDOCAINE

>D>	AT	NOVOCOL INC	5%	A040911	001	May 23, 2011	Jun	CAHN
>A>	AT	SEPTODONT INC	5%	A040911	001	May 23, 2011	Jun	CAHN
	AT	TELIGENT PHARMA INC	5%	A205318	001	Feb 01, 2016	Jan	NEWA

LIDOCAINE HYDROCHLORIDE

## INJECTABLE;INJECTION

## LIDOCAINE HYDROCHLORIDE 0.4% IN DEXTROSE 5% IN PLASTIC CONTAINER

@	HOSPIRA	400MG/100ML		N018388	002		Feb	DISC
---	---------	-------------	--	---------	-----	--	-----	------

## LIDOCAINE HYDROCHLORIDE 0.8% IN DEXTROSE 5% IN PLASTIC CONTAINER

@	HOSPIRA	800MG/100ML		N018388	003	Nov 05, 1982	Feb	DISC
---	---------	-------------	--	---------	-----	--------------	-----	------

## JELLY;TOPICAL

## ANESTACON

@	BIONPHARMA INC	2%		A080429	001		Jan	CAHN
---	----------------	----	--	---------	-----	--	-----	------

## SOLUTION;TOPICAL

## LIDOCAINE HYDROCHLORIDE

AT	TELIGENT PHARMA INC	4%		A204494	001	Mar 12, 2014	May	CAHN
----	---------------------	----	--	---------	-----	--------------	-----	------

LINAGLIPTIN; METFORMIN HYDROCHLORIDE

## TABLET, EXTENDED RELEASE;ORAL

## JENTADUETO XR

	BOEHRINGER INGELHEIM	2.5MG;1GM		N208026	001	May 27, 2016	May	NEWA
--	----------------------	-----------	--	---------	-----	--------------	-----	------

+		5MG;1GM		N208026	002	May 27, 2016	May	NEWA
---	--	---------	--	---------	-----	--------------	-----	------

LINEZOLID

## SOLUTION;IV (INFUSION)

## LINEZOLID

AP	FRESENIUS KABI USA	600MG/300ML (2MG/ML)		A204764	001	Mar 15, 2016	Feb	NEWA
----	--------------------	----------------------	--	---------	-----	--------------	-----	------

## TABLET;ORAL

## LINEZOLID

AB	GATE PHARMS	600MG		A091210	001	Feb 05, 2016	Jan	NEWA
----	-------------	-------	--	---------	-----	--------------	-----	------

AB	GLENMARK PHARMS	600MG		A078987	001	Dec 21, 2015	Mar	CAHN
----	-----------------	-------	--	---------	-----	--------------	-----	------

LIOTHYRONINE SODIUM

## TABLET;ORAL

## LIOTHYRONINE SODIUM

AB	MAYNE PHARMA INC	EQ 0.005MG BASE		A090097	001	Mar 20, 2009	Mar	CAHN
----	------------------	-----------------	--	---------	-----	--------------	-----	------

AB		EQ 0.025MG BASE		A090097	002	Mar 20, 2009	Mar	CAHN
----	--	-----------------	--	---------	-----	--------------	-----	------

AB		EQ 0.05MG BASE		A090097	003	Mar 20, 2009	Mar	CAHN
----	--	----------------	--	---------	-----	--------------	-----	------

AB	SUN PHARM INDS LTD	EQ 0.005MG BASE		A091382	001	Apr 20, 2016	Apr	NEWA
----	--------------------	-----------------	--	---------	-----	--------------	-----	------

AB		EQ 0.025MG BASE		A091382	002	Apr 20, 2016	Apr	NEWA
----	--	-----------------	--	---------	-----	--------------	-----	------

AB		EQ 0.05MG BASE		A091382	003	Apr 20, 2016	Apr	NEWA
----	--	----------------	--	---------	-----	--------------	-----	------

LISINOPRIL

## TABLET;ORAL

## ZESTRIL

AB	ALVOGEN MALTA	2.5MG		N019777	005	Apr 29, 1993	Jan	CAHN
----	---------------	-------	--	---------	-----	--------------	-----	------

AB		5MG		N019777	001	May 19, 1988	Jan	CAHN
----	--	-----	--	---------	-----	--------------	-----	------

AB		10MG		N019777	002	May 19, 1988	Jan	CAHN
----	--	------	--	---------	-----	--------------	-----	------

AB		20MG		N019777	003	May 19, 1988	Jan	CAHN
----	--	------	--	---------	-----	--------------	-----	------

AB		30MG		N019777	006	Jan 20, 1999	Jan	CAHN
----	--	------	--	---------	-----	--------------	-----	------

AB	+	40MG		N019777	004	May 19, 1988	Jan	CAHN
----	---	------	--	---------	-----	--------------	-----	------

LITHIUM CARBONATE

## CAPSULE;ORAL

## LITHIUM CARBONATE

AB	DELCOR ASSET CORP	150MG		A076243	002	Feb 24, 2003	Feb	CAHN
----	-------------------	-------	--	---------	-----	--------------	-----	------

AB		300MG		A076243	001	Jun 27, 2002	Feb	CAHN
----	--	-------	--	---------	-----	--------------	-----	------

AB		600MG		A078763	001	Apr 15, 2008	Feb	CAHN
----	--	-------	--	---------	-----	--------------	-----	------

	CAPSULE;ORAL						
	LITHIUM CARBONATE						
AB	HIKMA PHARMS	600MG	A078763	001	Apr 15, 2008	Jan	CMFD
	<u>LOMITAPIDE MESYLATE</u>						
	CAPSULE;ORAL						
	JUXTAPID						
	AEGERION	EQ 20MG BASE	N203858	003	Dec 21, 2012	Jan	CRLD
	+	EQ 60MG BASE	N203858	006	Apr 23, 2015	Jan	CRLD
	<u>LOPERAMIDE HYDROCHLORIDE</u>						
	CAPSULE;ORAL						
	IMODIUM						
	@ J AND J CONSUMER INC	2MG	N017694	001		Feb	DISC
	LOPERAMIDE HYDROCHLORIDE						
AB	+	MYLAN	A072741	001	Sep 18, 1991	Feb	CRLD
	<u>LOSARTAN POTASSIUM</u>						
	TABLET;ORAL						
	LOSARTAN POTASSIUM						
BX	HETERO LABS LTD V	25MG	A203835	001	Aug 12, 2015	Apr	CTEC
BX		50MG	A203835	002	Aug 12, 2015	Apr	CTEC
BX		100MG	A203835	003	Aug 12, 2015	Apr	CTEC
BX	LUPIN LTD	25MG	A078232	001	Oct 06, 2010	Apr	CTEC
BX		50MG	A078232	002	Oct 06, 2010	Apr	CTEC
BX		100MG	A078232	003	Oct 06, 2010	Apr	CTEC
	<u>LOVASTATIN</u>						
	TABLET;ORAL						
	LOVASTATIN						
AB	SUN PHARM INDS	10MG	A077520	001	Apr 14, 2006	Mar	CAHN
AB		20MG	A077520	002	Apr 14, 2006	Mar	CAHN
AB		40MG	A077520	003	Apr 14, 2006	Mar	CAHN
	<u>LOXAPINE</u>						
	POWDER;INHALATION						
	ADASUVE						
	+	ALEXZA PHARMS	N022549	001	Dec 21, 2012	Feb	CAHN
	<u>MAGNESIUM SULFATE</u>						
	INJECTABLE;INJECTION						
	MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER						
AP	FRESENIUS KABI USA	1GM/100ML	A206486	001	Mar 07, 2016	Feb	NEWA
AP	+	HOSPIRA	N020488	001	Jul 11, 1995	Feb	CFTG
AP	HQ SPCLT PHARMA	1GM/100ML	A207349	001	Mar 02, 2016	Feb	NEWA
	MAGNESIUM SULFATE IN PLASTIC CONTAINER						
AP	FRESENIUS KABI USA	4GM/100ML (40MG/ML)	A206485	001	Mar 15, 2016	Feb	NEWA
AP		4GM/50ML (80MG/ML)	A206485	002	Mar 15, 2016	Feb	NEWA
AP		2GM/50ML (40MG/ML)	A206485	003	Mar 15, 2016	Mar	NEWA
AP		20GM/500ML (40MG/ML)	A206485	004	Mar 15, 2016	Mar	NEWA
AP		40GM/1000ML (40MG/ML)	A206485	005	Mar 15, 2016	Mar	NEWA
AP	HOSPIRA	2GM/50ML (40MG/ML)	N020309	003	Jan 26, 2007	Mar	CFTG
AP	+	4GM/100ML (40MG/ML)	N020309	001	Jun 24, 1994	Feb	CFTG
AP	+	4GM/50ML (80MG/ML)	N020309	002	Jun 24, 1994	Feb	CFTG
AP		20GM/500ML (40MG/ML)	N020309	004	Jan 18, 1995	Mar	CFTG
AP		40GM/1000ML (40MG/ML)	N020309	005	Jan 18, 1995	Mar	CFTG
	SOLUTION;INTRAMUSCULAR, INTRAVENOUS						
	MAGNESIUM SULFATE						
	+	FRESENIUS KABI USA	N019316	003	Jan 29, 2016	Jan	NEWA
	+		N019316	004	Jan 29, 2016	Jan	NEWA
	<u>MECLIZINE HYDROCHLORIDE</u>						
	TABLET;ORAL						
	MECLIZINE HYDROCHLORIDE						
	@ RISING PHARMS INC	12.5MG	A040179	001	Jan 30, 1997	Jan	CAHN
	@	25MG	A040179	002	Jan 30, 1997	Jan	CAHN
>D>	TABLET, CHEWABLE;ORAL						
>D>	ANTIVERT						
>D>	+	CASPER PHARMA LLC	N010721	005		Jun	DISC
>A>	@	25MG	N010721	005		Jun	DISC

<u>MEFLOQUINE HYDROCHLORIDE</u>						
TABLET; ORAL						
MEFLOQUINE HYDROCHLORIDE						
	@ HIKMA INTL PHARMS	250MG	A077699	001	Apr 21, 2010	May CAHN
<u>MEGESTROL ACETATE</u>						
SUSPENSION; ORAL						
MEGACE ES						
AB	+ ENDO PHARMS INC	125MG/ML	N021778	001	Jul 05, 2005	Feb CAHN
<u>MELOXICAM</u>						
TABLET; ORAL						
MELOXICAM						
	@ SUN PHARM INDS	7.5MG	A077935	001	Jul 19, 2006	Jan CAHN
	@	15MG	A077935	002	Jul 19, 2006	Jan CAHN
<u>MELPHALAN</u>						
TABLET; ORAL						
ALKERAN						
	+ APOTEX INC	2MG	N014691	002		Jan CAHN
<u>MELPHALAN HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
ALKERAN						
AP	+ APOTEX INC	EQ 50MG BASE/VIAL	N020207	001	Nov 18, 1992	Jan CAHN
POWDER; IV (INFUSION)						
EVOMELA						
	SPECTRUM PHARMS	EQ 50MG BASE/VIAL	N207155	001	Mar 10, 2016	Mar NEWA
<u>MEPERIDINE HYDROCHLORIDE</u>						
INJECTABLE; INJECTION						
DEMEROL						
	@ US PHARM HOLDINGS	25MG/ML	N005010	007		Jan CAHN
	@	50MG/ML	N005010	002		Jan CAHN
	@	75MG/ML	N005010	009		Jan CAHN
	@	100MG/ML	N005010	003		Jan CAHN
SYRUP; ORAL						
DEMEROL						
	@ US PHARM HOLDINGS	50MG/5ML	N005010	005		Jan CAHN
TABLET; ORAL						
DEMEROL						
AA	+ US PHARM HOLDINGS	50MG	N005010	001		Jan CAHN
AA	+ US PHARM HOLDINGS	100MG	N005010	004		Jan CAHN
MEPERIDINE HYDROCHLORIDE						
	@ SUN PHARM INDS	50MG	A080448	001		Mar CAHN
	@	100MG	A080448	002		Mar CAHN
<u>MEPROBAMATE</u>						
TABLET; ORAL						
MEPROBAMATE						
	@ AUROLIFE PHARMA LLC	400MG	A080655	001		Feb CAHN
	@ SUN PHARM INDS	200MG	A080699	001		Mar CAHN
	@	400MG	A080699	002		Mar CAHN
<u>MERCAPTOPYRINE</u>						
TABLET; ORAL						
MERCAPTOPYRINE						
AB	DR REDDYS LABS INTL	50MG	A040461	001	Feb 11, 2004	Apr CAHN
PURINETHOL						
	@ STASON PHARMS	50MG	N009053	002		Jan CAHN
<u>MEROPENEM</u>						
INJECTABLE; INJECTION						
MEROPENEM						
AP	AMNEAL PHARMS	500MG/VIAL	A205883	001	Apr 12, 2016	Mar NEWA
AP		1GM/VIAL	A205883	002	Apr 12, 2016	Mar NEWA
AP	GLAND PHARMA LTD	500MG/VIAL	A206141	001	Jun 08, 2016	May NEWA
AP		1GM/VIAL	A206141	002	Jun 08, 2016	May NEWA
AP	PAR STERILE PRODUCTS	500MG/VIAL	A204139	001	Jun 09, 2016	May NEWA
AP		1GM/VIAL	A204139	002	Jun 09, 2016	May NEWA

## INJECTABLE; INJECTION

## MEROPENEM

AP	SAVIOR LIFETEC CORP	500MG/VIAL	A206086	001	Apr 19, 2016	Apr NEWA
AP		1GM/VIAL	A206086	002	Apr 19, 2016	Apr NEWA

MESALAMINE

## CAPSULE, DELAYED RELEASE; ORAL

## DELZICOL

+	APIL	400MG	N204412	001	Feb 01, 2013	Jan CAHN
---	------	-------	---------	-----	--------------	----------

## TABLET, DELAYED RELEASE; ORAL

## ASACOL

@	APIL	400MG	N019651	001	Jan 31, 1992	Jan CAHN
---	------	-------	---------	-----	--------------	----------

## ASACOL HD

+	APIL	800MG	N021830	001	May 29, 2008	Jan CAHN
---	------	-------	---------	-----	--------------	----------

METFORMIN HYDROCHLORIDE

## TABLET; ORAL

## METFORMIN HYDROCHLORIDE

>A>	AB	CSPC OUYI PHARM CO	500MG	A205096	001	Jul 11, 2016	Jun NEWA
>A>	AB		850MG	A205096	002	Jul 11, 2016	Jun NEWA
>A>	AB		1GM	A205096	003	Jul 11, 2016	Jun NEWA
	AB	SUN PHARM INDS	500MG	A076038	001	Feb 21, 2002	Mar CAHN
	AB		850MG	A076038	002	Feb 21, 2002	Mar CAHN
	AB		1GM	A076038	003	Feb 21, 2002	Mar CAHN

## TABLET, EXTENDED RELEASE; ORAL

## GLUMETZA

AB3		SANTARUS INC	500MG	N021748	001	Jun 03, 2005	Jan CTEC
AB3	+		1GM	N021748	002	Jun 03, 2005	Jan CTEC
		METFORMIN HYDROCHLORIDE					
	@	IMPAX LABS	500MG	A076249	001	Jul 30, 2004	Mar DISC
	@		750MG	A076985	001	Sep 13, 2005	Mar DISC
AB1		MARKSANS PHARMA	500MG	A090295	001	Apr 29, 2016	Apr NEWA
AB			750MG	A090295	002	Apr 29, 2016	Apr NEWA
	@	SUN PHARM INDS	500MG	A077124	001	Dec 21, 2005	Mar CAHN

METHENAMINE HIPPURATE

## TABLET; ORAL

## HIPREX

AB	+	US PHARM HOLDINGS	1GM	N017681	001		Jan CAHN
		METHENAMINE HIPPURATE					
>A>	AB	AUROBINDO PHARMA LTD	1GM	A205661	001	Jul 05, 2016	Jun NEWA

METHIMAZOLE

## TABLET; ORAL

## METHIMAZOLE

AB		RISING PHARMS INC	5MG	A202068	001	Mar 07, 2012	Jan CAHN
AB			10MG	A202068	002	Mar 07, 2012	Jan CAHN

METHOCARBAMOL

## SOLUTION; IM-IV

## METHOCARBAMOL

AP		AUROBINDO PHARMA LTD	1GM/10ML (100MG/ML)	A206128	001	May 27, 2016	May NEWA
----	--	----------------------	---------------------	---------	-----	--------------	----------

## TABLET; ORAL

## METHOCARBAMOL

@	SANDOZ	500MG	A084616	001		Feb DISC
---	--------	-------	---------	-----	--	----------

@		750MG	A084615	001		Feb DISC
---	--	-------	---------	-----	--	----------

@	SUN PHARM INDS	500MG	A084488	001		Mar CAHN
---	----------------	-------	---------	-----	--	----------

@		750MG	A084486	001		Mar CAHN
---	--	-------	---------	-----	--	----------

## ROBAXIN

AA	+	AUXILIUM PHARMS INC	500MG	N011011	004		Mar CAHN
----	---	---------------------	-------	---------	-----	--	----------

## ROBAXIN-750

AA	+	AUXILIUM PHARMS INC	750MG	N011011	006		Mar CAHN
----	---	---------------------	-------	---------	-----	--	----------

METHOHEXITAL SODIUM

## INJECTABLE; INJECTION

## BREVITAL SODIUM

>D>	+	PAR STERILE PRODUCTS	200MG/VIAL	N011559	004	Dec 21, 2012	Jun DISC
>A>	@		200MG/VIAL	N011559	004	Dec 21, 2012	Jun DISC



METHOTREXATESOLUTION; SUBCUTANEOUS  
OTREXUP

ANTARES PHARMA INC	12.5MG/0.4ML (12.5MG/0.4ML)	N204824	006	Mar 24, 2016	May NEWA
	17.5MG/0.4ML (17.5MG/0.4ML)	N204824	007	Mar 24, 2016	May NEWA
	22.5MG/0.4ML (22.5MG/0.4ML)	N204824	008	Mar 24, 2016	May NEWA

METHOTREXATE SODIUMINJECTABLE; INJECTION  
METHOTREXATE SODIUM PRESERVATIVE FREE

AP	SANDOZ INC	EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A090039	001	Mar 31, 2009	Jan CAHN
AP		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A090039	002	Mar 31, 2009	Jan CAHN
AP		EQ 1GM BASE/40ML (EQ 25MG BASE/ML)	A090029	001	Mar 31, 2009	Jan CAHN

METHOXSALLENINJECTABLE; INJECTION  
UVADEX

+	MALLINCKRODT HOSP	0.02MG/ML	N020969	001	Feb 25, 1999	Apr CAHN
---	-------------------	-----------	---------	-----	--------------	----------

METHYLDOPATABLET; ORAL  
METHYLDOPA

@	SUN PHARM INDS	125MG	A070073	001	Oct 09, 1986	Mar CAHN
@		250MG	A070060	001	Oct 09, 1986	Mar CAHN
@		500MG	A070074	001	Oct 09, 1986	Mar CAHN

METHYLENE BLUESOLUTION; INTRAVENOUS  
PROVAYBLUE

+	PROVEPHARM SAS	50MG/10ML (5MG/ML)	N204630	001	Apr 08, 2016	Apr NEWA
---	----------------	--------------------	---------	-----	--------------	----------

METHYLERGONOVINE MALEATETABLET; ORAL  
METHERGINE

@	EDISON THERAPS LLC	0.2MG	N006035	003		Jan DISC
+	NOVEL LABS INC	0.2MG	A091577	001	May 02, 2011	Jan CRLD

METHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL  
METHYLPHENIDATE HYDROCHLORIDE

>A>	AB1	WATSON LABS INC	60MG	A078458	004	Jun 23, 2016	Jun NEWA
		RITALIN LA					
>D>	+	NOVARTIS	60MG	N021284	005	Oct 27, 2014	Jun CFTG
>A>	AB1	+	60MG	N021284	005	Oct 27, 2014	Jun CFTG

SOLUTION; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	NOSTRUM LABS INC	5MG/5ML	A201466	001	Nov 12, 2013	Feb CAHN
AA		10MG/5ML	A201466	002	Nov 12, 2013	Feb CAHN

TABLET, EXTENDED RELEASE; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	TEDOR PHARMA INC	10MG	A204772	001	Feb 29, 2016	Feb NEWA
AB		20MG	A204772	002	Feb 29, 2016	Feb NEWA

METHYLPREDNISOLONE SODIUM SUCCINATE

INJECTABLE; INJECTION

METHYLPREDNISOLONE SODIUM SUCCINATE

AP	HIKMA FARMACEUTICA	EQ 500MG BASE/VIAL	A202691	001	Feb 16, 2016	Feb NEWA
AP		EQ 1GM BASE/VIAL	A202691	002	Feb 16, 2016	Feb NEWA
AP	SAGENT PHARMS	EQ 40MG BASE/VIAL	A040888	001	Jul 18, 2011	Jan CAHN
AP		EQ 125MG BASE/VIAL	A040888	002	Jul 18, 2011	Jan CAHN
AP		EQ 500MG BASE/VIAL	A040888	003	Jul 18, 2011	Jan CAHN
AP		EQ 1GM BASE/VIAL	A040888	004	Jul 18, 2011	Jan CAHN
AP		EQ 2GM BASE/VIAL	A040888	005	Jul 18, 2011	Jan CAHN

METHYLTESTOSTERONE

TABLET; ORAL

ANDROID 10

@ VALEANT PHARM INTL

10MG

A 086450 001

Apr DISC

METHYLTESTOSTERONE

@ IMPAX LABS

25MG

A 084310 001

Mar DISC

METOCLOPRAMIDE HYDROCHLORIDE

TABLET; ORAL

METOCLOPRAMIDE HYDROCHLORIDE

AB SUN PHARM INDS

EQ 5MG BASE

A 071536 002 Jan 16, 1997

Mar CAHN

@

EQ 10MG BASE

A 071536 001 Apr 28, 1993

Mar CAHN

METOPROLOL TARTRATE

INJECTABLE; INJECTION

METOPROLOL TARTRATE

AP EUROHLTH INTL SARL

1MG/ML

A 076495 001 Jul 07, 2003

Apr CAHN

TABLET; ORAL

METOPROLOL TARTRATE

@ SANDOZ

50MG

A 073288 001 Mar 25, 1994

May DISC

@

100MG

A 073289 001 Mar 25, 1994

May DISC

AB SUN PHARM INDS

25MG

A 073654 002 Jul 15, 2009

Mar CAHN

AB

100MG

A 073654 001 Dec 21, 1993

Mar CAHN

METRONIDAZOLE

GEL; VAGINAL

NUVESSA

+ ALLERGAN SALES LLC

1.3%

N 205223 001 Mar 24, 2014

Apr CAHN

TABLET; ORAL

METRONIDAZOLE

AB FLAMINGO PHARMS

250MG

A 207309 001 May 16, 2016

May NEWA

AB

500MG

A 207309 002 May 16, 2016

May NEWA

AB NOSTRUM LABS INC

250MG

A 070772 001 Jul 16, 1986

Jan CAHN

AB

500MG

A 070773 001 Jul 16, 1986

Jan CAHN

AB STRIDES PHARMA

250MG

A 208162 001 May 25, 2016

May NEWA

AB

500MG

A 208162 002 May 25, 2016

May NEWA

AB VIVIMED LABS

250MG

A 070040 001 Jan 29, 1985

May CMFD

AB

500MG

A 070039 001 Jan 29, 1985

May CMFD

MICONAZOLE

TABLET; BUCCAL

ORAVIG

+ MIDATECH PHARMA US

50MG

N 022404 001 Apr 16, 2010

Jan CAHN

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP EUROHLTH INTL SARL

EQ 1MG BASE/ML

A 075247 002 Jun 23, 2000

May CAHN

AP

EQ 1MG BASE/ML

A 075421 002 Jun 20, 2000

Apr CAHN

AP

EQ 5MG BASE/ML

A 075247 001 Jun 23, 2000

May CAHN

AP

EQ 5MG BASE/ML

A 075421 001 Jun 20, 2000

Apr CAHN

MIGLITOL

TABLET; ORAL

GLYSET

AB + PHARMACIA AND UPJOHN

25MG

N 020682 001 Dec 18, 1996

Feb CRLD

AB

100MG

N 020682 003 Dec 18, 1996

Feb CRLD

MILNACIPRAN HYDROCHLORIDE

TABLET; ORAL

MILNACIPRAN HYDROCHLORIDE

AB AMNEAL PHARMS

12.5MG

A 205081 001 Apr 22, 2016

Apr NEWA

AB

25MG

A 205081 002 Apr 22, 2016

Apr NEWA

AB

50MG

A 205081 003 Apr 22, 2016

Apr NEWA

AB

100MG

A 205081 004 Apr 22, 2016

Apr NEWA

@ LIBERTY PHARMA INC

12.5MG

A 205071 001 Jan 27, 2016

Jan DISC

@

12.5MG

A 205071 001 Jan 27, 2016

Jan NEWA

@

25MG

A 205071 002 Jan 27, 2016

Jan DISC

@

25MG

A 205071 002 Jan 27, 2016

Jan NEWA

@

50MG

A 205071 003 Jan 27, 2016

Jan DISC

@

50MG

A 205071 003 Jan 27, 2016

Jan NEWA

## TABLET; ORAL

## MILNACIPRAN HYDROCHLORIDE

	@	100MG		A205071	004	Jan 27, 2016	Jan DISC
		100MG		A205071	004	Jan 27, 2016	Jan NEWA
			SAVELLA				
AB		CYPRESS BIOSCIENCE	12.5MG	N022256	001	Jan 14, 2009	Apr CFTG
AB			25MG	N022256	002	Jan 14, 2009	Apr CFTG
AB	+		50MG	N022256	003	Jan 14, 2009	Apr CFTG
AB			100MG	N022256	004	Jan 14, 2009	Apr CFTG

MILRINONE LACTATE

## INJECTABLE; INJECTION

## MILRINONE LACTATE

AP		EUROHLTH INTL SARL	EQ 1MG BASE/ML	A075660	001	May 28, 2002	Apr CAHN
			MILRINONE LACTATE IN DEXTROSE 5%				
AP		CLARIS	EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A077151	002	Jul 20, 2005	Mar CAHN
			MILRINONE LACTATE IN DEXTROSE 5% IN PLASTIC CONTAINER				
>D>	AP	BEDFORD LABS	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008	Jun CAHN
>D>	AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008	Jun CAHN
		@ CLARIS	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A077151	001	Jul 20, 2005	Mar CAHN
>A>	AP	EUROHLTH INTL SARL	EQ 20MG BASE/100ML (EQ 0.2MG BASE/ML)	A078113	001	May 21, 2008	Jun CAHN
>A>	AP		EQ 40MG BASE/200ML (EQ 0.2MG BASE/ML)	A078113	002	May 21, 2008	Jun CAHN

MINOCYCLINE HYDROCHLORIDE

## TABLET; ORAL

## MINOCYCLINE HYDROCHLORIDE

AB		SUN PHARM INDS	EQ 50MG BASE	A090217	001	Jan 29, 2016	Jan NEWA
AB			EQ 75MG BASE	A090217	002	Jan 29, 2016	Jan NEWA
AB			EQ 100MG BASE	A090217	003	Jan 29, 2016	Jan NEWA

## TABLET, EXTENDED RELEASE; ORAL

## MINOCYCLINE HYDROCHLORIDE

AB		AUROBINDO PHARMA LTD	EQ 80MG BASE	A202261	006	Jun 13, 2016	May NEWA
AB			EQ 105MG BASE	A202261	007	Jun 13, 2016	May NEWA
		@ IMPAX LABS INC	EQ 45MG BASE	A090024	001	Feb 03, 2009	Mar DISC
		@	EQ 90MG BASE	A090024	002	Feb 03, 2009	Mar DISC
		@	EQ 135MG BASE	A090024	003	Feb 03, 2009	Mar DISC

MINOXIDIL

## TABLET; ORAL

## MINOXIDIL

AB		SUN PHARM INDS	10MG	A072709	001	Dec 14, 1995	Mar CAHN
----	--	----------------	------	---------	-----	--------------	----------

MIPOMERSEN SODIUM

## SOLUTION; SUBCUTANEOUS

## KYNAMRO

>D>	+	GENZYME CORP	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013	Jun CAHN
>A>	+	KASTLE THERAPS LLC	200MG/ML (200MG/ML)	N203568	001	Jan 29, 2013	Jun CAHN

MIRTAZAPINE

## TABLET; ORAL

## MIRTAZAPINE

@	ACTAVIS LABS FL INC	15MG
@		30MG
@		45MG

A076336	001	Jun 20, 2003	Jan DISC
A076336	002	Jun 20, 2003	Jan DISC
A076336	003	Jun 20, 2003	Jan DISC

MITOMYCIN

## INJECTABLE; INJECTION

## MITOMYCIN

AP		EUROHLTH INTL SARL	5MG/VIAL	A064117	001	Apr 19, 1995	Apr CAHN
AP			5MG/VIAL	A064180	001	Dec 23, 1999	Jan CAHN
AP			20MG/VIAL	A064117	002	Apr 19, 1995	Apr CAHN
AP			20MG/VIAL	A064180	002	Dec 23, 1999	Jan CAHN

MODAFINIL

TABLET;ORAL

MODAFINIL

AB	WATSON LABS INC	100MG	A076715	001	Nov 01, 2012	Jan CAHN
AB		200MG	A076715	002	Nov 01, 2012	Jan CAHN

MOMETASONE FUROATE

SPRAY, METERED;NASAL

MOMETASONE FUROATE

AB	APOTEX INC	EQ 0.05MG BASE/SPRAY	A091161	001	Mar 22, 2016	Mar NEWA
	NASONEX					
AB	+ MERCK SHARP DOHME	EQ 0.05MG BASE/SPRAY	N020762	001	Oct 01, 1997	Mar CFTG

MORPHINE SULFATE

CAPSULE, EXTENDED RELEASE;ORAL

KADIAN

AB	+ ACTAVIS LABS UT INC	10MG	N020616	008	Apr 20, 2007	Feb CTEC
AB		20MG	N020616	001	Jul 03, 1996	Feb CTEC
AB		30MG	N020616	004	Mar 09, 2001	Feb CTEC
AB		40MG	N020616	009	Jul 09, 2012	Feb CTEC
AB		50MG	N020616	002	Jul 03, 1996	Feb CTEC
AB		60MG	N020616	005	Mar 09, 2001	Feb CTEC
AB		70MG	N020616	010	Jul 09, 2012	Feb CTEC
AB		80MG	N020616	006	Oct 27, 2006	Feb CTEC
AB	+	100MG	N020616	003	Jul 03, 1996	Feb CTEC
	+	200MG	N020616	007	Feb 27, 2007	Feb CTEC
AB	+ ALLERGAN SALES LLC	10MG	N020616	008	Apr 20, 2007	Apr CAHN
AB		20MG	N020616	001	Jul 03, 1996	Apr CAHN
AB		30MG	N020616	004	Mar 09, 2001	Apr CAHN
AB		40MG	N020616	009	Jul 09, 2012	Apr CAHN
AB		50MG	N020616	002	Jul 03, 1996	Apr CAHN
AB		60MG	N020616	005	Mar 09, 2001	Apr CAHN
AB		70MG	N020616	010	Jul 09, 2012	Apr CAHN
AB		80MG	N020616	006	Oct 27, 2006	Apr CAHN
AB	+	100MG	N020616	003	Jul 03, 1996	Apr CAHN
		130MG	N020616	011	Jul 09, 2012	Apr CAHN
		150MG	N020616	012	Jul 09, 2012	Apr CAHN
	+	200MG	N020616	007	Feb 27, 2007	Apr CAHN

MORPHINE SULFATE

AB	IMPAX LABS INC	20MG	A200411	001	Apr 12, 2016	Mar NEWA
AB		30MG	A200411	002	Apr 12, 2016	Mar NEWA
AB		50MG	A200411	003	Apr 12, 2016	Mar NEWA
AB		60MG	A200411	004	Apr 12, 2016	Mar NEWA
AB		80MG	A200411	005	Apr 12, 2016	Mar NEWA
AB		100MG	A200411	006	Apr 12, 2016	Mar NEWA
AB	PAR PHARM INC	20MG	A200812	001	Nov 10, 2011	Feb CTEC
AB		30MG	A200812	002	Nov 10, 2011	Feb CTEC
AB		50MG	A200812	003	Nov 10, 2011	Feb CTEC
AB		60MG	A200812	004	Nov 10, 2011	Feb CTEC
AB		80MG	A200812	005	Nov 10, 2011	Feb CTEC
AB		100MG	A200812	006	Nov 10, 2011	Feb CTEC
AB	TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014	Feb CTEC
AB		30MG	A202718	002	Dec 29, 2014	Feb CTEC
AB		40MG	A202718	007	Jun 03, 2015	Feb CTEC
AB		50MG	A202718	003	Dec 29, 2014	Feb CTEC
AB		60MG	A202718	004	Dec 29, 2014	Feb CTEC
AB		70MG	A202718	008	Jun 03, 2015	Feb CTEC
AB		80MG	A202718	005	Dec 29, 2014	Feb CTEC
AB		100MG	A202718	006	Dec 29, 2014	Feb CTEC
AB	UPSHER SMITH	10MG	A202104	001	Jun 03, 2013	Feb CTEC
AB		20MG	A202104	002	Jun 03, 2013	Feb CTEC
AB		30MG	A202104	003	Jun 03, 2013	Feb CTEC
AB		50MG	A202104	004	Jun 03, 2013	Feb CTEC
AB		60MG	A202104	005	Jun 03, 2013	Feb CTEC
AB		80MG	A202104	006	Jun 03, 2013	Feb CTEC
AB		100MG	A202104	007	Jun 03, 2013	Feb CTEC

SOLUTION;ORAL

MORPHINE SULFATE

AA	NOSTRUM LABS INC	10MG/5ML	A201011	001	Feb 05, 2014	Mar CAHN
AA		20MG/5ML	A201011	002	Feb 05, 2014	Mar CAHN
>A>	AA RHODES PHARMS	20MG/5ML	A206420	001	Jul 12, 2016	Jun NEWA
AA	TRIS PHARMA INC	20MG/5ML	A203519	001	May 18, 2016	May NEWA

TABLET, EXTENDED RELEASE;ORAL  
MORPHINE SULFATE

>A>	AB	COREPHARMA	15MG	A091357	001	Jun 23, 2016	Jun NEWA
>A>	AB		30MG	A091357	002	Jun 23, 2016	Jun NEWA
>A>	AB		60MG	A091357	003	Jun 23, 2016	Jun NEWA
>A>	AB		100MG	A091357	004	Jun 23, 2016	Jun NEWA
>A>	AB		200MG	A091357	005	Jun 23, 2016	Jun NEWA

MOXIFLOXACIN HYDROCHLORIDE

TABLET;ORAL  
MOXIFLOXACIN HYDROCHLORIDE

AB		CROSSMEDIKA SA	EQ 400MG BASE	A205348	001	Jan 14, 2016	Jan NEWA
----	--	----------------	---------------	---------	-----	--------------	----------

MYCOPHENOLATE MOFETIL

CAPSULE;ORAL  
MYCOPHENOLATE MOFETIL

>D>	AB	CADISTA PHARMS	250MG	A090762	001	Dec 15, 2014	Jun CAHN
>A>	AB	JUBILANT CADISTA	250MG	A090762	001	Dec 15, 2014	Jun CAHN

TABLET;ORAL  
MYCOPHENOLATE MOFETIL

>D>	AB	CADISTA PHARMS	500MG	A090661	001	Dec 15, 2014	Jun CAHN
>A>	AB	JUBILANT CADISTA	500MG	A090661	001	Dec 15, 2014	Jun CAHN

NALIDIXIC ACID

TABLET;ORAL  
NALIDIXIC ACID

>D>		@ MUTUAL PHARM	500MG	A070271	001	Jun 29, 1988	Jun CAHN
		@ SUN PHARM INDS	250MG	A070270	001	Jun 29, 1988	Mar CAHN
>A>		@	500MG	A070271	001	Jun 29, 1988	Jun CAHN
		@	1GM	A070272	001	Jun 29, 1988	Mar CAHN

NALOXONE HYDROCHLORIDE

INJECTABLE;INJECTION  
NALOXONE HYDROCHLORIDE

>A>	AP	MYLAN INSTITUTIONAL	0.4MG/ML	A205014	001	Jun 29, 2016	Jun NEWA
-----	----	---------------------	----------	---------	-----	--------------	----------

NAPROXEN

SUSPENSION;ORAL  
NAPROSYN

>A>	AB	+ ATNAHS PHARMA US	25MG/ML	N018965	001	Mar 23, 1987	Jun CAHN
>D>	AB	+ PEDIAPHARM INC	25MG/ML	N018965	001	Mar 23, 1987	Jun CAHN

TABLET;ORAL  
NAPROSYN

AB		ATNAHS PHARMA US	250MG	N017581	002		Feb CAHN
AB			375MG	N017581	003		Feb CAHN
AB	+		500MG	N017581	004	Apr 15, 1982	Feb CAHN

NAPROXEN  
@ SANDOZ  
@  
@

			250MG	A074140	001	Dec 21, 1993	Feb DISC
			375MG	A074140	002	Dec 21, 1993	Feb DISC
			500MG	A074140	003	Dec 21, 1993	Feb DISC

TABLET, DELAYED RELEASE;ORAL  
EC-NAPROSYN

AB	+	ATNAHS PHARMA US	375MG	N020067	002	Oct 14, 1994	Feb CAHN
AB	+		500MG	N020067	003	Oct 14, 1994	Feb CAHN
		NAPROXEN					
		@ SANDOZ	375MG	A075061	001	Feb 18, 1998	Feb DISC
		@	500MG	A075061	002	Feb 18, 1998	Feb DISC

NAPROXEN SODIUM

TABLET;ORAL  
ANAPROX

AB		ATNAHS PHARMA US	EQ 250MG BASE	N018164	001		Feb CAHN
AB	+	ANAPROX DS					
AB	+	ATNAHS PHARMA US	EQ 500MG BASE	N018164	003	Sep 30, 1987	Feb CAHN

NATEGLINIDE

TABLET;ORAL  
NATEGLINIDE

>A>	AB	ZYDUS PHARMS USA INC	60MG	A205248	001	Jul 06, 2016	Jun NEWA
>A>	AB		120MG	A205248	002	Jul 06, 2016	Jun NEWA

>A>	<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN</u>								
>A>	TABLET; ORAL								
>A>	BYVALSON								
>A>	FOREST LABS LLC	EQ 5MG BASE; 80MG			N206302	001	Jun 03, 2016	Jun	NEWA
	<u>NEFAZODONE HYDROCHLORIDE</u>								
	TABLET; ORAL								
	NEFAZODONE HYDROCHLORIDE								
	@ SUN PHARM INDS LTD	50MG			A076409	001	Sep 16, 2003	Feb	DISC
	@	100MG			A076409	002	Sep 16, 2003	Feb	DISC
	@	150MG			A076409	003	Sep 16, 2003	Feb	DISC
	@	200MG			A076409	004	Sep 16, 2003	Feb	DISC
	@	250MG			A076409	005	Sep 16, 2003	Feb	DISC
	<u>NEOMYCIN SULFATE</u>								
	TABLET; ORAL								
	NEOMYCIN SULFATE								
AA	LANNETT HOLDINGS INC	500MG			A204435	001	Jun 10, 2016	May	NEWA
	<u>NICARDIPINE HYDROCHLORIDE</u>								
	CAPSULE; ORAL								
	CARDENE								
	@ CHIESI USA INC	20MG			N019488	001	Dec 21, 1988	May	DISC
	@	30MG			N019488	002	Dec 21, 1988	May	DISC
	NICARDIPINE HYDROCHLORIDE								
AB	+ MYLAN	30MG			A074642	002	Jul 18, 1996	May	CRLD
	INJECTABLE; INJECTION								
	NICARDIPINE HYDROCHLORIDE								
>D>	AP	BEDFORD	25MG/10ML (2.5MG/ML)		A078714	001	Dec 28, 2009	Jun	CAHN
>A>	AP	EUROHLTH INTL SARL	25MG/10ML (2.5MG/ML)		A078714	001	Dec 28, 2009	Jun	CAHN
	<u>NIFEDIPINE</u>								
	CAPSULE; ORAL								
	NIFEDIPINE								
	@ VALIDUS PHARMS	10MG			A073250	001	Oct 08, 1991	Mar	CAHN
	@	20MG			A074045	001	Apr 30, 1992	Mar	CAHN
	TABLET, EXTENDED RELEASE; ORAL								
	ADALAT CC								
AB1	ALVOGEN	30MG			N020198	001	Apr 21, 1993	Feb	CAHN
AB1	+	60MG			N020198	002	Apr 21, 1993	Feb	CAHN
AB1	+	90MG			N020198	003	Apr 21, 1993	Feb	CAHN
	NIFEDIPINE								
>D>	AB2	OSMOTICA PHARM	30MG		A077127	001	Nov 21, 2005	Jun	CAHN
>D>	AB2		60MG		A077127	002	Nov 21, 2005	Jun	CAHN
>A>	AB2	OSMOTICA PHARM US	30MG		A077127	001	Nov 21, 2005	Jun	CAHN
>A>	AB2		60MG		A077127	002	Nov 21, 2005	Jun	CAHN
	AB1	VALEANT PHARMS NORTH	30MG		A075269	001	Dec 04, 2000	Jan	CAHN
	AB1		60MG		A075269	002	Dec 04, 2000	Jan	CAHN
	AB1		90MG		A076070	001	Aug 16, 2002	Jan	CAHN
	<u>NIMODIPINE</u>								
	CAPSULE; ORAL								
	NIMODIPINE								
AB	+ BIONPHARMA INC	30MG			A076740	001	Jan 17, 2008	Jan	CAHN
	<u>NITISINONE</u>								
	CAPSULE; ORAL								
	ORFADIN								
>A>	+	SWEDISH ORPHAN	20MG		N021232	004	Jun 13, 2016	Jun	NEWA
	SUSPENSION; ORAL								
	ORFADIN								
	+	SWEDISH ORPHAN	4MG/ML		N206356	001	Apr 22, 2016	Apr	NEWA
	<u>NITRIC OXIDE</u>								
	GAS; INHALATION								
	INOMAX								
	+	MALLINCKRODT HOSP	800PPM		N020845	003	Dec 23, 1999	Jan	CAHN

NITROFURANTOINSUSPENSION;ORAL  
FURADANTIN

>A>	AB	+	CASPER PHARMA LLC	25MG/5ML	N009175	001		Jun	CAHN
>D>	AB	+	SHIONOGI INC	25MG/5ML	N009175	001		Jun	CAHN

NITROFURANTOIN

	AB		ACTAVIS MID ATLANTIC	25MG/5ML	A205180	001	May 03, 2016	Apr	NEWA
	AB		NOSTRUM LABS INC	25MG/5ML	A201355	001	Aug 14, 2013	Feb	CAHN

NITROFURANTOIN, MACROCRYSTALLINECAPSULE;ORAL  
NITROFURANTOIN

	AB		SUN PHARM INDS	25MG	A201722	001	Feb 16, 2016	Feb	NEWA
	AB			50MG	A201722	002	Feb 16, 2016	Feb	NEWA
	AB			100MG	A201722	003	Feb 16, 2016	Feb	NEWA

NITROFURANTOIN; NITROFURANTOIN, MACROCRYSTALLINECAPSULE;ORAL  
MACROBID

	AB	+	ALVOGEN MALTA	75MG;25MG	N020064	001	Dec 24, 1991	Jan	CAHN
--	----	---	---------------	-----------	---------	-----	--------------	-----	------

NITROGLYCERINFILM, EXTENDED RELEASE;TRANSDERMAL  
MINITRAN

	AB1		VALEANT PHARMS NORTH	0.2MG/HR	A089772	001	Aug 30, 1996	May	CAHN
>A>			POWDER;SUBLINGUAL						
>A>			GONITRO						
>A>		+	POHL BOSKAMP	0.4MG/PACKET	N208424	001	Jun 08, 2016	Jun	NEWA

NIZATIDINESOLUTION;ORAL  
AXID@ BRAINTREE 15MG/ML  
NIZATIDINE

+ AMNEAL PHARMS 15MG/ML

N021494	001	May 25, 2004	Feb	DISC
A090576	001	Nov 18, 2009	Feb	CRLD

NOREPINEPHRINE BITARTRATEINJECTABLE;INJECTION  
NOREPINEPHRINE BITARTRATE

	AP		CLARIS	EQ 1MG BASE/ML	A040859	001	Mar 27, 2012	Jan	CAHN
	AP		EUROHLTH INTL SARL	EQ 1MG BASE/ML	A040462	001	Oct 31, 2003	Apr	CAHN

NORETHINDRONETABLET;ORAL-28  
NOR-QD

	AB1	+	APIL	0.35MG	N017060	001		Jan	CAHN
--	-----	---	------	--------	---------	-----	--	-----	------

NORTRIPTYLINE HYDROCHLORIDECAPSULE;ORAL  
NORTRIPTYLINE HYDROCHLORIDE

@ AUROLIFE PHARMA LLC EQ 10MG BASE

@ EQ 25MG BASE

@ EQ 50MG BASE

@ EQ 75MG BASE

@ IDT AUSTRALIA LTD EQ 10MG BASE

@ EQ 25MG BASE

@ EQ 50MG BASE

@ EQ 75MG BASE

A074835	001	Jun 30, 1997	Feb	CAHN
A074835	002	Jun 30, 1997	Feb	CAHN
A074835	003	Jun 30, 1997	Feb	CAHN
A074835	004	Jun 30, 1997	Feb	CAHN
A074054	001	Dec 31, 1992	May	CAHN
A074054	002	Dec 31, 1992	May	CAHN
A074054	003	Dec 31, 1992	May	CAHN
A074054	004	Dec 31, 1992	May	CAHN

NYSTATINTABLET;ORAL  
NYSTATIN

	AA		SUN PHARM INDS	500,000 UNITS	A062838	001	Dec 22, 1988	Mar	CAHN
--	----	--	----------------	---------------	---------	-----	--------------	-----	------

NYSTATIN; TRIAMCINOLONE ACETONIDECREAM;TOPICAL  
NYSTATIN TRIAMCINOLONE ACETONIDE

@ PHARMADERM 100,000 UNITS/GM;0.1%

A062596	001	Oct 08, 1985	Mar	CMS1
---------	-----	--------------	-----	------

OINTMENT;TOPICAL  
MYKACET

AT	G AND W LABS INC	100,000 UNITS/GM;0.1%	A062733	001	Mar 06, 1987	May CMS1
	NYSTATIN AND TRIAMCINOLONE ACETONIDE					
>A> AT	GLENMARK PHARMS LTD	100,000 UNITS/GM;0.1%	A208300	001	Jun 23, 2016	Jun NEWA

OBETICHOLIC ACID

TABLET;ORAL  
OCALIVA

	INTERCEPT PHARMS INC	5MG	N207999	001	May 27, 2016	May NEWA
+		10MG	N207999	002	May 27, 2016	May NEWA

OCTREOTIDE ACETATE

INJECTABLE;INJECTION  
OCTREOTIDE ACETATE

@	WOCKHARDT USA	EQ 0.2MG BASE/ML	A090986	001	May 11, 2011	Jan DISC
@		EQ 1MG BASE/ML	A090986	002	May 11, 2011	Jan DISC
	OCTREOTIDE ACETATE (PRESERVATIVE FREE)					
@	WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Jan DISC
@		EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Jan DISC
@		EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Jan DISC
	OCTREOTIDE ACETATE PRESERVATIVE FREE					
@	WOCKHARDT USA	EQ 0.05MG BASE/ML	A090985	001	May 11, 2011	Feb CMS1
@		EQ 0.1MG BASE/ML	A090985	002	May 11, 2011	Feb CMS1
@		EQ 0.5MG BASE/ML	A090985	003	May 11, 2011	Feb CMS1

OFLOXACIN

SOLUTION/DROPS;OPHTHALMIC  
OFLOXACIN

AT	ALVOGEN	0.3%	A076830	001	Aug 31, 2004	Mar CAHN
	SOLUTION/DROPS;OTIC					
	FLOXIN OTIC					
	@ DAIICHI	0.3%	N020799	001	Dec 16, 1997	Feb DISC
	OFLOXACIN					
AT	ALVOGEN	0.3%	A090395	001	Aug 11, 2009	Mar CAHN
AT	+ BAUSCH AND LOMB	0.3%	A076128	001	Mar 17, 2008	Feb CRLD

OLANZAPINE

TABLET;ORAL  
OLANZAPINE

AB	INVAGEN PHARMS	2.5MG	A203333	001	Mar 15, 2016	Feb NEWA
AB		5MG	A203333	002	Mar 15, 2016	Feb NEWA
AB		7.5MG	A203333	003	Mar 15, 2016	Feb NEWA
AB		10MG	A203333	004	Mar 15, 2016	Feb NEWA
AB		15MG	A203333	005	Mar 15, 2016	Feb NEWA
AB		20MG	A203333	006	Mar 15, 2016	Feb NEWA
AB	QILU PHARM CO LTD	2.5MG	A204319	001	Jan 27, 2016	Jan NEWA
AB		5MG	A204319	002	Jan 27, 2016	Jan NEWA
AB		7.5MG	A204319	003	Jan 27, 2016	Jan NEWA
AB		10MG	A204319	004	Jan 27, 2016	Jan NEWA
AB		15MG	A204319	005	Jan 27, 2016	Jan NEWA
AB		20MG	A204319	006	Jan 27, 2016	Jan NEWA

TABLET, ORALLY DISINTEGRATING;ORAL  
OLANZAPINE

AB	INVAGEN PHARMS	5MG	A203456	001	Mar 16, 2016	Feb NEWA
AB		10MG	A203456	002	Mar 16, 2016	Feb NEWA
AB		15MG	A203456	003	Mar 16, 2016	Feb NEWA
AB		20MG	A203456	004	Mar 16, 2016	Feb NEWA

OLOPATADINE HYDROCHLORIDE

SOLUTION/DROPS;OPHTHALMIC  
OLOPATADINE HYDROCHLORIDE

AT	SOMERSET THERAPS LLC	EQ 0.1% BASE	A206306	001	Dec 07, 2015	Mar CAHN
----	----------------------	--------------	---------	-----	--------------	----------

OMEGA-3-ACID ETHYL ESTERS

CAPSULE;ORAL  
OMEGA-3-ACID ETHYL ESTERS

AB	AMNEAL PHARMS	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A204940	001	Nov 27, 2015	Jan CMS1
----	---------------	--	---------	-----	--------------	----------



OMEGA-3-ACID ETHYL ESTERS TYPE A

CAPSULE;ORAL

OMTRYG

	+	TRYGG	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Mar	CAIN
--	---	-------	--	---------	-----	--------------	-----	------

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

AB	+	SANDOZ	20MG	A075757	002	Jan 28, 2003	Mar	CRLD
AB	+		40MG	A076515	001	Jan 21, 2009	Mar	CRLD
>D>		PRILOSEC						
>D>	AB	ASTRAZENECA PHARMS	10MG	N019810	003	Oct 05, 1995	Jun	DISC
>A>		@	10MG	N019810	003	Oct 05, 1995	Jun	DISC
>D>	AB	+	20MG	N019810	001	Sep 14, 1989	Jun	DISC
>A>		@	20MG	N019810	001	Sep 14, 1989	Jun	DISC
>D>	AB	+	40MG	N019810	002	Jan 15, 1998	Jun	DISC
>A>		@	40MG	N019810	002	Jan 15, 1998	Jun	DISC

ONDANSETRON

FILM;ORAL

ZUPLENZ

>D>		GALENA BIOPHARMA INC	4MG	N022524	001	Jul 02, 2010	Jun	CAHN
>D>	+		8MG	N022524	002	Jul 02, 2010	Jun	CAHN
>A>		MIDATECH PHARMA US	4MG	N022524	001	Jul 02, 2010	Jun	CAHN
>A>	+		8MG	N022524	002	Jul 02, 2010	Jun	CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

AP		EUROHLTH INTL SARL	EQ 2MG BASE/ML	A076967	001	Dec 26, 2006	Apr	CAHN
		ONDANSETRON HYDROCHLORIDE PRESERVATIVE FREE						
AP		ACCORD HLTHCARE	EQ 2MG BASE/ML	A206845	001	Mar 10, 2016	Feb	NEWA
AP		EUROHLTH INTL SARL	EQ 2MG BASE/ML	A077011	001	Dec 26, 2006	Apr	CAHN

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

@	HIKMA INTL PHARMS	EQ 4MG BASE	A077545	001	Sep 06, 2007	May	CAHN
@		EQ 8MG BASE	A077545	002	Sep 06, 2007	May	CAHN
@		EQ 24MG BASE	A077545	003	Sep 06, 2007	May	CAHN

OXALIPLATIN

INJECTABLE;IV (INFUSION)

ELOXATIN

>D>	AP	+	SANOFI AVENTIS US	200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	Jun	DISC
>A>		@		200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	Jun	DISC
	AP	+		200MG/40ML (5MG/ML)	N021759	003	Nov 17, 2006	May	CFTG
			OXALIPLATIN						
AP			QILU PHARM CO LTD	50MG/10ML (5MG/ML)	A204368	001	Jun 07, 2016	May	NEWA
AP				50MG/VIAL	A204616	001	May 11, 2016	Apr	NEWA
AP				100MG/20ML (5MG/ML)	A204368	002	Jun 07, 2016	May	NEWA
AP				100MG/VIAL	A204616	002	May 11, 2016	Apr	NEWA
>D>	AP			200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jun	CRLD
>A>		+		200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	Jun	CRLD
AP				200MG/40ML (5MG/ML)	A204368	003	Jun 07, 2016	May	NEWA
AP			SANDOZ INC	50MG/10ML (5MG/ML)	A078812	001	Aug 07, 2009	Jan	CAHN
AP				100MG/20ML (5MG/ML)	A078812	002	Aug 07, 2009	Jan	CAHN

OXAZEPAM

CAPSULE;ORAL

OXAZEPAM

@	SUN PHARM INDS	10MG	A071026	002	Aug 10, 1987	Mar	CAHN
@		15MG	A071026	003	Aug 10, 1987	Mar	CAHN
@		30MG	A071026	001	Aug 10, 1987	Mar	CAHN

TABLET;ORAL

OXAZEPAM

>D>		@	MUTUAL PHARM	15MG	A070683	001	Jan 16, 1987	Jun	CAHN
>A>		@	SUN PHARM INDS	15MG	A070683	001	Jan 16, 1987	Jun	CAHN

OXCARBAZEPINE

TABLET; ORAL

OXCARBAZEPINE

>D>	@ ANI PHARMS INC	150MG	A 078005	001	Dec 11, 2007	Jun	CMFD
>A>	AB	150MG	A 078005	001	Dec 11, 2007	Jun	CMFD
>D>	@	300MG	A 078005	002	Dec 11, 2007	Jun	CMFD
>A>	AB	300MG	A 078005	002	Dec 11, 2007	Jun	CMFD
>D>	@	600MG	A 078005	003	Dec 11, 2007	Jun	CMFD
>A>	AB	600MG	A 078005	003	Dec 11, 2007	Jun	CMFD

OXICONAZOLE NITRATE

CREAM; TOPICAL

OXICONAZOLE NITRATE

AB	TARO	EQ 1% BASE	A 205076	001	Mar 07, 2016	Feb	NEWA
AB	+ FOUGERA PHARMS	EQ 1% BASE	N 019828	001	Dec 30, 1988	Feb	CFTG

OXYBUTYNIN

FILM, EXTENDED RELEASE; TRANSDERMAL

OXYTROL

AB	+ ALLERGAN SALES LLC	3.9MG/24HR	N 021351	002	Feb 26, 2003	Apr	CAHN
	GEL, METERED; TRANSDERMAL						
	GELNIQUE 3%						
	+ ALLERGAN SALES LLC	3%	N 202513	001	Dec 07, 2011	Apr	CAHN

OXYBUTYNIN CHLORIDE

GEL; TRANSDERMAL

GELNIQUE

	+ ALLERGAN SALES LLC	10% (100MG/PACKET)	N 022204	001	Jan 27, 2009	Apr	CAHN
--	----------------------	--------------------	----------	-----	--------------	-----	------

TABLET, EXTENDED RELEASE; ORAL

OXYBUTYNIN CHLORIDE

AB	ACCORD HLTHCARE	5MG	A 207138	001	Feb 29, 2016	Feb	NEWA
AB		10MG	A 207138	002	Feb 29, 2016	Feb	NEWA
AB		15MG	A 207138	003	Feb 29, 2016	Feb	NEWA
>D>	AB	OSMOTICA PHARM	A 078503	001	Feb 04, 2009	Jun	CAHN
>D>	AB		A 078503	002	Feb 04, 2009	Jun	CAHN
>D>	AB		A 078503	003	Feb 04, 2009	Jun	CAHN
>A>	AB	OSMOTICA PHARM US	A 078503	001	Feb 04, 2009	Jun	CAHN
>A>	AB		A 078503	002	Feb 04, 2009	Jun	CAHN
>A>	AB		A 078503	003	Feb 04, 2009	Jun	CAHN
AB	UNIQUE PHARM LABS	5MG	A 206121	001	May 27, 2016	May	NEWA
AB		10MG	A 206121	002	May 27, 2016	May	NEWA
AB		15MG	A 206121	003	May 27, 2016	May	NEWA

OXYCODONE

CAPSULE, EXTENDED RELEASE; ORAL

XTAMPZA ER

	COLLEGIUM PHARM INC	9MG	N 208090	001	Apr 26, 2016	May	CAIN
		13.5MG	N 208090	002	Apr 26, 2016	May	CAIN
		18MG	N 208090	003	Apr 26, 2016	May	CAIN
		27MG	N 208090	004	Apr 26, 2016	May	CAIN
	+	36MG	N 208090	005	Apr 26, 2016	May	CAIN

OXYCODONE HYDROCHLORIDE

CAPSULE; ORAL

OXYCODONE HYDROCHLORIDE

AB	ANI PHARMS INC	5MG	A 205177	001	Mar 31, 2016	Mar	NEWA
----	----------------	-----	----------	-----	--------------	-----	------

CAPSULE, EXTENDED RELEASE; ORAL

XTAMPZA ER

	COLLEGIUM PHARM INC	EQ 9MG BASE	N 208090	001	Apr 26, 2016	Apr	NEWA
		EQ 13.5MG BASE	N 208090	002	Apr 26, 2016	Apr	NEWA
		EQ 18MG BASE	N 208090	003	Apr 26, 2016	Apr	NEWA
		EQ 27MG BASE	N 208090	004	Apr 26, 2016	Apr	NEWA
	+	EQ 36MG BASE	N 208090	005	Apr 26, 2016	May	CRLD
		EQ 36MG BASE	N 208090	005	Apr 26, 2016	Apr	NEWA

TABLET; ORAL

OXYCODONE HYDROCHLORIDE

AB	ALVOGEN MALTA	5MG	A 202116	001	Dec 30, 2011	Jan	CAHN
AB		15MG	A 202116	002	Dec 30, 2011	Jan	CAHN
AB		30MG	A 202116	003	Dec 30, 2011	Jan	CAHN
AB	COASTAL PHARMS	10MG	A 091313	004	Apr 29, 2016	Apr	NEWA

## TABLET;ORAL

## OXYCODONE HYDROCHLORIDE

AB		20MG	A091313	005	Apr 29, 2016	Apr	NEWA
AB	KEN LIFESCIENCE	5MG	A207119	001	Apr 12, 2016	Mar	NEWA
AB		10MG	A207119	002	Apr 12, 2016	Mar	NEWA
AB		15MG	A207119	003	Apr 12, 2016	Mar	NEWA
AB		20MG	A207119	004	Apr 12, 2016	Mar	NEWA
AB		30MG	A207119	005	Apr 12, 2016	Mar	NEWA

>A> OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE

&gt;A&gt; SPRAY, METERED;NASAL

&gt;A&gt; KOVANAZE

>A>	+	ST RENATUS	0.1MG/SPRAY;6MG/SPRAY	N208032	001	Jun 29, 2016	Jun	NEWA
-----	---	------------	-----------------------	---------	-----	--------------	-----	------

OXYMORPHONE HYDROCHLORIDE

## TABLET;ORAL

## OXYMORPHONE HYDROCHLORIDE

AB	AUROLIFE PHARMA LLC	5MG	A204459	001	Apr 26, 2016	Apr	NEWA
AB		10MG	A204459	002	Apr 26, 2016	Apr	NEWA

PACLITAXEL

## INJECTABLE;INJECTION

## PACLITAXEL

AP	SANDOZ INC	6MG/ML	A078167	001	Dec 26, 2007	Jan	CAHN
----	------------	--------	---------	-----	--------------	-----	------

PALIPERIDONE PALMITATE

## SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR

## INVEGA SUSTENNA

JANSSEN PHARMS 117MG/0.75ML (117MG/0.75ML)

N022264 003 Jul 31, 2009 Mar CRLD

+ 156MG/ML (156MG/ML)

N022264 004 Jul 31, 2009 Mar CRLD

PALONOSETRON HYDROCHLORIDE

## INJECTABLE;INTRAVENOUS

## PALONOSETRON HYDROCHLORIDE

AP	DR REDDYS LABS LTD	EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)	A201533	001	Apr 21, 2016	Apr	NEWA
----	--------------------	---	---------	-----	--------------	-----	------

AP		EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)	A201533	002	Apr 21, 2016	Apr	NEWA
----	--	--	---------	-----	--------------	-----	------

## SOLUTION;INTRAVENOUS

## PALONOSETRON HYDROCHLORIDE

DR REDDYS LABS LTD EQ 0.075MG BASE/1.5ML (EQ 0.05MG BASE/ML)

N203050 001 Mar 01, 2016 Mar NEWA

EQ 0.25MG BASE/5ML (EQ 0.05MG BASE/ML)

N203050 002 Mar 01, 2016 Mar NEWA

PAMIDRONATE DISODIUM

## INJECTABLE;INJECTION

## PAMIDRONATE DISODIUM

AP	SAGENT PHARMS	30MG/10ML (3MG/ML)	A078373	001	Dec 23, 2008	Jan	CAHN
----	---------------	--------------------	---------	-----	--------------	-----	------

AP		90MG/10ML (9MG/ML)	A078373	002	Dec 23, 2008	Jan	CAHN
----	--	--------------------	---------	-----	--------------	-----	------

PANTOPRAZOLE SODIUM

## INJECTABLE;IV (INFUSION)

## PANTOPRAZOLE SODIUM

AP	AUROBINDO PHARMA LTD	EQ 40MG BASE/VIAL	A205675	001	Mar 30, 2016	Mar	NEWA
----	----------------------	-------------------	---------	-----	--------------	-----	------

## TABLET, DELAYED RELEASE;ORAL

## PANTOPRAZOLE SODIUM

AB	AMNEAL PHARMS	EQ 20MG BASE	A205119	001	Jan 26, 2016	Jan	NEWA
----	---------------	--------------	---------	-----	--------------	-----	------

AB		EQ 40MG BASE	A205119	002	Jan 26, 2016	Jan	NEWA
----	--	--------------	---------	-----	--------------	-----	------

PARICALCITOL

## CAPSULE;ORAL

## PARICALCITOL

AB	BIONPHARMA INC	1MCG	A202539	001	Mar 27, 2014	Jan	CAHN
----	----------------	------	---------	-----	--------------	-----	------

AB		2MCG	A202539	002	Mar 27, 2014	Jan	CAHN
----	--	------	---------	-----	--------------	-----	------

AB		4MCG	A202539	003	Mar 27, 2014	Jan	CAHN
----	--	------	---------	-----	--------------	-----	------

AB	LOTUS PHARM CO LTD	1MCG	A206710	001	Feb 24, 2016	Feb	NEWA
----	--------------------	------	---------	-----	--------------	-----	------

AB		2MCG	A206710	002	Feb 24, 2016	Feb	NEWA
----	--	------	---------	-----	--------------	-----	------

AB		4MCG	A206710	003	Feb 24, 2016	Feb	NEWA
----	--	------	---------	-----	--------------	-----	------

## SOLUTION;INTRAVENOUS

## PARICALCITOL

AP	ACCORD HLTHCARE	0.002MG/ML (0.002MG/ML)	N207174	001	Feb 04, 2016	Feb	NEWA
----	-----------------	-------------------------	---------	-----	--------------	-----	------

SOLUTION; INTRAVENOUS								
PARICALCITOL								
AP		0.005MG/ML (0.005MG/ML)		N207174	002	Feb 04, 2016	Feb	NEWA
AP		0.01MG/2ML (0.005MG/ML)		N207174	003	Feb 04, 2016	Feb	NEWA
<u>PAROXETINE HYDROCHLORIDE</u>								
TABLET, EXTENDED RELEASE; ORAL								
PAROXETINE HYDROCHLORIDE								
AB	KREMERS URBAN PHARMS	EQ 12.5MG BASE		A204744	001	Jun 10, 2016	May	NEWA
AB		EQ 25MG BASE		A204744	002	Jun 10, 2016	May	NEWA
AB		EQ 37.5MG BASE		A204744	003	Jun 10, 2016	May	NEWA
<u>PENBUTOLOL SULFATE</u>								
TABLET; ORAL								
LEVATOL								
	@ AUXILIUM PHARMS INC	10MG		N018976	001	Dec 30, 1987	Mar	CAHN
	@	20MG		N018976	004	Jan 05, 1989	Mar	CAHN
<u>PENCICLOVIR</u>								
CREAM; TOPICAL								
DENVIR								
+	DENCO ASSET	1%		N020629	001	Sep 24, 1996	Apr	CAIN
<u>PENTETATE CALCIUM TRISODIUM</u>								
SOLUTION; INHALATION, INTRAVENOUS								
PENTETATE CALCIUM TRISODIUM								
+	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)		N021749	001	Aug 11, 2004	Apr	CMFD
	@	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)		N021749	001	Aug 11, 2004	Feb	CAHN
<u>PENTETATE ZINC TRISODIUM</u>								
SOLUTION; INHALATION, INTRAVENOUS								
PENTETATE ZINC TRISODIUM								
+	HAMELN PHARMA PLUS	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)		N021751	001	Aug 11, 2004	Apr	CMFD
	@	EQ 1GM BASE/5ML (EQ 200MG BASE/ML)		N021751	001	Aug 11, 2004	Feb	CAHN
<u>PENTOBARETAL SODIUM</u>								
INJECTABLE; INJECTION								
NEMBUTAL SODIUM								
AP	+	OAK PHARMS	50MG/ML	A083246	001		May	CTEC
PENTOBARBITAL SODIUM								
AP		MYLAN INSTITUTIONAL	50MG/ML	A206404	001	May 23, 2016	May	NEWA
<u>PENTOXIFYLLINE</u>								
TABLET, EXTENDED RELEASE; ORAL								
PENTOXIFYLLINE								
AB	+	APOTEX	400MG	A075191	001	Jun 09, 1999	Mar	CRLD
	@	IMPAX LABS	400MG	A075093	001	Aug 10, 1999	Mar	DISC
	@	PLIVA	400MG	A074874	001	May 25, 1999	Mar	DISC
TRENENTAL								
	@	US PHARM HOLDINGS	400MG	N018631	001	Aug 30, 1984	Jan	CAHN
<u>PERAMPANEL</u>								
SUSPENSION; ORAL								
FYCOMPA								
+	EISAI INC	0.5MG/ML		N208277	001	Apr 29, 2016	Apr	NEWA
<u>PERPHENAZINE</u>								
TABLET; ORAL								
PERPHENAZINE								
AB		WILSHIRE PHARMS INC	2MG	A205973	001	Dec 17, 2015	Jan	CAHN
AB			4MG	A205973	002	Dec 17, 2015	Jan	CAHN
AB			8MG	A205973	003	Dec 17, 2015	Jan	CAHN
AB			16MG	A205973	004	Dec 17, 2015	Jan	CAHN
<u>PHENAZOPYRIDINE HYDROCHLORIDE; SULFAMETHOXAZOLE; TRIMETHOPRIM</u>								
TABLET; ORAL								
SULFAMETHOXAZOLE AND TRIMETHOPRIM AND PHENAZOPYRIDINE HYDROCHLORIDE								
	@ ABLE	200MG, N/A, N/A; N/A, 800MG, 160MG		N021105	001	Jun 26, 2001	Jan	CMS1

PHENTERMINE HYDROCHLORIDE

CAPSULE;ORAL

PHENTERMINE HYDROCHLORIDE

AA	SUN PHARM INDS	30MG	A040525	001	Oct 23, 2003	Mar	CAHN
	@	37.5MG	A040527	001	Oct 23, 2003	Mar	CAHN

TABLET;ORAL

PHENTERMINE HYDROCHLORIDE

AA	INGENUS PHARMS NJ	37.5MG	A091451	001	Sep 21, 2012	Jan	CAHN
AA	SUN PHARM INDS	37.5MG	A040526	001	Oct 23, 2003	Mar	CAHN

&gt;D&gt; TABLET, ORALLY DISINTEGRATING;ORAL

&gt;D&gt; SUPRENZA

>D>	CITIUS PHARMS	15MG	N202088	001	Jun 13, 2011	Jun	DISC
>A>	@	15MG	N202088	001	Jun 13, 2011	Jun	DISC
>D>		30MG	N202088	002	Jun 13, 2011	Jun	DISC
>A>	@	30MG	N202088	002	Jun 13, 2011	Jun	DISC
>D>	+	37.5MG	N202088	003	Mar 27, 2012	Jun	DISC
>A>	@	37.5MG	N202088	003	Mar 27, 2012	Jun	DISC

PHENYLBUZAZONE

CAPSULE;ORAL

PHENYLBUZAZONE

@	SUN PHARM INDS	100MG	A088994	001	Dec 04, 1985	Mar	CAHN
---	----------------	-------	---------	-----	--------------	-----	------

TABLET;ORAL

PHENYLBUZAZONE

@	SUN PHARM INDS	100MG	A088863	001	Dec 04, 1985	Mar	CAHN
---	----------------	-------	---------	-----	--------------	-----	------

PHYTONADIONE

INJECTABLE;INJECTION

AQUAMEPHYTON

@	TELIGENT PHARMA INC	1MG/0.5ML	N012223	002		Jan	CAHN
@		10MG/ML	N012223	001		Jan	CAHN

PIMAVANSERIN TARTRATE

TABLET;ORAL

NUPLAZID

+	ACADIA PHARMS INC	EQ 17MG BASE	N207318	001	Apr 29, 2016	Apr	NEWA
---	-------------------	--------------	---------	-----	--------------	-----	------

PINDOLOL

TABLET;ORAL

PINDOLOL

@	IDT AUSTRALIA LTD	5MG	A073608	001	Mar 29, 1993	May	CAHN
@		10MG	A073609	001	Mar 29, 1993	May	CAHN
AB	SUN PHARM INDS	5MG	A074063	001	Jan 27, 1994	Mar	CAHN
AB		10MG	A074063	002	Jan 27, 1994	Mar	CAHN

PIROXICAM

CAPSULE;ORAL

PIROXICAM

AB	MYLAN PHARMS INC	20MG	A074118	001	Jun 15, 1993	Jan	CAHN
@	SUN PHARM INDS	20MG	A073536	001	Mar 12, 1993	Mar	CAHN

PODOFILOX

GEL;TOPICAL

CONDYLOX

+	ALLERGAN SALES LLC	0.5%	N020529	001	Mar 13, 1997	Mar	CAHN
---	--------------------	------	---------	-----	--------------	-----	------

SOLUTION;TOPICAL

CONDYLOX

AT	+	ALLERGAN SALES LLC	0.5%	N019795	001	Dec 13, 1990	Mar	CAHN
----	---	--------------------	------	---------	-----	--------------	-----	------

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SOLUTION;ORAL

COLYTE

@	MEDA PHARMS	227.1GM/BOT;2.82GM/BOT;6.36GM/BOT; 5.53GM/BOT;21.5GM/BOT	N018983	010	Jan 31, 1989	May	DISC
---	-------------	---	---------	-----	--------------	-----	------

POLYMYXIN B SULFATEINJECTABLE; INJECTION  
POLYMYXIN B SULFATE

AP	AUROBINDO PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A206589	001	Apr 04, 2016	Mar	NEWA
AP	GLAND PHARMA LTD	EQ 500,000 UNITS BASE/VIAL	A207322	001	Apr 14, 2016	Apr	NEWA

POTASSIUM CHLORIDECAPSULE, EXTENDED RELEASE; ORAL  
POTASSIUM CHLORIDE

AB	GLENMARK PHARMS LTD	10MEQ	A202868	001	Jan 19, 2016	Jan	NEWA
AB	KREMERS URBAN PHARMS	8MEQ	A204210	001	Mar 28, 2016	Mar	NEWA
AB		10MEQ	A204210	002	Mar 28, 2016	Mar	NEWA
AB	TRIS PHARMA INC	8MEQ	A201944	001	Mar 04, 2016	Feb	NEWA
AB		10MEQ	A201944	002	Mar 04, 2016	Feb	NEWA

TABLET, EXTENDED RELEASE; ORAL  
POTASSIUM CHLORIDE

AB1	NOVEL LABS INC	10MEQ	A206347	001	Jan 21, 2016	Jan	NEWA
AB1		20MEQ	A206347	002	Jan 21, 2016	Jan	NEWA

PRAMIPEXOLE DIHYDROCHLORIDETABLET, EXTENDED RELEASE; ORAL  
PRAMIPEXOLE DIHYDROCHLORIDE

AB	ACTAVIS ELIZABETH	0.375MG	A201963	001	Apr 21, 2016	Apr	NEWA
AB		0.75MG	A201963	002	Apr 21, 2016	Apr	NEWA
AB		1.5MG	A201963	003	Apr 21, 2016	Apr	NEWA
AB		3MG	A201963	004	Apr 21, 2016	Apr	NEWA
AB		4.5MG	A201963	005	Apr 21, 2016	Apr	NEWA
>A>	MACLEODS PHARMS LTD	0.375MG	A206156	001	Jun 24, 2016	Jun	NEWA
>A>		0.75MG	A206156	002	Jun 24, 2016	Jun	NEWA
>A>		1.5MG	A206156	003	Jun 24, 2016	Jun	NEWA
>A>		2.25MG	A206156	004	Jun 24, 2016	Jun	NEWA
>A>		3MG	A206156	005	Jun 24, 2016	Jun	NEWA
>A>		4.5MG	A206156	007	Jun 24, 2016	Jun	NEWA

PRAVASTATIN SODIUMTABLET; ORAL  
PRAVASTATIN SODIUM

AB	CIPLA LTD	80MG	A077904	004	Mar 22, 2016	Mar	NEWA
	@ MYLAN	10MG	A077013	001	Oct 23, 2006	Mar	DISC
	@	20MG	A077013	002	Oct 23, 2006	Mar	DISC
	@	40MG	A077013	003	Oct 23, 2006	Mar	DISC
	@	80MG	A077013	004	Dec 28, 2007	Mar	DISC

PRAZOSIN HYDROCHLORIDECAPSULE; ORAL  
PRAZOSIN HYDROCHLORIDE

	@ IDT AUSTRALIA LTD	EQ 1MG BASE	A072576	001	May 16, 1989	May	CAHN
	@	EQ 2MG BASE	A072577	001	May 16, 1989	May	CAHN
	@	EQ 5MG BASE	A072578	001	May 16, 1989	May	CAHN

PREDNISOLONETABLET; ORAL  
PREDNISOLONE

	@ AUROLIFE PHARMA LLC	5MG	A084773	001		Feb	CAHN
--	-----------------------	-----	---------	-----	--	-----	------

PREDNISOLONE SODIUM PHOSPHATESOLUTION; ORAL  
ORAPRED

	@ CONCORDIA PHARMS INC	EQ 15MG BASE/5ML	A075117	001	Dec 14, 2000	Mar	DISC
AA	+ WOCKHARDT	EQ 15MG BASE/5ML	A076895	001	Oct 04, 2004	Mar	CRLD

PREDNISONETABLET; ORAL  
PREDNISONE

	@ AUROLIFE PHARMA LLC	5MG	A084774	001		Mar	CAHN
	@	10MG	A089983	001	Jan 12, 1989	Mar	CAHN
	@	20MG	A085813	001		Mar	CAHN
	@	50MG	A089984	001	Jan 12, 1989	Mar	CAHN
AB	DELCOR ASSET CORP	5MG	A080292	001		Mar	CAHN
AB		10MG	A088832	001	Dec 04, 1985	Mar	CAHN

TABLET;ORAL									
PREDNISONE									
AB		20MG		A083677	001			Mar	CAHN
>D>	@ MUTUAL PHARM	50MG		A086596	001			Jun	CAHN
AB	SUN PHARM INDS	20MG		A089247	001	Dec 04, 1985		Mar	CAHN
>A>	@	50MG		A086596	001			Jun	CAHN
<u>PRIMAQUINE PHOSPHATE</u>									
TABLET;ORAL									
PRIMAQUINE PHOSPHATE									
>A>	AB	INGENUS PHARMS NJ	EQ 15MG BASE	A206043	001	Jun 23, 2016		Jun	NEWA
<u>PRIMIDONE</u>									
TABLET;ORAL									
PRIMIDONE									
	@ IMPAX LABS	50MG		A040717	001	Feb 12, 2008		Mar	DISC
	@	250MG		A040717	002	Feb 12, 2008		Mar	DISC
AB	SUN PHARM INDS	50MG		A040626	001	Sep 29, 2005		Mar	CAHN
AB		250MG		A040626	002	Sep 29, 2005		Mar	CAHN
<u>PROCAINAMIDE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
PROCAINAMIDE HYDROCHLORIDE									
	@ IDT AUSTRALIA LTD	375MG		A089220	001	Jul 01, 1986		May	CAHN
<u>PROCHLORPERAZINE EDISYLATE</u>									
INJECTABLE;INJECTION									
PROCHLORPERAZINE EDISYLATE									
>A>	AP	AMPHASTAR PHARMS INC	EQ 5MG BASE/ML	A040540	001	May 28, 2004		Jun	CAHN
>D>	AP	EUROHLTH INTL SARL	EQ 5MG BASE/ML	A040540	001	May 28, 2004		Jun	CAHN
	AP		EQ 5MG BASE/ML	A040540	001	May 28, 2004		Apr	CAHN
<u>PROGESTERONE</u>									
CAPSULE;ORAL									
PROGESTERONE									
AB	BIONPHARMA INC	100MG		A200900	001	Aug 16, 2013		Jan	CAHN
AB		200MG		A200900	002	Aug 16, 2013		Jan	CAHN
PROMETRIUM									
>D>	AB	ABBVIE INC	100MG	N019781	001	May 14, 1998		Jun	CAHN
>D>	AB	+	200MG	N019781	002	Oct 15, 1999		Jun	CAHN
>D>		@	300MG	N019781	003	Oct 15, 1999		Jun	CAHN
>A>	AB	VIRTUS PHARMS	100MG	N019781	001	May 14, 1998		Jun	CAHN
>A>	AB	+	200MG	N019781	002	Oct 15, 1999		Jun	CAHN
>A>		@	300MG	N019781	003	Oct 15, 1999		Jun	CAHN
GEL;VAGINAL									
CRINONE									
	+	ALLERGAN SALES LLC	4%	N020701	001	Jul 31, 1997		Apr	CAHN
	+		8%	N020701	002	Jul 31, 1997		Apr	CAHN
INJECTABLE;INJECTION									
PROGESTERONE									
AO	+	ALLERGAN SALES LLC	50MG/ML	N017362	002			Apr	CAHN
<u>PROMETHAZINE HYDROCHLORIDE</u>									
SYRUP;ORAL									
PROMETHAZINE HYDROCHLORIDE									
AA	NOSTRUM LABS INC	6.25MG/5ML		A040891	001	Mar 13, 2009		Feb	CAHN
TABLET;ORAL									
PROMETHAZINE HYDROCHLORIDE									
	@ IMPAX LABS	12.5MG		A040724	001	Feb 12, 2008		Mar	DISC
	@	25MG		A040724	002	Feb 12, 2008		Mar	DISC
	@	50MG		A040791	001	May 20, 2008		Mar	DISC
	@ SUN PHARM INDS	12.5MG		A084555	001			Mar	CAHN
	@	25MG		A084554	001			Mar	CAHN
	@	50MG		A084557	001			Jan	CAHN
<u>PROPAFENONE HYDROCHLORIDE</u>									
CAPSULE, EXTENDED RELEASE;ORAL									
PROPAFENONE HYDROCHLORIDE									
AB	MYLAN PHARMS INC	225MG		A203803	001	Apr 29, 2016		Apr	NEWA
AB		325MG		A203803	002	Apr 29, 2016		Apr	NEWA
AB		425MG		A203803	003	Apr 29, 2016		Apr	NEWA

## TABLET;ORAL

## PROPAFENONE HYDROCHLORIDE

AB	ORION CORP ORION	150MG	A202445	001	May 11, 2016	Apr	NEWA
AB		225MG	A202445	002	May 11, 2016	Apr	NEWA
AB		300MG	A202445	003	May 11, 2016	Apr	NEWA
AB	SUN PHARM INDS	150MG	A075998	001	Nov 29, 2001	Mar	CAHN
AB		225MG	A075998	002	Nov 29, 2001	Mar	CAHN
AB		300MG	A075998	003	Nov 29, 2001	Mar	CAHN

PROPRANOLOL HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL  
INDERAL LA

AB	ANI PHARMS INC	60MG	N018553	004	Mar 18, 1987	Apr	CAHN
AB		80MG	N018553	002	Apr 19, 1983	Apr	CAHN
AB		120MG	N018553	003	Apr 19, 1983	Apr	CAHN
AB	+	160MG	N018553	001	Apr 19, 1983	Apr	CAHN

## PROPRANOLOL HYDROCHLORIDE

>D>	@ UPSHER SMITH	60MG	A078311	001	Mar 06, 2009	Jun	CMFD
>A>	BX	60MG	A078311	001	Mar 06, 2009	Jun	CMFD
	@	60MG	A078311	001	Mar 06, 2009	May	DISC
	BX	60MG	A078311	001	Mar 06, 2009	Mar	CTEC
>D>	@	80MG	A078311	002	Mar 06, 2009	Jun	CMFD
>A>	BX	80MG	A078311	002	Mar 06, 2009	Jun	CMFD
	@	80MG	A078311	002	Mar 06, 2009	May	DISC
	BX	80MG	A078311	002	Mar 06, 2009	Mar	CTEC
>D>	@	120MG	A078311	003	Mar 06, 2009	Jun	CMFD
>A>	BX	120MG	A078311	003	Mar 06, 2009	Jun	CMFD
	@	120MG	A078311	003	Mar 06, 2009	May	DISC
	BX	120MG	A078311	003	Mar 06, 2009	Mar	CTEC
>D>	@	160MG	A078311	004	Mar 06, 2009	Jun	CMFD
>A>	BX	160MG	A078311	004	Mar 06, 2009	Jun	CMFD
	@	160MG	A078311	004	Mar 06, 2009	May	DISC
	BX	160MG	A078311	004	Mar 06, 2009	Mar	CTEC

## INJECTABLE;INJECTION

## PROPRANOLOL HYDROCHLORIDE

>A>	AP	AMPHASTAR PHARMS INC	1MG/ML	A075792	001	Aug 29, 2000	Jun	CAHN
>D>	AP	EUROHLTH INTL SARL	1MG/ML	A075792	001	Aug 29, 2000	Jun	CAHN
	AP		1MG/ML	A075792	001	Aug 29, 2000	Apr	CAHN
	@	SANDOZ	1MG/ML	A076400	001	Feb 26, 2003	Mar	DISC

## TABLET;ORAL

## PROPRANOLOL HYDROCHLORIDE

>D>	@	MUTUAL PHARM	60MG	A070321	001	Sep 24, 1986	Jun	CAHN
	@	SUN PHARM INDS	10MG	A070319	001	Oct 22, 1985	Mar	CAHN
	@		20MG	A070320	001	Oct 22, 1985	Mar	CAHN
	@		40MG	A070103	001	Oct 22, 1985	Mar	CAHN
>A>	@		60MG	A070321	001	Sep 24, 1986	Jun	CAHN
	@		80MG	A070322	001	Aug 04, 1986	Mar	CAHN

PROPYLTHIOURACIL

## TABLET;ORAL

## PROPYLTHIOURACIL

>A>	@	HIKMA INTL PHARMS	50MG	A080154	001		Jun	CAHN
	@	SUN PHARM INDS	50MG	A083982	001		Mar	CAHN
>D>	@	WEST WARD	50MG	A080154	001		Jun	CAHN

PYRIDOSTIGMINE BROMIDE

## TABLET, EXTENDED RELEASE;ORAL

## PYRIDOSTIGMINE BROMIDE

AB	ALVOGEN MALTA	180MG	A204737	001	Jun 26, 2015	Jan	CAHN
----	---------------	-------	---------	-----	--------------	-----	------

QUAZEPAM

## TABLET;ORAL

## DORAL

	@	CUTIS HEALTH LLC	7.5MG	N018708	003	Feb 26, 1987	Mar	CAHN
	+		15MG	N018708	001	Dec 27, 1985	Apr	CMFD
	@		15MG	N018708	001	Dec 27, 1985	Mar	CAHN



QUETIAPINE FUMARATE

## TABLET; ORAL

## QUETIAPINE FUMARATE

	@	ACTAVIS GRP PTC	EQ 25MG BASE	A201762	001	Feb 27, 2013	Apr	DISC
	@		EQ 50MG BASE	A201762	002	Feb 27, 2013	Apr	DISC
	@		EQ 100MG BASE	A201762	003	Feb 27, 2013	Apr	DISC
	@		EQ 150MG BASE	A201762	004	Feb 27, 2013	Apr	DISC
	@		EQ 200MG BASE	A201762	005	Feb 27, 2013	Apr	DISC
	@		EQ 300MG BASE	A201762	006	Feb 27, 2013	Apr	DISC
	@		EQ 400MG BASE	A201762	007	Feb 27, 2013	Apr	DISC
AB		MACLEODS PHARMS LTD	EQ 25MG BASE	A203359	001	May 17, 2016	May	NEWA
AB			EQ 50MG BASE	A203359	002	May 17, 2016	May	NEWA
AB			EQ 100MG BASE	A203359	003	May 17, 2016	May	NEWA
AB			EQ 200MG BASE	A203359	004	May 17, 2016	May	NEWA
AB			EQ 300MG BASE	A203359	005	May 17, 2016	May	NEWA
AB			EQ 400MG BASE	A203359	006	May 17, 2016	May	NEWA
AB		UNICHEM LABS LTD	EQ 25MG BASE	A202674	001	Mar 08, 2016	Feb	NEWA
AB			EQ 50MG BASE	A202674	002	Mar 08, 2016	Feb	NEWA
AB			EQ 100MG BASE	A202674	003	Mar 08, 2016	Feb	NEWA
AB			EQ 200MG BASE	A202674	004	Mar 08, 2016	Feb	NEWA
AB			EQ 300MG BASE	A202674	005	Mar 08, 2016	Feb	NEWA
AB			EQ 400MG BASE	A202674	006	Mar 08, 2016	Feb	NEWA

QUINAPRIL HYDROCHLORIDE

## TABLET; ORAL

## QUINAPRIL HYDROCHLORIDE

	@	ACTAVIS LABS FL INC	EQ 5MG BASE	A076049	001	Jan 14, 2005	Jan	DISC
	@		EQ 10MG BASE	A076049	002	Jan 14, 2005	Jan	DISC
	@		EQ 20MG BASE	A076049	003	Jan 14, 2005	Jan	DISC
	@		EQ 40MG BASE	A076049	004	Jan 14, 2005	Jan	DISC

QUINIDINE GLUCONATE

## TABLET, EXTENDED RELEASE; ORAL

## QUINIDINE GLUCONATE

	@	AUROLIFE PHARMA LLC	324MG	A089894	001	Dec 15, 1988	Mar	CAHN
BX	+	SUN PHARM INDS	324MG	A089338	001	Feb 11, 1987	Mar	CAHN

QUINIDINE SULFATE

## TABLET; ORAL

## QUINIDINE SULFATE

>D>	@	MUTUAL PHARM	100MG	A081029	001	Apr 14, 1989	Jun	CAHN
>A>	@	SUN PHARM INDS	100MG	A081029	001	Apr 14, 1989	Jun	CAHN
AB			200MG	A081030	001	Apr 14, 1989	Mar	CAHN
AB			300MG	A081031	001	Apr 14, 1989	Mar	CAHN

QUININE SULFATE

## CAPSULE; ORAL

## QUALAQUIN

>D>	AB	+	MUTUAL PHARM CO INC	324MG	N021799	001	Aug 12, 2005	Jun	CAHN
>A>	AB	+	SUN PHARM INDS	324MG	N021799	001	Aug 12, 2005	Jun	CAHN

RABEPRAZOLE SODIUM

## CAPSULE, DELAYED RELEASE; ORAL

## ACIPHEX SPRINKLE

>D>			EISAI INC	5MG	N204736	001	Mar 26, 2013	Jun	CAHN
>D>		+		10MG	N204736	002	Mar 26, 2013	Jun	CAHN
>A>			FSC THERAP	5MG	N204736	001	Mar 26, 2013	Jun	CAHN
>A>		+		10MG	N204736	002	Mar 26, 2013	Jun	CAHN

RALOXIFENE HYDROCHLORIDE

## TABLET; ORAL

## RALOXIFENE HYDROCHLORIDE

AB		AMNEAL PHARMS	60MG	A208206	001	Apr 08, 2016	Mar	NEWA
AB		GLENMARK PHARMS LTD	60MG	A204491	001	Mar 22, 2016	Mar	NEWA

RANITIDINE HYDROCHLORIDE

## INJECTABLE; INJECTION

## RANITIDINE HYDROCHLORIDE

AP		MYLAN LABS LTD	EQ 25MG BASE/ML	A079076	001	Jun 09, 2016	May	NEWA
AP		ZYDUS PHARMS USA INC	EQ 25MG BASE/ML	A091534	001	Feb 22, 2013	May	CPOT

## INJECTABLE; INJECTION

ZANTAC									
AP	+ IGI LABS INC	EQ 25MG BASE/ML	N019090	001	Oct 19, 1984	Jan	CAHN		
ZANTAC IN PLASTIC CONTAINER									
	@ IGI LABS INC	EQ 1MG BASE/ML	N019593	002	Sep 27, 1991	Jan	CAHN		
	@	EQ 50MG BASE/100ML	N019593	001	Dec 17, 1986	Jan	CAHN		
SYRUP; ORAL									
RANITIDINE HYDROCHLORIDE									
AA	NOSTRUM LABS INC	EQ 15MG BASE/ML	A091091	001	Sep 20, 2011	Mar	CAHN		
	@ WOCKHARDT	EQ 15MG BASE/ML	A079211	001	May 26, 2009	Apr	DISC		
	@	EQ 15MG BASE/ML	A079212	001	Feb 23, 2009	Apr	DISC		

RASAGILINE MESYLATE

TABLET; ORAL									
RASAGILINE MESYLATE									
AB	ORCHID HLTHCARE	EQ 0.5MG BASE	A201970	001	Mar 15, 2016	Feb	NEWA		
AB		EQ 1MG BASE	A201970	002	Mar 15, 2016	Feb	NEWA		

RESERPINE

TABLET; ORAL									
RESERPINE									
	@ HIKMA INTL PHARMS	0.1MG	A080975	001		Feb	CAHN		
	@	0.25MG	A080975	002		Feb	CAHN		
	@	1MG	A080975	003		Feb	CAHN		

RETAPAMULIN

OINTMENT; TOPICAL									
ALTABAX									
	+ AQUA PHARMS LLC	1%	N022055	001	Apr 12, 2007	Jan	CAHN		

RIBOFLAVIN 5'-PHOSPHATE SODIUM

SOLUTION/DROPS; OPHTHALMIC									
PHOTREXA									
	+ AVEDRO INC	0.146%	N203324	001	Apr 15, 2016	Apr	NEWA		
PHOTREXA VISCOUS IN DEXTRAN 20%									
>A>	+ AVEDRO INC	0.146%	N203324	002	Apr 15, 2016	Jun	CMS1		
PHOTREXA VISCOUS IN DEXTROSE 20%									
>D>	+ AVEDRO INC	0.146%	N203324	002	Apr 15, 2016	Jun	CMS1		
	+	0.146%	N203324	002	Apr 15, 2016	Apr	NEWA		

RIFAMPIN

INJECTABLE; INJECTION									
RIFAMPIN									
AP	EUROHLTH INTL SARL	600MG/VIAL	A064217	001	Oct 29, 1999	Apr	CAHN		
AP	HIKMA PHARMS	600MG/VIAL	A205039	001	Mar 03, 2016	Feb	NEWA		
AP	WATSON PHARMS INC	600MG/VIAL	A206736	001	Jan 19, 2016	Jan	NEWA		

RILUZOLE

TABLET; ORAL									
RILUZOLE									
AB	ALKEM LABS LTD	50MG	A204048	001	Mar 30, 2016	Mar	NEWA		

SUSPENSION/DROPS; OPHTHALMIC									
VEXOL									
>D>	+ ALCON	1%	N020474	001	Dec 30, 1994	Jun	DISC		
>A>	@	1%	N020474	001	Dec 30, 1994	Jun	DISC		

RISEDRONATE SODIUM

TABLET; ORAL									
ACTONEL									
AB	APIL	5MG	N020835	002	Apr 14, 2000	Jan	CAHN		
AB		30MG	N020835	001	Mar 27, 1998	Jan	CAHN		
AB	+ @	35MG	N020835	003	May 25, 2002	Jan	CAHN		
		75MG	N020835	004	Apr 16, 2007	Jan	CAHN		
AB	+ @	150MG	N020835	005	Apr 22, 2008	Jan	CAHN		
TABLET, DELAYED RELEASE; ORAL									
ATELVIA									
AB	+ APIL	35MG	N022560	001	Oct 08, 2010	Jan	CAHN		

RISPERIDONE

SOLUTION;ORAL  
RISPERIDONE  
@ WOCKHARDT

1MG/ML

A078744 001 Oct 08, 2009 Apr DISC

RIVASTIGMINE

FILM, EXTENDED RELEASE;TRANSDERMAL  
RIVASTIGMINE

AB	ALVOGEN MALTA	4.6MG/24HR	A204403	001	Sep 03, 2015	Jan	CAHN
AB		9.5MG/24HR	A204403	002	Sep 03, 2015	Jan	CAHN
AB		13.3MG/24HR	A204403	003	Aug 31, 2015	Jan	CAHN

RIVASTIGMINE TARTRATE

CAPSULE;ORAL  
EXELON

AB	+ NOVARTIS	EQ 6MG BASE	N020823	006	Apr 21, 2000	Jan	CRLD
	RIVASTIGMINE TARTRATE						
AB	AUROBINDO PHARMA LTD	EQ 1.5MG BASE	A204572	001	Mar 25, 2016	Mar	NEWA
AB		EQ 3MG BASE	A204572	002	Mar 25, 2016	Mar	NEWA
AB		EQ 4.5MG BASE	A204572	003	Mar 25, 2016	Mar	NEWA
AB		EQ 6MG BASE	A204572	004	Mar 25, 2016	Mar	NEWA

RIZATRIPTAN BENZOATE

TABLET;ORAL  
RIZATRIPTAN BENZOATE

AB	ALKEM LABS LTD	EQ 5MG BASE	A203269	001	Feb 18, 2016	Feb	NEWA
AB		EQ 10MG BASE	A203269	002	Feb 18, 2016	Feb	NEWA
AB	NOSTRUM LABS INC	EQ 5MG BASE	A202047	001	Dec 31, 2012	Jan	CAHN
AB		EQ 10MG BASE	A202047	002	Dec 31, 2012	Jan	CAHN

ROPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION  
ROPIVACAINE HYDROCHLORIDE

AP	AKORN INC	5MG/ML	A203955	001	Apr 11, 2016	Mar	NEWA
	SOLUTION;INJECTION						
	NAROPIN						
	@ FRESENIUS KABI USA	50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	May	DISC
		50MG/10ML (5MG/ML)	N020533	013	May 01, 1998	May	NEWA
AP		20MG/10ML (2MG/ML)	N020533	001	May 01, 1998	May	CMS1
AP		20MG/10ML (2MG/ML)	N020533	001	Sep 24, 1996	Mar	CDFR
AP		40MG/20ML (2MG/ML)	N020533	002	Sep 24, 1996	Mar	NEWA
	@	75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Apr	DISC
		75MG/10ML (7.5MG/ML)	N020533	012	Sep 24, 1996	Apr	NEWA
>D>		100MG/20ML (5MG/ML)	N020533	003	May 01, 1998	Jun	CFTG
>A>	AP	100MG/20ML (5MG/ML)	N020533	003	May 01, 1998	Jun	CFTG
		100MG/20ML (5MG/ML)	N020533	003	May 01, 1998	May	CMS1
		100MG/20ML (5MG/ML)	N020533	003	Sep 24, 1996	Mar	CDFR
AP		100MG/10ML (10MG/ML)	N020533	005	Sep 24, 1996	Mar	NEWA
AP		150MG/20ML (7.5MG/ML)	N020533	004	Sep 24, 1996	Mar	CDFR
AP		150MG/30ML (5MG/ML)	N020533	008	Sep 24, 1996	Mar	NEWA
>D>		200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996	Jun	CFTG
>A>	AP	200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996	Jun	CFTG
		200MG/100ML (2MG/ML)	N020533	006	Sep 24, 1996	Mar	NEWA
AP	+	200MG/20ML (10MG/ML)	N020533	011	Sep 24, 1996	Mar	NEWA
		400MG/200ML (2MG/ML)	N020533	007	Sep 24, 1996	Mar	NEWA
		500MG/100ML (5MG/ML)	N020533	009	Jan 04, 2011	Apr	CMS1
		500MG/100ML (5MG/ML)	N020533	009	Sep 24, 1996	Mar	NEWA
		1GM/200ML (5MG/ML)	N020533	010	Jan 04, 2011	Apr	CMS1
		1GM/200ML (5MG/ML)	N020533	010	Sep 24, 1996	Mar	NEWA
	ROPIVACAINE HYDROCHLORIDE						
>A>	AP	AUROBINDO PHARMA LTD 40MG/20ML (2MG/ML)	A205612	001	Jul 13, 2016	Jun	NEWA
>A>	AP	100MG/20ML (5MG/ML)	A205612	003	Jul 13, 2016	Jun	NEWA
>A>	AP	100MG/10ML (10MG/ML)	A205612	006	Jul 13, 2016	Jun	NEWA
>A>	AP	150MG/30ML (5MG/ML)	A205612	004	Jul 13, 2016	Jun	NEWA
>A>	AP	150MG/20ML (7.5MG/ML)	A205612	005	Jul 13, 2016	Jun	NEWA
>A>	AP	200MG/100ML (2MG/ML)	A205612	002	Jul 13, 2016	Jun	NEWA
>A>	AP	200MG/20ML (10MG/ML)	A205612	007	Jul 13, 2016	Jun	NEWA
AP	HOSPIRA	20MG/10ML (2MG/ML)	A090194	001	Sep 23, 2014	Mar	CDFR
AP		40MG/20ML (2MG/ML)	A090194	005	Sep 23, 2014	Mar	NEWA
AP		100MG/10ML (10MG/ML)	A090194	004	Sep 23, 2014	Mar	CDFR
AP		150MG/30ML (5MG/ML)	A090194	002	Sep 23, 2014	Mar	CDFR
AP		150MG/20ML (7.5MG/ML)	A090194	003	Sep 23, 2014	Mar	CDFR

## SOLUTION;INJECTION

## ROPIVACAINE HYDROCHLORIDE

AP		200MG/20ML (10MG/ML)	A090194	006	Sep 23, 2014	Mar	NEWA
AP	NAVINTA LLC	150MG/30ML (5MG/ML)	A078601	002	Jul 17, 2014	Mar	CDFR
AP		200MG/20ML (10MG/ML)	A078601	003	Jul 17, 2014	Mar	CDFR
AP	SAGENT STRIDES	40MG/20ML (2MG/ML)	A090318	001	Sep 23, 2014	Mar	CDFR
AP		150MG/30ML (5MG/ML)	A090318	002	Sep 23, 2014	Mar	CDFR
AP		150MG/20ML (7.5MG/ML)	A090318	003	Sep 23, 2014	Mar	CDFR
AP		200MG/20ML (10MG/ML)	A090318	004	Sep 23, 2014	Mar	CDFR

ROSUVASTATIN CALCIUM

## TABLET;ORAL

## CRESTOR

AB	IPR	5MG	N021366	002	Aug 12, 2003	Apr	CFTG
AB		10MG	N021366	003	Aug 12, 2003	Apr	CFTG
AB		20MG	N021366	004	Aug 12, 2003	Apr	CFTG
AB	+	40MG	N021366	005	Aug 12, 2003	Apr	CFTG

## ROSUVASTATIN CALCIUM

AB	WATSON LABS INC	5MG	A079167	001	Apr 29, 2016	Apr	NEWA
AB		10MG	A079167	002	Apr 29, 2016	Apr	NEWA
AB		20MG	A079167	003	Apr 29, 2016	Apr	NEWA
AB		40MG	A079167	004	Apr 29, 2016	Apr	NEWA

RUFINAMIDE

## TABLET;ORAL

## BANZEL

AB	EISAI INC	200MG	N021911	002	Nov 14, 2008	May	CFTG
AB	+	400MG	N021911	003	Nov 14, 2008	May	CFTG

## RUFINAMIDE

AB	GLENMARK PHARMS LTD	200MG	A205075	001	May 16, 2016	May	NEWA
AB		400MG	A205075	002	May 16, 2016	May	NEWA
AB	MYLAN PHARMS INC	200MG	A205095	001	May 16, 2016	May	NEWA
AB		400MG	A205095	002	May 16, 2016	May	NEWA
AB	ROXANE	200MG	A204988	001	May 16, 2016	May	NEWA
AB		400MG	A204988	002	May 16, 2016	May	NEWA

SCOPOLAMINEFILM, EXTENDED RELEASE;TRANSDERMAL  
TRANSDERM SCOP

AB	+	GLAXOSMITHKLINE CON	1MG/72HR	N017874	001		May	CAHN
----	---	---------------------	----------	---------	-----	--	-----	------

SERTRALINE HYDROCHLORIDE

## TABLET;ORAL

## SERTRALINE HYDROCHLORIDE

@ SUN PHARM INDS EQ 25MG BASE  
 @ EQ 50MG BASE  
 @ EQ 100MG BASE

A077818	001	Feb 06, 2007	Mar	CAHN
A077818	002	Feb 06, 2007	Mar	CAHN
A077818	003	Feb 06, 2007	Mar	CAHN

SILDENAFIL CITRATE

## TABLET;ORAL

## SILDENAFIL CITRATE

>A>	AB	ACTAVIS GRP PTC	EQ 20MG BASE	A200149	001	Feb 25, 2013	Apr	DISC
		RUBICON RES PVT LTD	EQ 20MG BASE	A204883	001	Jun 20, 2016	Jun	NEWA
		TEVA	EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb	DISC
			EQ 25MG BASE	A077342	001	Mar 09, 2016	Feb	NEWA
			EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb	DISC
			EQ 50MG BASE	A077342	002	Mar 09, 2016	Feb	NEWA
			EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb	DISC
			EQ 100MG BASE	A077342	003	Mar 09, 2016	Feb	NEWA

SILODOSIN

## CAPSULE;ORAL

## RAPAFLO

+	ALLERGAN SALES LLC	4MG	N022206	001	Oct 08, 2008	Apr	CAHN
		8MG	N022206	002	Oct 08, 2008	Apr	CAHN

SIMVASTATIN

## SUSPENSION;ORAL

## SIMVASTATIN

+	ROSEMONT PHARMS LTD	20MG/5ML	N206679	001	Apr 21, 2016	Apr	NEWA
		40MG/5ML	N206679	002	Apr 21, 2016	Apr	NEWA

TABLET;ORAL									
SIMVASTATIN									
	@ SUN PHARM INDS LTD	5MG		A076285	001	Dec 20, 2006	Feb	DISC	
	@	10MG		A076285	002	Dec 20, 2006	Feb	DISC	
	@	20MG		A076285	003	Dec 20, 2006	Feb	DISC	
	@	40MG		A076285	004	Dec 20, 2006	Feb	DISC	
	@	80MG		A076285	005	Jun 23, 2006	Feb	DISC	
<u>SODIUM BENZOATE; SODIUM PHENYLACETATE</u>									
SOLUTION;IV (INFUSION)									
AMMONUL									
AP	+	MEDICIS	10%;10% (5GM/50ML;5GM/50ML)	N020645	001	Feb 17, 2005	Feb	CFTG	
SODIUM PHENYLACETATE AND SODIUM BENZOATE									
AP		AILEX PHARMS PVT LTD	10%;10% (5GM/50ML;5GM/50ML)	A207096	001	Feb 24, 2016	Feb	NEWA	
<u>SODIUM BICARBONATE</u>									
INJECTABLE;INJECTION									
SODIUM BICARBONATE									
		HOSPIRA INC	0.5MEQ/ML	A202981	001	Mar 04, 2016	Feb	NEWA	
<u>SODIUM CHLORIDE</u>									
INJECTABLE;INJECTION									
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER									
AP		JUBILANT HOLLISTRSTR	9MG/ML	A203352	001	May 18, 2016	May	NEWA	
<u>SODIUM FLUORIDE F-18</u>									
INJECTABLE;INTRAVENOUS									
SODIUM FLUORIDE F-18									
AP		KREITCHMAN PET CTR	10-200mCi/ML	A203936	001	May 19, 2016	May	NEWA	
AP		ZEVACOR PHARMA INC	10-200mCi/ML	A203592	001	Aug 18, 2015	Feb	CAHN	
<u>SODIUM IODIDE I-131</u>									
CAPSULE;ORAL									
SODIUM IODIDE I 131									
		JUBILANT DRAXIMAGE	0.009-0.1mCi	N021305	006	May 19, 2005	Mar	CMS1	
	@		2-200mCi	N021305	004	Nov 18, 2004	Mar	CMS1	
<u>SODIUM PHENYLBUTYRATE</u>									
POWDER;ORAL									
BUPHENYL									
AB	+	HORIZON PHARMA INC	3GM/TEASPOONFUL	N020573	001	Apr 30, 1996	Mar	CAHN	
SODIUM PHENYLBUTYRATE									
>A>	AB	PAR PHARM	3GM/TEASPOONFUL	A203918	001	Jun 15, 2016	Jun	NEWA	
TABLET;ORAL									
BUPHENYL									
AB	+	HORIZON PHARMA INC	500MG	N020572	001	May 13, 1996	Mar	CAHN	
SODIUM PHENYLBUTYRATE									
AB		PAR PHARM	500MG	A204395	001	Apr 15, 2016	Apr	NEWA	
<u>SODIUM POLYSTYRENE SULFONATE</u>									
POWDER;ORAL, RECTAL									
SODIUM POLYSTYRENE SULFONATE									
AA		BELCHER PHARMS LLC	454GM/BOT	A205727	001	Feb 23, 2016	Feb	NEWA	
AA		INVATECH PHARMA	454GM/BOT	A206815	001	Feb 18, 2016	Feb	NEWA	
>A>	<u>SOFOBUVIR; VELPATASVIR</u>								
>A>	TABLET;ORAL								
>A>	EPCLUSA								
>A>	+	GILEAD SCIENCES INC	400MG;100MG	N208341	001	Jun 28, 2016	Jun	NEWA	
<u>SOTALOL HYDROCHLORIDE</u>									
TABLET;ORAL									
SOTALOL HYDROCHLORIDE									
	@	IMPAX PHARMS	80MG	A075663	001	Nov 07, 2000	Mar	DISC	
	@		120MG	A075663	002	Nov 07, 2000	Mar	DISC	
	@		160MG	A075663	003	Nov 07, 2000	Mar	DISC	
	@		240MG	A075663	004	Nov 07, 2000	Mar	DISC	
	@	SUN PHARM INDS	80MG	A075515	001	Oct 15, 2001	Mar	CAHN	
	@		80MG	A076576	001	Apr 08, 2004	Mar	CAHN	
	@		120MG	A075515	004	Oct 15, 2001	Mar	CAHN	
	@		120MG	A076576	002	Apr 08, 2004	Mar	CAHN	
	@		160MG	A075515	002	Oct 15, 2001	Mar	CAHN	

## TABLET; ORAL

SOTALOL HYDROCHLORIDE

@	160MG	A076576	003	Apr 08, 2004	Mar CAHN
@	240MG	A075515	003	Oct 15, 2001	Mar CAHN

SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE

AB	SUN PHARM INDS	25MG	A089424	001	Jul 23, 1986	Mar CAHN
AB		50MG	A089424	002	Aug 11, 1999	Mar CAHN
AB		100MG	A089424	003	Aug 11, 1999	Mar CAHN

SUCRALFATE

TABLET; ORAL

SUCRALFATE

AB	MYLAN IRELAND LTD	1GM	A074415	001	Jun 08, 1998	Jan CAHN
----	-------------------	-----	---------	-----	--------------	----------

SUGAMMADEX SODIUM

SOLUTION; INTRAVENOUS

BRIDION

	ORGANON SUB MERCK	EQ 200MG BASE/2ML (EQ 100MG BASE/ML)	N022225	002	Dec 15, 2015	Jan CPOT
+		EQ 500MG BASE/5ML (EQ 100MG BASE/ML)	N022225	001	Dec 15, 2015	Jan CPOT

SULFAMETHOXAZOLE

TABLET; ORAL

SULFAMETHOXAZOLE

@	AUROLIFE PHARMA LLC	500MG	A085844	001		Feb CAHN
---	---------------------	-------	---------	-----	--	----------

SULFAMETHOXAZOLE; TRIMETHOPRIM

SUSPENSION; ORAL

BACTRIM

>D>	@ MUTUAL PHARM	200MG/5ML; 40MG/5ML	N017560	001		Jun CAHN
>A>	@ SUN PHARM INDS	200MG/5ML; 40MG/5ML	N017560	001		Jun CAHN
	BACTRIM PEDIATRIC					
>D>	@ MUTUAL PHARM	200MG/5ML; 40MG/5ML	N017560	002		Jun CAHN
>A>	@ SUN PHARM INDS	200MG/5ML; 40MG/5ML	N017560	002		Jun CAHN

TABLET; ORAL

BACTRIM

AB	SUN PHARM INDS	400MG; 80MG	N017377	001		Mar CAHN
	BACTRIM DS					
AB	+ SUN PHARM INDS	800MG; 160MG	N017377	002		Mar CAHN
	SULFAMETHOXAZOLE AND TRIMETHOPRIM					
AB	SUN PHARM INDS	800MG; 160MG	A071017	001	Aug 25, 1986	Mar CAHN

SULFASALAZINE

TABLET; ORAL

SULFASALAZINE

@	SUN PHARM INDS	500MG	A089590	001	Oct 19, 1987	Mar CAHN
---	----------------	-------	---------	-----	--------------	----------

SULFISOXAZOLE

TABLET; ORAL

SULFISOXAZOLE

@	AUROLIFE PHARMA LLC	500MG	A085628	001		Feb CAHN
---	---------------------	-------	---------	-----	--	----------

SULINDAC

TABLET; ORAL

SULINDAC

AB	SUN PHARM INDS	150MG	A072050	001	Apr 17, 1991	Mar CAHN
AB		200MG	A072051	001	Apr 17, 1991	Mar CAHN

SUMATRIPTAN

SPRAY; NASAL

IMITREX

AB	+ GLAXOSMITHKLINE	5MG/SPRAY	N020626	001	Aug 26, 1997	Feb CFTG
AB	+	20MG/SPRAY	N020626	003	Aug 26, 1997	Feb CFTG

SUMATRIPTAN

AB	LANNETT	5MG/SPRAY	A204841	001	Feb 19, 2016	Feb NEWA
AB		20MG/SPRAY	A204841	002	Feb 19, 2016	Feb NEWA

SUMATRIPTAN SUCCINATE

		INJECTABLE;SUBCUTANEOUS SUMATRIPTAN SUCCINATE						
>D>	AP	BEDFORD	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079123	001	Feb 06, 2009	Jun	CAHN
>A>	AP	EUROHLTH INTL SARL	EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML)	A079123	001	Feb 06, 2009	Jun	CAHN
		POWDER;INHALATION ONZETRA XSAIL						
	+	AVANIR PHARMS	EQ 11MG BASE	N206099	001	Jan 27, 2016	Jan	NEWA
		SOLUTION;SUBCUTANEOUS ZEMBRACE SYMTOUCH						
		DR REDDYS LABS LTD	EQ 3MG BASE/0.5ML (EQ 3MG BASE/0.5ML)	N208223	001	Jan 28, 2016	Jan	NEWA

TACROLIMUS

		OINTMENT;TOPICAL PROTOPIC						
>D>	AB	+ ASTELLAS	0.03%	N050777	001	Dec 08, 2000	Jun	CAHN
>D>	AB	+	0.1%	N050777	002	Dec 08, 2000	Jun	CAHN
>A>	AB	+ LEO PHARMA AS	0.03%	N050777	001	Dec 08, 2000	Jun	CAHN
>A>	AB	+	0.1%	N050777	002	Dec 08, 2000	Jun	CAHN

TAMOXIFEN CITRATE

		SOLUTION;ORAL SOLTAMOX						
		MIDATECH PHARMA US	EQ 10MG BASE/5ML	N021807	001	Oct 29, 2005	Jan	CAHN
		TABLET;ORAL TAMOXIFEN CITRATE						
	@	ACTAVIS LABS FL INC	EQ 10MG BASE	A076179	001	Feb 20, 2003	Jan	DISC
	@		EQ 20MG BASE	A076179	002	Feb 20, 2003	Jan	DISC

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATOR

		SOLUTION;INTRAVENOUS ULTRA-TECHNEKOW FM						
	+	MALLINKRODT NUCLEAR	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	Jan	CAHN
	@		0.25-3 CI/GENERATOR	N017243	002		Jan	CAHN

TEGASEROD MALEATE

		TABLET;ORAL ZELNORM						
	@	US WORLDMEDS LLC	EQ 2MG BASE	N021200	001	Jul 24, 2002	Jan	CAHN
	@		EQ 6MG BASE	N021200	002	Jul 24, 2002	Jan	CAHN

TELITHROMYCIN

		TABLET;ORAL KETEK						
	@	SANOFI AVENTIS US	300MG	N021144	002	Feb 09, 2005	Mar	DISC
	@		400MG	N021144	001	Apr 01, 2004	Mar	DISC

TELMISARTAN

		TABLET;ORAL TELMISARTAN						
AB		HETERO LABS LTD V	20MG	A205901	001	Apr 22, 2016	Apr	NEWA
AB			40MG	A205901	002	Apr 22, 2016	Apr	NEWA
AB			80MG	A205901	003	Apr 22, 2016	Apr	NEWA

TEMAZEPAM

		CAPSULE;ORAL TEMAZEPAM						
AB		AMNEAL PHARMS	7.5MG	A203482	001	May 23, 2016	May	NEWA
AB			15MG	A203482	002	May 23, 2016	May	NEWA
AB			22.5MG	A203482	003	May 23, 2016	May	NEWA
AB			30MG	A203482	004	May 23, 2016	May	NEWA
AB		SUN PHARM INDS	7.5MG	A078581	001	Sep 08, 2009	Mar	CAHN
	@		15MG	A071174	001	Jul 10, 1986	Mar	CAHN
AB			22.5MG	A071175	002	Sep 14, 2009	Mar	CAHN
	@		30MG	A071175	001	Jul 10, 1986	Mar	CAHN

TEMOZOLOMIDECAPSULE;ORAL  
TEMOZOLOMIDE

AB	IDT AUSTRALIA LTD	5MG	A206413	001	Apr 12, 2016	Mar	NEWA	
AB		20MG	A206413	002	Apr 12, 2016	Mar	NEWA	
AB		100MG	A206413	003	Apr 12, 2016	Mar	NEWA	
AB		140MG	A206413	004	Apr 12, 2016	Mar	NEWA	
AB		180MG	A206413	005	Apr 12, 2016	Mar	NEWA	
AB		250MG	A206413	006	Apr 12, 2016	Mar	NEWA	
AB	KREMERS URBAN PHARMS	5MG	A203898	001	Feb 10, 2016	Jan	NEWA	
AB		20MG	A203898	002	Feb 10, 2016	Jan	NEWA	
AB		100MG	A203898	003	Feb 10, 2016	Jan	NEWA	
AB		140MG	A203898	004	Feb 10, 2016	Jan	NEWA	
AB		180MG	A203898	005	Feb 10, 2016	Jan	NEWA	
AB		250MG	A203898	006	Feb 10, 2016	Jan	NEWA	
AB	LOTUS PHARM CO LTD	5MG	A206309	001	Apr 27, 2016	Apr	NEWA	
AB		20MG	A206309	002	Apr 27, 2016	Apr	NEWA	
AB		100MG	A206309	003	Apr 27, 2016	Apr	NEWA	
AB		140MG	A206309	004	Apr 27, 2016	Apr	NEWA	
AB		180MG	A206309	005	Apr 27, 2016	Apr	NEWA	
AB		250MG	A206309	006	Apr 27, 2016	Apr	NEWA	
>A>	AB	MYLAN PHARMS INC	5MG	A205227	001	Jun 29, 2016	Jun	NEWA
>A>	AB		20MG	A205227	002	Jun 29, 2016	Jun	NEWA
>A>	AB		100MG	A205227	003	Jun 29, 2016	Jun	NEWA
>A>	AB		140MG	A205227	004	Jun 29, 2016	Jun	NEWA
>A>	AB		180MG	A205227	005	Jun 29, 2016	Jun	NEWA
>A>	AB		250MG	A205227	006	Jun 29, 2016	Jun	NEWA

TERBUTALINE SULFATEINJECTABLE;INJECTION  
TERBUTALINE SULFATE

>A>	AP	+ AMPHASTAR PHARMS INC	1MG/ML	A076770	001	Apr 23, 2004	Jun	CAHN
>D>	AP	+ EUROHLTH INTL SARL	1MG/ML	A076770	001	Apr 23, 2004	Jun	CAHN
	AP	+	1MG/ML	A076770	001	Apr 23, 2004	Apr	CAHN

TABLET;ORAL

TERBUTALINE SULFATE

@ IMPAX LABS

2.5MG

A075877 001 Jun 26, 2001 Mar DISC

@

5MG

A075877 002 Jun 26, 2001 Mar DISC

LANNETT

2.5MG

A077152 001 Mar 25, 2005 Mar CTEC

5MG

A077152 002 Mar 25, 2005 Mar CTEC

TESTOSTERONEFILM, EXTENDED RELEASE;TRANSDERMAL  
ANDRODERM

+	ALLERGAN SALES LLC	2MG/24HR	N020489	003	Oct 20, 2011	Mar	CAHN
@		2.5MG/24HR	N020489	001	Sep 29, 1995	Mar	CAHN
+		4MG/24HR	N020489	004	Oct 20, 2011	Mar	CAHN
@		5MG/24HR	N020489	002	May 02, 1997	Mar	CAHN

PELLET;IMPLANTATION

TESTOPEL

+	AUXILIUM PHARMS INC	75MG	A080911	001		Mar	CAHN
---	---------------------	------	---------	-----	--	-----	------

TABLET, EXTENDED RELEASE;BUCCAL

STRIANT

+	AUXILIUM PHARMS INC	30MG	N021543	001	Jun 19, 2003	Mar	CAHN
---	---------------------	------	---------	-----	--------------	-----	------

TESTOSTERONE CYPIONATEINJECTABLE;INJECTION  
TESTOSTERONE CYPIONATE

>D>	AO	BEDFORD	100MG/ML	A090387	001	Jul 15, 2010	Jun	CAHN
>D>	AO		200MG/ML	A090387	002	Jul 15, 2010	Jun	CAHN
>A>	AO	EUROHLTH INTL SARL	100MG/ML	A090387	001	Jul 15, 2010	Jun	CAHN
>A>	AO		200MG/ML	A090387	002	Jul 15, 2010	Jun	CAHN

TETRABENAZINETABLET;ORAL  
TETRABENAZINE

AB	HETERO LABS LTD V	12.5MG	A204574	001	Feb 03, 2016	Jan	NEWA
AB		25MG	A204574	002	Feb 03, 2016	Jan	NEWA



TETRACAINE HYDROCHLORIDESOLUTION;OPHTHALMIC  
TETRACAINE HYDROCHLORIDE

+ ALCON RES LTD 0.5% N208135 001 Feb 29, 2016 Feb NEWA

TETRACYCLINE HYDROCHLORIDECAPSULE;ORAL  
TETRACYCLINE HYDROCHLORIDE

AB	CHARTWELL CIENCA	250MG	A062752	001	Aug 12, 1988	Apr	CMFD
AB		500MG	A062752	002	Aug 12, 1988	Apr	CMFD
	@ SUN PHARM INDS	250MG	A060736	001		Mar	CAHN
	@	500MG	A060736	002		Mar	CAHN

THEOPHYLLINECAPSULE, EXTENDED RELEASE;ORAL  
THEO-24

+ AUXILIUM PHARMS INC 400MG A081034 001 Feb 28, 1992 Mar CAHN

SOLUTION, ELIXIR;ORAL  
ELIXOPHYLLIN

+ NOSTRUM LABS INC 80MG/15ML A085186 001 Jan CAHN

TABLET, EXTENDED RELEASE;ORAL

THEOCHRON

AB	NOSTRUM LABS INC	100MG	A088320	001	Feb 21, 1985	Jan	CAHN
AB		200MG	A088321	001	Feb 21, 1985	Jan	CAHN
	@	300MG	A087400	002	Jan 11, 1983	Jan	CAHN

THEOPHYLLINE

AB	MYLAN IRELAND LTD	400MG	A040560	003	Apr 21, 2006	Jan	CAHN
AB	+	600MG	A040560	002	Apr 21, 2006	Jan	CAHN

THIORIDAZINE HYDROCHLORIDE

TABLET;ORAL

THIORIDAZINE HYDROCHLORIDE

AB	SUN PHARM INDS	10MG	A089953	004	Aug 01, 1986	Mar	CAHN
	@	15MG	A088461	001	Nov 18, 1983	Mar	CAHN
AB		25MG	A089953	003	Aug 01, 1986	Mar	CAHN
AB		50MG	A089953	002	Aug 01, 1986	Mar	CAHN
AB		100MG	A089953	001	Oct 07, 1988	Mar	CAHN
	@	150MG	A088737	001	Sep 26, 1984	Mar	CAHN
	@	200MG	A088738	001	Oct 16, 1984	Mar	CAHN

THIOTHIXENE

CAPSULE;ORAL

THIOTHIXENE

	@ SANDOZ	1MG	A071610	001	Jun 24, 1987	Mar	DISC
	@	2MG	A071570	001	Jun 24, 1987	Mar	DISC
	@	5MG	A071529	001	Jun 24, 1987	Mar	DISC
	@	10MG	A071530	001	Jun 24, 1987	Mar	DISC

TINIDAZOLE

TABLET;ORAL

TINIDAZOLE

BX	UNIQUE PHARM LABS	250MG	A202489	001	Oct 09, 2013	Apr	CTEC
BX		500MG	A202489	002	Oct 09, 2013	Apr	CTEC

TOBRAMYCIN SULFATE

INJECTABLE;INJECTION

TOBRAMYCIN SULFATE

&gt;A&gt; AP CLARIS EQ 40MG BASE/ML A206965 001 Jul 01, 2016 Jun NEWA

TOFACITINIB CITRATE

TABLET, EXTENDED RELEASE;ORAL

XELJANZ XR

+ PFIZER INC EQ 11MG BASE N208246 001 Feb 23, 2016 Feb NEWA

TOLAZAMIDE

TABLET;ORAL

TOLAZAMIDE

	@ SUN PHARM INDS	100MG	A071357	001	Jul 16, 1987	Mar	CAHN
	@	250MG	A071358	001	Jul 16, 1987	Mar	CAHN
	@	500MG	A071359	001	Jul 16, 1987	Mar	CAHN

TOLMETIN SODIUM

	CAPSULE;ORAL							
	TOLMETIN SODIUM							
	@	SUN PHARM INDS	EQ 400MG BASE	A073311	001	Nov 27, 1991	Mar	CAHN
	TABLET;ORAL							
	TOLMETIN SODIUM							
AB		SUN PHARM INDS	EQ 200MG BASE	A073310	001	Nov 27, 1991	Mar	CAHN

TOPIRAMATE

	TABLET;ORAL							
	TOPIRAMATE							
	@	ACTAVIS TOTOWA	25MG	A078637	001	Feb 27, 2013	Apr	DISC
AB			25MG	A078637	001	Feb 27, 2013	Jan	CAHN
	@		50MG	A078637	002	Feb 27, 2013	Apr	DISC
AB			50MG	A078637	002	Feb 27, 2013	Jan	CAHN
	@		100MG	A078637	003	Feb 27, 2013	Apr	DISC
AB			100MG	A078637	003	Feb 27, 2013	Jan	CAHN
	@		200MG	A078637	004	Feb 27, 2013	Apr	DISC
AB			200MG	A078637	004	Feb 27, 2013	Jan	CAHN

TRAMADOL HYDROCHLORIDE

	TABLET;ORAL							
	TRAMADOL HYDROCHLORIDE							
AB		ACI HEALTHCARE LTD	50MG	A202075	001	Nov 28, 2011	Mar	CAHN
AB		SUN PHARM INDS	50MG	A076100	001	Jun 20, 2002	Mar	CAHN
	TABLET, EXTENDED RELEASE;ORAL							
	ULTRAM ER							
AB1	+	VALEANT PHARMS	100MG	N021692	001	Sep 08, 2005	Mar	CAHN
AB1			200MG	N021692	002	Sep 08, 2005	Mar	CAHN
AB1			300MG	N021692	003	Sep 08, 2005	Mar	CAHN

TRANEXAMIC ACID

	INJECTABLE;INJECTION							
	TRANEXAMIC ACID							
AP		AKORN	100MG/ML	A206634	001	Jun 09, 2016	May	NEWA
AP		AUROBINDO PHARMA LTD	100MG/ML	A205035	001	Jan 14, 2016	Jan	NEWA
AP		NORTH CREEK PHARMS	100MG/ML	A202755	001	Feb 25, 2016	Feb	NEWA

TRAZODONE HYDROCHLORIDE

	TABLET;ORAL							
	TRAZODONE HYDROCHLORIDE							
	@	AUROLIFE PHARMA LLC	50MG	A072484	001	Apr 30, 1990	Feb	CAHN
AB		SUN PHARM INDS	50MG	A073137	002	Mar 24, 1993	Mar	CAHN
AB			100MG	A073137	001	Mar 24, 1993	Mar	CAHN
AB			150MG	A073137	003	Dec 22, 1995	Mar	CAHN

TRETINOIN

	CREAM;TOPICAL							
	TRETINOIN							
AB		ELAN PHARMA INTL LTD	0.025%	A075264	001	Dec 24, 1998	Feb	CAHN
AB1			0.05%	A075265	001	Dec 24, 1998	Feb	CAHN
AB			0.1%	A075213	001	Dec 24, 1998	Feb	CAHN
	GEL;TOPICAL							
	TRETINOIN							
AB		ELAN PHARMA INTL LTD	0.01%	A075589	001	Jun 11, 2002	Feb	CAHN
AB			0.025%	A075529	001	Feb 22, 2000	Feb	CAHN

TRIAMCINOLONE ACETONIDE

	LOTION;TOPICAL							
	TRIAMCINOLONE ACETONIDE							
>A>	AT	TELIGENT PHARMA INC	0.025%	A204608	001	Jul 07, 2016	Jun	NEWA
>A>	AT		0.1%	A204606	001	Jul 07, 2016	Jun	NEWA
	OINTMENT;TOPICAL							
	TRIAMCINOLONE ACETONIDE							
AT		TELIGENT PHARMA INC	0.1%	A205373	001	May 13, 2016	May	NEWA

TRIMETHOBENZAMIDE HYDROCHLORIDE

CAPSULE;ORAL

TRIMETHOBENZAMIDE HYDROCHLORIDE

AB	SUN PHARM INDS	300MG	A076570	001	Aug 28, 2003	Mar	CAHN
----	----------------	-------	---------	-----	--------------	-----	------

TRIMETHOPRIM

TABLET;ORAL

TRIMETHOPRIM

>D>	@ MUTUAL PHARM	100MG	A070494	001	Jan 22, 1986	Jun	CAHN
>A>	@ SUN PHARM INDS	100MG	A070494	001	Jan 22, 1986	Jun	CAHN
	@	200MG	A070495	001	Sep 24, 1986	Mar	CAHN

TRIMETHOPRIM HYDROCHLORIDE

SOLUTION;ORAL

PRIMSOL

>A>	+ AYTU BIOSCIENCE INC	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Jun	CAHN
>D>	@ AYTU PHARMS	EQ 25MG BASE/5ML	\$074374	001	Jun 23, 1995	Jun	CMS2
>A>	@	EQ 25MG BASE/5ML	N074374	001	Jun 23, 1995	Jun	CMS2
	@	EQ 25MG BASE/5ML	A074374	001	Jun 23, 1995	Jan	CAHN
>D>	+	EQ 50MG BASE/5ML	N074973	001	Jan 24, 2000	Jun	CAHN
	+	EQ 50MG BASE/5ML	1074973	001	Jan 24, 2000	Jan	CAHN

TRIMIPRAMINE MALEATE

CAPSULE;ORAL

TRIMIPRAMINE MALEATE

AB	CROSSMEDIKA SA	EQ 25MG BASE	A208127	001	Apr 15, 2016	Apr	NEWA
AB		EQ 50MG BASE	A208127	002	Apr 15, 2016	Apr	NEWA
AB		EQ 100MG BASE	A208127	003	Apr 15, 2016	Apr	NEWA

TRIPTORELIN PAMOATE

INJECTABLE;INTRAMUSCULAR

TRELSTAR

	+ ALLERGAN SALES LLC	EQ 3.75MG BASE/VIAL	N020715	001	Jun 15, 2000	Apr	CAHN
	+	EQ 11.25MG BASE/VIAL	N021288	001	Jun 29, 2001	Apr	CAHN
	+	EQ 22.5MG BASE/VIAL	N022437	001	Mar 10, 2010	Apr	CAHN

TROSPIUM CHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL

TROSPIUM CHLORIDE

	@ SANDOZ INC	60MG	A091635	001	Apr 29, 2015	Apr	DISC
--	--------------	------	---------	-----	--------------	-----	------

UNOPROSTONE ISOPROPYL

SOLUTION/DROPS;OPHTHALMIC

RESCULA

	@ R-TECH UENO LTD	0.15%	N021214	001	Aug 03, 2000	Mar	DISC
	@ SUCAMPO PHARMA LLC	0.15%	N021214	001	Aug 03, 2000	Mar	CAHN

URSODIOL

CAPSULE;ORAL

ACTIGALL

AB	+ ALLERGAN SALES LLC	150MG	N019594	001	Dec 31, 1987	Mar	CAHN
	+	300MG	N019594	002	Dec 31, 1987	Mar	CAHN

VALGANCICLOVIR HYDROCHLORIDE

TABLET;ORAL

VALGANCICLOVIR HYDROCHLORIDE

AB	AUROBINDO PHARMA LTD	EQ 450MG BASE	A204750	001	Mar 31, 2016	Mar	NEWA
AB	HETERO LABS LTD V	EQ 450MG BASE	A205166	001	Mar 18, 2016	Mar	NEWA

VALPROATE SODIUM

INJECTABLE;INJECTION

VALPROATE SODIUM

>A>	AP	AMPHASTAR PHARMS INC	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Jun	CAHN
>D>	AP	EUROHLTH INTL SARL	EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Jun	CAHN
	AP		EQ 100MG BASE/ML	A076295	001	Nov 14, 2002	Apr	CAHN

VALPROIC ACID

CAPSULE;ORAL		VALPROIC ACID					
AB	BIONPHARMA INC	250MG	A073484	001	Jun 29, 1993	Jan	CAHN
SYRUP;ORAL		VALPROIC ACID					
AA	NOSTRUM LABS INC	250MG/5ML	A090517	001	May 28, 2010	Mar	CAHN

VANCOMYCIN HYDROCHLORIDE

INJECTABLE;INJECTION		VANCOMYCIN HYDROCHLORIDE					
AP	AMNEAL PHARMS CO	EQ 500MG BASE/VIAL	A065401	001	Jun 30, 2008	May	CAHN
AP		EQ 1GM BASE/VIAL	A065401	002	Jun 30, 2008	May	CAHN
AP	AUROBINDO PHARMA LTD	EQ 500MG BASE/VIAL	A205780	001	Mar 31, 2016	Mar	NEWA
AP		EQ 1GM BASE/VIAL	A205780	002	Mar 31, 2016	Mar	NEWA
AP		EQ 5GM BASE/VIAL	A205779	001	Mar 29, 2016	Mar	NEWA
AP		EQ 10GM BASE/VIAL	A205779	002	Mar 29, 2016	Mar	NEWA
AP	GLAND PHARMA LTD	EQ 500MG BASE/VIAL	A205694	001	Jan 21, 2016	Jan	NEWA
AP		EQ 1GM BASE/VIAL	A205694	002	Jan 21, 2016	Jan	NEWA

VANDETANIB

TABLET;ORAL		CAPRELSA					
>A>	GENZYME CORP	100MG	N022405	001	Apr 06, 2011	Jun	CAHN
>A>	+	300MG	N022405	002	Apr 06, 2011	Jun	CAHN
>D>	IPR PHARMS INC	100MG	N022405	001	Apr 06, 2011	Jun	CAHN
>D>	+	300MG	N022405	002	Apr 06, 2011	Jun	CAHN

VECURONIUM BROMIDE

INJECTABLE;INJECTION		VECURONIUM BROMIDE					
AP	EUROHLTH INTL SARL	10MG/VIAL	A075549	001	Jun 13, 2000	Apr	CAHN
AP		20MG/VIAL	A075549	002	Jun 13, 2000	Apr	CAHN
AP	GLAND PHARMA LTD	10MG/VIAL	A205390	001	May 26, 2016	May	NEWA
AP		20MG/VIAL	A205390	002	May 26, 2016	May	NEWA
AP	SAGENT PHARMS	10MG/VIAL	A078274	001	Dec 29, 2008	Jan	CAHN
AP		20MG/VIAL	A078274	002	Dec 29, 2008	Jan	CAHN

VENETOCLAX

TABLET;ORAL		VENCLEXTA					
	ABBVIE INC	10MG	N208573	001	Apr 11, 2016	Apr	NEWA
		50MG	N208573	002	Apr 11, 2016	Apr	NEWA
	+	100MG	N208573	003	Apr 11, 2016	Apr	NEWA

VERAPAMIL HYDROCHLORIDE

SOLUTION;INTRAVENOUS		VERAPAMIL HYDROCHLORIDE					
AP	EXELA PHARMA SCS LLC	5MG/2ML (2.5MG/ML)	N018925	001	Mar 30, 1984	Apr	CMFD
TABLET;ORAL		VERAPAMIL HYDROCHLORIDE					
>D>	@ MUTUAL PHARM	80MG	A071489	002	Jan 13, 1988	Jun	CAHN
>D>	@	120MG	A071489	001	Jan 13, 1988	Jun	CAHN
>A>	@ SUN PHARM INDS	80MG	A071489	002	Jan 13, 1988	Jun	CAHN
>A>	@	120MG	A071489	001	Jan 13, 1988	Jun	CAHN
TABLET, EXTENDED RELEASE;ORAL		CALAN SR					
	@ PFIZER	180MG	N019152	002	Dec 15, 1989	Feb	DISC

VINORELBINE TARTRATE

INJECTABLE;INJECTION		VINORELBINE TARTRATE					
AP	EUROHLTH INTL SARL	EQ 10MG BASE/ML	A076461	001	Dec 11, 2003	Apr	CAHN

VORICONAZOLE

FOR SUSPENSION;ORAL		VORICONAZOLE					
AB	AMNEAL PHARMS	200MG/5ML	A205034	001	Apr 13, 2016	Mar	NEWA
AB	NOVEL LABS INC	200MG/5ML	A206799	001	May 31, 2016	May	NEWA

## INJECTABLE; IV (INFUSION)

AP	ALVOGEN INC	200MG/VIAL	A206398	001	Mar 23, 2016	Mar NEWA
VORICONAZOLE						
TABLET; ORAL						
VORICONAZOLE						
AB	AJANTA PHARMA LTD	50MG	A206181	001	May 24, 2016	May NEWA
AB		200MG	A206181	002	May 24, 2016	May NEWA
AB	APPCO PHARMA LLC	50MG	A206762	001	May 24, 2016	May NEWA
AB		200MG	A206762	002	May 24, 2016	May NEWA
AB	AUROBINDO PHARMA LTD	50MG	A206837	001	Jan 22, 2016	Jan NEWA
AB		200MG	A206837	002	Jan 22, 2016	Jan NEWA
AB	NOVEL LABS INC	50MG	A207371	001	May 24, 2016	May NEWA
AB		200MG	A207371	002	May 24, 2016	May NEWA
AB	ZYDUS PHARMS USA INC	50MG	A206747	001	May 24, 2016	May NEWA
AB		200MG	A206747	002	May 24, 2016	May NEWA

VORTIOXETINE HYDROBROMIDE

## TABLET; ORAL

>D>	BRINTELLIX					
>D>	TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013	Jun CTNA
>D>		EQ 10MG BASE	N204447	002	Sep 30, 2013	Jun CTNA
>D>		EQ 15MG BASE	N204447	003	Sep 30, 2013	Jun CTNA
>D>	+	EQ 20MG BASE	N204447	004	Sep 30, 2013	Jun CTNA
>A>	TRINTELLIX					
>A>	TAKEDA PHARMS USA	EQ 5MG BASE	N204447	001	Sep 30, 2013	Jun CTNA
>A>		EQ 10MG BASE	N204447	002	Sep 30, 2013	Jun CTNA
>A>		EQ 15MG BASE	N204447	003	Sep 30, 2013	Jun CTNA
>A>	+	EQ 20MG BASE	N204447	004	Sep 30, 2013	Jun CTNA

XENON XE-133

## GAS; INHALATION

## XENON XE 133

LANTHEUS MEDCL	20mCi/VIAL	N017284	002			Feb CTEC
MALLINKRODT NUCLEAR	10mCi/VIAL	N018327	001	Mar 09, 1982		Feb CMFD
	20mCi/VIAL	N018327	002	Mar 09, 1982		Feb CMFD

ZOLMITRIPTAN

## TABLET; ORAL

## ZOLMITRIPTAN

AB	AJANTA PHARMA LTD	2.5MG	A204041	001	May 20, 2016	May NEWA
AB		5MG	A204041	002	May 20, 2016	May NEWA
AB	AUROBINDO PHARMA LTD	2.5MG	A207021	001	May 11, 2016	Apr NEWA
AB		5MG	A207021	002	May 11, 2016	Apr NEWA

ZOLPIDEM TARTRATE

## TABLET; ORAL

## ZOLPIDEM TARTRATE

@ SUN PHARM INDS	5MG	A077288	001	Apr 23, 2007		Mar CAHN
@	10MG	A077288	002	Apr 23, 2007		Mar CAHN

ZONISAMIDE

## CAPSULE; ORAL

## ZONEGRAN

AB	SUNOVION PHARMS INC	25MG	N020789	003	Aug 22, 2003	Feb CAHN
AB		50MG	N020789	002	Aug 22, 2003	Feb CAHN
AB	+	100MG	N020789	001	Mar 27, 2000	Feb CAHN
ZONISAMIDE						
AB	BIONPHARMA INC	25MG	A077813	001	Aug 16, 2006	Jan CAHN
AB		50MG	A077813	002	Aug 16, 2006	Jan CAHN
AB		100MG	A077813	003	Aug 16, 2006	Jan CAHN
@ SUN PHARM INDS	25MG	A077635	001	Dec 22, 2005		Mar CAHN
@	50MG	A077635	002	Dec 22, 2005		Mar CAHN
@	100MG	A077635	003	Dec 22, 2005		Mar CAHN

ACETAMINOPHEN; ASPIRIN; CAFFEINE

TABLET;ORAL

EXCEDRIN (MIGRAINE)

+	GLAXOSMITHKLINE CONS	250MG;250MG;65MG	N020802	001	Jan 14, 1998	Feb	CAHN
---	----------------------	------------------	---------	-----	--------------	-----	------

BUDESONIDE

SPRAY, METERED;NASAL

BUDESONIDE

	APOTEX INC	0.032MG/SPRAY	A078949	002	Nov 20, 2015	Apr	NEWA
--	------------	---------------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE

CAPSULE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

	BIONPHARMA INC	5MG	N022429	001	Jul 23, 2009	Jan	CAHN
--	----------------	-----	---------	-----	--------------	-----	------

+		10MG	N022429	004	Jul 23, 2009	Jan	CAHN
---	--	------	---------	-----	--------------	-----	------

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

	BIONPHARMA INC	5MG	N022429	003	Jul 23, 2009	Jan	CAHN
--	----------------	-----	---------	-----	--------------	-----	------

+		10MG	N022429	002	Jul 23, 2009	Jan	CAHN
---	--	------	---------	-----	--------------	-----	------

SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

@	CYPRESS PHARM	5MG/5ML	A090300	001	Oct 10, 2008	Apr	DISC
---	---------------	---------	---------	-----	--------------	-----	------

	NOSTRUM LABS INC	5MG/5ML	A091327	001	Oct 17, 2011	Mar	CAHN
--	------------------	---------	---------	-----	--------------	-----	------

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@	CYPRESS PHARM	5MG/5ML	A090300	002	Oct 10, 2008	Apr	DISC
---	---------------	---------	---------	-----	--------------	-----	------

	NOSTRUM LABS INC	5MG/5ML	A091327	002	Oct 17, 2011	Mar	CAHN
--	------------------	---------	---------	-----	--------------	-----	------

TABLET, CHEWABLE;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

	NOVEL LABS INC	5MG	A206793	001	Mar 08, 2016	Feb	NEWA
--	----------------	-----	---------	-----	--------------	-----	------

		10MG	A206793	002	Mar 08, 2016	Feb	NEWA
--	--	------	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE

SPONGE;TOPICAL

CHLORHEXIDINE GLUCONATE

>D>		BECTON DICKINSON	4%	A072525	001	Oct 24, 1989	Jun	CRLD
-----	--	------------------	----	---------	-----	--------------	-----	------

>A>	+		4%	A072525	001	Oct 24, 1989	Jun	CRLD
-----	---	--	----	---------	-----	--------------	-----	------

>D>		PHARMASEAL SCRUB CARE						
-----	--	-----------------------	--	--	--	--	--	--

>D>	+	CAREFUSION	4%	N019793	001	Dec 02, 1988	Jun	DISC
-----	---	------------	----	---------	-----	--------------	-----	------

>A>	@		4%	N019793	001	Dec 02, 1988	Jun	DISC
-----	---	--	----	---------	-----	--------------	-----	------

CHLORHEXIDINE GLUCONATE; ISOPROPYL ALCOHOL

SPONGE;TOPICAL

CHLORAPREP ONE-STEP

+	BECTON DICKINSON CO	2%;70% (3ML)	N020832	001	Jul 14, 2000	May	CAHN
---	---------------------	--------------	---------	-----	--------------	-----	------

+		2%;70% (10.5ML)	N020832	004	Aug 20, 2003	May	CAHN
---	--	-----------------	---------	-----	--------------	-----	------

+		2%;70% (26ML)	N020832	006	Nov 21, 2006	May	CAHN
---	--	---------------	---------	-----	--------------	-----	------

CHLORAPREP ONE-STEP FREPP

+	BECTON DICKINSON CO	2%;70% (1.5ML)	N020832	003	Apr 26, 2002	May	CAHN
---	---------------------	----------------	---------	-----	--------------	-----	------

CHLORAPREP WITH TINT

+	BECTON DICKINSON CO	2%;70% (26ML)	N020832	002	May 03, 2005	May	CAHN
---	---------------------	---------------	---------	-----	--------------	-----	------

+		2%;70% (10.5ML)	N020832	005	Apr 03, 2006	May	CAHN
---	--	-----------------	---------	-----	--------------	-----	------

+		2%;70% (3ML)	N020832	007	Oct 10, 2006	May	CAHN
---	--	--------------	---------	-----	--------------	-----	------

SWAB;TOPICAL

CHLORAPREP ONE-STEP SEPP

+	BECTON DICKINSON CO	2%;70% (0.67ML)	N021555	001	Oct 07, 2002	May	CAHN
---	---------------------	-----------------	---------	-----	--------------	-----	------

CHLORAPREP SINGLE SWABSTICK

+	BECTON DICKINSON CO	2%;70% (1.75ML)	N021555	002	May 10, 2005	May	CAHN
---	---------------------	-----------------	---------	-----	--------------	-----	------

CHLORAPREP TRIPLE SWABSTICK

+	BECTON DICKINSON CO	2%;70% (5.25ML)	N021555	003	Jun 10, 2009	May	CAHN
---	---------------------	-----------------	---------	-----	--------------	-----	------

CHLORPHENIRAMINE MALEATE

CAPSULE, EXTENDED RELEASE;ORAL

CHLORPHENIRAMINE MALEATE

@	AUROLIFE PHARMA LLC	12MG	A070797	001	Aug 12, 1988	Feb	CAHN
---	---------------------	------	---------	-----	--------------	-----	------

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

BIONPHARMA INC 25MG;EQ 200MG FREE ACID AND POTASSIUM SALT A 090397 001 Nov 22, 2010 Jan CAHN

FAMOTIDINE

TABLET;ORAL

FAMOTIDINE

AUROBINDO PHARMA LTD 10MG A 206531 001 Apr 26, 2016 Apr NEWA  
20MG A 206531 002 Apr 26, 2016 Apr NEWA

FLUTICASONE PROPIONATE

SPRAY, METERED;NASAL

FLUTICASONE PROPIONATE

ROXANE 0.05MG/SPRAY A 207957 001 May 26, 2016 May NEWA

IBUPROFEN

CAPSULE;ORAL

IBUPROFEN

BIONPHARMA INC EQ 200MG FREE ACID AND POTASSIUM SALT A 078682 001 Mar 24, 2009 Jan CAHN

>A> PURACAP PHARM LLC EQ 200MG FREE ACID AND POTASSIUM SALT A 206568 001 Jun 21, 2016 Jun NEWA

MIDOL LIQUID GELS

+ BIONPHARMA INC 200MG N 021472 001 Oct 18, 2002 Jan CAHN

TABLET;ORAL

IBUPROFEN

STRIDES PHARMA 200MG A 079129 001 Mar 28, 2011 May CAHN  
200MG A 091355 001 Apr 04, 2011 May CAHN  
@ SUN PHARM INDS 200MG A 070493 001 Dec 24, 1985 Mar CAHN  
@ 200MG A 070908 001 Sep 26, 1986 Mar CAHN  
@ 200MG A 071462 001 Oct 02, 1986 Mar CAHN

LANSOPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

LANSOPRAZOLE

MYLAN PHARMS INC 15MG A 203187 001 Jun 01, 2016 May NEWA

TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE;ORAL

LANSOPRAZOLE

>A> DEXCEL PHARMA 15MG N 208025 001 Jun 07, 2016 Jun NEWA

LEVONORGESTREL

TABLET;ORAL

HER STYLE

NOVAST LABS LTD 1.5MG A 207976 001 Mar 11, 2016 Feb NEWA

LEVONORGESTREL

GLENMARK PHARMS LTD 1.5MG A 207044 001 Mar 25, 2016 Mar NEWA

+ PERRIGO R AND D 0.75MG A 090740 001 Dec 30, 2010 Apr CRLD

@ WATSON LABS 0.75MG A 078665 001 Aug 28, 2009 Apr DISC

PLAN B

@ TEVA BRANDED PHARM 0.75MG N 021045 002 Aug 24, 2006 Apr DISC

LOPERAMIDE HYDROCHLORIDE

CAPSULE;ORAL

LOPERAMIDE HYDROCHLORIDE

BIONPHARMA INC 1MG N 021855 001 Aug 04, 2005 Jan CAHN

+ 2MG N 021855 002 Aug 04, 2005 Jan CAHN

MICONAZOLE NITRATE

CREAM, SUPPOSITORY;TOPICAL, VAGINAL

MONISTAT 3 COMBINATION PACK

+ MEDTECH PRODUCTS 2%,200MG N 020670 002 Apr 16, 1996 Mar CMS1

NAPROXEN SODIUM

CAPSULE;ORAL

NAPROXEN SODIUM

+ BIONPHARMA INC EQ 200MG BASE N 021920 001 Feb 17, 2006 Mar CAHN

TABLET;ORAL

NAPROXEN SODIUM

AUROBINDO PHARMA LTD EQ 200MG BASE A 205497 001 Mar 18, 2016 Mar NEWA

NICOTINE POLACRILEX

GUM, CHEWING;BUCCAL

NICOTINE POLACRILEX

ACTAVIS LABS NY INC EQ 2MG BASE  
EQ 4MG BASEA204794 001 May 10, 2016 Apr NEWA  
A204833 001 Feb 26, 2016 Feb NEWAOXYBUTYNYN

FILM, EXTENDED RELEASE;TRANSDERMAL

OXYTROL FOR WOMEN

+ ALLERGAN SALES LLC 3.9MG/24HR

N202211 001 Jan 25, 2013 Jan CAHN

POTASSIUM IODIDE

SOLUTION;ORAL

POTASSIUM IODIDE

MISSION PHARMACAL CO 65MG/ML

A206211 001 Mar 24, 2016 Mar NEWA

TABLET;ORAL

THYRO-BLOCK

@ MEDA PHARMS 130MG

N018307 001 May CAHN

RANITIDINE HYDROCHLORIDE

TABLET;ORAL

RANITIDINE HYDROCHLORIDE

STRIDES PHARMA EQ 75MG BASE

A201745 001 Feb 29, 2012 May CAHN



**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 06 JUNE 2016**

NO JUNE 2016 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO JUNE 2016 ADDITIONS

PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001	9242986	Dec 08, 2029	DS DP			
<u>ACETAMINOPHEN - OFIRMEV</u>						
N 022450 001	>A> 6028222	Aug 05, 2017	DP		>A> PED	Jan 11, 2017
	>A> 6028222*PED	Feb 05, 2018				
	>A> 6992218	Jun 06, 2021	DP			
	>A> 6992218*PED	Dec 06, 2021				
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	9327028	Jul 21, 2031	U-1839			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 001	8747894	May 08, 2032	DP U-1373			
<u>ACETYLCYSTEINE - CETYLEV</u>						
N 207916 002	8747894	May 08, 2032	DP U-1373			
<u>ACLIDINIUM BROMIDE - TUDORZA PRESSAIR</u>						
N 202450 001	9333195	Jul 07, 2020	DP U-1263			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO FORTE</u>						
N 207917 001	8809305	Dec 23, 2022	U-1078			
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 001	8426586	Oct 10, 2029	DS		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 002	8426586	Oct 10, 2029	DS		ODE	Apr 15, 2023
	RE43431	Jan 22, 2022	DS			
<u>AFATINIB DIMALEATE - GILOTTRIF</u>						
N 201292 003	8426586	Oct 10, 2029	DS		I-730	Apr 15, 2019
	RE43431	Jan 22, 2022	DS		ODE	Apr 15, 2023
<u>ALBUTEROL SULFATE - PROAIR RESPICLICK</u>						
N 205636 001	8978966	Jan 13, 2032	DP		NPP	Apr 28, 2019
	9216260	Jun 28, 2031	DP			
<u>ALECTINIB HYDROCHLORIDE - ALECENSA</u>						
N 208434 001	>A> 9365514	Mar 04, 2032	DP		ODE	Dec 11, 2022
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002					M-177	Apr 05, 2019

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005					M-177	Apr 05, 2019
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006					M-177	Apr 05, 2019
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - AMELUZ</u>						
N 208081 001					NP	May 10, 2019
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 001	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 002	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 003	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 004	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 005	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>AMPHETAMINE - ADZENYS XR-ODT</u>						
N 204326 006	8709491	Jun 28, 2032	DP			
	8840924	Jun 05, 2026	DP			
	9017731	Jun 28, 2032	DP			
	9265737	Jun 28, 2032	DP			
<u>APIXABAN - ELIQUIS</u>						
N 202155 001	9326945	Feb 24, 2031	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APIXABAN - ELIQUIS</u>						
N 202155 002	9326945	Feb 24, 2031	DP			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001 >A>	9359302	Sep 25, 2022	DS DP U-1859			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002 >A>	9359302	Sep 25, 2022	DS DP U-1859			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003 >A>	9359302	Sep 25, 2022	DS DP U-1859			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004 >A>	9359302	Sep 25, 2022	DS DP U-1859			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005 >A>	9359302	Sep 25, 2022	DS DP U-1859			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 006 >A>	9359302	Sep 25, 2022	DS DP U-1859			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 002 >A>	9359302	Sep 25, 2022	DS DP U-1859			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 003 >A>	9359302	Sep 25, 2022	DS DP U-1859			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 004 >A>	9359302	Sep 25, 2022	DS DP U-1859			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 005 >A>	9359302	Sep 25, 2022	DS DP U-1859			
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 001					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 002					PC	Nov 28, 2016
<u>ARMODAFINIL - ARMODAFINIL</u>						
A 200043 003					PC	Nov 28, 2016
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	9216150	Sep 29, 2032	DP			
	9226892	Sep 29, 2032	U-1731			
	9226892	Sep 29, 2032	U-1732			
	9226892	Sep 29, 2032	U-1733			
>A>	9351984	Dec 19, 2021	DP			
<u>AVANAFIL - STENDRA</u>						
N 202276 001	6656935	Apr 27, 2025	DS DP U-155			
<u>AVANAFIL - STENDRA</u>						
N 202276 002	6656935	Apr 27, 2025	DS DP U-155			
<u>AVANAFIL - STENDRA</u>						
N 202276 003	6656935	Apr 27, 2025	DS DP U-155			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AVIBACTAM SODIUM; CEFTAZIDIME - AVYCAZ</u>						
N 206494 001					>A> I-738	Jun 22, 2019
<u>AXITINIB - INLYTA</u>						
N 202324 001	6534524	Apr 29, 2025	DS DP			
<u>AXITINIB - INLYTA</u>						
N 202324 002	6534524	Apr 29, 2025	DS DP			
<u>AZELAIC ACID - FINACEA</u>						
N 207071 001	9265725	Dec 08, 2027	DP			
<u>AZELASTINE HYDROCHLORIDE; FLUTICASONE PROPIONATE - DYMISTA</u>						
N 202236 001	9259428	Jun 13, 2023	U-644			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 001	9169238	Feb 04, 2030	DP			
<u>AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE - EDARBYCLOR</u>						
N 202331 002	9169238	Feb 04, 2030	DP			
<u>BALSALAZIDE DISODIUM - GIAZO</u>						
N 022205 001	9192616	Aug 02, 2026	U-1229			
<u>BENDAMUSTINE HYDROCHLORIDE - BENDEKA</u>						
N 208194 001	9265831	Jan 28, 2031	DP			
<u>BETAMETHASONE DIPROPIONATE - SERNIVO</u>						
N 208079 001	>A> 9364485	Aug 31, 2030	DP U-1858		NDF	Feb 05, 2019
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	9241918	Mar 16, 2025	DP U-1814			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	9216183	Jan 15, 2023	U-1487			
	9226931	Jan 15, 2023	U-1799			
<u>BOCEPREVIR - VICTRELIS</u>						
N 202258 001	>A> RE43298	Dec 22, 2024	DS DP U-1128			
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021262 001	9295641	Jul 10, 2021	U-1833			
	9295641*PED	Jan 10, 2022				
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	9295641	Jul 10, 2021	U-1833			
	9295641*PED	Jan 10, 2022				
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 002	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 003	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 004	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205836 005	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205837 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BRIVARACETAM - BRIVIACT</u>						
N 205838 001	6784197	Feb 21, 2021	DS DP U-1815		NCE	May 12, 2021
	6911461	Feb 21, 2021	DS DP U-1815			
	8492416	Feb 21, 2021	U-1815			
<u>BROMFENAC SODIUM - BROMSITE</u>						
N 206911 001	8778999	Sep 03, 2029	DP U-1834		NP	Apr 08, 2019
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	9192576	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - ENTOCORT EC</u>						
N 021324 001					M-178 NPP	Apr 29, 2019 Apr 29, 2019
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	9320716	Jun 09, 2020	DP U-1325			
<u>BUPRENORPHINE HYDROCHLORIDE - PROBUPHINE</u>						
N 204442 001					NP	May 26, 2019
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	9259421	Sep 18, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 005	9259421	Sep 18, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	9248123	Jan 13, 2032	U-1808			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 001	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024		U-1220	NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 002	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024		U-1220	NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CABOZANTINIB S-MALATE - CABOMETYX</u>						
N 208692 003	7579473	Sep 24, 2024	DS DP		NCE	Nov 29, 2017
	8497284	Sep 24, 2024		U-1220	NP	Apr 25, 2019
	8877776	Oct 08, 2030	DS DP			
<u>CALCIFEDIOL - RAYALDEE</u>						
N 208010 001	>A> 6582727	Aug 22, 2020	DP		>A> NP	Jun 17, 2019
	>A> 8207149	Apr 25, 2028		U-1871		
	>A> 8361488	Jul 19, 2028	DP			
	>A> 8426391	Aug 27, 2028	DP	U-1872		
	>A> 8778373	Apr 25, 2028		U-1873		
	>A> 8906410	Feb 02, 2027	DP			
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 001					I-733	May 20, 2019
<u>CANAGLIFLOZIN - INVOKANA</u>						
N 204042 002					I-733	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003					I-735	May 20, 2019
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004					I-735	May 20, 2019
<u>CANGRELOR - KENGREAL</u>						
N 204958 001	9295687	Jul 10, 2035	DP			
<u>CARFILZOMIB - KYPROLIS</u>						
N 202714 001	>A> 7417042	Jul 20, 2026	DS DP		I-722	Jan 21, 2019
	>A> 8129346	Apr 14, 2025		U-1260	I-723	Jan 21, 2019
<u>CEFIXIME - SUPRAX</u>						
N 202091 001	9233112	Dec 14, 2028	DP	U-1676		
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 001					NPP	May 27, 2019
					NPP	May 27, 2019
<u>CEFTAROLINE FOSAMIL - TEFLARO</u>						
N 200327 002					NPP	May 27, 2019
					NPP	May 27, 2019

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	9320740	Mar 14, 2034	DP			
<u>CERTINIB - ZYKADIA</u>						
N 205755 001	9309229	Jan 18, 2032	DS DP			
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 001					NCE	Mar 17, 2020
<u>CHOLIC ACID - CHOLBAM</u>						
N 205750 002					NCE	Mar 17, 2020
<u>CIPROFLOXACIN - OTIPRIO</u>						
N 207986 001	9233068	Dec 11, 2029	DP		NP	Dec 10, 2018
<u>CIPROFLOXACIN HYDROCHLORIDE; FLUOCINOLONE ACETONIDE - OTOVEL</u>						
N 208251 001	8932610	Mar 24, 2030	DP U-1578		NC	Apr 29, 2019
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537 001	9345714	Sep 13, 2022	DP U-1578			
<u>COBICICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - GENVOYA</u>						
N 207561 001	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7803788	Feb 02, 2022		U-257		
	9296769	Aug 15, 2032	DS DP U-257			
<u>COBIMETINIB FUMARATE - COTELLIC</u>						
N 206192 001					ODE	Nov 10, 2022
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001					ODE	Mar 11, 2023
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002					ODE	Mar 11, 2023
<u>CYCLOBENZAPRINE HYDROCHLORIDE - AMRIX</u>						
N 021777 001	>A> 9375410	Nov 14, 2023		U-1088		
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	9248191	Aug 27, 2024		U-1479		
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001	9233077	Jun 17, 2034	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002	9233077	Jun 17, 2034	DP			
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 001	9233956	May 04, 2029		U-1811	M-170	Nov 20, 2018
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806 002	9233956	May 04, 2029		U-1811	M-170	Nov 20, 2018
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001					D-161 D-162 I-726 I-727	Feb 05, 2019 Feb 05, 2019 Feb 05, 2019 Feb 05, 2019

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 001					D-161 D-162 I-726 I-727	Feb 05, 2019 Feb 05, 2019 Feb 05, 2019 Feb 05, 2019
<u>DACLATASVIR DIHYDROCHLORIDE - DAKLINZA</u>						
N 206843 002					D-161 D-162 I-726 I-727	Feb 05, 2019 Feb 05, 2019 Feb 05, 2019 Feb 05, 2019
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883 001					D-154	Jan 20, 2019
<u>DAPSONE - ACZONE</u>						
N 207154 001	5863560	Sep 11, 2016	DP		NS	Feb 24, 2019
	6060085	Sep 11, 2016	U-124			
	6620435	Sep 11, 2016	DP			
	9161926	Nov 18, 2033	DP			
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001	8492386	Sep 04, 2032	U-1840		D-163	Apr 22, 2019
	8685984	Sep 04, 2032	U-1840			
<u>DEFERASIROX - JADENU</u>						
N 206910 001	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 002	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFERASIROX - JADENU</u>						
N 206910 003	9283209	Nov 21, 2034	DS DP		ODE	Jan 23, 2020
<u>DEFIBROTIDE SODIUM - DEFITELIO</u>						
N 208114 001					NCE ODE	Mar 30, 2021 Mar 30, 2023
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001	9283178	Oct 20, 2020	U-1205			
<u>DEXAMETHASONE; TOBRAMYCIN - TOBRADEX ST</u>						
N 050818 001	8450287	Dec 19, 2027	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	9233103	Mar 05, 2032	U-1805			
	9238029	Jan 17, 2026	DP			
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	6238994	May 17, 2019	DP			
	6238994*PED	Nov 17, 2019				
	6462058	Jun 15, 2020	DS DP U-950			
	6462058	Jun 15, 2020	DS DP U-951			
	6462058*PED	Dec 15, 2020				
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276*PED	Jul 30, 2023				
	6939971	Jun 15, 2020	U-950			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT SOLUTAB</u>						
N 208056 001	6939971	Jun 15, 2020	U-951			
	6939971*PED	Dec 15, 2020				
	7285668	Jun 15, 2020	DS			
	7285668*PED	Dec 15, 2020				
	7399485	May 26, 2018	DP			
	7399485*PED	Nov 26, 2018				
	7431942	May 17, 2019	DP			
	7431942*PED	Nov 17, 2019				
	7875292	May 17, 2019	DP			
	7875292*PED	Nov 17, 2019				
	8461187	Jan 17, 2026	DP			
	8461187*PED	Jul 17, 2026				
	8784885	Oct 15, 2023	DP			
	8784885*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
	8871273*PED	Jul 11, 2028				
	9011926	Feb 24, 2026	DP			
	9145389	Jun 15, 2020	DS DP			
	9238029	Jan 17, 2026	DP			
	9241910	Mar 10, 2029	DP			
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	9220784	Oct 17, 2027	U-1488			
	>A> 9339551	Oct 17, 2027	U-1488			
	>A> 9339552	Oct 17, 2027	DP U-1488			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 001	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 002	9308195	Sep 30, 2033	DP			
<u>DOCETAXEL - DOCETAXEL</u>						
N 205934 003	9308195	Sep 30, 2033	DP			
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 001				>A> PC		Dec 04, 2016
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 002				>A> PC		Dec 04, 2016
<u>DOFETILIDE - DOFETILIDE</u>						
A 207058 003				>A> PC		Dec 04, 2016
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 001	9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 002	>A> 8129385	Oct 05, 2027	DS DP			
	>A> 9242986	Dec 08, 2029	DS DP			
<u>DOLUTEGRAVIR SODIUM - TIVICAY</u>						
N 204790 003	>A> 8129385	Oct 05, 2027	DS DP			
	>A> 9242986	Dec 08, 2029	DS DP			
<u>DOXEPIH HYDROCHLORIDE - SILENOR</u>						
N 022036 001	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DOXEPIIN HYDROCHLORIDE - SILENOR</u>						
N 022036 002	8513299	Sep 07, 2030	U-620			
	9107898	May 01, 2028	U-620			
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	9241946	Apr 05, 2022	U-1063			
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431 003					PC	Nov 19, 2016
<u>DOXYCYCLINE HYCLATE - DOXYCYCLINE HYCLATE</u>						
A 090431 005					PC	Nov 15, 2016
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795 007	>A> 6958161	Dec 15, 2022	DP U-918			
	>A> 8715724	Feb 03, 2028	DP			
	>A> 9295652	Oct 23, 2034	DP U-918			
<u>DOXYCYCLINE HYCLATE - DORYX MPC</u>						
N 050795 008	>A> 6958161	Dec 15, 2022	DP U-918			
	>A> 8715724	Feb 03, 2028	DP			
	>A> 9295652	Oct 23, 2034	DP U-918			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	9302009	Oct 24, 2030	DP			
<u>ELBASVIR; GRAZOPREXIN - ZEPATIER</u>						
N 208261 001	7973040	Jul 24, 2029	DS DP U-1813		NCE	Jan 28, 2021
	8871759	May 04, 2031	DS DP U-1813			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	8551957	Oct 19, 2029	DP U-1651		M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	8551957	Oct 19, 2029	DP U-1651		M-174	Mar 18, 2019
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 001	7407955	May 02, 2025	DS DP			
<u>EMPAGLIFLOZIN; LINAGLIPTIN - GLYXAMBI</u>						
N 206073 002	7407955	May 02, 2025	DS DP			
	>A> 8673927	May 04, 2027	DP U-1652			
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR ALAFENAMIDE FUMARATE - ODEFSEY</u>						
N 208351 001	5814639	Sep 29, 2015	DS DP		NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-257			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	6838464	Feb 26, 2021	DS DP			
	7067522	Dec 20, 2019	DS DP			
	7125879	Aug 09, 2022	DS DP U-257			
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022	U-257			
	8080551	Apr 11, 2023	DS DP			
	8101629	Aug 09, 2022	DP			
	8754065	Aug 15, 2032	DS DP U-257			
	9296769	Aug 15, 2032	DS DP U-257			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - DESCOVY</u>						
N 208215 001	5814639	Sep 29, 2015	DS DP	Y	NCE	Nov 05, 2020
	5814639*PED	Mar 29, 2016				
	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6642245	Nov 04, 2020	U-257			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
	7390791	May 07, 2022	DS DP			
	7803788	Feb 02, 2022	U-257			
	8754065	Aug 15, 2032	DS DP U-257			
	9296769	Aug 15, 2032	DS DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	5914331	Jul 02, 2017	DS			
	5914331*PED	Jan 02, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 002	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 003	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 004	5814639	Sep 29, 2015	DS DP			
	5814639*PED	Mar 29, 2016				
	5914331	Jun 02, 2017	DS			
	5914331*PED	Dec 02, 2017				
	5922695	Jul 25, 2017	DS U-248			
	5922695	Jul 25, 2017	DS U-541			
	5922695	Jul 25, 2017	DS U-1170			
	5922695	Jul 25, 2017	DS U-1259			
	5935946	Jul 25, 2017	DS DP U-248			
	5935946	Jul 25, 2017	DS DP U-541			
	5935946	Jul 25, 2017	DS DP U-1170			
	5935946	Jul 25, 2017	DS DP U-1259			
	5935946*PED	Jan 25, 2018				
	5977089	Jul 25, 2017	DS DP U-248			
	5977089	Jul 25, 2017	DS DP U-541			
	5977089	Jul 25, 2017	DS DP U-1170			
	5977089	Jul 25, 2017	DS DP U-1259			
	5977089*PED	Jan 25, 2018				
	6043230	Jul 25, 2017	U-248			
	6043230	Jul 25, 2017	U-541			
	6043230	Jul 25, 2017	U-1170			
	6043230	Jul 25, 2017	U-1259			
	6043230*PED	Jan 25, 2018				
	6642245	Nov 04, 2020	U-248			
	6642245	Nov 04, 2020	U-541			
	6642245	Nov 04, 2020	U-1170			
	6642245	Nov 04, 2020	U-1259			
	6642245*PED	May 04, 2021				
	6703396	Mar 09, 2021	DS DP			
	6703396*PED	Sep 09, 2021				
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 001	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			
<u>EPINEPHRINE - AUVI-Q</u>						
N 201739 002	9238108	Jan 22, 2027	DP			
	9259539	Feb 01, 2026	DP			
	9278182	Feb 01, 2026	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EPINEPHRINE - ADRENALIN</u>						
N 204200 001	9119876	Mar 13, 2035	DP			
	9295657	Mar 13, 2035	U-1829			
	9295657	Mar 13, 2035	U-1830			
<u>EPINEPHRINE - ADRENALIN</u>						
N 204640 001	9295657	Mar 13, 2035	U-1829			
<u>EPINEPHRINE HYDROCHLORIDE - EPINEPHRINE</u>						
N 205029 001	9283197	Aug 15, 2034	DP U-1828			
	9283197	Aug 15, 2034	DP U-1829			
	9283197	Aug 15, 2034	DP U-1830			
<u>ERIBULIN MESYLATE - HALAVEN</u>						
N 201532 001	6469182	Jun 16, 2019	U-1096		I-721	Jan 28, 2019
	6469182	Jun 16, 2019	U-1812		ODE	Jan 28, 2023
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 001					D-164	May 20, 2019
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 002					D-164	May 20, 2019
<u>ERLOTINIB HYDROCHLORIDE - TARCEVA</u>						
N 021743 003					D-164	May 20, 2019
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 001	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 002	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 003	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESLICARBAZEPINE ACETATE - APTIOM</u>						
N 022416 004	5753646	Jun 27, 2017	DS DP U-1451			
	5753646	Jun 27, 2017	DS DP U-1746			
	5753646	Jun 27, 2017	DS DP U-1842			
	9206135	Apr 21, 2026	DS			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE IN PLASTIC CONTAINER</u>						
N 205703 001	>A> 6310094	Jan 12, 2021	DP			
	>A> 6310094*PED	Jul 12, 2021				
	>A> 6528540	Jan 12, 2021	DP			
	>A> 6528540*PED	Jul 12, 2021				
	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 205703 002	>A> 6310094	Jan 12, 2021	DP			
	>A> 6310094*PED	Jul 12, 2021				
	>A> 6528540	Jan 12, 2021	DP			
	>A> 6528540*PED	Jul 12, 2021				



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ESMOLOL HYDROCHLORIDE - ESMOLOL HYDROCHLORIDE DOUBLE STRENGTH IN PLASTIC CONTAINER</u>						
N 205703 002	8829054	Mar 15, 2033	DP			
	8835505	Mar 15, 2033	DP			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	9220698	Mar 10, 2031		U-1781		
	>A> 9345695	May 31, 2022	DP			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	>A> 9345695	May 31, 2022	DP			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001	8410131	Nov 01, 2025		U-1368	I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022		U-1396		
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002	8410131	Nov 01, 2025		U-1368	I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022		U-1396		
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003	8410131	Nov 01, 2025		U-1368	I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022		U-1396		
	8436010*PED	Aug 22, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004	8410131	Nov 01, 2025		U-1368	I-724	Feb 26, 2019
	8410131*PED	May 01, 2026				
	8436010	Feb 22, 2022		U-1396		
	8436010*PED	Aug 22, 2022				
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	9238076	Apr 15, 2024	DP U-412			
<u>EXENATIDE SYNTHETIC - BYDUREON PEN</u>						
N 022200 002	5424286	Dec 01, 2016		U-1108		
	6479065	Aug 10, 2020	DP			
	6495164	May 25, 2020	DP			
	6667061	May 25, 2020	DP			
	6824822	Oct 09, 2022	DP			
	6858576	Jan 06, 2017		U-656		
	6872700	Jan 14, 2020		U-654		
	6956026	Jan 07, 2018		U-687		
	7223440	Aug 31, 2021	DP			
	7456254	Jun 30, 2025	DP	U-1223		
	7563871	Apr 15, 2024	DP			
	7612176	Apr 13, 2025	DP	U-1223		
	7741269	Jan 07, 2018		U-1224		
	8216180	Jan 12, 2028	DP		Y	
	8329648	Aug 18, 2026		U-1313		
	8431685	Apr 13, 2025	DP	U-412		
	8439864	Mar 25, 2028	DP		Y	
	8461105	Apr 13, 2025	DP	U-412		
	8906851	Aug 18, 2026		U-1313		
	9238076	Apr 15, 2024	DP	U-412		
<u>FENOFIBRATE - ANTARA (MICRONIZED)</u>						
N 021695 005	9314447	May 31, 2033	DP	U-1447		
	9314447	May 31, 2033	DP	U-1448		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FENTANYL - SUBSYS</u>						
N 202788 001	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	9241935	Jan 25, 2027	DP			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	9241935	Jan 25, 2027	DP			
<u>FENTANYL HYDROCHLORIDE - IONSYS</u>						
N 021338 001 >A>	9364656	Sep 30, 2031	U-736			
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	8586551	Jul 15, 2023	DS DP			
<u>FLUCICLOVINE F-18 - AXUMIN</u>						
N 208054 001 >A>	5808146	Nov 09, 2016	DS		NCE	May 27, 2021
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	9320862	Nov 06, 2024	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	9333310	Oct 02, 2027	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 002	9333310	Oct 02, 2027	DP			
<u>FORMOTEROL FUMARATE; GLYCOPYRROLATE - BEVESPI AEROSPHERE</u>						
N 208294 001	8324266	May 28, 2030	U-1841		NP	Apr 25, 2019
	8703806	May 28, 2030	U-1841			
	8808713	May 28, 2030	DP U-1841			
	8815258	Mar 17, 2031	U-1841			
<u>FOSAPREPITANT DIMEGLUMINE - EMEND</u>						
N 022023 002					D-155	Feb 01, 2019
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001 >A>	6774122	Jan 09, 2021	U-596		I-725	Feb 19, 2019
>A>	6774122	Jan 09, 2021	U-1826			
>A>	6774122*PED	Jul 09, 2021				
>A>	7456160	Jan 09, 2021	U-596			
>A>	7456160	Jan 09, 2021	U-1826			
>A>	7456160*PED	Jul 09, 2021				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FULVESTRANT - FASLODEX</u>						
N 021344 001	8329680	Jan 09, 2021	U-596			
	8329680	Jan 09, 2021	U-1826			
	8329680*PED	Jul 09, 2021				
>A>	8466139	Jan 09, 2021	U-596			
>A>	8466139	Jan 09, 2021	U-1826			
>A>	8466139*PED	Jul 09, 2021				
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					I-731	Apr 27, 2019
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006	5980864	Nov 09, 2021	DS DP U-1119			
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 001					PC	Jul 27, 2016
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 002					PC	Apr 25, 2016
<u>GLIPIZIDE - GLIPIZIDE</u>						
A 202298 003					PC	Apr 25, 2016
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	5968979	Jul 28, 2018	DS DP U-1378			
	9254278	Mar 09, 2032	U-1816			
	9326966	Mar 09, 2032	U-1816			
<u>GLYCOPYRROLATE - SEEBRI</u>						
N 207923 001	6582678	Apr 24, 2018	DP			
<u>GLYCOPYRROLATE ; INDACATEROL MALEATE - UTIBRON</u>						
N 207930 001	6582678	Apr 24, 2018	DP			
	6878721	Feb 25, 2025	DS DP U-1773			
<u>GRANISETRON - SANCUSO</u>						
N 022198 001	7608282	Jan 22, 2025	DP U-1011			
<u>HALOBETASOL PROPIONATE - ULTRAVATE</u>						
N 208183 001					NP	Nov 06, 2018
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	9265760	Jul 25, 2033	U-1810			
	9326982	Jul 25, 2033	U-1810			
	9333201	Jul 25, 2033	U-1810			
	9339499	Jul 25, 2033	U-1810			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	9289391	Oct 30, 2021	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	9289391	Oct 30, 2021	DP			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	9296753	Oct 30, 2033	DS DP		D-165	May 06, 2019
					I-729	Mar 04, 2019
					I-736	May 06, 2019
					I-737	May 06, 2019
					ODE	Mar 04, 2023
					ODE	May 06, 2023
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	9295639	Sep 30, 2029	U-1756			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001					NCE	Jul 26, 2017
<u>LLOPERIDONE - FANAPT</u>						
N 022192 001					M-180	May 26, 2019
<u>LLOPERIDONE - FANAPT</u>						
N 022192 002					M-180	May 26, 2019
<u>LLOPERIDONE - FANAPT</u>						
N 022192 003					M-180	May 26, 2019

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006					M-180	May 26, 2019
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007					M-180	May 26, 2019
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 001					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - IMATINIB MESYLATE</u>						
A 078340 002					PC	Jul 30, 2016
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001	7544799	Jul 16, 2018	DS DP	Y		
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002	7544799	Jul 16, 2018	DS DP	Y		
	7544799*PED	Jan 16, 2019				
	RE43932	Jul 16, 2018	DS DP			
	RE43932*PED	Jan 16, 2019				
<u>INDACATEROL MALEATE - ARCAPTA NEOHALER</u>						
N 022383 001	6878721	Feb 25, 2025	DS DP U-1168			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	7410656	Oct 10, 2020	U-1222			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	7410656	Oct 10, 2020	U-1222			
<u>INSULIN ASPART PROTAMINE RECOMBINANT; INSULIN ASPART RECOMBINANT - NOVOLOG MIX 70/30 FLEXPEN</u>						
N 021172 004	9265893	Sep 23, 2032	DP			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXPEN</u>						
N 020986 003	9265893	Sep 23, 2032	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXPEN</u>						
N 021536 002	9265893	Sep 23, 2032	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN GLARGINE RECOMBINANT - TOUJEO SOLOSTAR</u>						
N 206538 001	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
	>A> 9345750	May 18, 2031	DP U-1855			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	9011391	Mar 26, 2024	U-1832			
	9233211	Mar 02, 2024	DP			
<u>INSULIN HUMAN - HUMULIN R</u>						
N 018780 004	7291132	Aug 09, 2024	DP			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	>A> 9358352	Feb 15, 2031	DP U-1861			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	>A> 9358352	Feb 15, 2031	DP U-1861			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 003	8950397	Jul 20, 2021	DP			
	9283193	Sep 14, 2026	DP			
	9339615	Oct 20, 2029	DP			
	>A> 9358352	Feb 15, 2031	DP U-1861			
<u>IRINOTECAN HYDROCHLORIDE - ONIVYDE</u>						
N 207793 001	9339497	Jun 12, 2033	U-1848		ODE	Oct 22, 2022
	>A> 9364473	Jun 12, 2033	U-1856			
<u>IVACAFTOR; LUMACAFTOR - ORKAMBI</u>						
N 206038 001	9216969	Nov 08, 2026	DS DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001	9233117	Mar 13, 2034	U-1631			
	9233118	Mar 13, 2034	U-1631			
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 001	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 002	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>IXAZOMIB CITRATE - NINLARO</u>						
N 208462 003	9233115	Aug 12, 2024	U-1778		ODE	Nov 20, 2022
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	9216167	May 28, 2024	U-1800			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - OMIIDRIA</u>						
N 205388 001	9278101	Jul 30, 2023	U-1518			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001	>A> 9339504	Jul 02, 2028	DP U-1596			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002 >A>	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003 >A>	9339504	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004 >A>	9339504	Jul 02, 2028	DP U-1596			
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834 001	9284342	Sep 13, 2030	DS DP U-1470		D-158 D-159 D-160	Feb 12, 2019 Feb 12, 2019 Feb 12, 2019
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 001					I-734	May 13, 2019
<u>LENVATINIB MESYLATE - LENVIMA</u>						
N 206947 002					I-734	May 13, 2019
<u>LESINURAD - ZURAMPIC</u>						
N 207988 001	8003681	Aug 25, 2025	DS			
	8084483	Aug 17, 2029		U-1801		
	8283369	Nov 26, 2028		U-1802		
	8283369	Nov 26, 2028		U-1804		
	8357713	Nov 26, 2028	DP	U-1801		
	8357713	Nov 26, 2028	DP	U-1802		
	8357713	Nov 26, 2028	DP	U-1803		
	8546436	Feb 29, 2032	DS DP			
	8546437	Apr 29, 2029		U-1803		
	9216179	Aug 02, 2030		U-1806		
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021379 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021488 001	9283282	Oct 28, 2018	DS DP			
<u>LEUPROLIDE ACETATE - ELIGARD</u>						
N 021731 001	9283282	Oct 28, 2018	DS DP			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 002 >A>	9339489	Mar 14, 2034	DP U-1850			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 003 >A>	9339489	Mar 14, 2034	DP U-1850			
<u>LEVETIRACETAM - SPRITAM</u>						
N 207958 004 >A>	9339489	Mar 14, 2034	DP U-1850			
<u>LIDOCAINE HYDROCHLORIDE - ZINGO</u>						
N 022114 001 >A>	9358338	Apr 27, 2035		U-1870		
	>A> 9370622	Sep 28, 2035		U-1870		
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	7407955	May 02, 2025	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	7407955	May 02, 2025	DS DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 001	>A> 6303661	Apr 24, 2017		U-802		
	>A> 6340475	Sep 19, 2016	DP	U-1852		
	>A> 6488962	Jun 20, 2020	DP			
	>A> 6635280	Sep 19, 2016	DP			
	>A> 6890898	Feb 02, 2019		U-803		
	>A> 7078381	Feb 02, 2019		U-803		
	>A> 7407955	May 02, 2025	DS DP			
	>A> 7459428	Feb 02, 2019		U-803		
	>A> 8119648	Aug 12, 2023		U-802		
	>A> 8178541	Aug 12, 2023	DP	U-1853		
	>A> 8673927	May 04, 2027		U-1503		
	>A> 8846695	Jun 04, 2030		U-1503		
	>A> 8883805	Nov 26, 2025	DP			
	>A> 9155705	May 21, 2030	DP			
	>A> 9173859	May 04, 2027	DP	U-1503		
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO XR</u>						
N 208026 002	>A> 6303661	Apr 24, 2017		U-802		
	>A> 6340475	Sep 19, 2016	DP	U-1852		
	>A> 6488962	Jun 20, 2020	DP			
	>A> 6635280	Sep 19, 2016	DP			
	>A> 6890898	Feb 02, 2019		U-803		
	>A> 7078381	Feb 02, 2019		U-803		
	>A> 7407955	May 02, 2025	DS DP			
	>A> 7459428	Feb 02, 2019		U-803		
	>A> 8119648	Aug 12, 2023		U-802		
	>A> 8178541	Aug 12, 2023	DP	U-1853		
	>A> 8673927	May 04, 2027		U-1503		
	>A> 8846695	Jun 04, 2030		U-1503		
	>A> 8883805	Nov 26, 2025	DP			
	>A> 9155705	May 21, 2030	DP			
	>A> 9173859	May 04, 2027	DP	U-1503		
<u>LIRAGLUTIDE RECOMBINANT - VICTOZA</u>						
N 022341 001	9265893	Sep 23, 2032	DP		M-176	Apr 22, 2019
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	5712279	Feb 21, 2020	DS DP	U-1317		
	9265758	Mar 07, 2025		U-1316		
	>A> 9364470	Mar 07, 2025		U-1851		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	5712279	Feb 21, 2020	DS DP	U-1317		
	9265758	Mar 07, 2025		U-1316		
	>A> 9364470	Mar 07, 2025		U-1851		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	5712279	Feb 21, 2020	DS DP	U-1317		
	9265758	Mar 07, 2025		U-1316		
	>A> 9364470	Mar 07, 2025		U-1851		
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 004	5712279	Feb 21, 2020	DS DP	U-1317		
	9265758	Mar 07, 2025		U-1316		
	>A> 9364470	Mar 07, 2025		U-1851		



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 005	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
>A>	9364470	Mar 07, 2025	U-1851			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 006	5712279	Feb 21, 2020	DS DP U-1317			
	9265758	Mar 07, 2025	U-1316			
>A>	9364470	Mar 07, 2025	U-1851			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	>A> 9370629	May 20, 2024	DP			
<u>LULICONAZOLE - LUZU</u>						
N 204153 001	5900488	Jul 05, 2017	DS DP U-540			
	9199977	Sep 06, 2033	DS DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	9259423	May 23, 2031	U-1822			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	9259423	May 23, 2031	U-1822			
<u>MACITENTAN - OPSUMIT</u>						
N 204410 001	9265762	May 29, 2027	DP U-1820			
<u>MEGESTROL ACETATE - MEGESTROL ACETATE</u>						
A 203139 001					PC	Jan 24, 2016
<u>MELPHALAN HYDROCHLORIDE - EVOMELA</u>						
N 207155 001	8410077	Mar 13, 2029	DP		ODE	Mar 10, 2023
	9200088	Mar 13, 2029	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 001	9233184	Aug 01, 2027	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 002	9233184	Aug 01, 2027	DP			
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 001					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE - METFORMIN HYDROCHLORIDE</u>						
A 091664 002					PC	Jul 30, 2016
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 001	9320714	Feb 03, 2029	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET</u>						
N 021842 002	9320714	Feb 03, 2029	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	9339472	Oct 14, 2025	DP		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1097			
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002	RE44186	Jul 31, 2023	DS DP U-1097		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003	RE44186	Jul 31, 2023	DS DP U-1097		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1838			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 001	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET</u>						
N 022044 002	7326708	Nov 24, 2026	DS DP U-802			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 001	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 002	7326708	Nov 24, 2026	DS DP U-1227			
<u>METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE - JANUMET XR</u>						
N 202270 003	7326708	Nov 24, 2026	DS DP U-1227			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 006	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP			
	8945063	Mar 19, 2030	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 007	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP			
	8945063	Mar 19, 2030	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 008	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP			
	8945063	Mar 19, 2030	DP			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHYLENE BLUE - PROVAYBLUE</u>						
N 204630 001					ODE	Apr 08, 2023

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 001	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 002	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLICHEW ER</u>						
N 207960 003	8999386	Aug 14, 2033	DP		NP	Dec 04, 2018
	9295642	Aug 14, 2033	DP U-1827			
<u>MINOCYCLINE HYDROCHLORIDE - MINOCIN</u>						
N 050444 001	9278105	May 12, 2031		U-282		
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	6346532	Mar 27, 2022	DS DP			
	RE44872	Nov 04, 2023		U-1527		
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	6346532	Mar 27, 2022	DS DP			
	RE44872	Nov 04, 2023		U-1527		
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 001	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 002	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 003	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 004	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHINE SULFATE</u>						
N 204223 005	9248229	Mar 12, 2034	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 001	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 002	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 003	7955619	Aug 12, 2028	DP			
<u>MORPHINE SULFATE - MORPHABOND</u>						
N 206544 004	7955619	Aug 12, 2028	DP			
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	9238108	Jan 22, 2027	DP			
	9278182	Feb 01, 2026	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	9205082	Dec 22, 2018	DP U-1556			
	9283216	May 10, 2022	DP U-1819			
	9345701	May 10, 2022	DP U-1819			
<u>NEBIVOLOL HYDROCHLORIDE; VALSARTAN - BYVALSON</u>						
N 206302 001	>A> 7803838	Aug 29, 2026	DP		>A> NC	Jun 03, 2019
	>A> 7838552	Oct 04, 2027	U-185			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 002	>A> 9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 003	>A> 9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER</u>						
N 019734 004	>A> 9364564	Dec 26, 2027	DP			
<u>NICARDIPINE HYDROCHLORIDE - CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER</u>						
N 019734 005	>A> 9364564	Dec 26, 2027	DP			
<u>NITISINONE - ORFADIN</u>						
N 206356 001	9301932	Feb 02, 2033	DP U-1836			
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	9265911	Jan 06, 2031	DP U-1824			
	9265911*PED	Jul 06, 2031				
	9279794	Feb 19, 2034	DP U-1823			
	9279794*PED	Aug 19, 2034				
	9295802	Jan 06, 2031	DP U-1226			
	9295802*PED	Jul 06, 2031				
<u>NITROGLYCERIN - GONITRO</u>						
N 208424 001	>A> 9101592	Mar 11, 2032	DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 001	>A> 7138390	Nov 16, 2022	DS DP		>A> NCE	May 27, 2021
	>A> 8058267	Feb 21, 2022	U-1854		>A> ODE	May 27, 2023
	>A> 8377916	Feb 21, 2022	U-1854			
	>A> 9238673	Jun 17, 2033	DP			
<u>OBETICHOLIC ACID - OCALIVA</u>						
N 207999 002	>A> 7138390	Nov 16, 2022	DS DP		>A> NCE	May 27, 2021
	>A> 8058267	Feb 21, 2022	U-1854		>A> ODE	May 27, 2023
	>A> 8377916	Feb 21, 2022	U-1854			
	>A> 9238673	Jun 17, 2033	DP			
<u>OLODATEROL HYDROCHLORIDE; TIOTROPIUM BROMIDE - STIOLTO RESPIMAT</u>						
N 206756 001					M-173	Mar 18, 2019
<u>OMEGA-3-ACID ETHYL ESTERS TYPE A - OMTRYG</u>						
N 204977 001					NCE	Apr 23, 2019
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2017	DP		NCE	May 05, 2019
	5948818	May 13, 2017	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056 001	5900424	May 04, 2016	DS U-864			
	5900424	May 04, 2016	DS U-1817			
	6428810	Nov 03, 2019	DP U-864			
	6428810	Nov 03, 2019	DP U-1817			
<u>OMEPRAZOLE MAGNESIUM - PRILOSEC</u>						
N 022056 002	5900424	May 04, 2016	DS U-864			
	5900424	May 04, 2016	DS U-1817			
	6428810	Nov 03, 2019	DP U-864			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	5840737	Jul 15, 2016	U-588			
	6489346	Jul 15, 2016	DP U-588		Y	
	6645988	Jul 15, 2016	DP		Y	
	6699885	Jul 15, 2016	U-588		Y	
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-588			
	RE45198	Jul 15, 2016	U-588			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	5840737	Jul 15, 2016	U-623			
	5840737	Jul 15, 2016	U-624			
	6489346	Jul 15, 2016	DP U-623		Y	
	6489346	Jul 15, 2016	DP U-624		Y	
	6645988	Jul 15, 2016	DP		Y	
	6699885	Jul 15, 2016	U-623		Y	
	6699885	Jul 15, 2016	U-624		Y	
	6780882	Jul 15, 2016	DS DP			
	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
	RE45198	Jul 15, 2016	U-623			
	RE45198	Jul 15, 2016	U-624			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 001	7399772	Jul 15, 2016	U-588			
<u>OMEPRAZOLE; SODIUM BICARBONATE - ZEGERID</u>						
N 021849 002	7399772	Jul 15, 2016	U-623			
	7399772	Jul 15, 2016	U-624			
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 001					ODE	Nov 13, 2022
<u>OSIMERTINIB MESYLATE - TAGRISSO</u>						
N 208065 002					ODE	Nov 13, 2022
<u>OSPHEMIFENE - OSPHENA</u>						
N 203505 001	9241915	Feb 13, 2024	U-1369			
	9241915	Feb 13, 2024	U-1370			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	9351975	Apr 13, 2027	DP			
	>A> 9370525	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	9351975	Apr 13, 2027	DP			
	>A> 9370525	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	9351975	Apr 13, 2027	DP			
	>A> 9370525	Apr 13, 2027	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYBUTYNIN CHLORIDE - GELNIQUE</u>						
N 022204 001	9259388	Nov 06, 2029	U-1644			
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 001					NP	Apr 26, 2019
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 002					NP	Apr 26, 2019
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 003					NP	Apr 26, 2019
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 004					NP	Apr 26, 2019
<u>OXYCODONE - XTAMPZA ER</u>						
N 208090 005					NP	Apr 26, 2019
<u>OXYMETAZOLINE HYDROCHLORIDE; TETRACAINE HYDROCHLORIDE - KOVANAZE</u>						
N 208032 001					>A> NC	Jun 29, 2019
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 001	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 002	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALBOCICLIB - IBRANCE</u>						
N 207103 003	7456168	Jan 16, 2023	U-1658		I-725	Feb 19, 2019
	7456168	Jan 16, 2023	U-1818			
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	9066980	Jan 30, 2024	DP U-528			
	9066980*PED	Jul 30, 2024				
	9125905	Jan 30, 2024	DP			
	9125905*PED	Jul 30, 2024				
	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	9173942	Jan 30, 2024	DP			
	9173942*PED	Jul 30, 2024				
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 001	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 002	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 003	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - PEXEVA</u>						
N 021299 004	7598271	May 04, 2025	DS			
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	7598271	May 04, 2025	DS			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PERAMPANEL - FYCOMPA</u>						
N 208277 001	6949571	Jun 08, 2021	DS DP U-106		NCE	Oct 22, 2017
	8772497	May 16, 2026	DS			
<u>PHENTOLAMINE MESYLATE - ORAVERSE</u>						
N 022159 001					NPP	Mar 18, 2019
<u>PIMAVANSERIN TARTRATE - NUPLAZID</u>						
N 207318 001	6756393	Mar 06, 2021	DS DP		NCE	Apr 29, 2021
	6815458	Mar 06, 2021	DS DP U-1843			
	7115634	Oct 06, 2021	DS DP			
	7601740	Jun 17, 2027	DS DP			
	7659285	Aug 24, 2026		U-1844		
	7732615	Jun 03, 2028	DS DP			
	7858789	Dec 13, 2020	DS DP			
	7923564	Sep 26, 2025	DS DP			
	8110574	Dec 13, 2020	DS DP			
	8618130	Jan 15, 2024		U-1845		
	8921393	Jan 15, 2024		U-1846		
	9296694	Mar 06, 2021	DS DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	>A> 9358297	Jun 24, 2031	DP U-1454			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206 004					PC	May 18, 2016
<u>PRAMIPEXOLE DIHYDROCHLORIDE - PRAMIPEXOLE DIHYDROCHLORIDE</u>						
A 202206 006					>A> PC	Jan 01, 2017
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 001	5288726	Apr 14, 2017	DS DP U-991			
	5288726*PED	Oct 14, 2017				
	8404703	Jan 02, 2023		U-1381		
	8404703*PED	Jul 02, 2023				
	8569325	Jan 02, 2023		U-1381		
	8569325*PED	Jul 02, 2023				
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 002	5288726	Apr 14, 2017	DS DP U-991			
	5288726*PED	Oct 14, 2017				
	8404703	Jan 02, 2023		U-1381		
	8404703*PED	Jul 02, 2023				
	8569325	Jan 02, 2023		U-1381		
	8569325*PED	Jul 02, 2023				
<u>PROPOFOL - PROPOFOL</u>						
A 205307 001					PC	Feb 24, 2016
<u>REGADENOSON - LEXISCAN</u>						
N 022161 001	9289446	Jun 22, 2019	DP U-116			
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA</u>						
N 203324 001					>A> NP ODE	Apr 15, 2019 Apr 15, 2023
<u>RIBOFLAVIN 5'-PHOSPHATE SODIUM - PHOTREXA VISCOUS IN DEXTRAN 20%</u>						
N 203324 002					>A> NP ODE	Apr 15, 2019 Apr 15, 2023

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	9271968	Feb 27, 2026	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	9271968	Feb 27, 2026	DP			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 001	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 002	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
<u>RIVAROXABAN - XARELTO</u>						
N 022406 003	7157456	Aug 28, 2024	DS DP U-1301			
	7157456	Aug 28, 2024	DS DP U-1302			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 006	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 007	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 002	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 003	6858618	Dec 17, 2021	U-618		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1032			
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 004	6858618	Dec 17, 2021	U-618		I-732	May 27, 2019
	6858618	Dec 17, 2021	U-1032		ODE	May 27, 2023
	6858618	Dec 17, 2021	U-1807			
	6858618*PED	Jun 17, 2022				
<u>ROSUVASTATIN CALCIUM - CRESTOR</u>						
N 021366 005					ODE	May 27, 2023
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 001	9216178	Nov 01, 2032	DP			
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 002	7612073	Nov 17, 2024			U-1010	
	7612073*PED	May 17, 2025				
	9216178	Nov 01, 2032	DP			
	RE43797	Nov 17, 2024			U-1590	
	RE43797*PED	May 17, 2025				



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001	RE44186	Jul 31, 2023	DS DP U-995		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1837			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002	RE44186	Jul 31, 2023	DS DP U-995		M-175	Apr 05, 2019
	RE44186	Jul 31, 2023	DS DP U-1837			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 001	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 002	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 003	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 004	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 005	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 006	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 007	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SELEXIPAG - UPTRAVI</u>						
N 207947 008	7205302	Apr 04, 2023	DS DP U-1797		ODE	Dec 21, 2022
	8791122	Aug 01, 2030	DS DP			
	9173881	Aug 12, 2029	U-1798			
	9284280	Jun 25, 2030	U-1831			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 001	9095509	Dec 06, 2030	DP			
<u>SEVELAMER CARBONATE - RENVELA</u>						
N 022318 002	9095509	Dec 06, 2030	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	>A> 9353103	Jul 28, 2026	U-1467		M-171 M-179	Feb 26, 2019 May 20, 2019
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 001	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 002	7326708	Nov 24, 2026	DS DP U-802			
<u>SITAGLIPTIN PHOSPHATE - JANUVIA</u>						
N 021995 003	7326708	Nov 24, 2026	DS DP U-802			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	9284342	Sep 13, 2030	DS DP U-1470			
<u>SOFOSBUVIR; VELPATASVIR - EPCLUSA</u>						
N 208341 001					>A> NCE	Jun 28, 2021
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 001	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SUGAMMADEX SODIUM - BRIDION</u>						
N 022225 002	7265099	Aug 07, 2020	U-1795		NCE	Dec 15, 2020
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001					I-728	Mar 31, 2019
<u>SUMATRIPTAN SUCCINATE - ZECUITY</u>						
N 202278 001	9272137	Sep 07, 2027	DP			
	9327114	Oct 08, 2032	DP U-1328			
<u>SUMATRIPTAN SUCCINATE - ONZETRA XSAIL</u>						
N 206099 001	6715485	Mar 03, 2020	DP			
	7975690	Aug 18, 2025	DP U-1809			
	8047202	Jul 02, 2023	DP			
	8327844	Oct 03, 2023	U-1809			
	8550073	Oct 22, 2029	DP			
	8555877	Mar 03, 2020	DP			
	8590530	Sep 15, 2025	DP U-1809			
	8875704	Apr 07, 2028	DP U-1809			
	8899229	Aug 18, 2030	DP			
	8978647	Dec 06, 2030	DP			
	9108015	Sep 15, 2025	DP			
	9119932	Apr 23, 2024	DP			
<u>TAFIUPROST - ZIOPATAN</u>						
N 202514 001	5886035	Dec 18, 2022	DS DP U-778			
<u>TEDUGLUTIDE RECOMBINANT - GATTEX KIT</u>						
N 203441 001	5789379	Apr 14, 2020	DS DP U-1320			
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 001	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 002	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 021015 003	9125816	Aug 30, 2020	U-490			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-490			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020	U-1103			
	6503894*PED	Mar 02, 2021				
	9125816	Aug 30, 2020	U-1103			
	9125816*PED	Mar 02, 2021				
	9132089	Aug 30, 2020	U-1103			
	9132089*PED	Mar 02, 2021				
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	9289586	Feb 26, 2027	U-1390			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	9295675	Feb 11, 2034	DP U-1531			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	9295675	Feb 11, 2034	DP U-1531			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	6525060	Dec 02, 2019	DS DP U-1171			
	6525060	Dec 02, 2019	DS DP U-1860			
	6525060	Dec 02, 2019	DS DP U-1862			
	6525060	Dec 02, 2019	DS DP U-1863			
	>A> 7250419	Dec 02, 2019	DS DP U-1171			
	>A> 7250419	Dec 02, 2019	DS DP U-1860			
	>A> 7250419	Dec 02, 2019	DS DP U-1864			
	>A> 7250419	Dec 02, 2019	DS DP U-1865			
	>A> 7250419	Dec 02, 2019	DS DP U-1866			
	>A> 7250419	Dec 02, 2019	DS DP U-1867			
	>A> 7265124	Jul 09, 2021	DS DP U-1171			
	>A> 7265124	Jul 09, 2021	DS DP U-1860			
	>A> 7265124	Jul 09, 2021	DS DP U-1868			
	>A> 7265124	Jul 09, 2021	DS DP U-1869			
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	>A> 6525060	Dec 02, 2019	DS DP U-1171			
	>A> 6525060	Dec 02, 2019	DS DP U-1683			
	>A> 6525060	Dec 02, 2019	DS DP U-1860			
	>A> 6525060	Dec 02, 2019	DS DP U-1862			
	>A> 7250419	Dec 02, 2019	DS DP U-1171			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TICAGRELOR - BRILINTA</u>						
N 022433 002	>A> 7250419	Dec 02, 2019	DS DP U-1860			
	>A> 7250419	Dec 02, 2019	DS DP U-1864			
	>A> 7250419	Dec 02, 2019	DS DP U-1865			
	>A> 7250419	Dec 02, 2019	DS DP U-1866			
	>A> 7250419	Dec 02, 2019	DS DP U-1867			
	>A> 7265124	Jul 09, 2021	DS DP U-1171			
	>A> 7265124	Jul 09, 2021	DS DP U-1860			
	>A> 7265124	Jul 09, 2021	DS DP U-1868			
	>A> 7265124	Jul 09, 2021	DS DP U-1869			
<u>TIGECYCLINE - TYGACIL</u>						
N 021821 001	9254328	Mar 13, 2026	DP			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020912 001	6770660	May 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 001	6770660	Jun 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 002	6770660	Jun 01, 2023	U-1444			
<u>TIROFIBAN HYDROCHLORIDE - AGGRASTAT</u>						
N 020913 003	6770660	Jun 01, 2023	U-1444			
<u>TOFACITINIB CITRATE - XELJANZ XR</u>						
N 208246 001	6956027	Mar 25, 2023	DS		NCE	Nov 06, 2017
	6956041	Dec 08, 2020	DP			
	7091208	Dec 08, 2020	U-247			
	7265221	Dec 08, 2020	DS			
	7301023	May 23, 2022	DS			
	RE41783	Dec 08, 2020	DS			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	9271941	Jan 28, 2032	DP		M-170	Nov 20, 2018
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001	9339507	Mar 10, 2028	DP			
	9358240	May 05, 2028	U-1849			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	9278901	May 24, 2024	U-1475		D-156 D-157	Jan 28, 2019 Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	9278901	May 24, 2024	U-1475		D-156 D-157	Jan 28, 2019 Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	9278901	May 24, 2024	U-1475		D-156 D-157	Jan 28, 2019 Jan 28, 2019
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	9278901	May 24, 2024	U-1475		D-156 D-157	Jan 28, 2019 Jan 28, 2019

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	9283233	Apr 13, 2030	U-1821			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	9333310	Oct 02, 2027	DP		M-172	Feb 24, 2019
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	9333310	Oct 02, 2027	DP			
<u>URIDINE TRIACETATE - VISTOGARD</u>						
N 208159 001					ODE	Dec 11, 2022
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	>A> RE42353	Jun 27, 2022	DS DP			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	>A> RE42353	Jun 27, 2022	DS DP			
<u>VASOPRESSIN - VASOSTRICT</u>						
N 204485 001	>A> 9375478	Jan 30, 2035	U-1857			
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 001	8546399 9174982	Jun 27, 2031 May 26, 2030	DS DP U-1835		NCE ODE	Apr 11, 2021 Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 002	8546399 9174982	Jun 27, 2031 May 26, 2030	DS DP U-1835		NCE ODE	Apr 11, 2021 Apr 11, 2023
<u>VENETOCLAX - VENCLEXTA</u>						
N 208573 003	8546399 9174982	Jun 27, 2031 May 26, 2030	DS DP U-1835		NCE ODE	Apr 11, 2021 Apr 11, 2023
<u>VISMODEGIB - ERIVEDGE</u>						
N 203388 001	9278961	Dec 15, 2028	U-1825			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 001	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 002	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 003	9227946	Jun 15, 2027	U-1668			
<u>VORTIOXETINE HYDROBROMIDE - TRINTELLIX</u>						
N 204447 004	9227946	Jun 15, 2027	U-1668			
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 001					PC	Sep 18, 2016
<u>ZOLPIDEM TARTRATE - ZOLPIDEM TARTRATE</u>						
A 204299 002					PC	Sep 18, 2016
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 001	9265720	May 13, 2030	U-674			
<u>ZOLPIDEM TARTRATE - EDLUAR</u>						
N 021997 002	9265720	May 13, 2030	U-674			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 06 - June 2016

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ZOLPIDEM TARTRATE - ZOLPIMIST</u>						
N 022196 001	8236285	Aug 07, 2032	DS DP U-70			

## Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 36<sup>th</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at <http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>